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Parkinson’s disease (PD) is characterised by a progressive loss of dopaminergic 
neurones from the SNpc, leading to numerous downstream changes in the basal 
ganglia circuitry. Overactivity of the glutamatergic subthalamonigral pathway may 
underlie this continual degeneration of the nigrostriatal system. With this in mind, 
this thesis examined whether selective activation of group III metabotropic glutamate 
receptor subtypes may offer a novel strategy to halt persistent degeneration in PD.  
 
Initial distribution studies revealed mGlu4 and 7 group III mGlu receptor subtypes, 
demonstrated particularly intense immunoreactivity in the SNpc, suggesting these 
receptors may be ideally positioned to provide neuroprotective effects. Therefore, the 
first objective was to confirm this neuroprotective possibility using a broad spectrum 
agonist, L-AP4. Sub-chronic supranigral L-AP4 treatment mediated functional 
neuroprotection against a unilateral 6-OHDA lesion of the SN, confirmed by 
behavioural assessment and post-mortem analyses.  
 
Secondly, the pharmacological identity of the group III mGlu receptor mediating this 
protective effect was examined. To investigate mGlu4 receptors, the novel mGlu4 
selective PAM VU0155041, was also shown to provide functional neuroprotection in 
the 6-OHDA rat model to an almost comparable level reached with L-AP4. Whilst 
these neuroprotective effects are likely mediated by an inhibition of glutamate to 
protect from glutamate-mediated excitotoxicity, VU015504 also led to a significant 
reduction in levels of GFAP and IBA-1 suggesting an additional anti-inflammatory 
action. Further studies revealed little evidence for co-localisation of mGlu4 receptors 
with GFAP in the SN suggesting this anti-inflammatory component likely reflects an 
indirect effect via stimulation of neuronal mGlu4 receptors. 
 
Finally, to investigate mGlu7 receptors, the selective allosteric agonist AMN082, was 
also shown to protect the nigrostriatal tract and demonstrate a degree of preservation 
of motor function. In contrast, mGlu8 receptor activation using the selective agonist 
DCPG, failed to protect the nigrostriatal tract or preserve motor behaviour. 
Collectively, these findings demonstrate that, of the group III mGlu receptors 
investigated, mGlu4 offers the most potential as a promising target for establishing 
disease modification in PD.  
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HRP   Horseradish peroxidase 
IBA-1   ionised calcium binding adaptor molecule 1 
i.c.v.   Intracerebroventricular 
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iGlu   Ionotropic glutamate receptor 
IL-1β   Interleukin-1β 
i.p.   Intraperitoneal 
IP3   Inositol triphosphate 
IPSP   Inhibitory postsynaptic potential 
KA1-2   Kainate receptor subunits 
L-AAAD  L-aromatic amino acid decarboxylase 
L-AP4   L(+)-2-amino-4-phosphonobutyric acid  
L-DOPA   3,4-dihydroxy-L-phenylalanine 
LPS   Lipopolysaccharide 
LRRK2  Leucine-rich kinase 2 
L-SOP   O-Phospho-L-serine 
LTD   Long term depression  
LTP    Long term potentiation  
MAO   Monoamine oxidase   
MAOI   Monoamine oxidase inhibitor 
MAPK   Mitogen-activated protein kinase 
MFB   Median forebrain bundle 
 mGlu   Metabotropic glutamate receptor  
ML   Mediolateral 
MPP
+
   1-methyl-4-phenylpyridinium 
MPTP   1 –methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mPTP   Mitochondrial permeability transition pores 
MRI    Magnetic resonance imaging 
mRNA   Messenger ribonucleic acid  
MSN    Medium spiny neurone  
Complex I NADH-ubiquinone oxidoreductase (first enzyme of 
mitochondrial respiratory chain 
NGS   Normal goat serum   
NM   Neuromelanin 
NMDA   N-methyl-D-aspartate 
NO   Nitric oxide 
NOS   Nitric oxide synthase 
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NPY   Neuropeptide Y 
NR1-3   NMDA receptor subunits  
PARK 1-13  Familial Parkinson’s disease type 1-13  
PBS    Phosphate buffered saline  
PD    Parkinson’s disease  
PET    Positron emission tomography  
PFA   Paraformaldehyde 
PFC    Parafascicular thalamic complex  




PICK Protein interacting with C-kinase 
PINK1 Phosphatase and tensin kinase 1 
PKA    Protein kinase A  
PKC    Protein kinase C  
PPN    Pedunculopontine nucleus  
PSP   Progressive supranuclear palsy 
PUMA   p53 upregulated modulator of apoptosis 
PV   Parvalbumin 
RANTES Regulated upon Activation, Normal T-cell Expressed and 
Secreted 
RBD REM sleep behaviour disorder 
RF Reticular formation 
ROS    Reactive oxygen species 
RT-PCR  Reverse transcriptase polymerase chain reaction  
(S)-3,4-DCPG  (S)-3,4-dicarboxyphenylglycine 
SC    Superior colliculus 
SNCA   Gene encoding α-synuclein protein 
SN   Substantia nigra 
SNpc    Substantia nigra pars compacta  
SNpr    Substantia nigra pars reticulata  
SNP   Single nucleotide polymorphism 
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SP    Substance P  
SS   Somatostatin 
STN    Subthalamic nucleus  
TBS   Tris-buffered saline 
TGF-β   Transforming growth factor-β 
TH    Tyrosine hydroxylase  
TNF-α   Tumour necrosis factor-α 
TTX    Tetrodotoxin  
UCHL1  Ubiquitin carboxyl-terminal esterase L1 
UPDRS  Unified Parkinson’s disease rating scale  
UPS   Ubiquitin-proteasomal system 
VA    Vento anterior thalamic nuclei  
VGLUT1-3  Vesicular glutamate transporters 1-3 
VL    Ventral lateral thalamic nuclei  
VM cells  Ventral mesencephalon cells 
VMAT2  Vesicular monoamine transporter 
















































1.1 Parkinson’s disease 
 
1.1.1 Prevalence, symptoms and prognosis 
 
Parkinson’s disease (PD) was first identified by James Parkinson in 1817 in his 
“Essay of the shaking palsy”, which describes a progressive neurological disorder 
consisting of resting tremor and motor disability (Parkinson, 1817), now known as 
idiopathic PD. Currently the second most common neurodegenerative disorder after 
Alzheimer’s disease, PD affects 1% of the population aged 55 years or over, rising to 
approximately 1.5% in the 64-69 year old age group (von Campenhausen et al., 
2005). As these statistics indicate there is a large increase in the incidence of PD 
during the sixth decade of life, with the average age of diagnosis estimated to be 55 
years (Bezard et al., 1998). However the time of diagnosis does not reflect the age of 
onset of the disease since by the time PD becomes symptomatic and consequently 
diagnosable, it is estimated that approximately 60-70% of dopaminergic cells of the 
nigrostriatal tract have degenerated (German et al., 1983).  
 
PD is clinically characterised by a triad of motor symptoms namely resting tremor, 
rigidity and bradykinesia all of which worsen over time with the appearance of 
postural instability and gait dysfunction (Morris et al., 2001). Additional motor 
symptoms frequently observed are dystonia, micrographia (decreased size of writing), 
hypophonia (weakened or whispered voice), drooling, inability to swallow 
(dysphagia) and hypomania (mask-like face with infrequent blinking) (Pallone, 
2007). Aside from ‘motor disturbances’ numerous non-motor symptoms have also 
been described in PD. These include autonomic dysfunction such as constipation and 
urinary incontinence, psychiatric conditions such as dementia, depression, rapid eye 
movement (REM) sleep disorder and insomnia and in some cases hallucinations, 
delusions and paranoia with the latter conditions often a consequence of drug 
treatment (Pallone, 2007). Thus although the pathology of PD focuses largely on the 
degeneration of dopaminergic neurones from the nigrostriatal system, these non-
motor symptoms are due to degeneration of extranigral structures. These include the 
noradrenergic locus coeruleus, dorsal vagal nucleus and medullary nucleus, the 
glutamatergic pedunculopontine nucleus (PPN), the serotonergic raphé nucleus, the 
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nucleus basalis of Meynert and regions of the limbic system (Jellinger, 1999). This 
degeneration of numerous neuronal systems implicated in PD no doubt explains the 
array of clinical symptoms observed with this disorder.    
 
A major, although not exclusive, pathological hallmark of PD is the appearance of 
abnormal intracellular protein inclusions termed Lewy bodies, in the cytoplasm of 
vulnerable dopaminergic neurones of the substantia nigra pars compacta (SNpc) 
(Dunnett & Bjorklund, 1999). Lewy bodies, first described by Friedrich H. Lewy in 
1912 are fibrous, proteinaceous inclusions containing α-synuclein which are typically 
15μm in diameter and indentified by their dense hyaline core and clear halo 
appearance. Lewy bodies are present in 80-100% of PD post-mortem brains 
(McNaught et al., 2001) and according to the staging system of Lewy body pathology 
proposed by Braak et al., (2003) are thought to precede the degeneration of 
dopaminergic neurones in the SNpc. Examination of synuclein pathology in post-
mortem tissue from PD patients and those with no record of PD-associated 
symptoms, yet demonstrating Lewy body pathology revealed a definite pattern of 
Lewy body formation ascending from the hind brain. The brainstem, medulla and 
anterior olfactory nucleus are thought to be the initial sites of formation (stage 1 and 
2), whilst inclusions in the SNpc which are associated with PD symptoms comprise 
stage 3 and 4, and finally Lewy bodies in the cortex implicated in dementia are 
consigned to stage 5 and 6 (Braak et al., 2003). Recently, it has been suggested that 
two diseases associated with Lewy body pathology in stages 1 and 2 may in fact be 
precursors to PD. The first of which is REM sleep behaviour disorder (RBD) which 
refers to Lewy body pathology in the brainstem (Boeve et al., 2007) and occurs in 
approximately 30-66% of PD sufferers (Gagnon et al., 2002). It is thought more than 
65% of RBD sufferers go on to develop PD and/or associated dementia (Schenck & 
Mahowald, 2002). Secondly, hyposmia (severe olfactory dysfunction), is thought to 
result from Lewy body formation in the anterior olfactory nucleus and is reported in 
80-90% of PD patients (Muller et al., 2002), which in some cases has been reported 
prior to onset of motor symptoms (Ponsen et al., 2004). Indeed research in this area is 
very active at this moment in time in assessing the validity of both RBD and 




Despite the promising correlation between RBD and hyposmia with a pre-
symptomatic phase of PD, there remain no biomarkers that can be routinely used to 
confirm diagnosis of PD. Therefore definitive diagnosis to date relies on post-mortem 
examination. Considering this along with the fact PD shares numerous clinical 
symptoms with dementia, Alzheimer’s disease (AD) and parkinsonian syndromes 
such as dementia with Lewy bodies (DLB) and progressive supranuclear palsy (PSP), 
misdiagnosis of idiopathic PD can often occur. Indeed the poorly understood effects 
of co-existing pathologies on PD remain of considerable intrigue. For example, large 
atutopsy studies have revealed that as people age they harbour numerous cellular 
neuropathies, suggesting manifestation of parkinsonism in the elderly may be due to a 
combination of pathologies within the dopamine circuitry (Litvan et al., 2007). Thus 
the interaction between the pathologies of PD, AD and DLB requires further 
investigation.          
 
The chronically progressive nature of PD can leave people almost fully immobile (or 
akinetic) within 10-15 years of diagnosis. Currently there remains no therapy 
available to halt this progressive degenerative process which results in mortality 2-5 
times higher in PD patients than age-matched controls (Morens et al., 1996). PD 
alone however is rarely identified as the primary cause of death, with pneumonia and 
cancer unrelated to PD, posing the highest risks of death in PD patients (Beyer et al., 
2001). In a time in which the number of persons over 60 globally is expected to rise 
by 1 billion as we reach 2050 (United Nations, 2005), the occurrence of 
neurodegenerative diseases is likely to reach endemic proportions. In addition to the 
increased suffering, the cost of care, treatment and loss of earning is likely to pose a 
huge economical strain in years to come. The United States economy estimated this 
equated to $10.8 billion in 2009 (United Nations, 2009). Therefore it is of huge 
medical and economical importance to discover effective therapies to manage this 
disease. Ultimately, treatments which serve to halt disease progression i.e. 
neuroprotective agents are the most desired which ideally could be prescribed at the 
pre-symptomatic stage. Furthermore, it is hoped biomarkers, imaging technology and 
genetic screening for mutant genes ascribed to PD will be developed to identify pre-






1.1.2.1 Genetic factors 
 
Whilst it is clear genetics play a role in monogenic familial forms of PD, evidence of 
such a component in idiopathic PD remains controversial. Epidemiological studies 
and post-mortem analyses have shown 95% of patients demonstrate late onset 
idiopathic PD (Tanner, 2003). However, 15% of total patients with PD are thought to 
have a first-degree relative affected (Carr et al., 2003). Nonetheless, attempts to 
identify autosomal dominant or recessive pro-parkinsonian genes in idiopathic cases 
of PD using association studies and nonparametric linkage methods have been largely 
unsuccessful. There remains some evidence that genetic variations of SNCA (the gene 
encoding α-synuclein protein) which can cause familial monogenic parkinsonian 
syndromes, may alter the risk for idiopathic PD (Mueller et al., 2005). The underlying 
concept is that relatively common genetic variations such as single nucleotide 
polymorphisms (SNPs), may alter the expression pattern of the gene modifying 
binding of transcription factors, altering splicing patterns or affecting RNA stability 
(Litvan et al., 2007). Therefore, even though these variations do not directly result in 
a pathogenic form of α-synuclein, small changes in protein homeostasis may shift a 
cell towards its threshold to neurodegeneration. In addition, it is thought, that α-
synuclein mutations responsible for monogenic disease can influence the risk for 
idiopathic PD by altering the expression level of such proteins. Thus, assessing 
pathogenic mutations in familial monogenic cases of PD is crucial to developing our 
understanding of the pathogenesis of idiopathic PD. To date, thirteen monogenic 
forms of PD have been identified (PARK1-13), in which the causative genes are 
known in six of these cases and are discussed in more detail below.  
 
Mutations in the SNCA gene have been classified for causing familial type 1 
Parkinson’s disease (PARK1). The first reported observation of a genetic implication 
in PD which later became identified as alterations in PARK1, was of an Italian-
American family with autosomal dominant early onset PD who were found to have a 
missense mutation (A53T) in the SNCA gene (Polymeropoulos et al., 1997). Since 
then, numerous missense mutations in the α-synuclein gene have been identified in 
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German (A30P) and Spanish families (E46K) which cause early onset PD by gene 
duplication and triplication suggesting a correlation between the number of genes 
implicated and disease progression (Kruger et al., 1998; Zarranz et al., 2004). Wild-
type α-synuclein has been shown to accumulate in the presynaptic nerve terminals 
implicated in dopaminergic transmission and vesicle dynamics (Abeliovich et al., 
2000; Outeiro & Lindquist, 2003). However cellular localisation of studies of mutant 
versions of α-synuclein have shown deposition in Lewy bodies and Lewy neurites 
(Spillantini et al., 1997). The ubiquitin-proteasome system (UPS) disposes of 
abnormal proteins through a complex series of reactions preventing toxic 
accumulation. However, the increased expression of these mutant α-synuclein 
aggregates is believed to impair their ubiquitination leading to toxic accumulation 
(discussed in more detail in section 1.1.2.3.3).    
 
The discovery of Parkin (PARK2) originates from Japanese families found to have 
autosomal recessive juvenile parkinsonism (Kitada et al., 1998). Exonic deletions in 
the gene encoding the Parkin protein was discovered in approximately 50% of 
familial early-onset patients in which 77% of cases were in juvenile patients (onset < 
20 years) yet only in 3% of cases with late onset (>30 years, Lucking et al., 2000). 
For this reason and owing to the limited Lewy body pathology in this familial form of 
PD it is thought the mutated Parkin gene has little implication in idiopathic PD. 
However some SNPs have been associated with increased expression of wild-type 
Parkin. Indeed non mutated Parkin has been found in the protein aggregate of Lewy 
bodies from idiopathic PD patients (Schlossmacher et al., 2002). It is now thought 
that Parkin and α-synuclein may interact via an intermediate protein synphylin-1 
(Chung et al., 2001) which may be implicated in the pathological formation of Lewy 
bodies. 
 
Mutations in the UCHL1 gene (PARK5) resulting in a heterozygous I93H 
substitution, have also been identified from a pair of siblings affected by PD (Leroy et 
al., 1998). Ubiquitin carboxyl-terminal esterase L1 (UCHL1) along with a de-
ubiquitinating enzyme, and the ubiquitn protein ligase Parkin comprise components 
of the UPS which collectively serve to degrade abnormal protein. It would be 
pertinent to suggest therefore that mutations in UCHL1 and Parkin prevent the 
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effective disposal of abnormal proteins, leading to toxic accumulation and possible 
cell death (discussed in more detail in section 1.1.2.3.3).  
 
Additional mutations have been discovered in the gene encoding phosphatase and 
tensin kinase 1 (PINK1), which have been shown to cause familial type 6 PD 
(PARK6) (Valente et al., 2004). PINK1 mutations comprise approximately 1-7% of 
familial cases (Healy et al., 2004; Rohe et al., 2004) and monogenic forms of early-
onset PD resemble those of a form of idiopathic PD with atypical features, such as 
dystonia and psychiatric complications (Healy et al., 2004; Tan et al., 2006). 
Transfection of mutant PINK1 protein in HEK293 cells has been shown to prevent 
atractyloside-induced opening of mitochondrial permeability transition pores (mPTP) 
permitting the release of apoptogenic cytochrome c from the mitochondria (Wang et 
al., 2007a). Interestingly the same study revealed over-expression of wild-type 
PINK1 mediated neuroprotection through inhibition of pro-apoptotic, Bcl-2-
associated X protein (Bax) and prevented opening of mPTP. The authors go on to 
suggest the apoptotic mechanism of mPTP opening may be due to a Ser/Thr kinase 
mutation to PINK and inability to downregulate Bax. These findings would suggest 
PINK1 gene mutations may be implicated in mitochondrial dysfunction (discussed in 
greater detail in section 1.1.2.3.1), which is thought to be implicated in the pathology 
of PD.      
 
Mutations in the DJ-1 gene (PARK7) were first reported to cause a monogenic form 
of early onset PD in two European families (Bonifati et al., 2003). It is thought 
however many mutations in DJ-1 do not cause familial PD and account for less than 
1% of all cases of familial PD.  In the few cases in which DJ-1 is implicated, 
neurodegeneration from mutant forms is believed to be mediated via oxidative stress 
(discussed in greater detail in section 1.1.2.3.1). Although thought to comprise a 
minor role in familial cases it is interesting that in idiopathic PD, higher plasma levels 
of DJ-1 were found in patients with early onset PD compared to age-matched 
controls. Furthermore DJ-1 levels were higher still in patients with advanced disease 
progression (Waragai et al., 2007). These findings taken together would suggest 
levels of DJ-1 may correlate to disease progression and consequently may serve as a 
marker to detect pre-symptomatic PD. 
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Finally, mutations in leucine-rich kinase 2 (LRRK2) have also been shown to cause 
monogenic forms of PD (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). Through 
extensive screening in a range of ethnic populations the most common LRRK2 
protein mutation (G2019S), has been found to be responsible for 5-19% of idiopathic 
cases (Goldwurm et al., 2005; Hernandez et al., 2005a; Litvan et al., 2007; Zimprich 
et al., 2004). Generally, subjects indicative of this form of familial PD demonstrate 
idiopathic pathology i.e. presence of Lewy bodies and degeneration of dopaminergic 
neurones of the nigrostriatal system (Hernandez et al., 2005b). However, it currently 
remains unclear how mutations of the LRRK2 protein directly cause PD. Since some 
mutations in LRRK2 have been shown to cause late-onset PD indistinguishable from 
idiopathic disease (which is a unique characteristic amongst the PARK genes), further 
unravelling of the role of LRKK2 protein is now underway with the hope of 
providing valuable insight into the pathogenesis of idiopathic PD. 
 
1.1.2.2 Environmental factors 
 
The previous section clearly delineates a strong genetic contribution to the initiation 
of early-onset PD, although other factors are also likely to be involved. This has been 
best demonstrated in a study in which an octogenarian carrier of the LRKK2 G2019S 
mutation has been shown to be neurologically healthy (Kew & Kemp, 2005). This 
observation suggests genetic factors may simply predispose carriers of mutant genes 
to other risk factors. This is an appealing suggestion considering a lack of strong 
evidence for a genetic contribution in idiopathic cases, proposing environmental and 
also epigenetic factors may be of equal importance in disease progression.    
 
In 1979, it was discovered that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), a contaminant in a batch of heroin, induced an irreversible juvenile-onset 
parkinsonian syndrome in Californian drug addicts (Langston et al., 1983). It is now 
widely documented that MPTP when it is converted to its active metabolite 1-methyl-
4-phenylpyridinium (MPP
+
) in astrocytes by monoamine oxidase and then taken up 
into dopaminergic neurons via the dopamine transporter (DAT), causes a state of 
oxidative stress (Javitch et al., 1984). Toxicity of MPP
+
 lies in its ability to inhibit the 
first enzyme of the respiratory chain, NADH-ubiquinone oxidoreductase (complex I) 
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generating reactive oxygen species and consequent mitochondrial dysfunction leading 
to dopaminergic cell death, discussed in more detail in section 1.1.2.3.1 (Nicklas et 
al., 1987; Sherer et al., 2002). Owing to its specificity to induce dopaminergic 
degeneration, MPTP has become one of the most widely used toxins to model PD in 
mice and primates.  
 
A common household pesticide, rotenone, has also been shown to cause parkinsonism 
in rats where these animals demonstrate Lewy-body like inclusions containing α-
synuclein (Betarbet et al., 1997). Like MPTP, rotenone is known to act as an inhibitor 
to compex I (Ramsay et al., 1991), leading to the suggestion it may also induce PD in 
humans through mitochondrial dysfunction. Additionally, an agricultural herbicide 
paraquat, has also been shown to be toxic to dopaminergic cells, supported by a study 
demonstrating nigrostriatal degeneration following chronic exposure in mice 
(McCormack et al., 2002). Furthermore, chronic exposure to paraquat in mice has 
been shown to cause upregulation of α-synuclein in the substantia nigra (SN; 
Manning-Bog et al., 2002), posing a link between paraquat induced nigral damage 
and genetic processes. Finally, paraquat is also implicated in inhibiting the 
mitochondrial electron-transport demonstrating non-selective inhibition at all 
respiratory chain complexes (Nis-Oliveira et al., 2006).   
 
Other potential environmental risk factors for PD include heavy metal exposure, 
which has been supported by numerous epidemiological studies. Copper, iron, 
aluminium, manganese and zinc are all associated with an increased incidence of PD 
in metal workers with exposure of 20 years or longer (Gorell et al., 1997). The exact 
neurotoxic mechanism exerted by metals is unclear, however in the case of iron, zinc 
and copper, it is thought these metals initiate the production of free radicals to 
facilitate a state of oxidative stress (Montgomery, 1995). 
 
Aside from factors implicated in the pathogenesis of idiopathic PD, both smoking and 
caffeine have been shown to negatively correlate with the incidence of PD. Indeed, 
Ross et al., (2000) demonstrated in one study the risk of PD in non-coffee drinkers 
was more than five times that compared to coffee drinkers. Caffeine is a known 
antagonist at adenosine A2A receptors which are largely restricted to the striatum 
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(Fink et al., 1992), hence blockade of these receptors may underlie neuroprotection 
mediated by caffeine. In support of this notion, systemic administration of the 
A2A antagonist 8-(3-chlorostyryl) caffeine has been shown to attenuate a decrease in 
nigral tyrosine hydroxylase (TH) immunoreactivity induced by 6-OHDA confirming 
a neuroprotective role for these receptors (Bove et al., 2005). Furthermore, 
epidemiological studies have confirmed that there is an inverse correlation between 
smoking and PD, in which these effects are dose-dependent (Gorell et al., 1999). 
Additionally experimental findings have shown nicotine elevates dopamine 
transmission in the striatum and further provides neuroprotection in an animal model 
of PD (O'Neill et al., 2002; Visanji et al., 2006). 
 
Taken together, these findings present strong evidence that environmental toxins pose 
and important risk to PD, whilst in some cases may serve to alleviate this tendency. 
Therefore the general consensus within the literature accepts environmental factors 
are not exclusively responsible for idiopathic PD, which likely involves a 
combination including genetic and epigenetic factors.  
 
1.1.2.3 Mechanisms of nigrostriatal neurodegeneration 
 
Despite an extensive research effort spanning greater than 50 years since the first 
discovery that marked striatal dopamine deficiency is responsible for PD (Ehringer & 
Hornykiewicz, 1960) the underlying cause of nigral cell degeneration remains 
elusive, although several mechanisms have been proposed.  
 
1.1.2.3.1 Mitochondrial dysfunction and oxidative stress 
 
Considerable evidence supports a major role for mitochondrial dysfunction and 
oxidative stress in the pathogenesis of PD. Under normal conditions tight regulation 
of the production and removal of reactive oxygen species (ROS) enables effective 
mitochondrial metabolism for the production of ATP. ATP is produced by the 
transport of protons across the inner mitochondrial membrane via the use of an 
electron-transport chain in which the final destination for an electron along the chain 
is an oxygen molecule. In approximately 1-2% of cases, oxygen is reduced which can 
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lead to the formation of superoxide radicals. These radicals are highly unstable, 
therefore can easily react with mitochondrial DNA to alter the mitochondrial 
membrane potential to facilitate damaging processes. Under normal conditions, 
antioxidants such as Vitamin C, glutathione (GSH) and thiodeoxin serve to scavange 
these radicals to maintain a below toxic threshold. However, mitochondrial 
dysfunction as a result of inhibition to complex I of the respiratory chain, disrupts the 
flow of electrons along the electron –transport chain, leading to the increased 
production of superoxide radicals to levels that cannot be maintained by antioxidant 
defence systems. Furthermore superoxide radicals can react with nitric oxide to 
produce the extremely reactive peroxynitrite (Packer et al., 1996). Accumulation of 
both these oxidative and nitrative stressors ultimately leads to cellular damage, 
precipitating both necrotic and apoptotic cell death (Tan et al., 1998).  
 
Mitochondrial complex I-mediated oxidative stress is implicated in PD patients, with 
an approximate 30% reduction in complex I activity seen in the SNpc of PD patients 
post-mortem (Schapira et al., 1989). As previously mentioned, MPTP, rotenone and 
paraquat also inhibit complex I and are strongly implicated in inducing a PD-like 
syndrome in animals and in the case of MPTP, primates and humans. Dopaminergic 
cell death by MPTP supports a function for oxidative and nitrative stressors since 
both inhibition of neuronal nitric oxide synthase (which produces nitric oxide) and 
increased activity of superoxide dismutase (breaks down superoxide radicals) prevent 
MPTP induced parkinsonism in animal models (Ferrante et al., 1999; Przedborski et 
al., 1995). Free radical production by the Fenton reaction leading to Fe
2+
-induced 
oxidative stress (Olanow & Arendash, 1994) may also be implicated in PD since 
specific increases in Fe
2+
 have been found in the SNpc of PD patients post-mortem 
(Dexter et al., 1989).   
 
Additional production of ROS is driven through altered dopamine metabolism. As a 
result of uncoupling of the electron-transport chain, inhibition of mitochondrial 
complex I reduces production of ATP. Therefore processes dependent on ATP such 
as packaging of dopamine into cellular vesicles via the vesicular monoamine 
transporter (VMAT) become disrupted leading to a rise in cytosolic dopamine. Owing 
to the extremely reactive nature of oxidative free radicals, the elevated levels of 
29 
 
cytosolic dopamine can react to form radical intermediates such as quinones and 
semiquinones (Graham, 1978) leading to oxidative stress. Through their interaction 
with quinones, dopamine in this instance can also reduce the levels of the antioxidant 
GSH, further contributing to oxidative damage by reducing available GSH to detoxify 
such oxidative stressors.  Indeed, in the laboratory, GSH depletion has been shown to 
induce a strong and transient intracellular increase in ROS (Merad-Boudia et al., 
1998). Furthermore, this depletion in GSH was linked to altered activity in complexes 
1, II and IV of the electron transport chain. Numerous studies have since compounded 
the importance of GSH in the pathology of PD whereby many separate reports 
demonstrate decreased levels of GSH in the SNpc of PD patients (reviewed by 
Mayer, 2005). It is widely accepted GSH serves an essential role in maintaining the 
integrity of mitochondrial function to prevent a state of oxidative stress which can be 
severely challenged by oxidative and nitrative stressors.  
 
Mitochondrial dysfunction and oxidative stress has also been implicated in genetic 
and familial PD. Giasson et al., (2000) have shown extensive nitrated tyrosine 
residues of α-synuclein within Lewy bodies and neurites suggesting there may be a 
correlation between the extent of oxidative and nitrative damage with the 
pathogenesis of PD (Giasson et al., 2000). Prior to its association with PD, DJ-1 was 
thought to function as an inducible antioxidant on exposure to oxidative stimuli 
(Mitsumoto & Nakagawa, 2001). Furthermore an experimental study has revealed 
inhibition of DJ-1 leads to the accumulation of ROS, enhanced vulnerability to 
oxidative stress and ultimately degeneration of dopaminergic neurones (Yang et al., 
2005). Oxidative damage of DJ-1 has also been identified in the brains of PD patients 
with idiopathic PD (Choi et al., 2006).  
 
Overall there is a wealth of evidence that mitochondrial dysfunction and oxidative 
stress comprise a significant role in both idiopathic and familial forms of PD. This is 
likely through a combination of both an elevation in production of ROS and 
additional free radicals, in addition to a reduction in antioxidants such as GSH. One 
notion is that the pathogenesis of PD may be explained by the fact neurones of the 
SNpc are preferentially damaged by inhibitors of complex I as shown by studies 
using MPTP and rotenone in vivo (Betarbet et al., 2000; McCrodden et al., 1990). 
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This would imply dopaminergic neurones of the SNpc may be particularly vulnerable 
to higher levels of oxidative stress compared to other brain regions.  
 
1.1.2.3.2 Glutamate-mediated excitotoxicity  
 
It was first appreciated that excitatory amino acids could be neurotoxic in 1957 when 
Lucas & Newhouse found that high levels of glutamate given systemically to mice 
could induce damage of retinal neurones (Lucas & Newhouse, 1957). It is now 
known that following glutamate activation of ionotropic α-amino-3-hydroxy-5-
methylisoxazole-4-propionate (AMPA) receptors there is subsequent Na
+
 entry and 
neuronal depolarisation. However if the cell becomes chronically depolarised through 
continuous glutamate activation, the Mg
2+
 blockade of N-methyl-D-aspartate 
(NMDA) receptors is released enabling their activation by glutamate causing a huge 
influx of Ca
2+
 (Doble, 1999). This triggers a cascade of intracellular events, driven by 
activation of intracellular Ca
2+
-dependent enzymes, which disrupt the cell 
homeostasis leading to cell death. These enzymes include nucleases which disrupt the 
organisation of chromatin, causing DNA fragmentation (McConkey et al., 1988); 
cytosolic proteases, such as calpain, which attack the cytoskeleton (Siman et al., 
1989); kinases such as protein kinase C which modify the phosphorylation state of 
cytoplasmic proteins disrupting cell function (Favaron et al., 1990); and finally 
lipases such as phospholipase A2, which attack the cell membrane and further 
organelles (Doble, 1999). Furthermore, high extracellular glutamate can inhibit the 
cells antioxidant defence mechanisms by inhibiting the uptake of cysteine required 
for GSH production resulting in elevated levels of ROS (McNaught et al., 2006). 
 
A number of observations (Dawson & Dawson, 1998; Greene & Greenamyre, 1996) 
have demonstrated a potential source of excess glutamate in PD is the hyperactive 
subthalamic nucleus (STN) which has glutamatergic projections to the SNpc and may 
well induce glutamate mediated excitotoxicity of dopaminergic neurones. This theory 
forms the rationale for targeting the over-activity of the STN to protect from 
glutamate-mediated excitotoxicity and fundamentally underpins the main hypothesis 
examined in this thesis. The aforementioned impairment to the mitochondria may 
also lead to ‘indirect’ excitotoxicity since normal maintenance of the membrane 
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potential by ATP is lost, resulting in membrane depolarisation and expulsion of 
voltage-gated Mg
2+
 block. As a result, normal (non-toxic) levels of glutamate are able 
to activate NMDA receptors leading to Ca
2+
 influx and consequent excitotoxicity 
(Greenamyre, 2001). 
 
1.1.2.3.3 Ubiquitin-proteasomal system  
 
Within the last decade, the ubiquitin-proteasomal system (UPS) has also been 
implicated in the pathogenesis of PD largely attributed to the discovery of mutations 
in UPS members, Parkin, and UCHL1 in familial PD (previously discussed in section 
1.1.2.1). The UPS is a system essential in the removal and degradation of non-
lysosomal mutant, misfolded or mislocated proteins in eukaryotic cells (McNaught et 
al., 2001). The pathway comprises several enzyme-dependent reactions to enable 
selective targeting of ubiquitin-protein conjugates which can then be identified and 
consequently degraded by 26/20S proteasomes (primary enzymes involved in protein 
degradation within cells). The products of degradation can then be recycled to 
produce new proteins. 
 
In PD however, proteolytic activity of the 26/20S proteasomes are reduced by up to 
45% in the SN due to structural and functional defects in the 26/20S proteasome 
(McNaught et al., 2001). This prevents the complete degradation of misfolded, 
mutant and mislocated proteins leading to protein aggregation, including the 
formation of Lewy bodies. Currently, it remains a topic of controversy whether this 
process is a contributor to disease progression or a cytoprotective response to other 
toxic events (McNaught et al., 2006). In support of a pathogenic role, treatment with 
proteasomal inhibitors such as lactacystin, or epoxomicin led to selective 
degeneration of dopaminergic cells in culture (McNaught et al., 2002b; Miwa et al., 
2005; Rideout et al., 2005; Rideout et al., 2001) and degeneration of the nigrostriatal 
system accompanied with motor dysfunction in rats (Fornai et al., 2003; McNaught et 
al., 2002a). In addition, neuronal degeneration in these studies was accompanied with 
the accumulation of α-synuclein and ubiquitin containing Lewy body-like inclusions. 
In PD, UPS function can be further influenced by inhibition of Complex I of the 
mitochondria inhibiting ATP synthesis since ubiquitination, de-ubiquitination and 
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degradation via the 26/20S proteasome are ATP-dependent processes (McNaught et 
al., 2001). This no doubt contributes to the observed accumulation of cytotoxic 
ubiquitin containing proteins and α-synuclein on application of a complex I inhibitor 
rotenone. Therefore although the exact role of the UPS in PD remains unclear, there 
are numerous findings which suggest alterations in normal function contribute to the 




Considerable evidence suggests activation of neuroinflammatory cells provokes the 
process of neurodegeneration. Microglia operate as the resident immunocompetent 
and phagocytic cells in the CNS, serving a critical role in maintaining normal 
function. However it is thought chronic activation of microglia may cause neuronal 
damage through the release of cytotoxic molecules such as pro-inflammatory 
cytokines, ROS and proteinases (Dheen et al., 2007). An elevation in pro-
inflammatory cytokines such as interleukin (IL)-1β, tumour necrosis factor (TNF–α), 
and interferon-γ have been found in the striatum, SNpc and cerebrospinal fluid of PD 
patients (Boka et al., 1994; Hunot et al., 1999; Nagatsu et al., 2000) suggesting the 
normal activity of microglia is compromised. Indeed, reactive microglia has been 
observed in the substantia nigra of patients up to 16 years following exposure to 
MPTP (Langston et al., 1999). Furthermore, the increase in microglial pro-
inflammatory cytokines are specific to the area of injury, an example of this is the 
cytokine IFN-γ which has been located exclusively in the SN of PD patients (Boka et 
al., 1994). It is thought the cytotoxic effects of pro-inflammatory cytokines relate to 
the activation of inducible nitric oxide synthase (iNOS) generating high levels of 
nitric oxide. This in turn creates nitrosylated proteins such as nitro-tyrosine, for 
example from tyrosine hydroxylase (TH), leading to oxidative stress. This has been 
supported by an observed increase in 3-nitrotyrosine immunostaining in Lewy bodies 







1.1.2.3.5 Vulnerability of dopaminergic cells 
 
Considering the previously described mechanisms, dopaminergic cells are thought to 
be particularly vulnerable to neurodegeneration and extensive efforts have been made 
to elucidate the impact of this contributing factor to the pathogenesis of PD. On closer 
inspection, degeneration of the SNpc in PD is not uniform as there appears to be a 
subset of selectively vulnerable neurones in the ventrolateral sensorimotor tier of the 
SNpc. Cell loss in this region has been shown to correlate well with levels of DAT 
expression (Sanghera et al., 1997), suggesting increased intracellular dopamine levels 
may lead to the accumulation of harmful dopamine oxidation products, or 
alternatively an increased transport of environmental toxins such as rotenone or 
MPTP (discussed in section 1.1.2.2). In fact, five subsets of vulnerable nigral cells 
within the SNpc, termed nigrosomes have been described (Damier et al., 1999) which 
all demonstrate low levels of the cytoplasmic protein calbindin. Under normal 
conditions, calbindin regulates intracellular Ca
2+
 to a level not deemed toxic by the 
surrounding cells (as discussed in section 1.1.2.3.2). Therefore a reduction in 
calbindin may well expose vulnerable cells to neurodegeneration by excess Ca
2+
. 
Furthermore the vulnerability of dopaminergic neurones in the SNpc has been linked 
to their high levels of neuromelanin (NM) pigment. In human tissue from PD 
patients, increased expression of NM has been shown in degenerate dopaminergic 
neurones of the SNpc, whereby neighbouring healthy dopaminergic cells demonstrate 
no increase in NM (Halliday et al., 2005). While the function of NM is not entirely 
clear, it is has a complex structure associating with proteins and lipids, leading to 
oxidative stress and iron loading (discussed in section 1.1.2.3.1), as well as possible 
precipitation of α-synuclein around NM lipids. Thererfore, it is thought that increases 
in NM may prelude neurodegeneration in vulnerable neurones of the SNpc.      
 
To summarise, it is unlikely there remains a single causative factor for the initiation 
of idiopathic PD rather a complex interaction of genetic, epigenetic and 
environmental factors is involved. These may include genetic mutations which may 
lead to the altered expression of proteins such as α-synuclein involved in the 
pathogenesis of PD, in addition to exposure of environmental toxins such as 
pesticides and heavy metals. The ensuing mechanisms of nigrostriatal degeneration 
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are equally complex, likely implicating numerous mechanisms such as mitochondrial 
dysfunction, oxidative stress, excitotoxicity, UPS dysfunction and 
neuroinflammation. Although there is a wealth of evidence to confirm their 
involvement, the precise order in which these mechanisms are implicated in the 
neurodegenerative process remains to be determined.  
 




In order to appreciate the pathophysiology outlined in PD it is important to consider 
the functional organisation of the basal ganglia (also referred to as the 
‘extrapyramidal’ system) in maintaining normal motor function. Five different basal 
ganglia-thalamocortical circuits have been indentified, involved in controlling motor 
function, cognition and emotion (Alexander et al., 1986). Since PD is predominantly 
a movement disorder, the most relevant to this work is the basal ganglia-
thalamocortical circuitry implicated in regulating motor function.  
 
1.2.2 Overview of the basal ganglia circuitry 
 
Located in the basal telencephalon, the basal ganglia (BG) consists of five 
interconnecting nuclei; comprising the caudate nucleus, putamen, and globus pallidus 
which is anatomically divided into an external component (GPe) and internal 
component (GPi or the Endopenduclular nucleus (EP) in the rodent) segments. 
Furthermore the substantia nigra, separated into the dopaminergic substantia nigra 
pars compacta (SNpc) and the GABAergic pars reticulata (SNpr) together with the 
subthalamic nucleus (STN) complete the motor loop. In primates a partial separation 
between the caudate nucleus and putamen by the internal capsule exists, however due 
to the overlap in both anatomical and functional characteristics the structures will 
collectively be referred to here as the striatum. Indeed in rodents, the species of focus 
in these studies, the striatum exists as a homogenous structure (Blandini et al., 2000).  
A simplified schematic of the organisation of the basal ganglia and other connected 
nuclei are illustrated in figure 1.1. It is important to note that basal ganglia nuclei do 
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not form direct connections with spinal motor neurones, therefore the role of the basal 
ganglia motor loop is not to provide initiation of movement. Rather, it is thought the 
basal ganglia serves to refine movement via intermediary control of strength of 
muscle contractions, and organisation of the requisite sequences of excitation of 
cortical cell columns. The functional components of the basal ganglia comprise the 
input regions, mainly the striatum (although the STN receives some cortical input) 
and output structures such as the SNpr and the GPi, juxtaposed between the STN, 
GPe and SNc. An anatomical layout of this kind enables the basal ganglia motor loop 
to integrate and modulate cortical input to be relayed to the thalamus and ultimately 

































Figure 1.1. Simplified schematic of the basal ganglia motor circuitry and connecting nuclei under 
normal physiological conditions. VA/ VL: Venteroanterior/ ventrolateral thalamic nuclei; CM/PFC: 
Centromedian/ Parafasicular thalamic complex;  GPi: internal globus pallidus; SNpr; Substantia nigra 
pars reticulata; STN: Subthalamic nucleus; GPe: external globus pallidus; SNpc: Substantia nigra pars 
compacta; D1, D2: Dopamine receptor subtypes; LC: Locus coeruleus; DR nucleus: Dorsal raphé 
nucleus; PPN: Pedunculopontine Nucleus; SC: Superior colliculus; RF: Reticular formation, 5-HT: 5-





1.2.3 Functional anatomy of the basal ganglia  
 
1.2.3.1 Corticostriatal projections 
 
The initial corticostriatal projections serve as the starting point for the flow of motor 
information through the basal ganglia. Cortical input to the striatum occurs from all 
areas of the cortex, although with differing degrees of intensity; for example, the 
visual cortex has much fewer projections than the sensorimotor cortex, which makes 
extensive striatal connections (Berendse et al., 1992). Since the cortex is organised in 
a highly topographical manner, it follows that the corticostriatal projection can be 
viewed as the transposition of the functional cortical map onto the basal ganglia; and 
accordingly the striatum is topographically arranged into distinct functional domains, 
such as associative, sensorimotor and limbic modalities (reviewed in Parent & 
Hazrati, 1995). These different areas receive input from associative (frontal, temporal 
and parietal lobes), sensorimotor (primary motor cortices and sensorimotor cortex) 
and limbic (limbic cortices, amygdala and hippocampus) areas respectively (Parent & 
Hazrati, 1995). This organisation into functional domains, with is believed to allow 
integration of cortical information passing through the striatum. The targets of the 
corticostriatal projections are both major striatal compartments, the striosomes (or 
patches) and the extrastriosomal matrix, where these projections form asymmetric 
(excitatory glutamatergic) synapses on striatal medium spiny neurons (Smith & 
Bolam, 1990). However, this idea is not supported by the observation that individual 
striatal neurons do not share more than approximately 1% of cortical afferents, 
implying each striatal neuron receives a unique cortical input (Kincaid et al., 1998). 
The cortical input to the striatum is further integrated with glutamatergic inputs from 
the midline and intralaminar nuclei of the thalamus, serotonergic input from the 
dorsal raphѐ nucleus, noradrenergic input from the locus coeruleus, and crucially to 








1.2.3.2 Striatal interneurones 
 
Striatal interneurons are morphologically characterised by the absence of spines on 
their dendrites and account for 1 in 9 striatal neurones in the rodent and 1 in 3 in 
primates (Graveland & Difiglia, 1985). These interneurons can be further subdivided 
into two main categories; cholinergic giant aspiny interneurons and GABAergic 
medium-sized interneurons. The giant aspiny interneurons account for between 1 and 
2% of the striatal neuronal population, and have a large (20-50µm diameter) cell 
body, with extensive axonal collaterals. Being cholinergic in nature, these giant 
aspiny neurons represent the major source of acetylcholine within the striatum. They 
are predominantly innervated by glutamatergic neurons from the corticostriatal and 
thalamocortical pathway. They also receive a minor dopaminergic input from the 
nigrostriatal pathway, with dopamine being able to modulate acetylcholine release by 
actions at the D2-type dopamine receptor (Chang, 1988). Cholinergic synapses have 
also been shown to synapse symmetrically onto medium spiny neuron dendrites and 
spines, suggesting a role for ACh in the modulation of striatal output.  
 
Medium-sized GABAergic interneurons can again be subdivided into three main 
categories, based on their neurochemistry and physiology. These are GABA, co-
expressed with either parvalbumin (PV), calretinin (CR) or neuropeptide Y (NPY), 
somatostatin (SS) and NADPH diaphorase (Kawaguchi et al., 1995). Important 
species differences exist in interneuron subtype expression with PV-positive striatal 
interneurons being the most common subtype in rats, accounting for around 1% of the 
total, whereas CR expressing interneurons are the most abundant in the striatum of 
human and nonhuman primates (Levesque et al., 2003). PV-containing interneurons 
have been the most widely characterised which make multiple synaptic connections 
with medium spiny neurons. These multiple connections permit potent feed-forward 
inhibition of spiny neurons, with single interneurons being able to inhibit spike 
occurrences (Tepper et al., 2004). Furthermore it has also been shown that 99% of 
GABAergic medium aspiny interneurones also express tyrosine hydroxylase (TH) 
suggesting co-expression with dopamine (Betarbet et al., 1997).  Experimentally it 
has been shown that striatal TH increases following a nigral lesion which may act as a 
possible compensatory mechanism to counteract the loss of dopamine in the SN 
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(Huot et al., 2008; Tande et al., 2006). Dopamine production by these interneurones 
has also been shown to stimulate growth factors (Bedard et al., 2006), posing an 
intriguing possibility that interneurones could replace nigral dopamine lost in PD. 
 
1.2.3.3 The striatofugal system 
 
A clear majority (95%) of output neurones from the striatum are the GABAergic 
medium spiny neurones (MSNs), collectively referred to as the striatofugal system. In 
this system information is relayed by MSNs from the striatum to three further basal 
ganglia nuclei, namely the GPi, GPe and the SNpr. The functional segregation of 
inputs to the striatum (associative, sensorimotor and limbic) is maintained, leading to 
topographical maps within striatal output structures too. Whilst MSN projections 
have traditionally been divided into those projecting to the GPi, GPe or the SNpr, 
anatomical studies in the rodent have suggested this may be an oversimplification. 
This is evidenced by MSNs giving rise to extensive local axon collaterals such that 
the three pathways are synaptically connected (Yung et al., 1996). Additionally, in 
monkeys up to 90% of striatofugal fibres aborise in all three target structures 
(Levesque et al., 2003), although each axon appears to have a preferential target 
structure, where upon it arborises extensively (Parent et al., 2001). Accepting this 
limitation, the striatofugal projections have been divided into two distinct populations 
termed the direct and indirect pathways based on their target structure, function and 
neurotransmitter co-localisation. 
 
1.2.3.3.1 Direct pathway 
    
The direct pathway projects directly from the striatum straight to the output nuclei of 
the basal ganglia, the GPi and the SNpr. The so-called striatonigral projections of the 
direct pathway are comprised predominantly of D
1 
receptor expressing medium spiny 
neurones which co-utilise the predominant neurotransmitter GABA, with either 
dynorphin and / or substance P (Beckstead & Kersey, 1985; Smith et al., 1998). 
Although initially thought to be a single entity, the two output nuclei are now thought 
to exert independent roles. The SNpr receives greater input from the associative 
striatal modality with some evidence of cross-talk between the three striatal 
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modalities. In the GPi however, the three striatal modalities remain separate where the 
predominant input is from the sensorimotor striatal modality (Parent & Hazrati, 1995).  
This topographical organisation of the striatonigral projection supports the view that 
cortical input to the striatum is then functionally subdivided into differing modalities, 
which when processed return to the cortical area from which they originated. The 
striatopallidal projections are also thought to be topographically organised in this way. 
For example a study in rodents using retrograde tracers has revealed the dorsal 
striatum projects to the dorsal EP whilst the ventral striatum projects to the ventral EP 
(Fink-Jensen & Mikkelsen, 1989). However it is thought there is huge convergence of 
information leaving the striatum owing to the small cell numbers in the output nuclei 
in comparison to the striatal projection fibres. For example, a rodent study identified 
27 million striatal neurones in comparison to 26,300 cells in the SNpr and 3,200 cells 
in the EP suggesting considerable integration of striatal modalities. 
 
Activation of the normally quiescent inhibitory direct pathway results in inhibition of 
the output nuclei of the basal ganglia. Consequently this leads to disinhibition of the 
GABAergic projection neurones of the SNpr/GPi releasing the motor thalamus from 
tonic inhibition. As a result, this causes activation of thalamocortical glutamatergic 
neurones in the motor cortex leading to an overall increase in movement.  
 
1.2.3.3.2 Indirect pathway 
 
In contrast to the direct pathway, striatal information is transferred via two additional 
brain nuclei, namely the GPe and STN before passing to the output nuclei. Also in 
contrast to the direct pathway, these MSNs express the inhibitory, Gi/o coupled D2 
receptor subtypes at their cell bodies, have GABA and enkephalin as their co-
transmitters and project almost exclusively to the GPe (Beckstead & Kersey, 1985). 
Thus, striatal GABAergic projection neurones connect firstly to the GPe before 
passing either mono-synaptically to the SNpr / GPi, or to the subthalamic nucleus 
(STN). The STN is a glutamatergic nuclei and information directed via this route 
comprises the classical indirect pathway (Smith et al., 1998). Activation of the first 
part of the indirect pathway termed the striatopallidal pathway results in inhibition of 
GPe neurones which serves to alleviate the tonic inhibition of STN neurones leading 
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to an increase in excitatory drive to the basal ganglia output structures. This enhanced 
activation of the inhibitory output nuclei further inhibits thalamic feedback to the 
motor cortex, resulting in decreased movement. Thus activation of the indirect 
pathways modulates movement with opposing physiological effects to the direct 
pathway.  
 
1.2.3.3.2.1 External segment of the globus pallidus 
 
The GPe receives two main inputs: a GABAergic pathway from the striatum, and a 
glutamatergic pathway from the STN. In addition, less prominent inputs have been 
observed from the SNpc, the dorsal raphé nucleus and the pedunculopontine nucleus. 
As with the nigrostriatal pathway, the topographical organisation of the striatum is 
maintained within the GPe. For example, the sensorimotor modality is maintained 
along striatopallidal projections forming rostrocaudal bands within the ventrolateral 
GPe (Parent, 1990). The main pallidofugal targets are the STN, the SNpr / GPi and to 
a lesser extent, the striatum. Classically, the GPe was viewed as no more than a relay 
to the STN, permitting the excitatory glutamatergic inputs from the STN to counter-
balance the inhibitory GABAergic striatal inputs within the SNpr / GPi. However, 
this view has been challenged with the discovery of the pallidostriatal and 
pallidonigral pathways, suggesting the GPe exerts more of a modulatory role with 
greater complexity in the GPe output neurones than originally thought. Indeed on the 
basis of their axonal targets, GABAergic GPe neurons can be divided into four main 
groups: (i) neurons projecting to the GPi, STN and SNpr (ii) neurons projecting to the 
GPi and STN (iii) neurons targeting the STN and SNpr and (iv) neurons projecting to 
the striatum (Parent et al., 2001). Owing to the numerous target projections presented 
to the GPe, this would suggest considerable plasticity may exist within the basal 
ganglia nuclei however this is a poorly understood notion at this time. Thus for 
simplicity, GPe projection neurones from this point will be considered as having one 
primary target nuclei only. 
 
The pallidostriatal pathway projects to the PV-positive GABAergic interneurons, 
forming contacts on their proximal regions. Thus, the pallidostriatal pathway can 
reciprocally control striatofugal pathway activity, via selective inhibition of these 
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interneurons which project to MSNs (Bolam et al., 2000). The alternative ‘indirect 
pathway’ projects to the SNpr / GPi, and forms symmetrical synapses with the 
proximal dendrites of these neurons. This arrangement may allow pallidal modulation 
of either striatal or subthalamic afferents within the output nuclei, permitting a further 
level of modulation of basal ganglia output.  
 
The pallidosubthalamic projection comprises the majority of the remaining GPe 
efferent neurons forming the principal inhibitory projection to the STN (Fonnum et 
al., 1978). Through these inhibitory connections, the GPe is able to exert powerful 
modulatory actions upon the STN, by directly suppressing spontaneous firing of STN 
neurons or indirectly inhibiting the excitation of STN neurons through additional 
afferents such as corticosubthalamic afferents (Parent & Hazrati, 1995). The GPe also 
receives a powerful reciprocal excitatory input from the STN to form the GPe-STN 
loop, which is believed to form a shared control mechanism, whereby activation of 
one nucleus is able to control the activity of the other. The importance of this GPe-
STN loop is evident from the pathophysiological changes in the activity of this 
pathway in PD, discussed below.  
 
1.2.3.3.2.2 The subthalamic nucleus 
 
The STN is the only glutamatergic nucleus of the basal ganglia, which is also 
topographically organised, with the dorso-caudal third of the nucleus relating to the 
sensorimotor modality (Joel & Weiner, 1997). The STN receives inhibitory afferents 
from the aforementioned pallidosubthalamic pathway as well as from the ventral 
pallidum and ventral striatum (Groenewegen et al., 1993; Kita, 1993). Opposing 
excitatory innervations of the STN is received from numerous sources such as the 
corticosubthalamic (glutamatergic), thalamosubthalamic (glutamatergic), 
nigrosubthalamic (dopaminergic), the cholinergic and glutamatergic 
pedunculopontine-subthalamic (cholinergic and glutamatergic), raphé-subthalamic 
(serotonergic) projections and parafasicular-subthalamic (glutamatergic) projections 





The direct corticosubthalamic pathway arises predominantly from the primary and 
supplementary motor areas in the cortex which project to the dorsal aspects of the 
STN (Nambu et al., 1996). Corticosubthalamic projections are mainly composed of 
axonal collaterals from the pyramidal tract, however some cortical fibres jointly 
innervate the striatum (Hamani et al., 2004). These axons make asymmetric 
glutamatergic synapses with the small dendrites of subthalamic neurons which 
predominantly project to the GPe. Electrical activation of the primary motor cortex 
thereby results in two excitatory peaks separated by a brief period of inhibition within 
the STN. The origin of the initial excitatory response is the direct mono-synaptic 
corticosubthalamic pathway. After the initial excitatory response from the STN, the 
inhibitory response then arises through reciprocal interactions between the STN and 
GABAergic efferents of the GPe. The second excitatory response is complex and less 
well understood involving a loop between the nucleus accumbens and ventral 
pallidum to drive disinhibtion of the STN (Maurice et al., 1998).  
 
Comprising the main efferent projections of the STN are the subthalamopallidal and 
subthalamonigral pathways although smaller projections to the striatum, PPN and 
parafasicular thalamic complex (PFC) have also been described (Parent & Hazrati, 
1995). Except for exclusive connections to the GPe and striatum (10.7% and 17.3% 
of total projections respectively), subthalamic projection neurones have been shown 
to innervate numerous targets in primates. These can be divided into three main 
groups based on their target nucleus beginning with those that project to the GPi and 
GPe (48%), those that project to the SNpr, GPi and GPe (21.3%) and finally those 
that project to the GPe and SNpr (2.7%) (Sato et al., 2000). Thus the main target of 
the STN in 82.7% of cases is the GPe in which these subthalamopallidal projections 
form asymmetric glutamatergic synapses on dendritic shafts which lie in dense bands. 
The organisation of these bands is similar to that observed with the striatopallidal 
pathway, and ultrastructural studies have shown convergence of inputs from both 
striatopallidal and subthalamopallidal pathways onto the same pallidal output 
neurons. Hence, activity of the GPe is likely controlled by counterbalancing this 
excitatory activity of the subthalamopallidal projections with the inhibitory 
striatopallidal projections. This subthalamopallidal projection back to the GPe 
completes the reciprocal loop between the GPe and the STN. The other 
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subthalamopallidal (subthalamo-entopeduncular nucleus) pathway is formed from 
collaterals of STN efferents innervating the GPi, although this is formed 
predominantly of collaterals which innervate the GPe, thus forming one half of the 
classical indirect pathway.  
 
As mentioned, the subthalamonigral projection is of primary focus in the studies 
described in this thesis, therefore its key role in the indirect pathway is discussed 
below. Subthalamonigral fibres target both segments of the SN, although the majority 
of these fibres selectively innervate the SNpr. The remainder innervate the SNpc, 
forming part of an STN-SNpc feedback loop (discussed in more detail in section 
1.3.3.2.3). This loop comprises excitatory STN efferents to the SNpc which drives 
dopamine release (Groenewegen et al., 1993); whilst SNpc projections to the STN are 
believed to activate inhibitory D2 receptors (Hassani et al., 1997) (discussed in 
section 1.3.3.2.2). Upon entry to the SN, subthalamonigral neurons arborise 
extensively, forming local collaterals which predominantly contact dendritic shafts of 
nigral neurons (Hamani et al., 2004). Whilst this pathway accounts for the majority of 
glutamatergic neurotransmission within the SN, overall glutamatergic synapses only 
account for a minority (approximately 10%) of the total synapses present, with 
GABAergic symmetrical synapses accounting for the majority (Rinvik & Ottersen, 
1993). With STN projections to the GPi, the subthalamonigral pathway completes the 
classical indirect pathway. Activation of these excitatory subthalamonigral 
projections drives nigral inhibition of thalamocortical loops, resulting in an overall 
net decrease in movement. Furthermore the subthalamonigral projection neurons have 
also been shown to converge with striatonigral and pallidonigral inputs, upon single 
nigral target neurons (Kolomiets et al., 2003). This convergence of inputs onto single 
nigral cells permits interaction between the direct pathway, with both projections of 
the indirect pathway to modulate basal ganglia output. 
 
1.2.3.4. The thalamocortical loop 
 
The thalamus facilitates the passage of information from the basal ganglia output 
nuclei (SNpr/GPi) back to the cortex. Consistent with the basal ganglia nuclei 
described, there are several topographically organised thalamocortical loops 
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innervating distinct cortical areas. Traditionally, the motor thalamus refers to the 
more ventral thalamic region which is usually sub-divided into two major territories; 
the ventral anterior thalamic nuclei (VA) which receives input largely from the basal 
ganglia, and the ventral lateral thalamic nuclei (VL) which receives afferents 
predominantly from the cerebellum. The glutamatergic VA pathways predominantly 
innervate caudal cortical regions and are primarily involved in motor function, whilst 
those projections from the VL nuclei innervate the rostral cortical areas and are 
primarily involved in cognitive aspects of motor function, including motor learning 
(Haber & McFarland, 2001). Whilst the exact mechanisms by which the 
thalamocortical loop serves to modify motor behaviour are not yet known, this final 
link within the basal ganglia is well placed to integrate limbic, associative and 
sensorimotor inputs to impact motor behaviour.  
 
1.2.3.5. Normal basal ganglia function 
 
Under resting conditions the overall net output of the basal ganglia is thought to be 
one of inhibition. This arises from the tonically active inhibitory GABAergic 
projections from the SNpr and GPi to the thalamic nuclei and further to the cortex in 
addition to brainstem pre-motor regions such as the PPN, the superior colliculus (SC) 
and the reticular formation (RF) (Parent & Hazrati, 1995). Resting conditions are 
maintained by balancing the activity of both the direct and the indirect pathways of 
the striatofugal system. Thus activation of the direct pathway relieves tonic inhibition 
of thalamocortical feedback whereas activation of either indirect pathway acts to 
maintain this inhibition. In order to initiate movement, activation of the direct 
corticostriato-pallidal projections results in inhibition of the output nuclei, and 
resultant disinihibition of thalamic nuclei, which in turn leads to activation of the 
thalamocortical feedback loop, returning to the motor cortex. Conversely, execution 
of movement arises from activation of the indirect corticostriatal-pallidal-subthalamic 
circuit. This leads to stimulation of the output nuclei, resulting in inhibition of 
thalamo-cortical afferents. The temporal balance between these two pathways is such 
that following direct pathway activation, and resulting initiation of movement, 
indirect pathway activation serves to either focus the resultant movement, or inhibit 
further unwanted movements (Haber & McFarland, 2001). This complex interplay of 
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pathway activation is dependent on integration of the actions of numerous 
neurotransmitters, loss of which results in basal ganglia dysfunction and resultant 
aberrations in motor control, as will now be discussed in PD. 
 




As previously discussed in section 1.1.1 of this chapter, it is the dopaminergic 
denervation of the striatum that is thought to underlie the motor symptoms associated 
with PD. Nonetheless onset of degeneration of the nigrostriatal pathway precedes the 
onset of symptoms by some years. This is in part due to the compensatory 
mechanisms taken into effect by remaining nigral and striatal dopaminergic neurones 
to counteract the loss of dopamine (Zigmond et al., 1990). However a point is 
reached in which the ongoing degenerative process reaches a severity whereby 
remaining intact dopaminergic neurones are no longer able to compensate the ensuing 
degeneration. This leads initially to decreased stimulation of both pre- and 
postsynaptic dopamine receptors within the striatum followed by numerous 
alterations in the basal ganglia circuitry such as modulation of corticostriatal input 
and disruptions in the striatofugal system. These alterations in the basal ganglia 















Figure 1.2: Alterations within the interconnecting circuitry of the basal ganglia and 






Figure 1.2. Simplified schematic of the basal ganglia motor circuitry in Parkinson’s disease. 
Abbreviatons: VA/VL: Ventroanterior/ venterolateral thalamic nuclei; CM/PFC: Centromedian/ 
Parafascicular thalamic complex; GPi: internal globus pallidus; SNpc/r: Substantia nigra pars 
compacta/reticulata; STN: Subthalamic nucleus; GPe: external globus pallidus; D1, D2: Dopamine 
receptor subtypes; LC: Locus coeruleus; DR nucleus: Dorsal raphé nucleus; PPN: Pedunculopontine 




1.3.2 Effects of dopaminergic denervation on the striatum 
 
Under normal conditions, pre-synaptic D2 receptors on glutamatergic corticostriatal 
afferents serve to regulate glutamate release. However under parkinsonain conditions, 
loss of striatal dopamine leads to an increase in glutamatergic stimulation of the 
striatum. This loss of control of glutamatergic transmission results in increased 
AMPA and NMDA mediated excitation, due to loss of dopamine mediated cortico-
striatal long term depression (LTD) and consequent increased basal activity in MSNs 
(Calabresi et al., 1996).  
 
Furthermore, loss of dopamine from the striatum also results in changes in activity of 
both the direct and indirect pathways as a result of reduced stimulation of 
postsynaptic dopamine D1 and D2 receptors. Owing to their opposing influences, this 
leads to two main effects. Firstly the direct pathway becomes hypoactive as D1 
receptor mediated excitation on the striatonigral pathway is lost. Secondly the indirect 
pathway becomes hyperactive owing to the loss of D2 receptor mediated inhibition.  
Consequently this leads to inhibition of the GPe and further disinhibition of the STN, 
to a level in which the STN becomes hyperactive. This hyperactivity within the 
excitatory subthalamonigral pathway, coupled with the loss of the inhibitory 
striatonigral pathway leads to a net increase in activity of the GPi and SNpr. As a 
result this increased activity of the output nuclei inhibits thalamic relay nuclei 
consequently inhibiting thalamocortical feedback. It is the inhibition of 
thalamocortical feedback that is thought to underlie the akinetic and bradykinetic 
symptoms of PD.   
 
In addition to the influences on the activity of the GABAergic striatofugal pathways 
described above, dopamine depletion also leads to alterations in the expression of 
peptides and receptors within these pathways. In the direct pathway, the loss of 
excitatory effects of dopamine mediated by the D1 receptors results in decreased 
expression of both Substance P and dynorphin. Conversely, the loss of D2-mediated 
inhibition in the indirect pathway has been linked with an increase in enkephalin 
expression. It has also been suggested that alterations in peptide expression form an 
endogenous compensatory mechanism to counteract the loss of dopamine, which has 
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been supported by electrophysiological studies that have shown enkephalin can 
decrease inhibitory post-synaptic potentials (IPSPs) in GP neurones, presumed by 
activation of delta opioid receptors (Stanford & Cooper, 1999). These findings 
suggest that levels of expression of co-transmitter correlate well with activity within 
the direct and indirect pathway in which peptides are able to modulate activity 
directly. 
 
1.3.3 Effects of dopaminergic denervation on the external segment of the 
globus pallidus and subthalamic nucleus 
 
The alterations in activity within the striatofugal pathways proceed to influence 
downstream changes in the other basal ganglia structures including the GPe and STN. 
Crucially to the experimental chapters described in this thesis are the implications 
attributed to hyperactivity of the STN, therefore this particular aspect of the 
parkinsonian basal ganglia will be discussed in greater detail than the effects on the 
GPe. 
 
Ever since the model of basal ganglia anatomy and function was proposed by Albin 
and colleagues in 1989, which suggested for the first time an explanation of how 
dopamine deficiency led to motor disturbances in PD, the activity of the GPe and 
STN in the parkinsonian basal ganglia has been contentious. According to this 
classical model, loss of the dopaminergic nigrostriatal pathway results in reduced 
activity of the GPe which in turn disinhibits the STN, resulting in STN hyperactivity. 
This view was supported by initial experimental evidence assessing metabolic 
activity in both the GPe and STN by means of 2-deoxyglucose (2-DG), (a marker of 
synaptic afferent activity). In addition, ablation of the nigrostriatal tract by MPTP 
increased 2-DG uptake in the GPe (Crossman et al., 1985;Mitchell et al., 1989), but 
decreased uptake in the STN (Mitchell et al., 1989), suggesting hyperactivity in the 
striatopallidal tract, but decreased activity in the pallidosubthalamic pathway, as 
proposed by the model of Albin. Owing to the reciprocal anatomical connections with 
the STN, this would suggest hypoactivity in the GPe may well be implemented in the 




1.3.3.1 External segment of the globus pallidus 
     
The classical model of the basal ganglia circuitry has come under scrutiny over the 
debate surrounding the hypoactive state of the GPe in PD. Previous studies using 2-
DG to assess the activity of the GPe and STN have been questioned as changes on 2-
DG may also reflect alterations in intrinsic neurone activity rather than changes in 
GABAergic inputs. Additionally, 2-DG uptake does not differentiate between 
excitatory or inhibitory inputs to either nucleus, nor does it distinguish between 
presynaptic terminal activity or postsynaptic transmission (Parent & Cicchetti, 1998). 
With this in mind, in situ hybridisation studies of glutamic acid decarboxylase 
(GAD67 – enzyme responsible for the synthesis of GABA) are considered to be a far 
more accurate measure of GABAergic activity. Using this method, it has been shown 
that there is in fact no difference in GABAergic activity in the GPe between MPTP 
primates or PD patients and their controls (Levy et al., 1997). In this report, 
metabolic activity in the GPe neurones was also examined by assessing the activity in 
the first subunit of cytochrome oxidase (CO-1), an established marker of neuronal 
functional activity. In support of findings from the in situ studies, CO-1 activity was 
not altered in MPTP-treated primates or PD patients on comparison to their respective 
controls (Levy et al., 1997).     
 
On the contrary, decreased firing rates by up to 20% in the GPe of MPTP-treated 
monkeys and 6-OHDA-lesion rats have been demonstrated suggesting a hypoactive 
GPe (Filion & Tremblay, 1991; Pan & Walters, 1988). However in both these studies, 
these effects were associated with alterations in firing pattern to a burst-type firing. 
This actually may result in no net decrease in GPe activity at all, as burst-type firing 
is more suggestive of an excitatory stimulation when compared to normal. It is more 
likely that the GPe does not fire at a decreased rate in PD, rather that the loss of 
dopamine modifies the pattern of firing in GPe neurones. Moreover, lesioning of the 
pallidosubthalamic pathway induces only a slight increase (20%) in STN discharge 
rates and no change in the firing pattern when compared to control rats (Hassani et 
al., 1996). However, in 6-OHDA-lesioned rats a greater increase in STN firing was 
observed (106%), with a burst-type firing pattern (Hassani et al., 1996). These 
findings crucially demonstrate the increased firing of the STN neurones following 
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dopamine depletion are not solely due to a hypoactive GPe. This suggests there are 
likely additional, alternate pathways that may drive STN hyperactivity.    
 
1.3.3.2 The subthalamic nucleus 
 
Hyperactivity of the STN has been well documented both in animal models of PD 
and in PD patients. For example, electrical measurements of the spontaneous firing 
rate of STN neurons in MPTP-treated primates was shown to increase to 26Hz in 
comparison to 19Hz recorded in control animals, equating to a 27% increase in STN 
firing rates (Bergman et al., 1994). Additionally, biochemical dopamine depletion in 
reserpine and α-methyl-para-tyrosine-treated rats, led to a 53% increase in firing rates 
of STN neurones (Robledo & Feger, 1991). Furthermore, following chronic striatal 
dopamine depletion by 6-OHDA, STN neurons demonstrated discharge rates 
exceeding 233.3% of non-lesioned animals (Magill et al., 2001). In human PD 
patients, two microelectrode studies measuring firing in STN neurones have shown 
firing rates of 37 Hz and 41Hz comparable to those seen in primate studies with 
MPTP (Hutchison et al., 1998; Magnin et al., 2000). As in animal models of PD, 
high-frequency burst-type STN firing was also seen in 47% of STN cells recorded in 
PD patients with resting tremor whist no such activity was observed in patients 
without resting tremor (Levy et al., 2000). These findings would suggest the high 
frequency burst-type firing observed here may be associated with the rhythmic 
pathology underlying tremor in PD patients.  
 
A number of downstream changes in basal ganglia circuitry are supportive of 
hyperactivity of the glutamatergic STN. The first line of evidence equates to the 
downregulation of glutamate receptors in the projection nuclei of the STN (namely 
the SNpr, GPi and GPe), observed in 6-OHDA lesioned rodents (Porter et al., 1994; 
Wullner et al., 1994) presumably in response to enhanced glutamatergic stimulation 
from the STN. Indeed in PD patients, downregulation of NMDA receptors in the GPi 
has been observed in support of these animal studies (Lange et al., 1997). In addition 
a microdialysis study in 6-OHDA-lesioned rats has shown 10 to 16 fold increases in 
glutamate levels in the SNpr and GP respectively, compared to non-lesioned animals 




Additional evidence for a hyperactive STN, and subsequent increase in glutamatergic 
transmission in the GPi / SNpr contributes to the motor symptoms of PD is supported 
by the antiparkinsonian efficacy of subthalamotomy, which serves to reduce 
excessive glutamatergic transmission to the SNpr (Alvarez et al., 2005) Furthermore, 
systemic administration of the NMDA and AMPA antagonists, MK-801 and 
LY293558 respectively, has been shown to demonstrate antiparkinsonian efficacy in 
6-OHDA-lesioned rats (Vila et al., 1999). Indeed, targeting of hyperactive 
glutamatergic subthalamic terminals is the rationale behind various therapeutic 
approaches, discussed in sections 1.4.3 and 1.5 and comprise the focus of studies 
performed in this thesis. 
 
1.3.3.2.1 Alternative routes of hyperactivity in the subthalamic nucleus  
 
If a decrease in inhibitory transmission from the GPe does not solely underlie the 
increase in STN activity, it is possible that a number of other excitatory inputs could 
be involved. As mentioned, excitatory glutamatergic inputs to the STN arise from the 
PPN, the PFC and the cerebral cortex. In situ hybridisation for CO-1 mRNA in STN 
afferent neurones, from the PPN and PFC, revealed a 123% and 63% increase 
respectively in 6-OHDA-lesioned rodents compared to sham animals (Orieux et al., 
2000). This same study also revealed there was no significant effect on CO-1 activity 
in the GPe. These findings together suggest that the increase in glutamatergic 
transmission from the PFC and the PPN but not the GPe may underlie some of the 
elevated STN activity. However with respect to the PPN, closer examination of the 
literature would suggest the role of this nucleus in driving subthalamic hyperactivity 
in PD may be somewhat controversial, with evidence in favour of a hyperactive but 
also hypoactive role.  
 
If indeed alterations in PPN activity are responsible for the hyperactivity in the STN, 
one suggestion that may forge contradictions in the literature together, is that 
hyperactivity in GABAergic terminals from the GPi and SNpr drives IPSP generation 
in the PPN, leading to strong rebound spike generation in the PPN (Kang & Kitai, 
1990). It may be this rebound activity of the PPN that could drive STN hyperactivity, 
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therefore the PPN activity state may change during disease progression. In support of 
this hypothesis, the GABAA-receptor antagonist, bicuculline, when directly injected 
into the PPN is able to alleviate akinesia in the MPTP-treated monkey to a magnitude 
comparable to those seen with oral L-DOPA (Nandi et al., 2002). Therefore the initial 
consideration of whether the PPN is hypo or hyperactive is likely far too simplistic 
where there is clearly a more complex mechanism involved here. A similar situation 
is presented on assessing the activity of the PFC in which evidence in favour of 
increased and decreased glutamatergic innervations from the STN have been reported 
(Henderson et al., 2000; Orieux et al., 2000). Whilst it is clear glutamatergic 
excitatory afferent connections from the PPN, PFC and cortex are all potential 
candidates to increase activity in the STN in the parkinsonian basal ganglia, their 
contribution to this cause remains uncertain.   
 
1.3.3.2.2 Nigrosubthalamic projections  
 
One further possibility for the hyperactivity of the STN is that the degeneration of the 
SNpc initiates changes in dopaminergic transmission in extra-striatal regions. 
Although nigrosubthalamic projections are certainly in the minority compared to 
nigrostriatal projections, degeneration of this pathway may result in similar changes 
to those observed in the striatum. As mentioned previously, in normal conditions 
dopamine released from nigrosubthalamic projections act on D2 receptors in the STN, 
to maintain an inhibitory hold on glutamatergic subthalamonigral activity (Hassani et 
al., 1997). In PD, degeneration of the nigrosubthalamic pathway has been 
demonstrated (Francois et al., 2000) which would be expected to increase the activity 
of the STN through loss of D2 receptor mediated inhibition, however this hypothesis 
has not been proven experimentally.   
 
1.3.3.2.3 Subthalamonigral projections to the SNpc 
 
Reciprocal subthalamonigral projections to the SNpc have been identified as having a 
key pathological role in the neurodegeneration of the nigrostriatal pathway. As 
discussed in some detail, the activity of the STN has a profound impact on the 
parkinsonian basal ganglia. Thus, increased glutamate release from the 
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subthalamonigral terminals onto dopaminergic cells of the SNpc may cause glutamate 
mediated excitotoxicity resulting in cell death within the SNpc (discussed in section 
1.1.2.3.2). Although the initial dopaminergic cell death occurring in PD is not 
attributed to an hyperactive STN, subthalamic disinhibition ensuing the onset of 
nigrostriatal degeneration is thought to drive excess glutamatergic stimulation of the 
SNpc and hence increase the probability of excitotoxicity, creating a perpetuating 
degenerative cycle (Rodriguez et al., 1998).  For this reason, it is not surprising that 
the STN is receiving considerable interest in the pursuit to develop novel 
therapeutics. This has implications for symptomatic relief in PD, but more 
importantly to the work described in this thesis, potential to provide neuroprotection 
by suppressing the hyperactive STN to reduce a state of excitotoxicity.     
 
1.3.4 Dopaminergic denervation on the internal segment of the globus 
pallidus and the substantia nigra pars reticulata 
 
Under parkinsonian conditions alterations in the striatofugal system leads to profound 
changes in the output nuclei of the basal ganglia. As mentioned, the SNpr and the GPi 
receive increased glutamatergic transmission from the hyperactive STN in addition to 
decreased GABAergic transmission from the striatum and to an extent the GPe via 
the indirect pathway. Collectively, the net effect of these alterations in the basal 
ganglia is to increase GABAergic output from the SNpr and the GPi which has been 
supported experimentally by increased neuronal activity shown by increases in CO-1, 
GAD67 and 2-DG expression in parkinsonian rodent and primate SNpr and GPi nuclei 
(Herrero et al., 1996; Mitchell et al., 1989; Vila et al., 1997). Furthermore, in 6-
OHDA-lesioned rodents there is an increase in the proportion of burst-type firing in 
SNpr neurones, an effect which is lost by kainic acid lesioning of the STN (Tseng et 
al., 2000). In addition, 6-OHDA lesions of the SN in rodents, has been shown to 
increase GPi expression of GAD67 mRNA, where STN lesions have also been shown 
to inhibit this increase in GAD67 expression (Billings & Marshall, 2004). 
Furthermore, hyperactivity of the GPi has been shown in patients undergoing 
pallidotomy, where doses of apomorphine sufficient to reverse akinesia and tremor 
reduced the activity in the GPi by approximately 50% (Lozano et al., 1998). Taken 
together, these results support the notion that an increase in GPi/SNpr firing underlies 
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the motor symptoms of striatal dopamine denervation. Consequently, this increased 
activity in the output nuclei leads to increased inhibitory GABAergic stimulation of 
the thalamic relay nuclei and brainstem nuclei such as the PPN. It is thought that the 
resultant reduction in thalamocortical feedback primarily underlies the 
akinesia/bradykinesia, rigidity and tremor in PD (Lang & Lozano, 1996), whilst the 
suppression of brainstem nuclei such as the PPN, may lead to gait and postural 
disturbances (Pahapill & Lozano, 2000). 
 
Despite the profound advances in our understanding of the complex interplay within 
connections of the basal ganglia and proposed parkinsonian model (figure 1.2), there 
remains an element of caution owing to some inconsistencies from clinical data. For 
example in the model described, a surgical thalamotomy should negatively impact 
motor symptoms by reducing thalamocortical feedback, however there is little 
suggestion of this based on clinical findings. In addition, the GPe (thought to be 
hypoactive), may revert to a burst-type firing pattern with no net change in activity in 
the parkinsonian brain of primates and PD patients. Therefore this current model is 
unable to predict alterations in basal ganglia firing patterns and no doubt underlies 
these inconsistencies that have arisen (Lang & Lozano, 1996). Thus predicting the 
effects of dopamine denervation and therapeutic interventions within this elaborate 
network of the basal ganglia may not always reveal an expected outcome, which must 














1.4 Animal models of Parkinson’s disease 
 
Animal models are an important aid to investigate the pathogenic mechanisms and 
therapeutic strategies in human disease. Through the use of animal models, the 
striatal dopamine deficiency was associated with symptoms of PD and L-DOPA was 
first used to compensate for striatal dopamine loss (Carlsson et al., 1957). Prolonged 
use of L-DOPA however, commonly results in debilitating, dyskinesias (as 
previously discussed in section 1.4.1.1) and fails to address the progressive 
degeneration limiting its usefulness in the long-term. Moreover, the pathology of PD 
is poorly understood even to this day. Thus, it is of great importance to develop 
animal models to improve understanding into the pathogenesis of PD and to aid the 
discovery of novel therapeutics. As such, no single model is likely to be suitable for 
all studies and therefore numerous animal models have been characterized to 
selectively simulate the pathogenic, histological, neurochemical and clinical features 
of PD. These are summarised in table 1.1.  
 
1.4.1 Pharmacological models 
 
1.4.1.1 The Reserpine model 
 
The reserpine-treated rodent was one of the earliest animal models to be employed in 
PD research. In 1957 Carlsson et al., reported that systemic administration of 
reserpine causes depletion of brain catecholamines leading to an akinetic state in 
rabbits. These findings led to the hypothesis, later confirmed in humans 
(Hornykiewicz., 1966), that the motor symptoms of PD result from a depletion in 
striatal dopamine (Bernheimer et al., 1973). Furthermore this model was instrumental 
in first demonstrating the therapeutic efficacy of what still remains the gold standard 
treatment for PD, L-DOPA. The reserpine-treated mouse or most commonly rat has 
since become established as a robust screen for potential symptomatic efficacy of new 






Model Symptoms Pathological characteristics Pathogenic  
relevance 
Application Limitations 




Pharmacological depletion of 
dopamine, 5-HT and NA. 
Preclinical testing to improve 
symptoms 
No nigral degeneration; reversible 
loss of monoamines 
Haloperidol Muscle rigidity, catalepsy None Pharmacological depletion of 
dopamine, also 5-HT and NA? 
Elevation  in extracellular 
glutamate 
Preclinical testing to improve 
symptoms 
No pathological characteristics 
associated with PD; reversible  
6-OHDA Unilateral: rotations following 
apomorphine/ amphetamine; 
Bilateral: akinesia 
Decrease in striatal TH, 
dopamine; increase in glutamate 
release; degeneration of TH-
positive cells in SNpc 
Oxidative stress; 
inhibition of complex I and IV of 
mitochondria 
Preclinical testing of therapies to 
improve symptoms: screen 
pharmacological and genetic 
neuroprotective therapies  
Acute: usually unilateral 
(hemiparkinsonian); no Lewy body 
formation;  requires intracerebral 
injection 
MPTP Akinesia, rigidity, tremor in 
some species 
Decrease in striatal TH; 
degeneration of TH-positive cells 
in SNpc; some loss of locus 
coeruleus neurons; α-synuclein 
aggregation?! 
Chronic oxidative stress; chronic 
inhibition of mitochondrial complex 
I 
Screen pharmacological and 
genetic neuroprotective therapies 
Generally acute; rapid cell death; 
variable lesion size 
Rotenone Akinesia,  
rigidity, tremor,  
Decreased striatal TH 
immunoreactivity; degeneration 
of TH-positive cells in SNpc; 
some loss of locus coeruleus 
neurons; α-synuclein aggregation 
Chronic environmental toxin; 
chronic oxidative stress;  inhibition 
of mitochondrial complex I; 
inhibition of proteasomal activity 
Screen  potential neuroprotective 
pharmacological and genetic 
therapies 
High mortality rate; intrinsic 
resistance in some cases 
Paraquat-Maneb Decreased locomotor activity, 
hunched posture 
Decreased striatal TH 
immunoreactivity 
Environmental toxins/pesticide 
exposure; oxidative stress; 
inhibition of mitochondrial complex 
I and III 
Screen pharmacological and 
genetic neuroprotective therapies 
Minimal degree of cell death in 
SNpc; variable loss of striatal 




Bradykinesia, rigidity, tremor, 
postural instability 
Decreased striatal TH 
immunoreactivity, dopamine; 
degeneration of TH-positive cells 
in SNpc; proteinous inclusions 
related to Lewy bodies 
Impairment ubiquitin proteasomal 
system; oxidative stress 
Screen pharmacological and 
genetic neuroprotective therapies 
Difficult to reproduce; variable 
Genetic Decreased locomotor activity, 
hunched posture 
Decreased striatal TH 
immunoreactivity, dopamine 
Inhibition to  mitochondria; 
impairment to ubiquitin 
proteasomal system 
Current utility in assessing 
contribution of gene mutations in 
pathogenesis of PD; potential to 
screen pharmacological 
neuroprotective therapies 
No nigral degeneration; 
compensation following gene knock 
out  
 
Table 1.1: Key characteristics of current animal models of Parkinson’s disease 
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Reserpine (usual dose of 4-5 mg/kg s.c.) works by inhibiting the vesicular 
monoamine transporter, VMAT2. This leads to loss of storage capacity and hence 
depletion of brain (and peripheral) monoamines including noradrenaline and 5-HT as 
well as dopamine. Whilst this lack of selectivity for dopamine was once considered a 
drawback of the reserpine model to accurately reflect the biochemistry of PD, the 
subsequent realisation that noradrenergic and serotonergic systems are also affected 
in PD (Jellinger, 1991) argues in favour of the reserpine model being a relatively 
good mimic of the disease biochemistry. Most attention nevertheless has focused on 
the dopaminergic deficit, where reserpine has been shown to produce an 
approximately 85% loss of dopamine in the SNpc and greater than 95% dopamine 
depletion in the striatum (Heeringa & Abercrombie, 1995). Reserpine also induces 
changes in additional basal ganglia nuclei, where firing in the STN is increased by 
approximately 50% (Robledo & Feger, 1991), mimicking the increase in activity 
observed in PD. Whilst the reserpine model mimics major components of the 
biochemistry of PD and induces akinesia and rigidity that reflect clinical features of 
the disease, there is no nigral dopaminergic cell degeneration so the model is 
restricted to assessing novel approaches to symptomatic treatment. However, within 
this framework, the reserpine-treated rat has proven very useful at predicting the 
efficacy of both dopaminergic (pramipexole, L-DOPA) and non-dopaminergic drugs 
(muscarinic agonists such as benztropine). These findings highlight the strong 
predictive validity of the reserpine-treated rat and justify its maintained position as a 
key model of choice for early preclinical stages of drug discovery programmes.   
 
1.4.1.2 The Haloperidol model 
 
The other pharmacological model of PD is the haloperidol-treated rat which acts to 
antagonise dopamine D2 and to a lesser extent D1 receptors in medium spiny neurons. 
The resultant block of striatal dopamine transmission leads to abnormal downstream 
firing within the basal ganglia circuits resulting in muscle rigidity and catalepsy 
within 60 min of haloperidol (0.5-5 mg/kg i.p.) injection (Sanberg, 1980). Whilst 
rigidity is a characteristic of PD, providing a degree of face validity to this model 
(similarity in symptoms), catalepsy is not directly associated with this degenerative 
disorder. However, catalepsy may be likened to the instability of patients to initiate 
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movements and so could be considered a worthwhile measure. Initial evidence 
suggested haloperidol was a poor biochemical mimic of PD, but recent evidence 
demonstrating haloperidol reduces striatal dopamine along with 5-HT and 
noradrenaline (Kulkarni et al., 2009) may suggest otherwise. In addition, elevated 
levels of extracellular glutamate likely attributed from an increase in STN activity, 
have been reported in the entopeduncular nucleus following haloperidol injection 
supporting the construct validity (similar pathogenesis) of this model. 
 
In common with the reserpine model, the haloperidol model fails to display any of the 
characteristic pathology associated with PD, so its use is again limited. Nonetheless, 
it remains a popular choice for assessing the potential symptomatic efficacy of novel 
non-dopaminergic agents including mGlu4 positive allosteric modulators (PAMs) and 
adenosine A2A/A1 antagonists (Niswender et al., 2008; Neustadt et al., 2009). 
 
On a general note, whilst the pharmacological models have value in the discovery of 
symptomatic drugs for PD, they have serious limitations. Firstly, they remain 
transient, which hinders their long-term usefulness. In a condition such as PD, where 
drugs will be administered chronically, the need to assess the long-term symptom 
relief in animal models amenable to chronic dosing regimens is paramount. Secondly, 
these pharmacological models do not display any pathology of PD and consequently 
are no use in investigating novel strategies aimed at providing neuroprotective 
strategies.  
 
1.4.2 Toxin-induced models 
 
1.4.2.1 6-OHDA lesion model 
 
Greater than 40 years ago Ungerstedt (1968) demonstrated that the hydroxylated 
analogue of dopamine, 6-hydroxydopamine (6-OHDA) led to degeneration of central 
monoamine neurones. Today the 6-OHDA-lesioned rat model is one of the most 
commonly used animal models of PD. Owing to its structural similarities to 
dopamine, following stereotactic injection into specific regions (due to its inability to 
cross the blood brain barrier), 6-OHDA is taken up into dopaminergic and 
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noradrenergic neurones via the high affinity dopamine and noradrenaline transporters 
(Blum et al., 2001). Depending on the site of injection, 6-OHDA is either taken 
directly in the cell body (nigral administration) or retrogradely transported to cell 
bodies (MFB and striatal administration), leading to the accumulation of the toxin and 
induction of cell death. 6-OHDA differs from symptomatic models of PD such as 
reserpine or haloperidol since it leads to irreversible degeneration within the neurones 
that have taken it up by their respective transporters. Cell death via 6-OHDA is 
thought to occur by several mechanisms, including the production of reactive oxygen 
species (Kumar et al., 1995), inhibition of complexes I and IV of the mitochondrial 
respiratory chain (Glinka & Youdim, 1995), a reduction of striatal antioxidants such 
as glutathione and superoxide dismutase (Betarbet et al., 2002) and more recently 
activation of pro-apoptotic proteins, Bax and p53 upregulated modulator of apoptosis 
(PUMA) (Gomez-Lazaro et al., 2008). All of these mechanisms, apart from the 
induction of apoptosis promote cell death by oxidative stress and mitochondrial 
dysfunction as discussed in detail in section.1.1.2.3.1. The 6-OHDA model also 
mimics many of the biochemical features of PD by reducing levels of striatal 
dopamine and TH. An important similarity with PD to this thesis is the increased 
firing of the STN (Hassani et al., 1996; Hutchison et al., 1998; Breit et al., 2006) and 
parallel increase in glutamate levels which leads to alterations in firing of the basal 
ganglia output regions following a 6-OHDA lesion (Hutchison et al., 1994). This has 
rendered the 6-OHDA model particularly useful to investigate glutamatergic agents 
which may provide neuroprotection by reducing hyperactivity within the STN and is 
discussed in greater detail in section 3.3.1.1.  
 
The 6-OHDA model shares a common failing with many other animal models of PD 
in that it does not lead to Lewy body formation. Although the exact role of Lewy 
body formation remains to be established, drugs shown to reduce aggregate formation 
are considered a potential future strategy for treating PD. Nonetheless 6-OHDA 
displays robust degeneration of the nigrostriatal tract successfully mimicking this 
additional pathological hallmark of PD. Furthermore the extent of degeneration can 
be established post-mortem by assessing the reduction in various parameters in the 
lesion (ipsilateral) hemisphere, compared with the intact (contralateral) hemisphere 
such as levels of TH or DAT immunoreactivity in the SNpc and dopamine levels in 
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the striatum. Behavioural indices can also be taken to predict lesion size and provide 
additional measures of efficacy using potential symptomatic and neuroprotective 
agents, the latter of which is drawn upon considerably in this thesis and discussed in 
greater detail in section 3.3.1.2. 
 
1.4.2.2 MPTP-treated model 
 
MPTP is a commonly used to toxin for inducing both rodent and primate models of 
PD based on its ability to induce persistent Parkinsonism in man (Davis et al., 1979; 
Langston et al., 1983). Subsequent studies in non-human primates have revealed the 
selective destruction of dopaminergic neurons of the nigrostriatal tract was the 
pathological basis behind the motor deficits observed (Burns et al., 1983; Jenner et 
al., 1989) which ultimately led to MPTP becoming the most widely used animal 
model to date.  
 
The neurotoxic mechanism of action of MPTP is relatively well understood. 
Following systemic injection (usually i.p.), MPTP rapidly crosses the BBB, which 
once inside the brain is converted by MAO-B into MPP
+
 (Chiba et al., 1984). On 
release into the extracellular space, MPP
+
 is taken up via DAT into dopaminergic 
neurons where cytoplasmic MPP
+
 triggers the production of ROS leading to 
neurotoxicity (Javitch et al., 1984). MPP
+
 also inhibits complex I of the electron 
transport chain, leading to a reduction in ATP production and further generation of 
ROS. These factors combined are most likely responsible for initiation of cell death 
related signalling pathways such as p38 mitogen-activated kinase (Karunakaran et al., 
2008) and JNK (Saporito et al., 2000).  
 
The MPTP-treated mouse presents a clear advantage over the 6-OHDA model in 
being systemically active and not requiring skilled stereotaxic surgery to produce a 
lesion. The systemic injection also produces a bilateral degeneration of the 
nigrostriatal tract which is more reflective of that seen in PD. However, the MPTP 
model does have some clear disadvantages to the 6-OHDA model, particularly in 
terms of reproducibility and potential to investigate behavioural measures. Mice are 
far less sensitive to MPTP than primates, therefore high doses are often required 
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which can lead to higher mortality. The handling of MPTP also poses a risk to 
researchers and therefore extreme care must be taken to reduce exposure when 
handling the toxin and biological waste products from the treated animals 
(Przedborski et al., 2001). Variability in lesion size is also an issue, whereby strain of 
mice, age, gender and weight, have all been shown to influence the reproducibility of 
an MPTP lesion. On a separate note, controversy still surrounds the issue of whether 
MPTP treated mice develop Lewy body-like inclusions. One of the first studies to 
assess this possibility revealed chronic treatment of MPTP for a period of 24 weeks, 
led to several of the remaining TH-positive cells in the SNpc containing α-synuclein 
and ubiquitin-containing inclusions, although these did not resemble classical Lewy 
bodies found in the disease (Meredith et al., 2002). Later studies have since failed to 
corroborate these findings using the same treatment regimen (Fornai et al., 2005) or 
following multiple-acute or sub-chronic paradigms (Shimoji et al., 2005). Further 
investigation is certainly required before this model can be used for assessing agents 
that may prevent aggregate formation. The MPTP model in mice has been able to 
predict the efficacy of non-dopaminergic agents such as the A2A antagonist, 
istradefylline (Shiozaki et al., 1999), therefore this model would be expected to 
predict the ability of agents to provide protection against the degeneration in the 
MPTP-treated primate, given they share a common inducer.     
 
1.4.3 Pesticide-induced models 
 
1.4.3.1 Rotenone model 
 
On finding MPTP produced nigrostriatal tract degeneration through the targeting of 
mitochondrial complex I, the search for additional mitochondrial toxins to model PD 
led to the emergence of the rotenone model. Like MPTP, the insecticide rotenone is 
highly lipophilic, so it readily crosses the BBB and diffuses into neurons where it 
accumulates within the mitochondria and inhibits complex I.  The cause of toxicity is 
thought to be a result of the ensuing production of ROS and subsequent glutathione 
depletion rather than the direct reduction in ATP. Furthermore extensive microglial 
activation observed in both the SNpc and striatum following rotenone infusion 
(Sherer et al., 2003) is consistent with the inflammatory characteristic found in 
63 
 
idiopathic PD (Gerhard et al., 2006; Whitton, 2007) further supporting the validity of 
this model. Additional support of the rotenone model is offered by a recent finding 
demonstrating rotenone inhibits proteasomal activity (Wang et al., 2006c). 
Unfortunately, in addition to its central toxicity, rotenone shows a high degree of 
systemic (predominantly cardiovascular) toxicity that leads to high mortality rates 
(~30% of animals). There also appears to be an intrinsic resistance of some rats to 
rotenone, with some studies reporting as few as 50% displaying degeneration 
(Betarbet et al., 2000), requiring additional animals. 
 
Administration of rotenone, typically 2-3 mg/kg i.p. daily, demonstrates a dose-
dependent loss of striatal TH and dopamine up to a period of 2 months accompanied 
with a reduction in locomotor activity and marked catalepsy that is reversed by L-
DOPA (Alan & Schmidt, 2004). The pattern of cell death mirrors that seen in 
idiopathic PD, where greater cell loss is apparent in the ventral tier of the SNpc with 
relative sparing of the VTA and only a degree of degeneration of noradrenergic 
neurones in the locus coeruleus. Furthermore α-synuclein and ubiquitin-positive 
Lewy body-like intracytoplasmic inclusions have been reported with rotenone 
(reviewed in Duty, 2011) lending support to the construct validity of this model, 
although there has been some difficultly in reproducing these findings. 
 
Whilst the variable nature of rotenone has been useful to examine aspects related to 
the pathophysiology of PD, the current model does not provide a robust platform to 
assess the effects of symptomatic drugs. Indeed, L-DOPA and apomorphine to date 
remain the only clinically available drugs that have shown to reverse locomotor 
deficits in the rotenone model (Alam & Schmidt, 2004). However, worthy of mention 
is that selegiline and pramipexole, both of which were examined for disease 
modifying potential in clinical trials but then failed due to lack of efficacy, did protect 
against rotenone-induced degeneration (Saravanan et al., 2006; Inden et al., 2009), 
suggesting the rotenone model may show promise for selecting the efficacy of 






1.4.3.2 Paraquat and Maneb 
 
Exposure to the herbicide 1,1’-dimethyl-4,4’-bipyridinium (paraquat) or the fungicide 
ethylene-bis-dithiocarbamate (Maneb) has been associated with an increased 
incidence of PD (Ascherio et al., 2006; Costello et al., 2009). As a result, attempts 
have been made to model PD using both these agents. Following systemic injection in 
mice, paraquat crosses the BBB, which once inside cells, leads to both indirect 
mitochondrial toxicity via redox cycling and also direct inhibition of complex I whilst 
Maneb preferentially inhibits complex III following entry into the brain. Paraquat and 
Maneb have been shown to produce enhanced toxicity when combined 
(Thiruchelvam et al., 2000), likely a result of Maneb increasing the brain 
concentration and reducing clearance of paraquat (Barlow et al.,2003). Also since 
both pesticides are used in the same geographical regions, human exposure to one of 
these pesticides alone is unlikely, providing a clear rationale for combining their 
administration in order to produce an animal model of PD. Indeed, combined 
paraquat and Maneb exposure in both mice and rats led to greater denervation of the 
dopaminergic system than either chemical alone (Thiruchelvam et al., 2000). In most 
cases in mice, this is typically accompanied with motor deficits manifest as hunched 
posture and a decline in locomotor activity. Some treated animals however, suffer 
from progressive weight loss and respiratory pathology leading to quite high 
mortality. Furthermore this model has been criticised for its minimal degree of cell 
death and variable loss (if any) of striatal dopamine content. There currently remains 
no evidence for presence of inclusions, which taken together has limited the use of 
this model in drug discovery programmes. Nonetheless, the paraquat and Maneb 
models do provide credence to the theory that environmental toxins and pesticides 
might have a role in PD pathogenesis. 
  
1.4.4 Proteasomal inhibitor models 
 
Interest in Lewy body formation was rekindled by the discovery of mutations in α-
synuclein being responsible for rare forms of familial PD. When Lewy bodies were 
shown to be intensely immunoreactive for α-synuclein and also to contain nitrated 
forms of the protein, the failure of protein metabolism in PD was proposed as the root 
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cause to the neuronal loss (Spillantini et al., 1998; Duda et al., 2000). The following 
discovery of two mutations in familial PD, UCHL1 and Parkin, both of which affect 
ubiquitin proteasomal function (see section 1.1.2.1), provided additional weight to 
this possibility. Therefore, when a reduction in proteasomal catalytic activity in the 
SN in PD was demonstrated, attempts to use this as a means of developing a new 
model began (McNaught & Jenner, 2001). Proteasomal inhibitors such as lactacystin, 
PSI and epoximycin, have since been shown to selectively kill dopaminergic cells in 
culture and further induce nigrostriatal degeneration following intranigral injection, 
reduce striatal dopamine content and induce motor deficits in rats (McNaught et al., 
2002a). More encouragingly, a report that systemic administration of PSI/epoximycin 
could reproduce many components of PD as affected in man, suggested this model 
may have strong face value (McNaught et al., 2004). 
 
Unfortunately these early findings have proven difficult to reproduce and reports of 
failure in mice, rats and primates have since emerged. Recent investigations have 
shown that the dose of PSI is critical with optimal dosage levels above which toxicity 
decreases (Bukhatwa et al., 2010). Differences between routes of administration with 
effects observed following subcutaneous and oral administration but not 
intraperitoneal injection have also contributed to the variability in response to PSI. 
These factors have all been a frustrating hindrance since PSI could potentially be a 
valuable model of PD in which to test neuroprotective strategies, yet nothing has so 
far appeared in the literature. 
 
1.4.5 Genetic models  
 
There have been major advances in determining the underlying gene defects in 
familial PD that have led to numerous attempts to produce transgenic models of PD 
in mice. The gene products identified have shown both commonality with 
mechanisms of neuronal cell death in sporadic PD, via mitochondrial dysfunction (α-
synuclein, PINK1, DJ-1 and LRKK2) and alterations in protein folding and 
metabolism (α-synuclein, parkin UCHL1). Indeed, attempts to produce knockouts, 
transgenics and over-expressers have revealed a variety of abnormalities. For 
example LRKK2 transgenic mice demonstrate dopaminergic dysfunction along with 
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behavioural deficits that are L-DOPA responsive although no noticeable nigral 
degeneration has been reported (Lin et al., 2009). Furthermore PINK1, DJ-1 and 
Parkin knockouts all demonstrate mitochondrial dysfunction and reduced evoked 
striatal dopamine release yet also failed to replicate nigral pathology. The reason for 
this failure remains largely a mystery although one suggestion is that gene defects 
reported may not themselves be the cause of familial PD, but rather operate through 
epigenetic effects that allow, for example the expression of effects of ‘silent genes’ 
which then initiate dopaminergic degeneration. An additional explanation may be that 
when genes are knocked out or over-expressed embryonically, compensatory 
mechanisms may occur in the dopaminergic system to effectively mask the effects of 
genetic manipulation. This would imply a shift to conditional knockouts or viral 
vector-mediated delivery of transgenes may yield improved models for the future. 
Although the genetic mice models have not yet contributed to drug discovery for PD, 
it is possible that with further optimization, such models will one day contribute in 
this way. However at this moment in time, the current genetic models have most 
utility in investigating how the gene mutations associated with PD may contribute to 



















1.4 Current therapeutic strategies for Parkinson’s disease 
 
1.4.1 Dopamine replacement therapy 
 
To date the most successful attempts at pharmacotherapy for PD have focused largely 
on the symptomology. As the underlying pathology of PD involves loss of 
dopaminergic innervation within the striatum, these therapies have focused on either 
replicating the actions of dopamine at dopaminergic receptors or dopamine 
replacement strategies. Currently, dopaminergic strategies remain the primary 




The current gold standard for PD therapy is treatment with the dopamine precursor L-
3,4-dihydoxyphenylalanine (L-DOPA). Unlike dopamine, L-DOPA readily crosses 
the blood brain barrier (BBB) where in the brain it is converted by dopa 
decarboxylase into dopamine by the remaining dopaminergic neurons, thus replacing 
lost dopamine from the nigrostriatal projections. L-DOPA is typically administered 
concominantly with a peripheral L-aromatic amino acid decarboxylase (L-AAAD) 
inhibitor such as carbidopa or benserazide to prevent conversion of L-DOPA to 
dopamine in the periphery. Carbidopa can increase the amount of L-DOPA entering 
the brain from 1 to 10% of the administered dose enabling a 10-fold decrease in the 
therapeutic dose required. Furthermore, by reducing peripheral dopamine, there are 
improvements in peripheral side effects such as hypotension in addition to nausea and 
vomiting which are a result of effects mediated by dopamine on the medullary 
vomiting centre (which is not protected by the BBB) (Jankovic, 2002). In addition, 
monoamine oxidae B (MAO-B) inhibitors such as selegiline are often given as an 
adjunct therapy to increase the effectiveness of L-DOPA by blocking the breakdown 
of dopamine in the brain, further enabling the use of reduced doses of L-DOPA. 
 
Initial treatment with L-DOPA is very effective with patients demonstrating 
significant improvements in rigidity and akinesia, and in some cases complete 
restoration to normal. However, L-DOPA does not halt the progression of the disease, 
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nor does it pose any therapeutic efficacy to non-motor symptoms. Furthermore with 
persistent L-DOPA treatment, patients begin to experience end of dose deterioration 
and an emergence of motor fluctuations- the wearing ‘on’ and ‘off’ phenomena. In 
these circumstances rigidity and bradykinesia may suddenly appear, as well as the 
gradual initiation of excess involuntary movements of choreic, dystonic nature known 
as dyskinesias. Although a reduction in dosage of L-DOPA reduces the incidence of 
these motor complications, bradykinesia and rigidity can resume, and the therapeutic 
window for L-DOPA becomes progressively smaller with time. This phenomenon 
affects approximately 40% of PD patients after approximately 5 years of treatment 
with L-DOPA, increasing to around 95% after 10 years (Ahlskog & Muenter, 2001). 
Several mechanisms have been proposed to underlie the motor complications induced 
by L-DOPA and will be discussed in more detail below.  
 
With ongoing degeneration in PD it has been suggested that the site of L-DOPA 
decarboxylation changes from striatal terminals to non-dopaminergic sites, such as 
interneurons and glia. This shift in decarboxylation site may contribute towards the 
development of motor complications such as dyskinesias (Guigoni et al., 2005). In 
addition to this putative shifting of L-DOPA decarboxylation, the unrelenting 
neurodegeneration leads to more pulsatile dopamine receptor stimulation in contrast 
to the expected continuous stimulation in normal conditions. This may attribute to the 
cyclic blood plasma levels associated with oral administration of L-DOPA, in 
addition to the ongoing degeneration of the nigrostriatal tract in which the effects of 
endogenous dopamine progressively deteriorate. It has been proposed that pulsatile 
stimulation can alter the electrophysiological firing patterns of basal ganglia nuclei, 
particularly the STN and contribute to the emergence of the on-off phenomena and 
dyskinesias (Olanow et al., 2004). Indeed, both short acting D1 agonists such as SKF 
82958 and D2 agonists given to MPTP-treated monkeys by repeated pulsatile 
administration, gives rise to increased levels of dyskinesia, when compared to 
continuous receptor stimulation brought about by dopamine agonists with longer half-
lives (Calon et al., 2000; Jenner, 2000). Furthermore, concomitant administration of 
catechol-O-methyl transferase (COMT) inhibitors such as tolcapone and entacapone 
with L-DOPA has been shown to reduce the on-off phenomena (Brooks & Sagar, 
2003). These compounds prevent the peripheral conversion of L-DOPA into its 
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metabolite 3-O-methyldopa (3-OMD) which accumulates due to its long half-life 
(>15 hours) and competes with L-DOPA for transport across the BBB. Thus the use 
of COMT inhibitors increases the bioavailability of L-DOPA in the brain and 
improves motor complications by resuming continuous dopamine receptor 
stimulation within the striatum. 
 
An additional explanation for the motor complications relating to L-DOPA treatment, 
particularly in the cause of dyskinesias is dopamine receptor ‘supersensitivity’. It is 
thought long-term dopamine receptor stimulation may lead to supersensitivity and 
consequent imbalance between the direct and indirect pathways (Obeso et al., 2000). 
Indeed in parkinsonian conditions, supersensitivity to dopamine may be explained by 
the observed increase in striatal expression of D2 receptors despite the continuing 
degeneration of the nigrostriatal system. In further support of this notion is evidence 
for increased downstream signalling of D1 receptors, at the level of the G-protein, 
through extracellular signal-related kinase 1/2 (ERK1/2) and mitogen-activated 
protein kinase (MAPK) pathways, which may also be a result of receptor 
supersensitivity (Hurley & Jenner, 2006). Thus, although the exact mechanism 
underlying the initiation of motor complications following treatment with L-DOPA 
remains to be determined, it would appear these effects may implement some, if not 
all of the mechanisms described.  
 
Whilst dopamine replacement therapy with L-DOPA has been shown to be highly 
efficacious in PD patients, some controversy remains about its possible toxicity. Both 
L-DOPA and dopamine are known to undergo auto-oxidation which can lead to 
increased levels of reactive oxygen species and free radicals, in addition to a 
reduction in antioxidants (described in section 1.1.2.3.1). These agents can then lead 
to lipid peroxidation and damage to DNA, possibly resulting in apoptosis. A number 
of in vitro studies have reported L-DOPA mediated toxicity on dopaminergic cell 
cultures (Michel & Hefti, 1990; Pardo et al., 1993; Steece-Collier et al., 1990) which 
could be inhibited by antioxidants implying oxidative stress is a likely mechanism 
(Ziv et al., 1997). Nonetheless, there are many criticisms of these studies such as the 
lack of supporting glial components and the absence of the antioxidant, ascorbate, in 
addition to the high doses of L-DOPA used in these studies. Indeed in the presence of 
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ascorbate and the glial cell component, L-DOPA was no longer found to be toxic to 
cultured dopaminergic neurons (Mena et al., 1997). Moreover, there is almost no in 
vivo data to support the hypothesis that L-DOPA is toxic. Examples of such studies 
include a 6-month treatment study with L-DOPA in 6-OHDA-lesioned rats which 
revealed no alterations in dopaminergic cell numbers with respect to vehicle-treated 
animals in the lesioned hemisphere (Murer et al., 1998). Furthermore in the clinic, 
chronic L-DOPA treatment for tremor and dystonia revealed no toxic effects on 
dopaminergic neurones in the SNpc (Rajput et al., 1997). The neurotoxicity of L-
DOPA therefore remains unproven in both animal models and in the clinic. Despite 
the obvious motor complications and extensive efforts to reveal more suitable 
alternatives, L-DOPA, has remained the gold standard in PD treatment for more than 
40 years.     
 
1.4.1.2 Dopamine agonists 
 
Dopamine agonists form the main therapeutic alternative to L-DOPA in PD. Current 
dopamine agonists such as pramipexole, ropinirole and cabergoline have been 
designed with longer half lives when compared to L-DOPA, in an attempt to 
minimise the pulsatile stimulation thought to trigger dyskinesias, whilst maintaining 
antiparkinsonian efficacy. Indeed, such compounds have been demonstrated to 
control the motor symptoms of PD for up to 5 years with a lower incidence of 
dyskinesias when compared to L-DOPA therapy (Rascol, 2000). This has been 
confirmed in a study in which administration of L-DOPA to MPTP-treated primates 
led to the rapid onset of severe dyskinesia, yet in contrast, ropinirole produced only 
mild dyskinesia (Jackson et al., 2007). Accordingly treatment of PD with longer 
lasting dopamine agonists is now thought to be an effective early monotherapy. D2-
like (D2, D3 & D4) inhibitory receptors are particular preferred to produce anti-
parkinsonian effects, in order to target the profound effect of the indirect pathway, 
therefore most current dopamine agonists demonstrate affinity at these receptors. 
Indeed, pramiprexole has no affinity for the D1 receptor, high for D2 and higher still 
for the D3 receptor (Jenner, 2002). Furthermore, partial agonists have also been 
considered to reduce dopamine-mediated side effects such as hallucinations and 
psychosis which are associated with the modulation of healthy mesolimbic and 
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mesocortical pathways. For example, dihydroergocriptine a partial agonist at D1 
receptors and full agonist at D2 receptors has shown antiparkinsonian efficacy in 
humans (Albanese & Colosimo, 2003). It is thought the side effect profile with these 
agents is reduced by exerting maximum effect in the denervated striatum, but a lesser 
effect when competing with endogenous dopamine in healthy normal regions. 
Considerable evidence would also suggest dopamine agonists may be neuroprotective 





I]-beta-CIT, a slower loss of striatal dopamine 
storage in PD patients initially treated with ropinirole and pramipexole was observed 
compared to L-DOPA (Whone et al., 2003). However it is important to point out no 
control group was available therefore we cannot be certain of a neuroprotective effect 
here since this may also be a result of toxicity caused by L-DOPA. 
 
A recent advance in the treatment of PD is the development of slower release agents 
and use of transdermal patches to administer dopamine agonists which enables stable 
continuous release of drug throughout the day. One of these, rotigotine, is a mixed  
D1-3 receptor agonist which has been developed as a transdermal patch and has shown 
efficacy in numerous pre-clinical models of PD (Jenner, 2005). In the clinic rotigotine 
is well tolerated in humans providing an effective monotherapy for early PD which 
also decreases ‘off’ time in subjects with advanced PD which cannot be controlled 
with L-DOPA (Lewitt et al., 2007; Watts et al., 2007).  
 
1.4.2 Non-dopaminergic pharmacotherapy 
 
1.4.2.1 Cholinergic drugs 
 
Before the discovery of L-DOPA, cholinergic drugs were one of the first available 
options for therapy in PD intended to correct the imbalance between dopamine and 
acetylcholine (ACh) by negatively regulating cholinergic striatal interneurones. 
Currently a number of anticholinergic drugs are available such as trihexylphenidyl 
and benzatropine. Whilst proven to be effective in reducing tremor in PD, these drugs 
offer few improvements in additional motor symptoms and are also associated with 
adverse cognitive side effects (reviewed in Katzenschlager et al., 2003). In an attempt 
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to address this issue the more recent cholinesterase inhibitors, rivastigmine and 
donepezil (which were originally marketed for Alzheimer’s disease) have been found 
to improve cognition in PD patients with dementia, although benefits on motor 
function were at best mild (Emre et al., 2004; Fabbrini et al., 2002; Leroi et al., 
2004). Thus, owing to the mild antiparkinsonian efficacy of cholinergic drugs, they 
are rarely used as a monotheapy, rather favoured in a combination with a dopamine 
replacement agent to selectively address clinical symptoms.      
 
1.4.2.2 Amantadine  
 
Amantadine is an anti-viral drug for the prohylaxis of influenza and was discovered 
to have antiparkinsonian efficacy accidentally. Although amantadine was originally 
thought to increase dopamine release likely via a mechanism on dopamine 
transporters or the receptors themselves, further investigation into the pharmacology 
has shown amantadine is an NMDA receptor antagonist (Starr, 1998). Consequently, 
amantadine may reduce the effects of hyperactivity in the glutamatergic 
subthalamonigral pathway and the potential of targeting such ionotropic glutamate 
receptors is discussed in greater detail in section 1.5.2.1 Amantadine itself however, 
has demonstrated only mild antiparkinsonian effects although it has been shown to be 
effective in reducing the prevalence of L-DOPA-induced motor complications 
(Verhagen et al., 1998). Therefore, amantadine is primarily used as combination 
therapy with L-DOPA in patients who do not tolerate optimal doses, where it may 
help reduce motor fluctuations.      
 
1.4.3 Future therapeutic prospects 
 
1.4.3.1 Neurotrophic factors 
 
A reduction in neurotrophic factors such as brain-derived neurotrophic factor (BDNF) 
has been identified in PD (Howells et al., 2000), therefore replacement of such 
factors has been suggested to hold therapeutic potential. In fact several neurotrophic 
factors have been examined in human clinical trials. These include glial-derived 
neurotrophic factor (GDNF), a potent growth factor that supports the survival of 
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dopaminergic neurones and has shown to be neuroprotective in animal models of PD 
(Eslamboli et al., 2005; Kordower et al., 2000). So far, focus has been on delivering 
GDNF primarily by direct infusion, which into MPTP-treated primates has shown to 
increase dopamine levels in the putamen by up to 2-fold resulting in improved motor 
function and decreased incidence of dyskinesias (Grondin et al., 2002). A small open-
label trial involving putamenal infusion of GDNF also demonstrated significant 
clinical improvements reporting a reduction in dyskinesias and increase in dopamine 
storage after 18 months determined by PET scans of [
18
F]-fluorodopa uptake (Gill et 
al., 2003). However, a larger controlled study involving 34 PD patients was halted 
due to severe adverse effects in three cases and several other patients developing 
serum antibodies to GDNF (Lang et al., 2006). A follow-up toxicology study in 
monkeys revealed infusion of GDNF showed cerebellar cell loss raising further 
concerns regarding the safety of GDNF infusions. 
 
An alternative to direct infusion of trophic factors is delivery of these agents by gene 
transfer. Recent gene therapy efforts have used neurturin, a neurotrophic factor 
related to GDNF that also promotes dopaminergic cell survival in mid-brain 
dopaminergic cultures (Horger et al., 1998). In addtion, delivery of an adeno-
associated viral (AAV-2) vector containing neurturin (CERE-120) protected against 
dopaminergic cell loss and improved motor function in MPTP-treated monkeys 
(Kordower et al., 2006). Furthermore an open-label clinical study involving 12 
patients with advanced PD, revealed promising findings, reporting off-medication 
UPDRS motor scores were significantly reduced and mean on time was increased at 
one year following injection (Marks et al., 2008). However, data from open-label 
trials (in which there is no blinding to treatment) must be interpreted cautiously. 
Therefore the potential antiparkinsonian efficacy of neurotrophic factors has revealed 
some encouraging findings and continues to remain an area of high interest within the 




Coenzyme Q10 (CoQ10, ubiquinone), in serving as the electron acceptor for complexes 
I and II of the mitochondrial electron transport chain, is an antioxidant. Therefore the 
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potential of CoQ10 to protect from mitochondrial dysfunction and/or oxidative 
damage in PD has been investigated. Bearing weight to this suggestion is a study that 
demonstrated following rotenone-induced toxicity in vitro, CoQ10 and an additional 
antioxidant, α-tocopherol reversed rotenone-induced toxicity (Sherer et al., 2007). 
Numerous clinical trials have since been undertaken, in which the most promising 
revealed 16-month treatment with oral CoQ10 facilitated a reduction in disability and 
slowed disease progression in mild PD (Shults et al., 2002). Additionally CoQ10 
appeared to demonstrate no adverse effects and appeared to be well-tolerated, laying 
the passage for larger controlled trials which are now underway to probe the potential 
of antioxidants in PD therapy. 
  
1.4.3.3 Adenosine receptor antagonists 
 
Epidemiological studies have indicated that caffeine may reduce the incidence of PD, 
at least in men (Ascherio et al., 2001; Ross et al., 2000). As caffeine mediates its 
actions by antagonising adenosine receptors, this finding has led to interest in 
evaluating adenosine receptor antagonists as potential neuroprotective agents. In the 
striatum the adenosine A2A receptor can heterodimerize with the D2 receptor to inhibit 
dopamine signalling (Ferre & Fuxe, 1992), whilst inhibition of the A2A receptor can 
promote dopamine function. The adenosine A2A antagonist ST1535 has been shown 
to potentiate a threshold dose of L-DOPA in both 6-OHDA lesioned rats and MPTP-
treated marmosets suggesting that these receptors may offer symptomatic relief in PD 
(Rose et al., 2006; Rose et al., 2007). Furthermore, two small clinical trials using the 
A2A antagonist istradefylline (KW-6002) have demonstrated potential symptomatic 
effects in advanced PD (Bara-Jimenez et al., 2003; Hauser et al., 2003) where more 
recent research has suggested that A2A antagonists may also afford neuroprotection. 
Caffeine and istradefylline have both been shown to be neuroprotective in MPTP-
treated primates, where caffeine at doses comparable to those of typical human 
exposure, attenuated MPTP-induced loss of striatal dopamine transported binding 
sites (Chen et al., 2001). Indeed recently, caffeine (and related adenosine A2A 
receptor antagonists) has been identified by NIH-appointed Committee to Identify 
Neuroprotective Agents in Parkinson’s disease (CINAPS) as a priority agent to be 
evaluated for neuroprotection in clinical trials. 
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1.4.4 Non-pharmacological therapy 
 
1.4.4.1 Stem cells and tissue transplantation 
 
Transplantation of dopaminergic tissues involving striatal infusions of autologous 
adrenal medullary cells, and later fetal ventral mesencephalon (VM) cells was 
pioneered by Swedish surgeons in 1982. Initially, these results were highly 
promising, although later double-blinded trials have failed to replicate these earlier 
findings. In one study, forty patients with severe PD were randomly assigned to 
receive transplants of fetal mesencephalic tissue or sham surgery and monitored for a 
year post-operation. This study found a significant benefit in UPDRS scores in 
patients under 60 although no improvements in older patients. Moreover, fibre 
outgrowth was present in 17 out of the 20 patients that underwent transplants, 
indicated by an increase in 
18
F-flurodopa uptake using PET imaging (Tintner & 
Jankovic, 2002). However this approach has been limited by poor neuronal survival 
recorded following transplantation (in certain instances up to 90% loss of grafted 
material after one week post transplantation), limited tissue availability and lack of 
homogenous product. Therefore alternative sources of cells have been considered 
such as embryonic stem (ES) cells in the early stages of development.   
 
Since stem cells are pluripotent, they can be isolated and expanded in culture to 
produce potentially large amount of uniform product. Early animal studies have 
compounded the potential of this approach, where a monumental study conducted by 
Bjorklund et al., (2002) demonstrated following transplantation of undifferentiated 
mouse cells into the striatum of 6-OHDA-lesioned rodents, led to the proliferation of 
ES cells into differentiated dopamine neurones. In addition, this same study revealed 
ES- cell derived dopaminergic neurones were functional, demonstrating behavioural 
restoration of dopamine-mediated motor asymmetry (Bjorklund et al., 2002). 
Consequently, ever since these early pre-clinical findings heavy investment has been 
poured into this area to determine if this approach offers the same potential in a 
clinical setting which may arguably offer the most promising hope to elucidate a 
‘cure’ for PD. Despite the mass media attention, the current consensus is that there 
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are still considerable lengths to be achieved before this approach becomes a viable 
alternative for the management of PD. 
 
1.4.4.2 Surgical interventions 
 
Since the invention of the human stereotactic frame in the 1950s, there has been 
interest in surgical lesioning techniques to ameliorate symptoms of PD. With the 
advent of levodopa therapy in the 1960s and 70s, interest in surgical approaches for 
PD therapy waned. However, in the last decade enthusiasm has re-emerged, as a 
consequence of increased understanding of the pathophysiology of PD, coupled with 
advances in medical imaging and surgical techniques. Given the relative success of L-
DOPA therapy, surgical approaches are generally reserved for those patients for 
whom the side-effects of L-DOPA therapy become untenable. Three main surgical 
targets have been evaluated, the thalamic nuclei, the GPi and the STN, with 
irreversible ablative procedures now being superseded by reversible deep brain 
stimulation (DBS). Bilateral DBS offers numerous advantages over lesioning since it 
is reversible, allows the levels of the stimulation to be adjusted and further reduces 
the likelihood of re-operation due to inadequate lesion volume. Bilateral DBS is also 
associated with decreased morbidity compared to bilateral lesioning (Tasker, 1997). 
Since thalamic stimulation has been shown to be highly effective in controlling 
tremor, yet shown limited effectiveness against other motor symptoms of PD, it is 
generally only recommended in a small number of cases demonstrating tremor-
predominant disease (Walter & Vitek, 2004). In contrast, DBS of the STN or GPi has 
been shown to be highly effective in treating the majority of motor symptoms of PD, 
allowing reductions in L-DOPA dosage (and thus reducing incidences of 
dyskinesias), improving tremor, bradykinesia and gait disturbances (Krack et al., 
2000).  
 
Of the two target areas, bilateral DBS of the STN is now thought to be the preferred 
target, showing greater motor improvements in ‘off’ medication states in addition to 
the greatest reduction in L-DOPA usage (Anderson et al., 2005). Furthermore two 
summary reviews of all published human STN-DBS studies, revealed Unified 
Parkinson’s Disease Rating Scales (UPDRS) motor scores in the ‘off’ phase of 
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treatment were improved by 56% after 12 months and maintained at 49% after 5 
years where both outcomes were compared to pre-operative off-medication scores.  In 
addition these studies revealed average reductions in L-DOPA dosage by 56% and 
dyskinesia incidence by 69% (Hamani et al., 2005; Kleiner-Fisman et al., 2006).  
 
Whilst highly effective in treating the motor symptoms of PD, STN-DBS surgery 
does have some limitations. The most serious relating to surgery is intercranical 
haemorrhage (3.9%), whilst adverse effects relating to stimulation include speech 
disorders (dysarthia, 9.3%), weight gain (8.4%) and depression (6.8%) however these 
latter effects can be reversed by altering stimulation parameters (Kleiner-Fisman et 
al., 2006). An additional drawback is that STN-DBS is a procedure not widely 
available especially in less well developed countries due to the high labour costs and 
expensive equipment required. Therefore on the basis of positive results in STN-
lesioned MPTP-treated primates (Guridi et al., 1996), bilateral subthalamotomy has 
been proposed as a feasible alternative to DBS where needed. However, this 
procedure has the disadvantage of being irreversible and may also result in 
hemiballism. Despite these limitations, a report by Alvarez et al., (2005) on the long 
term effects of bilateral subthalamotomy on 18 patients with advanced PD, revealed 
significant reductions in L-DOPA dosage (47%), L-DOPA-induced dyskinesias 
(50%), and “off” time (49.5%) 2 years post-operatively compared to pre-operative 
baseline levels. Adverse effects from the surgery were generally minimal and 
transitory in nature, e.g. dyskinesia lasting for only 3 months (17%), whilst motor 
improvements remained for 4 years (Alvarez et al., 2005). 
 
Since STN-DBS and subthalamotomy achieve similar outcomes there appears to be a 
paradox, with high frequency (100Hz) stimulation resulting in equivalent effects to 
that achieved by surgical ablation of the nucleus. As a result numerous mechanisms 
of action of STN-DBS have been proposed and will be discussed in detail here.  The 
first hypothesis is that high frequency stimulation of the STN may eventually lead to 
a block in neurotransmission. This could be achieved by a depolarising block of 
neuronal transmission through inactivation of voltage-dependent ion channels, or 
through stimulation-induced neurotransmitter depletion and consequent synaptic 
failure (Breit et al., 2004). An alternative hypothesis involves the role of the GPe in 
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STN-DBS. DBS of the STN may increase activity in the subthalamopallidal 
connections to the GPe – the main projection target of the STN. As a result this could 
activate inhibitory GABAergic projections of the GPe which as discussed previously 
form reciprocal connections with the STN and could potentially decrease STN 
hyperactivity, consequently reducing glutamate release in the basal ganglia output 
nuclei. Interestingly however, increased levels of GABA and not decreased levels of 
glutamate have been found in the SNpr following DBS in 6-OHDA-lesioned rats 
(Windels et al., 2005). This could again be explained by increased activity in the 
subthalamopallidal projections and resultant overactivity of the GPe, which would 
then lead to increased activity in the GABAergic pallidonigral projections potentially 
underlying the increase in GABA in the SNpr. Hence the mechanism of STN-DBS 
may be heavily dependent on modulation via the GPe, either to dampen glutamatergic 
activity through inhibitory reciprocal connections to the STN or to increase 
GABAergic activity in the SNpr, both of which would normalise thalamocortical 
feedback.   
 
A more recent proposal for the mechanism of action of STN-DBS has emerged 
through a better understanding of STN firing patterns in PD. In PD synchronised 
oscillatory activity in the range of 10-35 Hz often referred to as the β-band, is 
prevalent in the basal ganglia-thalamocortical circuits (Gatev et al., 2006). Thererfore 
‘jamming’ of the aberrant firing pattern of STN neurones from β-band frequencies, by 
imposing firing patterns at higher frequencies, may relieve PD symptoms (Breit et al., 
2004). Indeed a study in PD patients, where the effects of frequency of STN-DBS 
were investigated, demonstrated that stimulation between 5-10 Hz and 20-25 Hz were 
associated with bradykinesia, whilst higher frequencies (> 100 Hz) relieved 
bradykinesia (Fogelson et al., 2005).  
   
Clearly there are many benefits of both STN-DBS and subthalamotomy however 
there are still drawbacks to these approaches. These include cost, the limited 
availability and post-operative complications. Therefore attention has been drawn to 
establishing a pharmacological approach which may achieve comparable outcomes. 
Taking into account the positive outcomes of surgically targeting the STN in PD, a 
pharmacological alternative to decrease overactive glutamatergic innervations of the 
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basal ganglia output nuclei would have far more widespread application than surgical 
procedures. Owing to the glutamatergic nature of the STN and proposed hyperactivity 
in the parkinsonian brain, agents that can interfere with glutamatergic 
neurotransmission present a promising strategy for the potential development of 
novel antiparkinsonian therapies. This pharmacological possibility forms the major 


























1.5 Glutamatergic receptors and their potential in Parkinson’s 
disease 
 
The pivotal role of glutamatergic neurotransmission in the pathogenesis of PD has 
been discussed extensively in section 1.3. Whilst it is widely accepted glutamatergic 
function is implicated in the pathogenesis of PD it is surprising there is currently only 
one drug (amantadine) on the market that modulates the glutamatergic system. In this 
section it becomes clear why this is the case, largely owing to the fact glutamate is the 
core excitatory neurotransmitter in the mammalian CNS. Therefore manipulation of 
this system is likely to have vast implications and widespread side effects. 
Consequently recent developments in modulating the glutamatergic system have 
involved a more subtle approach. 
 
1.5.1 Glutamate transmission 
 
Following depolarisation-evoked glutamate release, synaptic accumulation of 
glutamate can lead to excitotoxicity (discussed in section 1.1.2.3.2) as well as 
receptor desensitisation and high background levels of glutamate, thus decreasing 
signal to noise ratio (Sinclair et al., 2003). Since no extracellular enzymes exist that 
are capable of metabolising glutamate, its concentration is maintained at 1µM in the 




-driven transporters (Nicholls & 
Attwell, 1990) known as excitatory amino acid transporters (EAATs 1-5). Of these, 
GLT-1 (EAAT1) and GLAST (EAAT2) are exclusively expressed on astrocytes, 
whilst EAAT3 is expressed on both glutamatergic and non-glutamatergic neurones in 
addition to astrocytes and oligondendrocytes (Schousboe et al., 2004). EAAT4 is 
expressed by Purkinje cells of the cerebellar molecular layer, whilst EAAT5 is 
restricted to Müller cells in the retina (Schousboe et al., 2004). The majority of 
glutamate is taken up by astrocytes where it may be metabolised in two ways, either 
by being converted into glutamine by the ATP-dependent, glutamine synthase or by 
conversion to α-ketoglutarate by glutamate dehydrogenase which is then metabolised 
to lactate in the Krebs cycle (Waagepetersen et al., 2005). Both glutamine (which is 
non-toxic) and lactate are then exported from astrocytes and taken up into neurones 
via a low affinity Na
+
-independent system A transporter (Broer & Brookes, 2001). 
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This enables glutamine to be hydrolysed by glutaminase within neurones to form 
glutamate creating an intracellular concentration of approximately 10mM (Nicholls & 
Attwell, 1990). The reformed glutamate is then packaged into vesicles by an 





 independent transporters driven by H
+
-ATPase. Finally, this repackaged 
glutamate in then set to be released into the synapse following propagation of an 
action potential generated in a Ca
2+
-dependent manner where it may act on numerous 
pre- and post-synaptic glutamate receptors. The general synaptic localisation and 
function of glutamatergic receptors and transporters in summarised is illustrated in 
figure 1.3.  
      
1.5.2 Glutamate receptors  
 
Glutamate receptors can be broadly divided into two main classes, referred to as the 
ionotropic and metabotropic families. Ionotropic glutamate receptors (iGlu) are ion-
channel gated receptors where ligand-mediated activation leads to fast channel 
opening. In contrast, metabotropic glutamate receptors (mGlu) receptors are G-
protein coupled receptors where activation leads to the initiation of secondary 
messenger and intracellular signalling cascades. Whilst the focus of this thesis lies on 
mGlu receptors, the potential in targeting these receptors arose from numerous 
experimental findings investigating a role for iGlu receptors. Therefore the ionotropic 





















Figure 1.3. Schematic illustration of the general synaptic localisation and function of glutamatergic 
receptors and transporters. The ionotropic glutamate receptors, N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate subtypes, function 
predominantly to mediate fast receptor transmission and use-dependent changes required for synaptic 
plasticity. The vesicular transporters (vGluT) load glutamate into vesicles presynaptically whilst glial 
and astrocyte postsynaptic glutamate transporters (excitatory amino acid transporters, EAAT1-5) 
mediate the uptake of glutamate required to terminate synaptic transmission. The metabotropic 
glutamate receptors have a diverse synaptic localisation and function pre- and postsynaptically to 
modulate neurotransmitter release and postsynaptic excitability, respectively (figure adapted from 






1.5.2.1 Ionotropic glutamate receptors 
 
There are three main types of iGlu receptors which are named after the preferential 
ligand that activates them. These are α-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA), N-methyl-D-aspartate (NDMA) and 2-carboxy-3-
carboxymethyl-4-isopropenylpyolidine (kainate). 
 
1.5.2.1.1 AMPA receptors: Signal transduction, general distribution and therapeutic 
potential in PD 
 
AMPA receptors are responsible for the majority of fast excitatory transmission in the 
CNS, although they exhibit a much lower affinity (EC50 of 1mM) for the endogenous 
ligand glutamate, than NMDA receptors (EC50 of 2.3µM) (Hestrin, 1992; Patneau & 
Mayer, 1990). AMPA receptors comprise four subunits (GluR1-4) which are 
assembled as functional tetramers which can be both homomeric or heteromeric in 
composition (Rosenmund et al., 1998). Upon activation, AMPA receptors mediate 





.  The GluR2 subunit plays an important role in the determination of divalent 
cation permeability, where incorporation of this subunit is indicative of a low 
permeability to the resultant channel. (Hollmann et al., 1991). However homomeric 
or heteromeric receptors composed of GluR1, GluR3 or GluR4, in the absence of 






.  Further 
complexity is introduced by alternative splicing in the second extracellular domain 
with all AMPA subunits (GluR1-4) subunits being expressed as two alternate splice 
variants known as ‘flip’ and ‘flop’. Flip variants exist predominantly pre-natally, 
whilst the flop variant is the major splice variant in adults. Flip and flop variants of 
AMPA receptors alter the sensitivity of these receptors to allosteric modulators in 
addition to regulating the extent of receptor desensitisation. In fact AMPA receptors 
respond rapidly to agonist application, displaying rapid (2-14 msec) desensitisation in 
response to full agonists, AMPA and glutamate, but not to partial agonists such as 




AMPA receptors are widely distributed throughout the basal ganglia where high 
levels of receptors containing the GluR1-3 subunits are found on striatal MSNs, the 
GPi and SNpc. Those containing the GluR4 subunit are expressed predominantly in 
the GPi, SNpr and on glial cells (Greenamyre, 2001). Therefore owing to their wide 
distribution and ability to mediate excitatory neurotransmission, AMPA receptors 
have been proposed as potential drug targets in the treatment of PD. 
 
Antiparkinsonian effects of AMPA receptor antagonists both alone and in 
combination with dopaminergic therapies have been reported. For example, systemic 
administration of the AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo[f]quinoxaline-2,3-dione (NBQX) has been shown to reverse reserpine-induced 
muscle rigidity (but not akinesia) in rats and motor deficits in MPTP-lesioned 
primates (Klockgether et al., 1991). In addition, NBQX has been found to prolong the 
action of L-DOPA and decrease on-off phenomena in parkinsonian rats (Marin et al., 
2000). Interestingly, a separate study revealed NBQX improved the ability of L-
DOPA to reverse motor deficits in SNpc-lesioned rats and primates (Loschmann et 
al., 1991; Loschmann et al., 1992; Wachtel et al., 1992), suggesting AMPA receptor 
blockade may be a useful adjunct for improving the efficacy of L-DOPA treatment.   
 
Owing to their role in excitotoxicity, as modulators of the initial depolarising 
stimulation and Ca
2+
 influx, AMPA receptors have also been suggested as potential 
targets to provide neuroprotection. These effects could be mediated through a number 
of mechanisms including; prevention of desensitisation of Ca
2+
-impermeable GluR2 
subunits, modulation of AMPA receptor binding partners such as postsynaptic density 
protein of 95 kDa (PSD-95), Glutamate receptor interacting protein (GRIP), and 
protein interacting with C-kinase (PICK) as well as directly modulating ion-channel 
function (reviewed by Jayakar & Dikshit, 2004). Indeed, AMPA receptor inhibition 
by the negative allosteric modulator, talampanel, has demonstrated neuroprotection in 
the striatum and cortex following ischemic brain injury in rodents (Erdo et al., 2005). 
Furthermore, the authors suggest a reduction in glutamate-mediated excitotoxicity 
through selective blockade of Ca
2+
 permeable AMPA receptor ion channels as the 
predominant mechanism of action. Interestingly a separate study using AMPA 
positive allosteric modulators LY404187 and LY503430, has been shown to provide 
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protection against MPTP-induced toxicity in mice and lead to functional, histological 
and neurochemical improvements following 6-OHDA-lesioning in rodents (O'Neill et 
al., 2005; O'Neill et al., 2004). Despite increasing glutamate-induced calcium influx 
into HEK 293 cells through AMPA ion channels (which would be expected to 
promote excitotoxicity as discussed above) these agents are thought to mediate 
neuroprotection by increasing BDNF production (O’Neill et al., 2004; O’Neill et al., 
2005). Consequently, AMPA positive allosteric modulators maintain to be evaluated 
for the treatment of PD in humans.  
  
1.5.2.1.2: NMDA receptors: Signal transduction, general distribution and therapeutic 
potential in PD 
 
NMDA receptors are composed of a family of seven subunits, NR1, NR2A-D and 
NR3A/B forming a tetrameric structure. Functional receptors contain NR1 together 
with one other NR2 subunit, or NR1 and both NR2 and NR3 subunits (Monyer et al., 
1992). The agonist binding site for glutamate is on the NR2 subunit and a co-agonist 
binding site for glycine exists on the NR1 subunits with receptor activation requiring 
occupancy of both sites (Kuryatov et al., 1994). In the majority of cases, glutamate-
mediated excitatory postsynaptic potentials (EPSPs) are comprised of a fast AMPA 
receptor mediated component that depolarises the cell and then a slower NMDA 
receptor mediated component. This is due to tonic inhibition of NMDA receptors by 
the Mg
2+
 present in the extracellular fluid. Thus if a sufficiently large enough 
depolarisation occurs, the Mg
2+
 block is relieved enabling opening of the NMDA 
channel permitting Ca
2+
 entry. It is this mechanism that underlies learning and 
memory, through a process of long term potentiation (LTP) (Lynch, 2004). As 
NMDA receptors desensitise slowly, the continuing rise in intracellular Ca
2+
 may also 
lead to excitotoxicity and consequent apoptosis.    
  
NMDA receptors demonstrate expression in numerous regions of the basal ganglia, 
particularly the NR1 and NR2D subunits (Hallett & Standaert, 2004). NR2A and 
NR2B subunits are exclusively expressed in the striatum, where as NR2C subunits 
have only low expression in the SNpc (Hallett & Standaert, 2004). Therefore owing 
to their expression in the basal ganglia, coupled with their roles in synaptic 
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transmission and excitotoxicity, NMDA receptors have also been evaluated as 
therapeutic targets in PD.   
 
Interestingly, an assortment of competitive antagonists (e.g. SDZ 220-581), non-
competitive antagonists (e.g. MK-801 and dextrorphan), and glycine site antagonists 
(e.g. MRZ 2/570) have all been shown to reverse catalepsy and muscle rigidity 
induced by dopamine receptor blockade in rat models of PD (reviewed by Johnson et 
al., 2009). MK-801 has also shown antiparkinsonian effects alone in 6-OHDA-
lesioned rats as well as potentiating the effects of L-DOPA in both primate and rodent 
models of PD (Greenamyre et al., 1994). Additionally MK-801 given by intra-
subthalamic injection was shown to reduce mean firing rates of STN neurones by up 
to 20% which may underlie its antiparkinsonian efficacy (Allers et al., 2005). 
 
NMDA receptor antagonists such as MK-801 however, have been associated with 
severe side effects in larger mammals. Systemic administration of MK-801 has been 
reported to cause sedation in parkinsonian macaques (Crossman et al., 1989), whilst 
ketamine, a NMDA antagonist used as a dissociative anaesthetic in humans can 
promote psychotomimetic action, memory deficits and addiction in low doses (Hallett 
& Standaert, 2004). Therefore, these complications have led to the search of more 
subtype-selective NMDA antagonists that might provide antiparkinsonian effects 
without cognitive side effects. One such target that has emerged from this search is 
the NR2B subunit which is almost exclusively expressed in the striatum. Indeed 
systemic administration of the NR2B selective antagonist ifenprodil relieves akinesia 
in reserpine-treated rats and MPTP-treated primates (Nash et al., 1999; Nash et al., 
2000). In addition, it has been shown systemic oral treatment with a highly selective 
NR1A/NR2B subunit antagonist, CI-1041, can prevent the initiation of L-DOPA 
induced dyskinesias in MPTP-lesioned primates (Hadj et al., 2004). In contrast, 
administration of an NR1/NR2B-selective NMDA antagonist, CP-101606 had no 
benefit on parkinsonian symptoms when administered as a monotherapy and provided 
only mild potentiation of L-DOPA-induced motor benefits (Nash et al., 2004). 
Therefore NR2B subtype specific NMDA antagonists may offer an improved 
therapeutic alternative to the classical non-selective NMDA antagonists, although 




1.5.2.1.3: Kainate receptors: Signal transduction, general distribution and 
therapeutic potential in PD 
 
Kainate receptors comprise five subunits, separated into two groups; the KA1 and 
KA2 (which demonstrate higher affinity for kainate) and secondly GluR5-7 
(Hollmann & Heinemann, 1994). Kainate receptors function as tetramers which likely 
exist in both homomeric and heteromeric configurations. Any combination of 
subunits is thought to be possible although only receptors formed from KA1 or KA2 
subunits demonstrate a functional channel. Kainate receptors containing Glu5-6 
subunits demonstrate a reduction in Ca
2+
 permeability (Burnashev et al., 1995). The 
function of kainate receptors remain poorly understood, however it is thought their 
postsynaptic receptors may be involved in carrying part of the current charge required 
in signal transduction where a potential role in synaptic plasticity has been suggested 
(reviewed in Lerma, 2006). Kainate receptors, in contrast to AMPA and NMDA iGlu 
receptors reside both pre and post-synaptically, where they are thought to modulate 
neurotransmitter release (Rodriguez-Moreno et al., 1997). 
 
Kainate receptors are presumed to be widely distributed throughout the CNS, 
although there are currently few distribution studies to support this notion. 
Consequently, few studies have been performed to examine the antiparkinsonian 
potential of these receptors. However one study has shown that kainite GluR6/7 
subunits expressed presynaptically on GABAergic pallidal terminals, function as 
heteroreceptors to modulate GABA release (Kane-Jackson & Smith, 2003). 
Furthermore, an electrophysiological study in the GP has shown kainate could 
significantly inhibit evoked inhibitory postsynaptic currents through a kainate 
mediated mechanism (Jin & Smith, 2007). This would suggest kainate receptors may 
have antiparkinsonian activity by decreasing the excessive GABA release within 







1.5.2.2 Metabotropic glutamate receptors 
 
Despite the promise of targeting iGlu receptors in the treatment of PD, their potential 
has been hampered by a lack of specificity in exclusively targeting overactive 
glutamatergic transmission. Owing to their wide distribution, blockade of these ion 
channel receptors can also interfere with learning and memory, potentially leading to 
severe side effects in humans. Thus focus has turned towards evaluating the 
metabotropic glutamate (mGlu) receptors as novel targets for the treatment of PD. In 
fact over the last few years, mGlu receptors have received a wealth of interest no 
doubt owing to their expression within the basal ganglia motor loop and ability to 
modulate glutamatergic transmission in a more subtle manner than iGlu receptors. 
Furthermore recent emphasis has focused more on developing ‘modulators’ rather 
than the classical ‘agonist’ which bind to a separate allosteric site and rely on the 
endogenous ligand i.e. glutamate to bind for activation. It is hoped this offers a far 
more exclusive approach to specifically targeting hyperactive glutamatergic 
transmission indicative of a diseased state as in PD. Since the focus of this thesis is to 
assess the therapeutic potential of targeting metabotropic glutamate receptors 
(particularly group III receptors) for PD, this family of receptors is discussed in 
greater detail below. 
 
1.5.2.2.1: Structure of metabotropic glutamate receptors 
 
 The mGlu receptors are G-protein coupled receptors (GPCRs), which on the basis of 
sequence homolog belong to family C GPCRs along with the GABAB receptors, Ca
2+
 
sensing receptors, pheromone receptors, olfactory and taste receptors (Schoepp, 
2001). As with many GPCRs, the mGlu receptors comprise a single polypeptide 
chain spanning seven transmembrane domains, where hydrophilic segments form the 
intracellular C-terminal domain and a characteristically large extracellular N-terminal 
domain. The N-terminal chain, forming two globular domains joined by a hinge 
region, similar to that of a Venus fly-trap configuration creates the ligand binding site 
for mGlu receptors (shown in figure 1.4; Conn & Pin, 1997). Interaction with the 
trimeric G-protein occurs in the central portion of the second intracellular loop, which 
is responsible for the selective recognition of the C-terminal end of the G-protein α-
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subunit (Havlickova et al., 2003). The G-protein becomes activated following ligand 
binding which facilitates the exchange of GDP for GTP within the α-subunit from the 
βγ subunits which are then able to regulate numerous enzymes and ion channels via 
secondary messengers to initiate numerous downstream cellular effects. 
 
The mGlu receptors are sub-divided into three groups, Group I, II and III based on 
sequence homology, second messenger coupling and pharmacological profile. Group 
I mGlu receptors comprise mGlu1 and 5, Group II- mGlu2 and 3, and Group III – 
mGlu4, 6, 7 and 8 where further multiplicity is achieved by alternative splicing of 
group I and III (detailed in table 1.2). Functionality in this family relies on the 
formation of homodimers linked by disulphide bonds. The group I mGlu receptors 
can also form a heterodimer with Ca
2+
-sensing receptors and adenosine A1 receptors, 
although such dimerisation has not been demonstrated for group II and III mGlu 
receptors (Jingami et al., 2003). Glutamate is the predominant endogenous ligand at 
these receptors, however there is evidence L-cysteic acid and L-cysteine sulphinic 
acid can also activate group I mGlu receptors (Croucher et al., 2001). In situ 
hybridisation and immunohistochemical studies reveal all mGlu receptors are found 
in abundance in the basal ganglia apart from mGluR6 which is exclusively expressed 























Figure 1.4. Schematic illustration of a metabotropic glutamate receptor with a characteristically large 
N-terminal extracellular domain that contains the orthosteric binding site for the endogenous ligand 
glutamate. The seven transmembrane domains (labelled in white) are connected by three intracellular 
and extraceullar loops followed by a C-terminal tail. Allosteric ligands bind to an additional site to the 
orthosteric glutamate-binding site within the seven transmembrane domains. Abbreviations: 7-TM 





1.5.2.2.2 Group I mGlu receptors: Signal transduction, general distribution and 
therapeutic potential in PD 
 
The group I mGlu receptors (mGlu1a-d and 5a/b) are predominantly postsynaptic 
although have been located at pre-synaptic terminals. All members of the group I 
mGlu receptors couple to the Gq G-protein which is positively coupled to 
phospholipase C (PLC), hydrolysing membrane phosphoinositide to form inositol 
triphosphate (IP3) and diacylglycerol (DAG). IP3 induces Ca
2+
 release from IP3-
sensitive intracellular stores whilst DAG triggers protein kinase C (PKC) activity 
(Takechi et al., 1998). Activation of group I mGlu receptors can also increase 
intracellular calcium in an IP3-independent manner through opening of L-type voltage 
dependent Ca
2+
 channels and inhibition of K
+
 channels. In addition, the long 
intracellular C-terminal tail of mGlu1a and mGlu5a/b enables binding to Homer 
adaptor proteins (Tu et al., 1998). Homer protein complexes allow mGlu receptors to 
come into close proximity with downstream targets. For example, homer connects 
mGlu1a and mGlu5a/b to ryanodine and IP3 receptors providing optimal organisation 
for Ca
2+
 release following receptor activation. Homer proteins also enable interaction 
between group I mGlu receptors and iGlu receptors, AMPA and NMDA (Tu et al., 
1999) which can lead to potentiation of excitatory responses due to increased 
intracellular Ca
2+
 concentration.  
 
Group I mGlu receptors are widely expressed throughout the basal ganglia, 
preferentially within postsynaptic regions of the striatum, globus pallidus, STN and 
substantia nigra (Testa et al., 1998). A degree of subtype differentiation exists since 
mGlu1 is found in abundance in the SNpc, where as mGlu5 is expressed 
predominantly in the striatum, STN and PFC with lower expression in other regions 
of the basal ganglia (Testa et al., 1998; Messenger et al., 2002). In the striatum, group 
I mGlu receptors are found both presynaptically on dopamine terminals that converge 
with MSNs and postsynaptically within the perisynaptic space on MSNs and 
interneurons (Gubellini et al., 2004; Smith et al., 2000; Zhang & Sulzer, 2003). In a 
state of elevated glutamate release, presynaptic group I mGlu receptors inhibit 
dopamine release by raising intracellular levels of Ca
2+





 channels leading to hyperpolarisation (Zhang & Sulzer, 2003). However, 
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activation of postsynaptic mGlu5 receptors on MSNs potentiates NMDA currents 
(Pisani et al., 2001). The activation of NMDA receptors can also potentiate mGlu5 
receptor signalling by the activation of the protein phosphatase calcineurin, thus 
limiting receptor desensitisation through subsequent dephosphorylation of mGlu5 
(Alagarsamy et al., 1999).   
 
The differential role of group I mGlu receptors within the striatofugal system is 
worthy of discussion here. With respect to the direct pathway, activation of group I 
mGlu receptors can inhibit D1 mediated responses by modulating the activity of 
dopamine and cyclic AMP-regulated phosphoprotein (DARPP-32). D1 responses are 
normally amplified by the phosphorylation of DARP-32 by protein kinase A (PKA), 
consequently converting DARP-32 to an inhibitor of protein phosphatase 1. However, 
this pathway is inhibited following activation of group I mGlu receptors, by the 
stimulation of casein kinase 1 (CK1) and cyclin-dependent kinase 5 (CDK5), which 
phosphorylate DARP-32, converting the protein to an inhibiter of PKA (Liu et al., 
2001). Thus, group I mGlu receptor activation inhibits the activity of D1 projections 
of the direct striatofugal pathway.  
 
In the indirect pathway, activation of group I mGlu receptors can suppress the actions 
of dopamine on MSNs that project to the GPe to increase neuronal excitability in the 
STN and SNpc. Furthermore, NMDA receptor currents in MSNs that project to the 
GPe are potentiated by ACh released by large spiny striatal interneurons in response 
to group I mGlu receptor activation (Gubellini et al., 2004). Therefore, these findings 
suggest that blockade of group I mGlu receptors could be therapeutic by suppressing 
hyperactive glutamatergic transmission in overactive corticostriatal, subthalamonigral 
and subthalamopallidal pathways or cholinergic transmission in striatal interneurons.  
Since group I mGlu receptor activation opposes the action of dopamine, group I 
mGlu receptor antagonists have been evaluated for antiparkinsonian effects. 
Currently, focus has been on mGlu5 where chronic treatment with a selective mGlu5 
negative allosteric modulator 2-methyl-6-(phenylethynyl)-pyridine (MPEP), 
significantly reversed akinesia in a bilateral 6-OHDA rodent model of PD (Breysse et 
al., 2002). In addition, microinjection of MPEP into the STN of unilaterally 6-
OHDA-lesioned rats significantly attenuated motor asymmetries with respect to 
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vehicle-treated animals, although microinjection into the SNpr and EP had no effect 
(Phillips et al., 2006). These findings would suggest antiparkinsonian effects of 
MPEP are predominantly mediated via the STN which is supported by an 
electrophysiological study confirming mGlu5 modulates glutamatergic transmission 
in the STN. Furthermore, acute and sub-chronic intranigral administration of MPEP 
and LY367385 (mGlu1 antagonists) in 6-OHDA lesioned rats has been shown to 
significantly protect TH-positive cells in the SNpc with respect to vehicle-treated 
animals (Vernon et al., 2007a). This is consistent with the notion that excitation of 
nigral dopaminergic neurones is regulated by the activation of group I mGlu receptors 
which may ultimately lead to excitotoxic effects.  
 
To date, the antiparkinsonian efficacy of group I mGlu receptor antagonists has not 
been tested clinically thus only time will tell if transfer of these compounds to clinical 
trials will be deemed worthwhile. However, the anxiolytic, fenobam, discovered to be 
a negative allosteric modulator of mGlu5 receptor (Porter et al., 2005), has previously 
been tested in Phase II clinical trials showing good anxiolytic efficacy and being 
generally well-tolerated, although some psychotomimetic activity was reported 
(Pecknold et al., 1982). Therefore these previous clinical trials with fenobam may 
help to accelerate the transfer of group I mGlu antagonists into clinical trials for PD, 
should this deemed to be worthwhile.      
 
1.5.2.2.3 Group II mGlu receptors: Signal transduction, general distribution and 
therapeutic potential in PD 
 
Group II mGlu receptors (mGlu2 and 3) are predominantly found presynaptically 
where they are usually located in pre-terminal axons (Shigemoto et al., 1997). They 
function largely in a very similar manner to group III mGlu receptors which are 
discussed in section 1.5.2.2.4, therefore their mechanism of action will be discussed 
in more detail there. In brief, group II mGlu receptors are negatively coupled to 
adenylate cyclase via Gi or Go-proteins resulting in a decrease in intracellular cAMP 
and presynaptic membrane hyperpolarisation (Conn & Pin, 1997). In addition, the βγ- 
subunit of group II mGlu receptors can inhibit L, N and P/Q type voltage dependent 
calcium channels. It is thought through these mechanisms group II mGlu receptors 
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can function as hetero- and auto-receptors by decreasing neurotransmission 
throughout the CNS at inhibitory and excitatory synapses respectively (Manzoni et 
al., 1997; Salt & Turner, 1998). 
 
Group II mGlu receptors are widely distributed throughout the basal ganglia. For 
example mGlu3 has shown robust gene expression throughout the motor loop 
particularly within the striatum (Messenger et al., 2002). Using in situ hybridisation, 
mGlu2 expression has been located within the premotor cortex, striatum and STN 
(Messenger et al., 2002; Ohishi et al., 1998). In addition, mGlu3 but not mGlu2 has 
been shown on glial cells, close to excitatory synapses (Testa et al., 1994). Indeed 
activation of mGlu3 receptors on astrocytes have been shown to be neuroprotective 
against NMDA-induced toxicity, which is thought to be driven by an increase in 
transforming growth factor-β (TGFβ) release (Bruno et al., 2001).  
 
Activation of group II mGlu receptors has been shown to inhibit glutamate release 
from corticostriatal and corticosubthalamic terminals (Lovinger & McCool, 1995). In 
addition, group II mGlu receptor activation on large aspiny interneurons has been 
shown to inhibit ACh release (Pisani et al., 2003). Electrophysiological studies have 
revealed group II mGlu receptors may also modulate dopamine release where their 
activation reduces transmission at excitatory synapses onto dopaminergic neurones 
(Wigmore & Lacey, 1998). However, a contrasting study has shown using 
microdialysis in the striatum and in vitro release from nigral slice preparations, group 
II mGlu receptor agonists can cause an increase in dopamine release (Campusano et 
al., 2002). Thus, the role of group II mGlu receptors in the regulation of 
dopaminergic function is unclear, although increasing dopamine release may well aid 
in normalising function of the striatofugal system in parkinsonian conditions. An 
important function of group II mGlu receptors has been revealed at the 
subthalamonigral terminals where activation of mGlu2 and 3 receptors have been 
shown to inhibit excitatory glutamatergic transmission (Bradley et al., 2000).  
Therefore, these actions may well cause antiparkinsonian effects by reducing 
overactive excitatory drive from the STN to the GPi and SNpr output nuclei to 




The potential of targeting group II mGlu receptors for treatment in PD has been 
addressed in several animal models of PD. Indeed, in vivo studies using the group II 
mGlu receptor agonist LY379268 have shown i.c.v. administration reduces reserpine-
induced akinesia although no antiparkinsonian efficacy was observed following 
systemic administration in the 6-OHDA-lesioned or reserpine-treated rat models 
(Murray et al., 2002). This may be due to dopamine-mediated alterations in function 
or poor bioavailability in the brain. It is thought there are two predominant 
mechanisms to mediate neuroprotection following group II mGlu receptor activation, 
either by prevention of glutamate-mediated excitotoxicity or through release of 
neurotrophic factors such as TGF-β from glial cells. An interesting study by Picconi et 
al., (2002) using LY379268 and an additional agonist DCG-IV found greater 
sensitivity in depressing excitatory transmission in the corticostriatal synapse of 6-
OHDA lesioned rodents with respect to controls. This hyper-responsiveness suggests 
group II mGlu receptors may become over-expressed as a compensatory mechanism 
in PD. 
 
Although the antiparkinsonian effects of group II mGlu receptor agonists has not 
been tested in humans, they have however been tested in phase II clinical trials for 
anxiety disorders. Although the group II mGlu selective agonist LY354740 showed 
no anxiolytic activity, it was well tolerated revealing minor side-effects limited to 
gastrointestinal complaints (Bergink & Westenberg, 2005). Group II agonists should 
therefore be able to progress into clinical trials in PD, should this be deemed 
worthwhile.  
 
1.5.2.2.4 Group III mGlu receptors: Signal transduction 
  
The group III mGlu receptors (mGlu4a/b, 6, 7a/b and 8a/b) similar to group II are 
expressed predominantly presynaptically usually within the presynaptic zone 
(Shigemoto et al., 1997). mGlu6 however is postsynaptic and is exclusively 
expressed in the retina, so will not be discussed further (Nakajima et al., 1999). 
Group III mGlu receptors are coupled to Gi/Go where their activation leads to 
inhibition of L,N, and P/Q type voltage dependent Ca
2+





 channels (signalling for all the  mGlu receptors are summarised in 
table 1.1).  
 
Electrophysiological studies have confirmed both an auto and hetero-receptor role 
following activation of group III mGlu receptors serving to inhibit glutamate release 
on excitatory synapses (Turner & Salt, 1999) and GABA release on inhibitory 
synapses (Turner & Salt, 2003). As group III mGlu receptors have a relatively low 
affinity for glutamate and consequently are only activated by excess glutamate 
release, their function may be considered to be of feedback inhibition (Scanziani et 
al., 1997). This property immediately raises the possibility that these receptors may 
play a key role in conditions where excitatory glutamate levels are raised, such as in 
PD. This potential is discussed at length in section 1.5.2.2.6. 
 
The second messenger systems are not widely described for group III mGlu receptors 
although those involved in mGlu7 have been studied more extensively than other 
subtypes, therefore are discussed in more detail here as a likely example. Activation 
of mGlu7 is negatively coupled to adenylate cyclase via direct interaction with the G-
protein, leading to a decrease in cAMP (Okamoto et al., 1994). Following mGlu7 
activation, fast inhibition of N-type Ca
2+
 channels occurs as a result of a direct 
interaction with the now dissociated G-protein βγ subunit and the α1 subunit of the 
calcium channel (Waard et al., 1997). 
 
Group III mGlu receptors can also bind calmodulin (CaM) in the C-terminal by a 
Ca
2+
-dependent process (Nakajima et al., 1999). Indeed, numerous 
electrophysiological studies have demonstrated CaM binding can promote the 
dissociation of the G-protein βγ subunit (Dev et al., 2001). Therefore, it has been 
suggested following nerve terminal depolarisation, high levels of intracellular Ca
2+
 
allow group III mGlu receptors to mediate feedback inhibition of glutamate release 
via a Ca
2+
/ CaM-dependent mechanism. There is however an additional level of 
complexity within mGlu7 signalling since receptor activation is also positively 
coupled to PLC (Perroy et al., 2000). This is somewhat of a surprise as this could lead 
to two mechanisms not indicative of an inhibitory role for mGlu7 receptors. The first 
of these is that PLC activation would cause an excitatory increase in intracellular 
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calcium. However this effect seems unlikely since this PLC mediated pathway has 
been shown to inhibit opening of P/Q type voltage-dependent Ca
2+
 channels (Perroy 
et al., 2000). Secondly, PLC activation is known to activate PKC, a known inhibitor 
of CaM-mGlu7 binding. Indeed, phosphorylation at Ser862 within the mGlu7 C-
terminus by PKC, inhibits CaM binding (Airas et al., 2001) and thus negatively 
regulates mGlu7 activity. Therefore, the role of PLC/PKC-mediated pathways 
implicated in downstream signalling following mGlu7 activation may result in a form 
of negative feedback upon receptor activation, although the exact function of this 
mechanism remains to be determined.     
 
An additional level of complexity within group III mGlu receptors is that mGlu4a, 7a, 
and 8a can all be phosphorylated by PKA, which effectively serves to inhibit the 
function of these receptors (Cai et al., 2001). It is widely accepted that group III 
mGlu receptor inhibition of cAMP results in decreased PKA activity, promoting CaM 
binding and inhibition of Ca
2+
 channels. However, Gs-coupled presynaptic receptors 
which activate PKA can negatively regulate the function of group III mGlu receptors. 
Similar crosstalk has been reported between the β-adrenergic receptor and group III 
mGlu receptors where the β-adrenergic agonist, isoproterenol has been shown to 
block inhibition of EPSPs mediated by L(+)-2-amino-4-phosphonobutyric acid (L-
AP4) in hippocampal slices (Cai et al., 2001). 
 
All group III mGlu receptor subtypes have been shown to interact with the adaptor 
protein PICK1 via a PDZ-binding domain in their C-terminal (El et al., 2000). PICK1 
has been shown to attenuate PKCα-evoked phosphorylation of mGlu7a to allow 
dissociation of βγ (Dev et al., 2001). Although the exact interplay between PICK1, 
PKC and group III mGlu receptors is far from understood, the presence of PICK1 
appears to be an absolute requirement for the inhibition of P/Q-type calcium channels 
by mGlu7a. Further proteins interacting with the group III mGlu receptor C-terminal 
domain include adaptor proteins, syntenin and GRIP, as well as protein phosphatase-
1, which could be important in dephosphorylating Ser862 (Enz & Croci, 2003; Hirbec 
et al., 2002). An additional group III mGlu receptor interacting protein, Filamin-A 
(Enz & Croci, 2003), induces the polymerisation of actin filaments, providing a 
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physical link between mGlu receptors and the actin cytoskeleton which could be 
important in regulating the macromolecular structure at the synapse. 
 
A further level of complexity regarding the signalling of group III mGlu receptors has 
been shown by L-AP4 activating MAPK and phosphatidylinositol-3-kinase (PI3K) 
pathways, which may lead to a neuroprotective effect following activation of these 
receptors (Iacovelli et al., 2002). L-AP4-mediated activation of group III mGlu 
receptors led to an activation of MAPK which was attenuated by overexpression of 
G-protein coupled receptor kinase-2 (GRK2) (Iacovelli et al., 2004). The authors of 
this report suggest GRK2 may interact with mGlu4 via the βγ subunit, as this effect 
was not dependent on its kinase activity.  
 
1.5.2.2.5 Group III mGlu receptors: General distribution 
  
The mGlu4 receptor subtype has been found to be expressed throughout the CNS, 
where the most intense expression is in the cerebellar granule cells (Kinoshita et al., 
1996). High expression of mGlu4 is also found in the olfactory bulb, entorhinal 
cortex, hippocampus, lateral septum, amygdala, thalamic nuclei, lateral mammillary 
nucleus, pontine nuclei and dorsal horn (Ferraguti & Shigemoto, 2006). At the 
electron-microscope (EM) level, mGlu4 immunoreactivity has been localised to the 
presynaptic active zone, within the medial nucleus of the trapezoid body and the 
dentate gyrus (Elezgarai et al., 1999; Shigemoto et al., 1997). 
 
The distribution of mGlu7a is the most extensively expressed of the group III mGlu 
receptors, where the most intense expression is present in the olfactory bulb, neurones 
of the medial septal nucleus and locus coeruleus (Kinoshita et al., 1996; Shigemoto et 
al., 1997). There is also high expression of mGlu7a in the neocortex, hippocampus, 
septum, claustrum, amygdala, hypothalamus, thalamus, SC, locus coeruleus and 
dorsal horn of the spinal cord (Ferraguti & Shigemoto, 2006). mGlu7b however, has a 
more limited expression and is usually found co-localised with mGlu7a (albeit to a 
lower level) in the neocortex, anterior thalamus, medial geniculate nucleus and locus 
coeruleus (Ferraguti & Shigemoto, 2006). At the EM level, both mGlu7a and mGlu7b 
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have been observed almost exclusively in the presynaptic active zone in axon 
terminals (Shigemoto et al., 1997). 
 
A more restricted pattern for mGlu8 is observed to that of mGlu7 (Corti et al., 1998), 
although high mGlu8 expression has been seen in the olfactory bulb, hippocampus, 
lateral reticular nucleus of the medulla oblongata as well as the cerebral, piriform, and 
entorhinal cortices (Ferraguti & Shigemoto, 2006). The expression of mGlu8a is 
higher than mGlu8b whilst both generally overlap in terms of expression, although 
the spinal vestibular nucleus and lateral nucleus of the medulla oblongata, only 
express mGlu8a (Corti et al., 1998). At the EM level mGlu8a has been observed in 
the presynaptic zone of axon terminals in the hippocampus (Shigemoto et al., 1997).          
 
1.5.2.2.6 Group III mGlu receptors: Distribution and function in the basal ganglia 
 
All group III mGlu receptors are expressed within the basal ganglia aside from 
mGluR6. In situ hybridisation studies have shown high mRNA levels for mGluR4 
and 7 within the striatum, moderate levels in the STN and lower levels in the SNpr, 
SNpc and GP (Messenger et al., 2002). Moderate levels of mGluR8 mRNA were 
found in the striatum and STN although expression was low in all other structures of 
the basal ganglia (Messenger et al., 2002). [
3
H]-L-AP4 binding studies in rat brain 
sections revealed high levels of binding in the GP and SNpr, with lower expression in 
the striatum, STN and SNpc (Hudtloff & Thomsen, 1998). These findings confirm 
receptor expression in the basal ganglia output structures, presumably on 
striatopallidal, striatonigral and subthalamonigral projections.  
 
EM studies using antibodies directed against mGlu4 have revealed a presynaptic 
localisation of mGlu4 within the striatum, GPe, SNpr and EP (Corti et al., 2002). In 
addition, mGlu4 immunoreactivity has been confirmed presynaptically at inhibitory 
synapses within the SNpr from subthalamonigral projections (Bradley et al., 1999; 
Corti et al., 2002). Immunoreactivity for mGlu7a has been shown within the striatum, 
GP and SNpr where EM studies have confirmed expression on axon terminals of 
corticostriatal and striatopallidal projections (Kosinski et al., 1999). mGlu7a was also 
confirmed on corticostriatal terminals although this study did not investigate synapses 
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within the SNpr. Thus, mGlu7a expression on subthalamonigral terminals remains 
unproven, although mRNA expression within the STN would suggest mGlu7a is 
likely to be present at these terminals. Currently, no immunohistochemical studies 
have investigated the distribution of mGlu8 within the basal ganglia.  
 
The widespread expression of group III mGlu receptors within the basal ganglia, 
coupled with their ability to modulate both excitatory and inhibitory transmission has 
rendered this group of mGlu receptors appealing targets for therapeutic modulation in 
PD. Electrophysiological studies have posed numerous beneficial effects group III 
mGlu receptor activation could provide in a parkinsonian basal ganglia. For example, 
at the striatopallidal synapse, activation of group III mGlu receptors was able to 
inhibit GABAA-mediated IPSPs through a presynaptic mechanism (Valenti et al., 
2003). Additionally these effects were absent in mGlu4 knock-out mice confirming 
an mGlu4-mediated response. As this is the first synapse in the indirect pathway 
which is thought to be heavily regulated by striatal D2 receptors, mGlu4 receptor 
activation may be able to exert a dopamine-like effect by reducing transmission at 
this synapse. Indeed the benefits of targeting the GPe have been confirmed in vivo, 
where intrapallidal injections of the group III broad spectrum agonist, O-Phospho-L-
serine (L-SOP) reversed reserpine-induced akinesia in rats (MacInnes et al., 2004). 
Furthermore, i.c.v. administration of the positive allosteric modulator of mGlu4, N-
Phenyl-7-(hydroxyamino)cyclopropa[b]chromen-1a-carboxamide (PHCCC), 
demonstrated activation of the mGlu4 receptor alone can reverse reserpine-induced 
akinesia in rats (Marino et al., 2003). However the effects of PHCCC in this study 
could also be due to modulation of glutamate release further downstream at the 
subthalamonigral synapse.   
 
Electrophysiological studies within the SNpr have demonstrated activation of group 
III mGlu receptors by L-AP4 was able to inhibit glutamate-mediated EPSPs, via a 
presynaptic mechanism (Wittmann et al., 2001). Furthermore, L-AP4 also inhibits 
excitatory neurotransmission in the SNpc, an effect potentiated by the mGlu4 positive 
allosteric modulator (PAM) PHCCC, suggesting mGu4 receptor activation may be 
key to this response (Valenti et al., 2005). Therefore, the potential benefits of group 
III mGlu receptor activation in the parkinsonian substantia nigra are two-fold; (i) to 
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decrease excess glutamate release in the SNpr, therefore normalising thalamocortical 
feedback and potentially reversing akinesia; and (ii) to decrease excess glutamate 
release in the SNpc, which may be responsible for neurodegeneration of 
dopaminergic neurones by excitotoxicity. It is the potential of group III mGlu 
receptor activation to mediate neuroprotection that the studies conducted in this thesis 
set out to address. A recent report demonstrating that sub-chronic intranigral 
administration of L-AP4 provided neuroprotection of nigral TH positive cells in the 
6-OHDA model of PD provided the initial support to this aim (Vernon et al., 2007b). 
 
Group Number  Receptor subtypes 
(splice variants)  
G-protein  Effects of activation  
1   
mGlu1 (a,b,c,d) 





↑ DAG, IP3 
↑ L-VDCC  







↓ cAMP  
↓ VDCC 
3  mGlu4 (a,b) 
mGlu6 
mGlu7 (a,b) 




↓ [Ca2+]  
↓ cAMP  
↓ VDCC  
 
 
Table 1.2: Summary of the classification and signalling of the different mGlu receptor subtypes. 
Abbreviations: DAG: Diacylglycerol; IP3: Inositol-1,4,5-phosphate; cAMP: cyclic adenosine 
monophosphate; L-VDCC: L-type voltage-dependent calcium channels VDCC: voltage-dependent 









1.6 General hypothesis 
 
Activation of Gi/o coupled group III mGlu receptors leads to inhibition of pre-synaptic 
Ca
2+ 
channels and hence transmitter release from neurons in which they reside. Group 
III mGlu receptors, notably mGlu4,7 and 8 are believed to be located pre-synaptically 
on subthalamonigral neurons.  
 
We hypothesise activation of group III mGlu receptors on the subthalamonigral 
pathway by inhibiting glutamate transmission in the SNpc may provide functional 























1.7 Broad aims of this thesis 
 
In order to investigate our hypothesis, the overall aim of the studies described in this 
thesis was to delineate the potential of targeting group III mGlu receptor subtypes to 
provide functional neuroprotection in the 6-OHDA rodent model of PD. 
 
In Chapter 2 of this thesis, preliminary immunohistochemical studies were 
undertaken to investigate the distribution patterns of group III mGlu receptors within 
the basal ganglia motor loop, with special focus on their distribution within the SNpc.  
 
In Chapter 3, an initial study was conducted to confirm the ability of broad spectrum 
agonist-induced activation of group III mGlu receptors to provide neuroprotection in 
the 6-OHDA lesion rat model of PD. These studies expanded on existing knowledge 
to assess if protection at the post-mortem level translated to preservation in motor 
function. Next, the pharmacological identity of the group III mGlu receptor mediating 
this protective effect was examined. Previous reports in the literature had suggested 
the mGlu4 receptor may be a key subtype in mediating neuroprotective effects 
therefore focus of Chapter 4 was to assess the potential of targeting mGlu4 receptors 
to provide functional neuroprotection in the 6-OHDA rat model of PD.  
 
Further studies were performed using a similar experimental paradigm to assess the 
potential of targeting mGlu7 and mGlu8 receptor subtypes, the findings of which are 
discussed in Chapter 5. Within Chapters 4 and 5, attempts were also made to begin to 
elucidate mechanisms involved in meditating neuroprotective effects. Previous work 
in this lab had already implicated inhibition of glutamate release in the actions of 
these agents; here potential neuroinflammatory mechanisms were explored using 
immunocytochemistry to assess astroglial and microglial function following 
treatment with selective group III mGlu receptor agents. By conducting these 
investigations it was hoped that the data generated would provide evidence in support 
of group III mGlu receptors subtypes as an alternative, non-dopaminergic, strategy to 





Chapter 2: Preliminary investigation to assess the 
distribution of group III metabotropic glutamate 



































Before we set out to investigate the neuroprotective potential of targeting group III 
mGlu receptors using selective pharmacological ligands, this preliminary study 
sought to determine the expression profile of each of the subtypes throughout the 
basal ganglia. As previously mentioned, there are four group III mGlu receptor 
subtypes, mGlu4, 6, 7 and 8; all of which are widely expressed throughout the CNS, 
with the exception of mGlu6 which is largely restricted to the retina (discussed in 
Chapter I, section 1.5.2.2.5). These Gi/Go-coupled receptors are found predominantly 
on pre-synaptic terminals of GABAergic and glutamatergic neurones where they are 
involved in regulating synaptic transmission, most likely through inhibition of 
voltage-gated calcium entry required for triggering transmitter release (Conn & Pin, 
1997; Trombley & Westbrook, 1992). These receptors have also been demonstrated 
at postsynaptic sites in some brain regions where their signalling through activation 
of G-protein coupled inwardly rectifying potassium channels is expected to produce 
membrane hyperpolarisation (Saugstad et al., 1996). 
 
Localization of group III mGlu receptors within the basal ganglia has been unravelled 
to some extent through a combination of in situ hybridization, immunohistochemistry 
and electron microscopy studies in rodents. Indeed, our understanding of the 
distribution of mGlu4 and mGlu7 receptors has not changed significantly in the last 
decade (compare Rouse et al., 2000 with Duty, 2010). Both mGlu4 and mGlu7 
receptors exhibit a predominantly pre-synaptic distribution. They have been found on 
terminals of the glutamatergic corticostriatal pathway which is considered to be 
overactive in PD and thereby contribute to the increased firing of the indirect basal 
ganglia pathway (Obeso et al., 2008). Furthermore, autoradiographic visualisation of 
group III mGlu receptors, using the broad spectrum group III mGlu agonist [
3
H]-L-
AP4, has shown high levels of binding within the GP and SNpr, moderate levels in 
the striatum, and low levels within the STN and SNpc in rat brain (Hudtloff & 
Thomsen, 1998). In support of this finding, mGlu4 and mGlu7 receptors have been 
found on terminals of the GABAergic striatopallidal and striatonigral pathways 
(Bradley et al., 1999; Corti et al., 2002; Kosinski et al., 1999) as well as on excitatory 
(presumed glutamatergic) terminals in the SNr (Kosinski et al., 1999; Corti et al., 
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2002). While the SNr receives excitatory inputs not only from the STN but also from 
the pedunculopontine nucleus and frontal cortex (Carter, 1982; Di Loreto et al., 1992; 
Kita & Kitai, 1987), the presence of mGlu4 and mGlu7 mRNA in the STN (Kosinski 
et al., 1999; Messenger et al., 2002; Testa et al., 1994) strongly supports their 
expression on terminals of STN efferents in the so-called subthalamonigral pathway. 
In a study in which antibodies were raised against the mGlu4 receptor, specifically 
the mGlu4a splice variant which demonstrates similar distribution patterns to the 
mGlu4b variant, showed co-localisation with the pre-synaptic terminal marker, 
synaptic vesicle protein-2, suggesting these receptors are located pre-synaptically on 
afferents in the SNpr (Bradley et al., 1999; Iversen et al., 1994). Whether these were 
subthalamonigral or striatonigral terminals was not examined.  
 
The distribution of mGlu8 receptors in the basal ganglia is the least well characterized 
of all, although expression of mRNA encoding mGlu8 receptors has been reported in 
the cortex, striatum and STN (Messenger et al., 2002). Therefore, it remains a 
possibility that mGlu8 receptors are found on pre-synaptic terminals of corticostriatal, 
striatonigral and subthalamonigral pathways. In addition, binding studies comparing 
[
3
H]-L-AP4 (30nM) binding in wild-type and mGlu4 receptor knock-out mice 
revealed 28% of specific binding remains in the SNpr of the knock-out mice 
(Thomsen & Hampson, 1999). Although these results confirm a significant 
proportion of L-AP4 binding is due to mGlu4 in this region, the remaining high-
affinity specific binding could be due to mGlu8. This study used a concentration of 
30 nM L-AP4, therefore the binding sites observed most likely reflect mGlu4 and 
mGlu8 binding, rather than mGlu7 which requires higher (µM range) concentrations 
for affinity (Cartmell & Schoepp, 2000). Unfortunately, no mGlu8 knock-out studies 
have been used to confirm this supposition. Therefore, the presence of mGlu8 in the 
SN remains uncertain.  
 
Taken together, these findings described above confirm group III mGlu receptors are 
widely distributed throughout the basal ganglia although some uncertainties remain. 
Studies investigating mRNA expression patterns, by themselves, are insufficient for 
the quantitative description of biological systems since they fail to account for post-
transcriptional mechanisms controlling the protein translation rate (Gygi et al., 1999), 
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the half-lives of specific proteins or mRNAs (Varshavsky, 1996) and the intracellular 
location and molecular association of the protein products (Urlinger et al., 1997). For 
example, in some genes expressed in the yeast Saccharomyces cerevisiae, while the 
mRNA levels were of the same value, the protein levels varied by more than 20-fold 
(Gygi et al., 1998). With this in mind, one must be cautious in assuming the presence 
of group III mGlu receptor mRNA is indicative of protein expression. Furthermore, it 
can be difficult to construct valid comparisons between group III mGlu receptor 
subtype expression from separate immunohistochemical studies, using different 
antibodies, likely of varying specificity and affinity, utilising various tissue 
processing methods. Indeed, generally when comparing the immunocytochemical 
results obtained from two laboratories, the results often differ (Hemmings et al., 
2009). In addition to this, mGlu8 receptor distribution in the basal ganglia still 
remains largely unexplored. Thus, the main objective of the studies outlined in this 
chapter was to provide a comprehensive analysis of group III mGlu receptor 
expression, examining each subtype in all regions of the basal ganglia motor loop. Of 
particular interest to these studies would be the presence of group III mGlu receptor 
expression in the SNpc. However, since in PD loss of dopaminergic neurones in this 
nucleus leads to degeneration in the terminal regions of the striatum and downstream 
changes in both the direct and indirect motor circuits, it was considered of interest to 
investigate receptor expression in each of the basal ganglia nuclei. The distribution of 
mGlu4 and mGlu7 has already been investigated in a number of basal ganglia nuclei 
















The overall aim of this preliminary study was to investigate the expression profile for 
the group III mGlu receptor subtypes mGlu4, 7 and 8 throughout the basal ganglia. 
Group III mGlu receptor expression was assessed in the basal ganglia nuclei of the 
striatum, GPe, EP/GPi, STN and SNpc/SNpr in naїve rat brain. 
 
More specifically the key objectives were: 
 
1. to conduct immunohistochemical studies using antibodies raised against 
specific group III mGlu receptor subtypes to confirm the expression profiles 
of mGlu4 and 7 in the SNpc and additional basal ganglia nuclei of interest 
2. to investigate the expression profile of mGlu8 in the SNpc and for 



























In studies of this nature it is important to consider the effect of age upon the 
parameters under investigation. Numerous changes in group I and group II mGlu 
receptor expression within ageing rats has been previously reported (Simonyi et al., 
2000), thus it is pertinent to suggest similar effects would likely occur to group III 
mGlu receptor expression. Indeed a significant reduction in mGlu4 mRNA in the 
cerebellar granule layer and mGlu7 in the cortex has been shown in aged rats 
(Simonyi et al., 2000). The effects of ageing on mGlu8 expression remain to be 
determined. It has also been suggested mGlu receptor function may also be 
compromised in ageing rats, whereby mGlu5 mediated LTP responses were lost in 
older rats (Wang et al., 2007b).     
 
Female reproductive hormones have also been shown to have a profound effect on 
previous studies similar to those described in this thesis.  For example, there are many 
examples where oestrogen, in particular oestradiol, has been shown to interfere with 
group I and group II mGlu receptor-mediated responses (Boulware et al., 2005; 
Hilton et al., 2006; Rao & Sikdar, 2006). Although to date there is no evidence 
oestrogen can affect group III mGlu receptor responses, this is a clear possibility 
owing to the high sequence homology shared with group I and II. There is also 
evidence to suggest differences in oestrogen levels during the reproductive cycle 
alters the susceptibility of nigral dopaminergic neurones to 6-OHDA. For example, 
loss of dopaminergic neurones in the substantia nigra was greater in animals lesioned 
at diestrus (low oestrogen), when compared with animals lesioned at proestrus (high 
oestrogen). Additionally, the density of the dopamine transporter (DAT), for which 6-
OHDA toxicity is dependent, was higher at diestrus (Datla et al., 2003). Furthermore, 
oestradiol has been implicated in preventing glutamate-mediated excitotoxicity 
through group I mGlu receptors (Hilton et al., 2006). Collectively these studies 
highlight a neuroprotective role for oestrogen, rendering female rats unsuitable for 
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studies investigating neuroprotection in the 6-OHDA lesion model, as described in 
this thesis. Thus, to avoid any potential age or sex related alterations to group III 
mGlu receptor expression or function, male Sprague Dawley rats weighing between 
270-300g, 8-10 weeks in age, were selected for all studies described in this thesis.      
 
2.3.1.2 Antibodies for group III mGlu receptor subtypes  
 
The group III mGlu receptor subtype antibodies selected for these studies were 
purchased from commercially available sources. Each of the primary antibodies used 
in these studies were synthetic peptides derived from the corresponding human 
equivalent raised in rabbit. With each of the group III mGlu receptor subtypes, 
western blot analysis conducted by the commercial supplier (Abcam), demonstrated 
positive immunoreactivity was blocked using an immunising peptide. Each of the 
antibodies used had previously been used in rat tissue, with the exception of mGlu7 
which was predicted to react with rat based on the high sequence homology with 
human mGlu7 receptors (~99%). 
 




Male Sprague Dawley rats (B & K or Harlan, U.K.) weighing 270 – 300 g were used 
in these studies. Food and water were provided ad libitum. Animals were housed in a 
temperature- and humidity-controlled environment with a 12-h light / dark cycle. All 
procedures conformed to the U.K. Animals (Scientific Procedures) Act, 1986 and 
every effort was made to minimise animal numbers and suffering. 
 
2.3.2.2 Immunohistochemical protocol 
 
Two naїve rats were deeply anaesthetised using pentobarbital (100mg kg-1, i.p.) and 
transcardially perfused with 200ml 100mM  phosphate-buffered 0.9% saline (PBS, 
composition in mM: NaCl 137, KCL 2.7, KH2PO4 1.8, Na2HPO4 10), followed by 
200ml 4% paraformaldehyde (PFA) in PBS. Brains were quickly removed and placed 
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in fixative overnight to ensure complete fixation. The brain was then cut into a rostral 
(striatal) and caudal (SN) segment, dehydrated and defatted before being manually 
embedded into paraffin wax. Coronal sections (6µm) containing all basal ganglia 
regions of interest (striatum, GPe, GPi and SNpr/pc), according to the rat brain atlas 
(Paxinos & Watson., 1998) were cut on a microtome and then transferred into a water 
bath kept at ~45°C, in which they were left to float on the water surface for a few 
minutes until the sections had expanded fully. Sections were then collected onto 
Superfrost Plus glass microscope slides, firmly pushed down against the slide using 
blotting paper dampened with 30% industrial methylated spirit (IMS), and incubated 
overnight at 60°C to ensure adhesion to the slide. Schematic images of these sections 
are presented in figure 2.1.  
 
For each animal, three adjacent sections from the region of interest were prepared for 
immunohistochemistry, firstly, by dewaxing and dehydrating them. Sections were 
immersed in 100% xylene for 2 x 5min time-periods and subsequently immersed in 
100% IMS for 4 x 2min time-periods, with solution changes separating each 
immersion. Sections were then immersed for 10min in 3% hydrogen peroxide to 
block endogenous peroxide activity. Thereafter, antigenicity was restored in the tissue 
sections using citric acid antigen retrieval. This was done by boiling the dewaxed 
sections in citric acid (1M, dissolved in dH2O, pH 6.0) for 8min in a microwave 
pressure cooker. After this, sections were removed from the citric acid solution and 
thoroughly rinsed in dH2O to wash away any remaining buffer solution. Excess dH2O 
was removed from the slides/sections by dabbing them lightly on blotting paper, after 
which a PAP pen was used to apply a hydrophobic barrier around each brain section. 
Sections were then incubated in blocking buffer (1% BSA in 0.5M TBS and 10% 
sodium azide, pH 7.6) for 10 min to block non-specific binding sites present in the 
tissue sections. The blocking solution was then removed, and the sections incubated 
with the primary antibody (rabbit polyclonal anti mGlu4-8, Abcam; dilutions are 
shown in Table 2.1) overnight at room temperature (RT). After washing in 0.1M TBS 
for 10 min to remove any unbound antibody, sections were incubated with a 
polyclonal secondary antibody (goat anti-rabbit IgG-biotinylated 1:200, Sigma) for 2 
hours at RT. An avidin-biotin-HRP complex was freshly prepared using an ABC kit 
(Vector Labs). This was done by mixing/diluting solution A (avidin) with solution B 
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(biotinylated HRP) in an appropriate ratio in TBS (10µl of solution A was added to 
every 1ml of 0.5M TBS, pH 7.6). Sections were washed for 10 min in TBS to remove 
any excess unbound secondary antibody and then incubated for 30 min in the freshly 
prepared avidin-biotin-HRP complex to allow the complex to conjugate to the 
biotinylated secondary antibody bound to the sections. Sections were then washed in 
TBS to remove any excess unbound avidin-biotin HRP complexes. Finally, antigen 
localisation was visualised by incubating sections in diaminobenzidine 
tetrahydrochloride (DAB) (0.05% DAB/0.03% H2O2) solution dissolved in TBS 
(0.1M TBS, pH 7.6) for 10 min. Following this, sections were removed from the 
DAB solution and thoroughly washed in dH2O to remove any remaining DAB 
solution from the slides.  Sections were then dehydrated in 100% IMS for 4 x 2min 
time-periods and then subsequently cleared in 100% xylene for 2 x 5min time-
periods, with solution changes separating each immersion period. Finally slides were 
cover-slipped with DPX mountant and allowed to dry overnight before being 
analysed using light microscopy. Digital images of the target nuclei from triplicate 
sections were captured using a Zeiss apotome microscope or an Epson Perfection 
V700 Photo scanner for qualitative visualisation of the relative levels of 
immunostaining, and recorded using Axiovision LE software (Carl Zeiss Ltd).  
 
2.3.2.3 Materials and suppliers 
 
For details of all reagents, consumables and supplier contacts refer to Appendix I. 
 
Supplier  Primary antibody  Dilution  
Abcam  Rabbit polyclonal anti-mGlu4 (ab53088)  1:100  
Abcam  Rabbit polyclonal anti mGlu7 (ab53705)  1:200  
Abcam  Rabbit polyclonal anti mGlu8 (ab53094)  1:50  
 Secondary antibody   
Dako  Goat anti-rabbit IgG-biotinylated  1:200  
 
Table 2.1: Primary and secondary antibodies used in immunohistochemical studies. 
113 
 





Figure 2.1: Schematic of coronal sections from the rat brain atlas (Paxinos & Watson, 1998) 
highlighting the basal ganglia nuclei of interest in blue. (A) Striatum, +0.20 mm anterior posterior 
(AP) from bregma. (B) External globus pallidus (GPe), -0.92 mm AP from bregma. (C) 
Entopeduncular nucleus (EP) or Internal globus pallidus in primates and humans (GPi), -2.56 mm AP 
from bregma. (D) Subthalamic nucleus (STN), -4.16mm AP from bregma. (E) Substantia nigra pars 




2.4 Results  
 
2.4.1 Distribution of group III mGlu receptor subtypes within the rodent 
basal ganglia 
 
2.4.1.1 mGlu4 receptor 
 
The regional distribution of mGlu4 receptors was investigated in the rat basal ganglia 
by light microscopic immunohistochemistry using mGlu4 specific antibodies utilising 
the avidin-biotin-horseradish peroxidase complex to activate the diaminobenzidine 
(DAB) reagent. Immunoreactivity with the mGlu4 antibodies demonstrated 
widespread DAB labelling throughout the brain and by qualitative analysis revealed 
reproducible distribution patterns in both animals examined. The results from a 
representative set of sections are shown in figure 2.2. 
 
Within the basal ganglia nuclei, immunoreactivity was most intense in the striatum 
(figure 2.2A), the external globus pallidus (GPe, figure 2.2B), SNpr (figure 2.2E), and 
of particular interest to these studies, the SNpc (figure 2.2E).  Moderate 
immunoreactivity was also seen in the other basal ganglia nuclei, the entopeduncular 
nucleus (EP/internal globus pallidus, GPi; figure 2.2C) and the subthalamic nucleus 
(STN; figure 2.2D). On closer examination of magnified images from each of the 
target nuclei (shown in the right hand panels of figure 2.2), staining for mGlu4 
appeared predominantly of a diffuse fibrous nature, suggesting a likely pre-synaptic, 
axon terminal location. The ‘no primary antibody’ control displayed negative DAB 
staining following application of only the anti-rabbit secondary antibody 
demonstrating no non-specific background staining of the secondary antibody (figure 
2.2F). In summary, the qualitative order of expression for mGlu4 in the rat basal 








Figure 2.2: Distribution of mGlu4 immunoreactivity in the rat basal ganglia. 
 
Figure 2.2: Photomicrographs showing the distribution of immunoreactivity for the mGlu4 receptor in 
the rodent basal ganglia. mGlu4 immunoreactivity is shown in (A) the striatum, (B) the external globus 
pallidus (GPe), (C) the entopeduncular nucleus (EP) or internal globus pallidus in primates and 
humans (GPi [arrow]), (D) the subthalamic nucleus (STN [arrow]) and (E) the substantia nigra pars 
compacta/ reticulata (SNpc [dashed arrow]/ SNpr [arrow]) and (F) no primary antibody control, 
showing immunoreactivity of the secondary anti-rabbit antibody in the substantia nigra. Arrows in the 
right hand panel indicate dorsal border of target nuclei. Scale bars equal 200µm.  
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2.4.1.2 mGlu7 receptor 
 
The regional distribution of mGlu7 receptors was investigated in the rat basal ganglia 
by light microscopic immunohistochemistry using mGlu7 specific antibodies coupled 
with DAB staining, with the results shown in figure 2.3. Immunoreactivity with the 
mGlu7 antibodies showed widespread DAB labelling throughout the brain.  
 
Within the basal ganglia nuclei, the most intense immunoreactivity was seen in the 
subthalamic nucleus (STN; figure 2.3D) and substantia nigra pars reticulata (SNpr; 
figure 2.3E). There was lower, but still moderate intensity, in the striatum (figure 
2.3A), external globus pallidus (GPe; figure 2.3B) and the entopeduncular nucleus 
(EP/ internal globus pallidus; figure 2.3C). Of particular interest to these studies was 
the notably high mGlu7 immunoreactivity observed in the substantia nigra pars 
compacta, particularly within the medial segment of the dorsal tier (SNpc; figure 
2.3E). Generally, staining for mGlu7 was diffuse and also punctate in nature 
suggesting pre but also post-synaptic origin. On closer inspection, mGlu7 staining in 
some circumstances demonstrated co-localisation with nuclei suggesting a degree of 
non-specific binding with this antibody (shown in the right hand panels of figure 2.3). 
The ‘no primary antibody’ control displayed negative DAB staining following 
application of only the anti-rabbit secondary antibody demonstrating no non-specific 
background staining of the secondary antibody (figure 2.3F). In summary, the 
qualitative order of expression for mGlu7 in the rat basal ganglia was STN ≥ SNpr ≥ 













Figure 2.3: Distribution of mGlu7 immunoreactivity in the rat basal ganglia 
 
Figure 2.3: Photomicrographs showing the distribution of immunoreactivity for the mGlu7 receptor in 
the rodent basal ganglia. mGlu7 immunoreactivity is shown in (A) the striatum, (B) the external globus 
pallidus (GPe), (C) the entopeduncular nucleus (EP) or internal globus pallidus in primates and 
humans (GPi [arrow]), (D) the subthalamic nucleus (STN [arrow]) and (E) the substantia nigra pars 
compacta/ reticulata (SNpc [dashed arrow]/ SNpr [arrow]) and (F) no primary antibody control, 
showing immunoreactivity of the secondary anti-rabbit antibody in the substantia nigra. Arrows in the 
right hand panel indicate dorsal border of target nuclei. Scale bars equal 200µm.  
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2.4.1.3 mGlu8 receptor 
 
The regional distribution of mGlu8 receptors was investigated by light microscopic 
immunohistochemistry using mGlu8 specific antibodies coupled with DAB staining, 
with results shown in figure 2.4. Immunoreactivity with the mGlu8 antibodies 
demonstrated widespread DAB labelling throughout the brain, although at a much 
lower intensity to that seen with mGlu4 or 7.  
 
Within the basal ganglia nuclei, the most intense immunoreactivity was seen in the 
striatum (figure 2.4A) and the external globus pallidus (GPe, figure2.4B). There was 
also moderate immunoreactivity in the entopeduncular nucleus (EP/internal globus 
pallidus, GPi; figure 2.4C) and the subthalamic nucleus (STN; figure 2.4D) but low 
immunoreactivity in the substantia nigra pars reticulata (SNpr; figure 2.4E). Of 
particular interest to these studies was the very low intensity of mGlu8 
immunoreactivity observed in the substantia nigra pars compacta (SNpc; figure 2.4E). 
Staining for mGlu8 in the SNpc revealed a similar distribution pattern to mGlu7 
demonstrating particular, albeit low intensity, staining in the medial segment with 
little to no immunoreactivity in the lateral region.  The ‘no primary antibody’ control 
displayed negative DAB staining following application of only the anti-rabbit 
secondary antibody demonstrating no non-specific background staining of the 
secondary antibody (figure 2.4F). In summary, the qualitative order of expression for 














Figure 2.4: Distribution of mGlu8 immunoreactivity in the rat basal ganglia 
 
Figure 2.4: Photomicrographs showing the distribution of immunoreactivity for the mGlu8 receptor in 
the rodent basal ganglia. mGlu8 immunoreactivity is shown in (A) the striatum, (B) the external globus 
pallidus (GPe), (C) the entopeduncular nucleus (EP) or internal globus pallidus in primates and 
humans (GPi [arrow]), (D) the subthalamic nucleus (STN [arrow]) and (E) the substantia nigra pars 
compacta/ reticulata (SNpc [dashed arrow]/ SNpr [arrow]) and (F) no primary antibody control, 
showing immunoreactivity of the secondary anti-rabbit antibody in the substantia nigra. Arrows in the 





The preliminary immunohistochemical studies described in this chapter demonstrate 
that group III mGlu receptors mGlu4, 7 and 8 are widely expressed throughout the 
basal ganglia. The expression of mGlu4 and 7 within these basal ganglia nuclei has 
previously been demonstrated and our findings are largely in good agreement with 
these studies. It is important to note findings from these studies are deduced solely 
from qualitative analysis since this was not a hypothesis led study, rather an 
explorative investigation to determine the distribution patterns of group III mGlu 
receptor subtypes in the basal ganglia. Thus it was important not to miss contextual 
detail which can often be the case following quantitative analysis. Furthermore, 
statistical models were not required in studies of this number to explain the observed 
findings where distribution patterns in each of the target nuclei were absolute, 
rendering quantification irrelevant.   
 
Analysis of the mGlu4 receptor revealed widespread distribution throughout the basal 
ganglia. Particularly intense staining was recorded in the striatum, GPe and the SNpr 
which is consistent with the findings of Corti et al (2002). In addition the clearly 
diffuse fibrous nature of the mGlu4 staining suggests a likely pre-synaptic, axon 
terminal location, which has previously been confirmed using electron-microscopy 
(Kosinski et al., 1999; Bradley et al., 1999; Corti et al., 2002).  Interestingly the 
immunohistochemical studies described here demonstrate particularly intense staining 
for mGlu4 in the SNpc, which together with previously identified moderate levels of 
mRNA expression in the STN may suggest mGlu4 receptors are localised on the 
subthalamonigral terminals (Messenger et al., 2002). At the anterior-posterior 
position of the SN examined in these studies (-5.3mm AP from bregma), this 
specifically refers to the dorsal tier of the SNpc in which the main target of efferent 
neurones is the sensorimotor dorsal striatum (Francois et al., 1999; Haber, 2003; Joel 
& Weiner, 2000). Therefore, taken together these findings indicate that mGlu4 
receptors may be suitably positioned to be worthy targets for providing symptomatic 
relief in PD on the one hand based on immunoreactivity observed in the SNpr, but 
more relevant to this thesis, provide functional neuroprotection owing to its 
distribution in the SNpc.  
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In contrast to mGlu4, only moderate intensity staining for mGlu7 was seen in the 
striatum, however intense immunoreactivity was seen in the STN and SNpr, with 
lower, but still moderate intensity, in both the GPe and GPi. Of particular interest to 
these studies was the high mGlu7 immunoreactivity observed in the SNpc, notably 
within a medial region of the SNpc dorsal tier with little to no immunoreactivity in 
the lateral segment. The presence of mGlu7 in the SNpc would suggest mGlu7 
receptors may be worthy of investigation for target potential in PD. However, it is 
unclear at this point how the regional distribution of these receptors exclusively to the 
medial dorsal tier of the SNpc may affect this possibility.  
 
Of cause for concern was the punctate nature of the mGlu7 staining, demonstrating 
co-localisation with nuclei in numerous regions of the basal ganglia. Confirmation of 
this co-localisation with a nissl stain would have indicated immunoreactivity was 
largely in the dendrites of neurones where one could have assumed mGlu7 receptors 
exist predominantly post-synaptically. Indeed, very low levels of mGlu7 
immunoreactivity have been found at post-synaptic dendritic sites in both the GP 
(Bradley et al., 1999; Kosinski et al., 1999) and striatum (Kosinski et al., 1999). 
However, the extent of the nuclear binding seen here coupled with previous reports 
that demonstrate mGlu7 receptors exist largely pre-synaptically, we can assume the 
mGlu7 antibody used in these studies was non-specific. This drawback is discussed 
more at length in the latter part of this discussion. Nonetheless, the pattern of mGlu7 
staining throughout the basal ganglia would suggest a degree of specific binding, 
demonstrating mGlu7 receptors are likely located in the STN and its target regions, 
the SNpr and SNpc. Thus mGlu7 receptors may also be worthy targets to provide 
functional neuroprotection in a rodent model of PD.  
 
The findings from these preliminary studies demonstrate for the first time the 
presence of mGlu8 in each of the basal ganglia nuclei investigated. Although this data 
has not been quantitatively compared, the levels of mGlu8 expression seen here 
appeared to be considerably lower than that seen for both mGlu4 and 7. This pattern 
is in agreement with in-situ hybridisation studies performed previously in our 
laboratory, which reported particularly low levels of mGlu8 mRNA in the GPe, GPi 
and the SNpr (Messenger et al., 2002). The relative levels of expression between the 
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in situ and present immunohistochemical studies correspond well in many instances. 
For example, the high levels of expression of mGlu8 mRNA previously reported 
within the cortex may account for the highest level of mGlu8 seen here within the 
striatum, assuming a pre-synaptic localisation of mGlu8 on corticostriatal terminals. 
Furthermore, the moderate mRNA levels within the striatum and STN could account 
for the low-moderate mGlu8 receptor expression within the SNpr, assuming they 
reside pre-synaptically on striatonigral or subthalamonigral terminals. It is also 
possible the mGlu8 immunoreactivity seen in the SNpr is due to mGlu8 receptors 
localised post-synaptically, and given the mGlu8 mRNA expression reported in the 
SNpr (Messenger et al., 2002), this possibility cannot be ruled out. These suggestions 
of course remain speculative until complimentary EM studies are performed to 
determine if mGlu8 immunoreactivity seen here corresponds to pre- or postsynaptic 
locations in the SN. A key finding from these studies is the very low intensity 
staining of mGlu8 in the SNpc with only a small degree of staining observed in the 
medial region adjacent to the ventral tegmental area (VTA). Collectively the findings 
described above demonstrate mGlu8 is widely distributed throughout the basal 
ganglia although based on the low immunoreactivity observed in the nuclei of the 
subthalamonigral pathway is the least favoured group III mGlu receptor subtype in 
terms of target potential.  
 
As mentioned, this was a preliminary investigation and was by no means a conclusive 
assessment of group III mGlu receptor expression in the basal ganglia. Consequently 
a number of limitations must be addressed here in performing small studies of this 
nature. For example, additional experiments would have been desirable to verify the 
pre-synaptic origin of each of the group III mGlu receptor subtypes, i.e. to investigate 
co-localisation with a pre-synaptic terminal marker such as synaptophysin or synaptic 
vesicle protein-2. An additional discrepancy was the punctate nature of the mGlu7 
staining, demonstrating co-localisation with nuclei in numerous regions of the basal 
ganglia, suggesting a degree of non-specific binding with this antibody. This may 
explain why this commercial antibody was only predicted to bind to mGlu7 in rat 
tissue based on its high sequence homology with human cDNA and would account 
for the lack of studies reporting using this antibody in rats. Furthermore, antibodies 
produced against synthetic, rather than natural peptides representative of their specific 
123 
 
receptor structures, may also contribute to the lack of specificity seen here. Indeed 
these non-specific effects are not uncommon, and demonstrate immunohistochemical 
studies of this nature, are by themselves inconclusive. Future studies would seek to 
use alternative antibodies, supported with western blot analysis to confirm specificity 
of the antibody using a corresponding blocking peptide. A positive control would also 
have been of worth here to determine the relative immunoreactivity observed in these 
studies. Based on the abundant immunoreactivity to mGlu4 and mGlu7 reported in 
the human brain, the cerebellum may have been a desirable region to assess the 
relative immunoreactivity of the group III mGlu receptors in the basal ganglia 
(Human Protein Atlas).  
    
Generally, very low dilution factors were required in these studies (typically 1:50) 
suggesting the affinity for the antigen with each of the antibodies tested was low. 
During washing with low affinity antibodies, dissociation from the epitope is more 
likely leading to a loss of staining and may account for the reduced immunoreactivity 
seen with mGlu8 in these studies. Additionally using paraffin embedded tissue, many 
antigens fail to survive the paraffin processing or the fixation process which may also 
have contributed to the reduced signal with the mGlu8 immunoreactive antibody. 
However these suggestions remain speculative until additional studies are carried out 
using alternative antibodies. Although frozen tissue offers much better antigen 
preservation, paraffin processing was favoured in these studies since the 
morphological detail and resolution of the frozen sections is usually considerably 
inferior to tissue that has been embedded during specimen processing. Nonetheless 
taking these considerations into account, the preliminary findings described here are 
in good agreement with previous reports describing mGlu4 and mGlu7 receptor 
distribution, and for the first time provides an insight into the distribution pattern of 
mGlu8 throughout the basal ganglia. 
 
Despite the clear limitations of these studies, our findings from this preliminary 
investigation demonstrate group III mGlu receptors are widely distributed throughout 
the basal ganglia, of especial significance here each revealing expression in the SNpc. 
Although it has been shown these receptors exist on both the pre and post-synaptic 
terminal, electrophysiological studies have found no evidence for a post-synaptic 
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action of group III mGlu receptors (Valenti et al., 2003). At the present time, 
therefore, focus remains fixed on pharmacologically targeting potential pre-synaptic 
receptors.  
 
Whilst the findings described in this chapter along with considerable evidence in the 
literature demonstrate group III mGlu receptors are widely distributed through the 
BG, few studies have examined the state of mGlu receptor expression in the motor 
loop under parkinsonian conditions. Given the important role of group III mGlu 
receptors in modulating glutamatergic and GABAergic transmission within the BG, it 
is likely that any changes in the expression of these receptors under the pathological 
condition of PD may exacerbate the already aberrant transmission within the motor 
loop and contribute to symptom generation. On the contrary, it is also possible that an 
elevation in glutamate may lead to plasticity of group III mGlu receptors thereby 
acting as a potential compensatory mechanism. Clearly, changes in the expression of 
mGlu receptors under parkinsonian conditions would therefore have important 
consequences on the overall outcome of these elevations in transmitter release in the 
BG and on the therapeutic potential of targeting these receptors.  
 
Remarkably, there remains only one study from our laboratory that has examined the 
state of mGlu receptor expression in the BG motor loop under parkinsonian 
conditions. This report revealed few alterations in group III mGlu receptor gene 
expression following a unilateral 6-OHDA lesion of the median forebrain bundle 
(MFB) with the exception of mGlu4, in which a significant reduction in mGlu4 
mRNA in the striatum (~14% reduction with respect to intact hemisphere) was 
observed. However these studies did not confirm if the decline in mGlu4 mRNA 
expression translated into changes at the receptor protein level. Whilst this possibility 
would likely serve more to exacerbate, rather than provide a compensatory 
mechanism against the ensuing nigrostriatal degeneration, the decline in mGlu4 
mRNA whilst significant remained relatively minor. Furthermore no alterations in 
mGlu7 or mGlu8 receptor expression were observed, thus the relative persistence of 
these mGlu receptor subtypes following nigrostriatal tract lesioning along with their 
robust expression in the subthalamonigral pathway, suggests activation of group III 
mGlu receptors may offer a promising approach to halt ongoing degeneration in PD. 
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The potential of pharmacologically targeting these receptors will be explored in 










































Chapter 3: Potential of targeting group III metabotropic 
glutamate receptors to provide functional 









In Chapter 2 of this thesis we identified immunoreactivity for each of the group III 
mGlu receptors (with the exception of mGlu6) in the five major nuclei of the basal 
ganglia, demonstrating particularly intense staining for mGlu4 and mGlu7 in the SN. 
Furthermore studies in our laboratory have suggested an autoreceptor role for group 
III mGlu receptors in the rat SNpr whereby activation of these receptors has been 
shown to reverse reserpine-induced akinesia using broad spectrum agonists (Austin et 
al., 2010). We have also shown that group III mGlu receptor activation using one of 
these broad spectrum agents, L-SOP, reduces glutamate release in the SN in vivo, 
suggesting these receptors may hold potential in combating certain aspects of the 
neurodegenerative processes in PD. Therefore studies in this chapter focused on the 
potential of targeting group III mGlu receptors to provide functional neuroprotection 
using the pathologically relevant unilateral 6-OHDA lesion rat model of PD.  
 
As detailed in Chapter I of this thesis, PD is characterised by a progressive 
degeneration of nigrostriatal dopaminergic neurons. It is thought this degeneration is 
caused by a complex interplay of factors, with oxidative stress, mitochondrial 
dysfunction and failure of the ubiquitin-proteasome system all strongly implicated in 
the neurodegenerative process. There is also considerable evidence to point to a role 
for glutamate-mediated excitotoxicity in the ongoing degeneration of nigral 
dopaminergic neurones in PD. A key factor supporting this notion is that loss of 
striatal dopamine in the parkinsonian basal ganglia drives downstream changes in the 
indirect pathway, ultimately leading to over-activity of the glutamatergic STN. The 
complex changes in the basal ganglia circuitry which lead to hyperactivity in the STN 
was the subject of detailed discussion in Chapter I (section 1.3.3) and will not be 
discussed again here. Of particular importance to the studies in this chapter however, 
are the increased levels of glutamate within the STN target regions caused by STN 
over-activity. These include the basal ganglia output regions (SNpr/ GPi), which 
drive the motor symptoms of PD, GPe, PPN and crucially the SNpc (Smith & Bolam, 
1990). The SNpc expresses ionotropic glutamate receptors of both AMPA and 
NMDA subtypes, whereby most of the excitatory transmission is thought to be 
mediated by the NMDA subtype (Christoffersen & Meltzer, 1995). Increased 
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glutamate in the SNpc may contribute to the pathology of PD, resulting from chronic 
depolarisation mediated by ionotropic glutamate receptors, and consequent excess 
Ca
2+
 influx through NMDA receptor activation once the Mg
2+
 block has been 
removed (Doble, 1999). High intracellular Ca
2+
 can lead to numerous cytotoxic 
effects, ultimately leading to cell death. For a more detailed account of excitotoxicity 
please refer back to Chapter I section 1.1.2.3.2. Additionally, mitochondrial 
dysfunction in the SNpc found in PD patients may also lead to ‘indirect’ 





 ATPase activity is lost as a result of compromised ATP production. The 
resulting membrane depolarisation and expulsion of voltage-gated Mg
2+
 block 
renders dopaminergic neurones vulnerable to physiological levels of glutamate 
(Greenamyre, 2001). It is important to stress here, glutamate-mediated excitotoxicity 
is not thought to be the primary cause of cell death in PD since the STN only 
becomes hyperactive following nigrostriatal degeneration and resulting alterations 
within the indirect pathway. However sustained excessive glutamate release may 
trigger the neurodegenerative progression within vulnerable dopaminergic neurones 
of the SNpc (Rodriguez et al., 1998). 
 
Treatment of PD to date has focused on dopamine replacement strategies using L-
DOPA and/or dopamine agonists, which effectively ameliorate the motor symptoms 
in the early stages of PD. However prolonged use results in disabling motor side 
effects, such as dyskinesias (discussed at length in Chapter 1 section 1.4.1.1). 
Furthermore these dopamine replacement strategies fail to address the ongoing 
progression of nigral degeneration. In an attempt to address this limitation, it has been 
suggested that surgical or pharmacological therapies which reduce STN over-activity, 
or modulate glutamate receptors in the SNpc, may be neuroprotective and serve to 
halt the progressive neurodegeneration in PD. Indeed, surgical intervention by 
ablation or deep brain high-frequency stimulation (DBS) of the STN have been 
shown to be effective in reducing the motor symptoms of PD, although these 
procedures have not been demonstrated to be neuroprotective in humans. A study in 
MPTP-treated primates however, has demonstrated that STN-DBS or kainic acid 
lesioning of the STN was neuroprotective, with 20-24% more dopaminergic neurones 
remaining within the SNpc (Wallace et al., 2007). The authors also suggested that 
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neuroprotection was mediated by a reduction in glutamate-mediated excitotoxicity. 
Of course, surgical procedures have many drawbacks as previously mentioned in 
Chapter 1, such as limited availability and post-operative complications since the 
majority of patients are elderly. Therefore there is an overwhelming need to devise a 
pharmacological approach to decrease the over-activity of the STN and resulting 
increase in glutamate release.  
 
In terms of pharmacological manipulation of glutamatergic transmission in the SNpc, 
a number of pre-clinical rodent studies have shown blockade of NMDA receptors acts 
to reduce the firing rates of STN neurones and protect nigral neurones from 
degeneration (Allers et al., 2005; Blandini et al., 2001; Sonsalla et al., 1998).  
Unfortunately the clinical usefulness of these compounds has been compromised by 
severe side effects including ataxia, sedation, psychotic effects and cognitive 
impairment (Lee et al., 1999). Thus in recent years attention has focused more on the 
potential of targeting mGlu receptors, which provide an alternative approach to 
negatively modulate excessive glutamate release within the SNpc, as well as offering 
improved side effect profiles. These factors have led to mGlu receptors being 
considered as potential targets to provide neuroprotection in PD (Nicoletti et al., 
1996). Indeed blockade of the excitatory group I mGlu receptors and activation of 
inhibitory group II mGlu receptors, have shown significant neuroprotection in 6-
OHDA lesioned rodents (Murray et al., 2002; Vernon et al., 2007a). 
 
Group III mGlu receptors, the focus of studies in this thesis, are also worthy 
candidates to consider here given that they are expressed in the SNpc and appear to 
function as autoreceptors. As shown in Chapter 2, immunohistochemistry revealed 
the presence of each of the group III mGlu receptors in the SN (albeit to a lesser 
extent with mGlu8) revealing particularly high intensity staining of mGlu4 receptors 
in the SNpc. In addition our laboratory has shown that activation of presynaptic group 
III mGlu receptors using the broad spectrum agonists L-AP4 and L-SOP, inhibited 
depolarisation-evoked [
3
H]-D-aspartate release (non-metabolised analogue of 
glutamate) by 44 and 33% respectively in nigral slices in vitro (Austin et al., 2010). 
Microdialysis revealed L-SOP also reduced glutamate release in the SNpr in vivo by 
48% with respect to vehicle treated animals (Austin et al., 2010). Furthermore initial 
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in vitro studies have revealed neuroprotective effects following activation of group III 
mGlu receptors. For example, L-AP4 (1-3 mM), demonstrated protection against 
NMDA-induced toxicity in mixed cultures of mouse cerebellar granule neurones 
(Lafon-Cazal et al., 1999a). In addition, this study demonstrated that L-AP4 could 
inhibit the 60-fold increase in glutamate (with respect to baseline) induced by NMDA 
by more than 60%, suggesting this neuroprotective effect was a result of combating 
glutamate-mediated excitotoxicity. 
 
To date, few studies have been performed to investigate the neuroprotective potential 
of targeting group III mGlu receptors in animal models of PD. In 2005 Vernon et al., 
were the first to demonstrate in vivo that group III mGlu receptor activation mediated 
neuroprotection. In this study sub-chronic intranigral infusion of L-AP4 for 7 days in 
6-OHDA-lesioned rats resulted in complete preservation of striatal dopamine levels 
in the lesioned hemisphere, although the number of TH positive cell bodies was 
improved to a lesser, but still significant extent (Vernon et al., 2005). However, no 
behavioural tests were performed in this study to indentify whether neuroprotection at 
the biological level correlated to a functional preservation in motor behaviour. 
Therefore it is clear further investigation into the involvement of group III mGlu 


















The overall aim of the studies described in this chapter was to further elucidate the 
potential of targeting group III mGlu receptors as an alternative, non-dopaminergic, 
therapy to provide neuroprotection in the treatment of PD. Initial studies sought to 
confirm the previously reported neuroprotective effects of L-AP4 in our 6-OHDA 
lesion model and to further investigate if this protection translated to preservation in 
motor function. We next investigated whether the effects of L-AP4 were indeed 
group III mGlu receptor mediated by examining whether the response to L-AP4 was 
lost following pre-treatment with a selective group III mGlu receptor antagonist 
CPPG.  
 
More specifically, the key objectives here were: 
 
1. to provide immunohistochemical and neurochemical confirmation of the 
neuroprotective effects of the broad spectrum group III mGlu receptor agonist 
L-AP4 against a unilateral 6-OHDA lesion of the SNpc in rats 
2. to ascertain whether neuroprotective effects of L-AP4 translate to functional 
restoration of motor function in both forced and habitual behavioural tasks 
3. to establish the effective dose range of L-AP4 to provide neuroprotection as 
determined by behavioural and immunohistochemical assessment 
4. to determine if functional neuroprotection achieved with L-AP4 is reversed on 














3.3.1 General methodological considerations 
 
3.3.1.1 6-OHDA-lesion model of Parkinson’s disease 
 
To investigate the neuroprotective potential of targeting group III mGlu receptors on 
the subthalamonigral pathway it was essential to utilise a pre-clinical model of PD 
that effectively mimicked the hyperactivity in the STN of PD patients. As mentioned 
in section 1.3.3.2, the MPTP model has shown a degree of hyperactivity in the STN, 
reporting a 27% increase in STN firing rates in the MPTP primate (Bergman et al., 
1994). However following a 6-OHDA lesion of the SNpc in rats, huge increases in 
STN activity have been reported, with STN neurons demonstrating discharge rates 
exceeding 233.3% of non-lesioned animals (Magill et al., 2001). This would suggest 
the 6-OHDA lesion model would provide an ideal test bed in which to investigate the 
potential of group III mGlu receptor ligands to mediate neuroprotection by inhibiting 
the hyperactivity in the STN. Therefore in the studies described in this thesis, the 
SNpc was chosen as the site of stereotaxic injection of 6-OHDA to induce 
degeneration of the dopaminergic nigrostriatal tract, although the striatum and the 
MFB are other common sites of administration.  
 
Nigral or MFB administration causes rapid cell loss which begins within 12-24 hours, 
resulting in maximal striatal dopamine-depletion typically after 2-3 days (Faull & 
Laverty, 1969). Conversely, striatal injections of 6-OHDA lead to a more protracted 
retrograde degeneration of the dopaminergic neurones within the SNpc, taking 
between one to three weeks to develop a stable lesion (Przedborski et al., 1995). The 
site of injection also has an impact on which dopaminergic cells degenerate. 
Lesioning of the MFB causes total destruction of both A9 nigral neurones, which 
project to the dorsolateral striatum and A10 mesolimbic neurones of the VTA, which 
project to the ventromedial striatum (Thomas et al., 1994; van Domburg & Ten 
Donkelaar, 1991). Nigral administration of 6-OHDA favours degeneration of A9 
cells, with a lesser degeneration of A10 neurones (Carman et al., 1991). Therefore 
injection of 6-OHDA into the SNpc was the most suitable site for use within our 
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studies to test the neuroprotective ability of sub-chronic (8 days) administration of 
group III mGlu receptor ligands on A9 nigral neurones. Furthermore, this approach 
allowed a single cannulation site for both lesioning and drug administration.  
 
Due to the small size of the SNpc there is often some variability in lesion size, 
therefore studies described in this thesis aimed for a minimum of 7 animals per group. 
The lesion size for these studies was based on a dose of 6-OHDA which induces a 
suitable deficit to measure changes in motor behaviour and is discussed further in 
section 3.3.1.2 on introduction of behavioural tests. To maintain specific destruction 
of dopaminergic neurones in these studies, the uptake-1 inhibitor, desipramine was 
given pre-lesion to prevent uptake of 6-OHDA into noradrenergic neurones. To 
enhance bioavailability of 6-OHDA within the brain, the monoamine oxidase-B 
inhibitor, pargyline was also given pre-lesion to inhibit 6-OHDA degradation.  
 
When modelling PD with stereotactic injection of 6-OHDA, it is possible to induce 
bilateral lesions which are not affected by any compensation from the intact side, and 
therefore mimic the pathology of idiopathic PD more closely (Deumens et al., 2002). 
Whilst bilateral lesions would have been desired for these studies, they are associated 
with a high level of mortality, with animals displaying extreme akinesia with aphagia 
(difficulty swallowing) and adipsia (deficit in drinking), requiring them to be tube-fed 
(Ungerstedt, 1971c). Therefore unilateral lesions are more commonly performed. 
Whilst bilateral 6-OHDA models are pathologically more relevant, unilateral lesion 
models allow for drug-induced rotations as behavioural indicators of lesion size, as 
well as maintaining the intact hemisphere to be used as a control for neurochemical 
and histological analyses. The ability to construct a unilateral lesion was an additional 
major factor in the selection of the 6-OHDA model for this thesis since it provides the 
opportunity to investigate functional neuroprotection by gauging the asymmetry 
between the lesioned and non-lesioned hemispheres. In addition the 6-OHDA lesion 
is quick, relatively inexpensive and reproducible in nature, and for these reasons 
remains one of the most regarded early pre-clinical models for the investigation of 






3.3.1.2 Behavioural tests 
 
Asymmetry in the dopaminergic nigrostriatal tract following 6-OHDA lesioning leads 
to quantifiable differences in basal ganglia function between the two hemispheres. 
This can be exploited by assessing motor function asymmetries in habitual or forced 
motor tasks or by assessing drug-induced rotational behaviour. Habitual motor tasks 
which can test forelimb asymmetry include the cylinder test, where the animal is 
placed in a transparent cylinder, and during a fixed time period rearing behaviour is 
monitored for asymmetry of paw use. This test is a sensitive measure to determine the 
functional integrity of the nigrostriatal system since the animals are left to their own 
devices. Such a test is ideal for neuroprotection studies to provide an insightful 
measure of motor asymmetry following a 6-OHDA lesion and to assess functional 
preservation following treatment with potential neuroprotective agents. For this 
reason this test was employed in all neuroprotection studies described in this thesis. 
However in some cases if animals are heavily lesioned and demonstrate a high level 
of akinesia, the number of rearing behaviours against which to assess motor 
asymmetry can be compromised. Therefore a forced motor task such as the adjusted 
steps test was also employed in these studies, where an asymmetry score could be 
reliably attained.   
 
The adjusted steps test is an examination of akinesia within each forepaw as the 
animal is moved slowly over a fixed distance along a bench, with only one forepaw 
bearing weight and adjusted steps counted. It has been shown that adjusted steps by 
the contralateral paw are profoundly reduced in both directions following 6-OHDA-
lesioning, whereas the ipsilateral paw remains largely unaffected (Olsson et al., 
1995). Furthermore, the same study revealed this test was robust enough to emphasise 
functional recovery from a 6-OHDA lesion, with significant improvements in 
contralateral backhand adjusted steps following striatal and nigral ventral 
mesencephalon transplants (Olsson et al., 1995). Therefore owing to its ability to 
identify motor asymmetries following 6-OHDA lesioning and detect improvements in 
adjusted steps following dopamine cell transplantation, as well as being relatively 
easy to perform, the adjusted steps test was selected to assess changes in motor 




Drug-induced rotational behaviour is commonly induced by two agents, the mixed 
D1/D2 receptor agonist, apomorphine or the indirectly acting sympathomimetic, 
amphetamine. Dopaminergic denervation induces postsynaptic dopamine receptor 
supersensitivity in the lesioned striatal hemisphere. Apomorphine-mediated 
stimulation of these receptors is therefore enhanced in comparison to those on the 
intact side (Ungerstedt, 1971b) and the resultant unilateral overactivity induces 
turning away from the side of the lesion referred to as contraversive rotations. 
However, only when greater than 90% of the nigrostriatal cells have degenerated will 
a 1mg/kg dose of apomorphine induce rotational behaviour of greater than 4 rotations 
min
-1
 (Hefti et al., 1980). Conversely, an injection of amphetamine results in the 
release of vesicular dopamine predominantly from the intact hemisphere, where 
dopaminergic terminals remain, therefore inducing rotational behaviour towards the 
lesioned side (ipsiversive rotations, Ungerstedt, 1971a). A 5mg/kg dose of 
amphetamine induces rotational behaviour once 50% or more of the nigrostriatal cells 
are lost (Hefti et al., 1980). Furthermore there is good correlation between the 
number of rotations and A9 nigral neurones lost for lesions between 50-100% (Kirik 
et al., 1998; Moore et al., 2001). In these studies, it was decided to use an almost full 
lesion size of 80-90%, in keeping with the neuroprotection studies of O’Neill et al., 
(2004), who also examined drug-induced rotational behaviour. This provides a lesion 
of sufficient size to monitor graded improvements in motor function to assess 
neuroprotective effects of group III mGlu receptor agonist/modulators. Thus, 
amphetamine-induced rotations were deemed preferential to apomorphine rotations, 
in animals with an 80-90% lesion size, as amphetamine offers a graded rotational 















Male Sprague Dawley rats (B & K or Harlan, U.K.) weighing 270 – 300 g were used 
in these studies. Food and water were provided ad libitum. Animals were housed in a 
temperature- and humidity-controlled environment with a 12-h light / dark cycle. All 
procedures conformed to the U.K. Animals (Scientific Procedures) Act, 1986 and 
every effort was made to minimise animal numbers and suffering. 
 
3.3.2.2 Experimental protocol for surgical cannulation  
 
Animals were bilaterally cannulated so that in an event of blockage of one cannula 
the animal could still be used if the second cannula was patent. Two 12mm, 23 gauge 
stainless steel guide cannulae (Coopers), spaced 4mm apart were attached using a 
guide cannula holder, to a stereotactic micromanipulator (Kopf). Animals were 
subjected to isoflurane (Abbott animal health) general anesthesia (3-5% in 95% O2/ 
5% CO2) in an induction chamber until they showed loss of pedal-withdrawal and 
corneal reflexes. Each animal was then placed into a small animal stereotactic frame 
(900 series, Kopf) with the incisor bar at -3.3mm below the interaural line and 
anesthesia was maintained at 2.5% isoflurane. The head was shaved and skin cleaned 
with an alcohol swab. A scalpel was used to make a rostrocaudal incision and the skin 
was held back using four artery clamps. The scalpel was then used to remove the 
periosteum from the skull, clearly exposing bregma, with excess blood removed with 
sterilized cotton buds and gauze. Three holes were then drilled through the skull (2 
anterior and 1 posterior), clear of bregma and expected sites of cannulae implantation, 
then microscrews were screwed into the holes. The stereotactic location was marked 
for two further holes, which were then drilled to allow the cannulae to pass through 
the skull. Using the micromanipulator the cannulae were then stereotactically 
implanted bilaterally 2mm above both SNpc using the following co-ordinates; 
anterioposterior (AP), -4.8mm, mediolateral (ML), ± 2.0mm; dorsoventral (DV), -
6.3mm from bregma (Paxinos & Watson, 1998). Cannulae were then secured into 
position using dental cement, which anchored the cannulae to the microscrews. The 
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cannulae holder was then withdrawn and a plastic collar (5mm section of a 1ml 
pipette tip) was secured into place with further dental cement, which protected the 
protruding cannulae ends from damage. Additionally, 30-gauge 12mm long stylets 
(Coopers) were placed into the cannulae to prevent blockage. A rehydrating solution 
of 0.9% saline with 0.1% glucose (5ml/kg, s.c., Baxter Healthcare) was administered 
and any loose skin surrounding the dental cement was sutured together. Following 
completion of surgery, animals were allowed to recover in clean cages placed on 
thermostatically heated mats until fully conscious.  
 
3.3.2.3 Supranigral drug administration 
 
A minimum of 5 days following cannulae implantation, the neuroprotection study 
commenced. Animals received their first dose of L-AP4 (0.1-30nmol dissolved in 4µl 
of 1 x PBS) or vehicle (4µl 1 x PBS) 1 hour prior to 6-OHDA infusion (detailed in 
3.3.2.4) and then once daily for 7 days post lesion. Since a severe lesion model was 
desired for these studies in which 6-OHDA is injected directly into the SNpc, 
degeneration is typically rapid. Unpublished findings from our collaborators at Eli 
Lilly have shown that degeneration of dopaminergic neurones in the SNpc begins 2 
hours after injection of 6-OHDA, with a further report demonstrating the majority of 
cell death in the SNpc occurs within the first 3 days of injection (Zuch et al., 2000). 
Thus, neuroprotective drug interventions are often, as in this case, introduced just 
prior to toxin injection to compensate for the acute nature of the 6-OHDA model. 
Furthermore, whilst the majority of degeneration likely occurs within the initial 3 
days post lesion, Vernon et al., (2007), have shown L-AP4 provides greater 
preservation of TH-positive cells in the SNpc following a 7 day treatment compared 
to a 3 day post-lesion treatment schedule. Consequently L-AP4 and all additional 
group III mGlu receptor agents were administered for 7 days post 6-OHDA lesion. 
Table 3.1 summarises the selectivity of L-AP4 and all other pharmacological agents 
administered supranigrally in this thesis.   
 
The doses of L-AP4 selected for these studies were based on a previous account 
investigating the neuroprotective profile of L-AP4 in vivo using a partial 6-OHDA 
lesion of the SNpc (Vernon et al., 2007). In this study 10nmol/4µl L-AP4 was shown 
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to significantly protect TH-positive cell loss in the SNpc whilst this effect was lost at 
a higher (50nmol/4µl) dose of L-AP4. The neuroprotection studies described in this 
chapter, therefore, sought to extend these initial findings by implementing additional 
doses of L-AP4 to gauge a fuller dose response profile and seek to identify if 
protection provides preservation of motor function which to date remained 
unexplored.  
 
Prior to infusion, the injection needle (13mm, 30-gauge stainless steel needle, 
Coopers), connecting tube (Portex) and 5µl microsyringe (Hamilton 7000 series) 
were filled with vehicle solution to ensure a closed system containing no air bubbles. 
Immediately prior to infusion, the plunger was pushed down, expelling vehicle 
solution, before the microsyringe was refilled with drug .After removing the stylet the 
injection needle was placed into the cannula so that the tip extended 1mm below the 
guide cannulae, reaching 1mm above the SNpc. Unilateral drug infusions were made 
into the right cannula (or left if the cannula was blocked) using a motorized 
micropump (KD Scientific), at a rate of 2µl min
-1
 so that each injection took 2 min. 
Following infusion, the needle was left inside the cannula housing for 2 min to allow 
diffusion of the drug from the site of injection and avoid it being drawn back up the 
cannula. The stylet was then replaced into the cannula. Animals then received daily 
infusions of L-AP4 for the next 7 days, each being made into fully conscious animals 
as described here for the pre-lesion infusion.  
 
In a separate study the neuroprotective effects of L-AP4 were investigated following 
pre-treatment with a broad spectrum group III mGlu receptor antagonist CPPG to 
confirm a receptor mediated process. This was achieved pharmacologically since 
there currently remain no group III mGlu receptor subtype knock out rats available. 
Thus to investigate the effects of CPPG on neuroprotection mediated by L-AP4, 
CPPG (75 nmol; dissolved in 4μl 0.1M NaOH) or its corresponding vehicle (4µl 
0.1M NaOH) were infused at a rate of 2µl min
-1
 unilaterally above the SNpc 30 min 







 mGlu4  mGlu6  mGlu7  mGlu8  Reference  
Group III mGlu agonist  
Glutamate  3-38  5-36  >1000  3-11  Cartmell & Schoepp., 2000  
L-AP4  0.2-1  0.2-0.9  >100  0.06-0.09  Cartmell & Schoepp., 2000  
DCPG 8.8  3.6  >100  0.031  Thomas et al., 2001  
Group III mGlu allosteric modulator 
VU0155041* 0.7-0.8 n.e n.e n.e Niswender et al., 2008 
Group III mGlu allosteric agonist 
AMN082 >10  >10  0.06-0.3 >10  Mitsukawa et al., 2005  
Group III mGlu antagonist 
CPPG 2.2 against L-AP4-mediated inhibition of 
cAMP (no specificity to mGlu receptor subtype 
described) 
Toms et al., 1996 
 
 
Table 3.1. Group III metabotropic glutamate receptor pharmacology: Potencies of agonists (EC50 
values) and antagonists (IC50 values) at cloned human mGlu receptors (expressed in µM), highlighted 
in bold for the main group III target for each agent. * VU0155041 also displays partial agonist activity 





3.3.2.4 Intranigral 6-OHDA lesioning 
 
Animals received an intranigral infusion of 6-OHDA (12µg) 1 hour after their 
supranigral infusion of L-AP4. 30 min prior to 6-OHDA infusion, animals were pre-
treated with desipramine (25 mg/kg i.p.) and pargyline (5 mg/kg i.p.). A schematic 
diagram of the experimental design and timeline for L-AP4 and all further 
neuroprotection studies is shown in figure 3.1. To facilitate safe infusion of 6-OHDA, 
animals were then anaesthetized using isoflurane (Abbot animal health) general 
anaesthesia (3-5% in 95% O2 / 5% CO2) in an induction chamber until they showed 
loss of pedal-withdrawal and corneal reflexes. Light anaesthesia was maintained at 1-
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3% isoflurane during the 6-OHDA infusion. On the basis of requiring a suitably large 
enough lesion to measure changes in motor behaviour, and offering sufficient scope 
to assess neuroprotection, an 80-90% lesion was selected for these neuroprotection 
studies. 
 
Initial studies in our laboratory investigating the dose-dependency of 6-OHDA (4-
12µg), revealed a 12µg nigral infusion of 6-OHDA was deemed necessary to produce 
a lesion size of 80-90% (Austin, unpublished). As with supranigral delivery, prior to 
infusion, the injection needle (14mm, 30-gauge stainless steel needle, Coopers) 
connecting tubing (Portex) and 5µl micro syringe (Hamilton 7000 series, VWR) were 
filled with vehicle. Immediately prior to infusion, the plunger was pushed down, 
expelling vehicle solution, before the microsyringe was refilled with 6-OHDA. After 
removing the stylet, the injection needle was placed into the cannula so that the tip 
extended 2mm below the guide cannula, this time directly into the SNpc. Unilateral 
lesions of the SNpc (into the same hemisphere as L-AP4 given 1 hour earlier) were 
made by infusion of 6-OHDA (12µg dissolved in 2.5µl 0.02% ascorbic acid, in 0.9% 
saline, kept on ice and shielded from light) using a motorized micropump (KD 
Scientific). Infusions were made at a rate of 1.25µl min
-1
 and therefore took a total of 
2 min. Following infusion, the needle was left inside the cannula housing for 2 min, 
before withdrawal and then the stylet was replaced in the cannula. Upon completion 
of 6-OHDA infusion, animals were allowed to recover in clean cages placed on 



















Figure 3.1. Schematic illustration of experimental design and timeline of events employed in L-AP4 neuroprotection studies. * When required, CPPG or corresponding 





3.3.2.5 Behavioural assessment 
 
The extent of motor impairment in animals following a 6-OHDA lesion was assessed 
at intervals using three behavioural tests: animal behaviour was assessed using the 
adjusted steps test on day 3 and 6 post-lesion, cylinder test on day 5 post-lesioning, 
(both tests also required a baseline assessment one day prior to lesioning) and 
amphetamine induced rotations on day 7 post-lesion.  
 
3.3.2.5.1 Cylinder Test 
 
Animals were placed individually in a transparent, perspex cylinder (21cm d x 34cm 
h) and the number of upward reaches video-recorded in 5-min intervals.  Use of the 
ipsilateral and contralateral paw was then assessed as a percentage of total reaches 
made, both pre- and post-lesion, by observers blinded to treatment.  
 
3.3.2.5.2 Adjusted Stepping Test 
 
The rat was held in one hand, with the hind limbs gently restrained and the torso 
slightly raised and with the other hand, the forelimb that was not to be tested was also 
restrained. The rat was then moved slowly sideways in backhand and forehand 
directions across a 90cm distance with the free forelimb bearing the weight of the 
animal. The number of steps made by the animal were recorded in forehand and 
backhand directions, for both ipsilateral and contralateral paws. On each day of 
testing the adjusted steps test was repeated three times.  
 
3.3.2.5.3 Amphetamine-induced rotations 
 
Amphetamine-induced rotational behaviour was assessed from video recorded 
observations of rats in 40cm diameter, flat-bottomed hemispherical bowls (Amee). 
After an initial 10 min baseline assessment period, animals received d-amphetamine 
(5mg/kg i.p.). Full 360° ipsiversive rotations were recorded in 5 min intervals for up 




Figure 3.2: Photomicrographs of behavioural tests employed in L-AP4 and all further 
neuroprotection studies.  
 
A) 






Figure 3.2. Behavioural tests employed in neuroprotection studies. In chronological order, (A) 
cylinder test, (B) adjusted stepping and (C) amphetamine-induced rotations. 
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3.3.2.6 Data analysis for behavioural tests 
 
Only behavioural data from animals showing correct cannula placement were 
included for subsequent data analysis. For the cylinder test, use of the ipsilateral and 
contralateral paw was assessed as a percentage of total reaches made, both pre- and 
post-lesion, by an observer blinded to treatment. Use of paw was then expressed as a 
percentage of total paw use for each animal. The mean percentage values were then 
obtained for each treatment group so that data are expressed as mean % paw use ± 
standard error of the mean (s.e.m.). Data was then analysed using a 2-way ANOVA 
with Bonferroni’s post-hoc test to determine whether there were significant 
differences between pre- and post-lesion scores between vehicle and L-AP4-treated 
animals.   
 
The raw data of adjusted steps consisted of three replicates from each day of testing, 
which were then used to calculate an average value for both forehand and backhand 
directions for each paw. Average values of adjusted steps from 3 and 6 days post-
lesion were then expressed as a percentage of the number of pre-lesion adjusted steps 
for each individual animal. The mean percentage values for each paw in each 
direction of movement at both 3 and 6 day time intervals were then obtained for each 
treatment group. Data are expressed as a mean % ± standard error of the mean 
(s.e.m.). These data were then analysed using a 2-way ANOVA with Bonferroni’s 
post-hoc test to determine whether there were significant differences between vehicle 
and L-AP4 treated animals at both time points tested.  
 
Ipsiversive amphetamine-induced rotations were quantified in 5 min time intervals, 
with any contraversive rotations recorded as negative rotations. The number of 
ipsiversive rotations was plotted as both time course and total rotations in 60 min. 
Data are expressed as mean ± standard error of the mean (s.e.m.). For time course 
data, a 2-way ANOVA with Bonferroni’s post-hoc test was used to determine 
whether differences between vehicle and the effects of L-AP4 were significant at each 
time point. For total rotations in 60 min, the effects of L-AP4 treatment compared to 
vehicle were investigated using a 1-way ANOVA with Bonferroni’s post-hoc test. In 
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all cases, P<0.05 was taken to be significant, with all statistical analysis performed 
using GraphPad Prism version 5.  
 
3.3.2.7 Immunohistochemistry protocol   
 
On the final day of L-AP4 dosing (day 8), animals were terminally anaesthetized 
using pentobarbital (100 mg.kg
–1
) then trans-cardially perfused with 0.1 M PBS, 
followed by 4% paraformaldehyde (PFA) in 0.1 M PBS. The brains were removed 
and cut into a rostral (striatal) and caudal (SN) segment and stored in PFA at 4°C. 
 
Once required, the striatal and nigral segments of brain were dehydrated, defatted and 
then paraffin embedded. 6μm coronal sections were taken through the striatum at 
+1.2, +0.2 and -0.26mm AP from bregma and through the SN at -4.8, -5.3, and -
5.8mm AP from bregma (Paxinos & Watson, 1986) as described in section 2.3.2.2.  
Striatal and nigral sections were stained with diaminobenzidine (DAB) for tyrosine 
hydroxylase (TH) and dopa decarboxylase (DDC) as previously described in section 
2.3.2.2 with the only alteration being the use of TH and DDC specific primary 
antibodies. TH is the first enzyme in the catecholamine biosynthesis pathway, 
catalyzing the conversion of L-tyrosine to L-DOPA and is therefore a useful marker 
of all catecholaminergic neurons. However in the striatum and SN, it is widely used a 
marker of dopaminergic cells since there are no noradrenergic neurons present. An 
additional marker of dopaminergic neurons, DDC, which catalyses the conversion of 
L-DOPA to dopamine was also investigated to confirm preserved levels of TH did 
not reflect increased expression of that marker.  
 
Briefly, sections were de-paraffinised in xylene and 100% industrial methylated spirit 
(IMS) before a 10 min incubation in 3% hydrogen peroxide to block endogenous 
peroxide activity. Following standard antigen retrieval with boiling hot citric acid 
(1mM) then a 10-min incubation with blocking buffer (1% BSA in 0.5M TBS and 
10% sodium azide, pH 7.6), sections were incubated for 2 hours at RT with rabbit-α -
TH antibody (1:1250; Chemicon) or overnight at RT with rabbit polyclonal DDC 
antibody (1:1500; Chemicon). After washing in 0.1M TBS all sections were 
incubated with secondary antibody (goat anti-rabbit IgG-biotinylated 1:200, Sigma) 
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for 1 h at RT before washing again in 0.1M TBS. Following 30- min incubation with 
an ABC kit (Vector Labs) at RT, sections were washed in TBS and the signal 
developed in 0.05% DAB/0.03% H2O2 solution dissolved in TBS (0.1M TBS, pH 
7.6) for 10min at RT. Sections were finally dehydrated in 100% IMS, cleared in 
xylene, cover-slipped with DPX mountant and allowed to dry before being analysed 
using light microscopy.  
 
3.3.2.8 Image and data analysis for immunohistochemical studies 
 
For TH and DDC immunohistochemistry in the striatum, digital images were 
captured on a mounted CCD Nikon camera, using Scion Image Software (Scion 
Corporation) at all three striatal regions. Initially TH optical density was recorded in 
four quadrants of the striatum and a background cortical region, the latter of which 
was subtracted from striatal readings (shown in figure 3.3). In order to control for 
variations in staining intensity between sections, the density of TH in each quadrant 
of the lesioned striatum was expressed as a percentage of that in the respective 
contralateral (intact) striatum. For DDC and further analysis of TH 
immunohistochemistry, the average of all four quadrants combined was also 
calculated to give an average value for the total striatal optical density of the intact 
hemisphere compared to the lesioned hemisphere. This process was repeated in 
triplicate sections from each animal to ultimately attain mean data for all rats per 
treatment group.  The mean optical density of the 6-OHDA lesioned side was 
expressed as % of the contralateral, intact striatal hemisphere and was compared 
between treatment groups using a 1-way ANOVA with Bonferroni’s post-hoc test.   
 
For the SN, TH staining results were captured on a Zeiss apotome microscope and 
recorded using Axiovision LE software (Carl Zeiss Ltd., UK). TH-immunoreactive 
cells were counted in the contralateral and ipsilateral hemispheres of the SNpc in 
three adjacent sections for each animal across the three rostrocaudal levels and the 
mean of these values taken per treatment group.  TH-positive cells were counted in 
regions of the SNpc which were clearly separated from the VTA by the medial 
terminal nucleus (MT) of the accessory optic tract. Within the SNpc, viable TH 
positive cells were counted at x50 magnification using image analysis software 
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(Image J). Since TH staining can be achieved in non-viable cells and sections were 
not stained for nuclei, only intact round cells displaying a clear nucleus and 
cytoplasm were included in these analyses. Thus, for each animal a total mean TH-
positive cell count for the lesioned ipsilateral and contralateral hemispheres was 
obtained and expressed as a % of the contralateral, intact hemisphere. Statistical 
comparisons were made between L-AP4 and vehicle-treated groups using a 1-way 
ANOVA with a Bonferroni post-hoc test. All data are expressed as mean ± standard 
error of the mean (s.e.m.), where n represents the number of animals in each 
experimental group. Statistical analyses were performed using GraphPad Prism 
(version 5.0) and in all cases P<0.05 was taken to indicate significance. 
 
Stereological counting techniques provide an unbiased alternative method to assess 
neuroprotection in disease studies, whereby the reference volume may undergo 
substantial nonlinear changes as a function of age and/or disease state (due to in vivo 
size changes, as well as differential shrinkage during tissue processing), rendering 
this approach desirable to counteract these effects. However, a recent report 
comparing manual counting with stereological analysis revealed in a neuroprotection 
study using the same 6-OHDA lesion rat model, no difference in the outcome of these 
two measures, supporting the validity of our analysis (Icziewicz et al., 2010). 
Consequently manual counting was performed in all neuroprotection studies detailed 



















Figure 3.3. Schematic illustrating striatal quadrants in which TH optical density was measured, shown 
here at +0.2mm anterioposterior (AP) from bregma (Paxinos & Watson., 1998). A background reading 
was taken from the cortex (shown in grey) and subtracted from the striatal readings taken from each 
quadrant of both lesioned and non-lesioned hemispheres (shown in blue).  DM: Dorsomedial; DL: 

















3.3.2.9 Protocol for neurochemical assessment of dopamine 
 
On the final day of L-AP4 dosing (day 8), animals were killed by CO2 asphyxiation 
and brains were quickly removed for dissection of striatum and SN. Initially the brain 
was placed on its dorsal surface in the trough of a rat brain cutting block which was 
kept cold on crushed ice. Razor blades (kept on ice) were carefully inserted through 
the 1mm thick cutting channels of the block, slicing the brain at right angles to the 
sagital axis. The brain was positioned so that an initial razor blade could be inserted 
tangential to the most posterior aspects of the olfactory tubercules as described by 
Heffner et al., 1980. At this position the initial blade slices through the sagital plane 
of the brain at the level of the body of the anterior commisure. The position of the 
first razor blade served as a reference point from which slices of the striatum and SN 
were subsequently taken. For dissection of the striatum, two additional razor blades 
were inserted anterior to the initial blade, along the rostral extent of the brain at 
intervals of 2mm. For the SN, two further razor blades were inserted posterior to the 
initial blade at intervals of 2mm. The razor blades were then removed from the block 
with the coronal brain slices adhering to their surfaces and placed on a glass petri dish 
containing dry ice. Using fine forceps the striatum was then dissected from these 
slices based on its distinct striated morphological appearance comprising tissue dorsal 
to the anterior commisure, ventral to the corpus callosum and medial to the external 
capsule. The stria terminalis was also removed from the ventrolateral borders of the 
septum (shown in figure 3.4A). Dissection of the SN was made from the furthest 
posterior brain slice from the initial cut in which the dark oval shape of the nigra was 
clearly visible on the ventrolateral portion of this section. A horizontal cut was then 
made across the brainstem at the level of the rhinal sulcus and dorsal edge of the SN 
(shown in figure 3.4B). After removing the telencephalic tissue lateral to the 
brainstem, tissue from the SN was obtained by extending ventromedially-directed 
cuts to the base of the brainstem to separate the VTA medial to the SN and ventral to 
the horizontal cut. Tissue was dissected bilaterally for both the striatum and SN and 
on completion was immediately placed in 1.5ml microtubes, weighed and placed in 





Figure 3.4. Diagrammatic representation of coronal sections from which the striatum/ caudate 
putamen (A) and substantia nigra (B) were dissected out. Dashed lines indicate boundaries of brain 
regions separated with forceps. C: Cortex; CP: Caudate putamen; S: Septum; H: Hippocampus; SN; 
Substantia nigra; VTA: Ventral tegmental area (figure adapted from Heffner et al., 1980).   
 
 
Striatal and SN samples were removed from frozen storage, homogenised in ice-cold 
buffer (0.1M PCA, 0.1mM EDTA, 2.5mg/L ascorbate) for approximately 4 sec and 
then centrifuged at 20,000g for 15 min at 4
o
C.  The supernatant was then extracted 
and subsequently filtered in preparation to be assayed for dopamine by high 
performance liquid chromatography (HPLC) with electrochemical detection.  
 
The HPLC system constituted a phase reservoir, on-line degasser (X-act degassing 
unit, Jour research, Sweden), pump (Rheos 4000, Flux Instruments AG, Switzerland) 
(flow rate 200μl/min), pulse dampener (Link, Antec Leyden, Holland) and an 
analytical column (150 x 2.1 mm; 3mm C18, Hypersil BDS). Samples were injected 
by means of an autosampler (Triathlon, Presearch, UK). Analytes were  detected at 
35°C by means of an electrochemical detector (Presearch, UK) with a thin layer 
electrochemical cell fitted with a glassy carbon working electrode maintained at 
+0.75V against a Ag / AgCl reference electrode. The mobile phase consisted of 100 
mM sodium dihydrogen orthophosphate (NaH2PO4) and 100mM phosphoric acid 
(H3PO4) mixed until a pH of 2.6 was obtained, added to 2mM 1-octane sulphonic 
acid (OSA), 1mM EDTA, and 13% methanol to reach a final pH of 2.8 required to 
achieve separation of analytes.. The flow rate was 200μl min-1 and the limit of 




3.3.2.10 Data analysis for neurochemical studies 
 
Chromatogram analysis was carried out using Millenium
32 
software (Version 3.05, 
Waters Corporation). Prior to the analysis of tissue dopamine, a standard curve was 
produced by running a series of standard solutions, containing known quantities of 
analyte dopamine, through the HPLC system at concentrations of 5, 10, 100, 500, 750 
and 1500nM. From the resultant chromatograms a standard curve, such as the one 
shown in figure 3.5A was produced. Using Millenium
32
 
software, the peak areas were 
selected manually and the concentration (nM) of dopamine was then quantified by 
calibration of the selected peak area with the appropriate standard curve. Figure 3.5B 
illustrates a typical chromatogram profile in the reduction channel of dopamine in the 
striatum. A 1-way ANOVA with Bonferroni’s post-hoc test was used to compare 
dopamine content of the 6-OHDA lesioned side, expressed as a % of the contralateral 
intact side between treatment groups. 
 
3.3.2.11 Materials and suppliers 
 


















Figure 3.5. Typical standard calibration plot and chromatogram for dopamine. 
  
      A) 
 
      B) 
 
Figure 3.5. (A) Example of standard calibration curve for dopamine produced by analysis of 5, 10, 
100, 500, 750, and 1500 nM dopamine standards run before and after each sample set to attain 
duplicate readings for each standard. (B) Example of a typical chromatogram illustrating striatal levels 
of dopamine (DA). Retention time (in min) is noted for dopamine peak.  
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3.3 Results  
 
3.3.1 Effects of sub-chronic supranigral infusion of the broad spectrum 
group III mGlu receptor agonist, L-AP4, in unilaterally 6-OHDA-lesioned 
rats 
 
3.3.1.1 Effects of sub-chronic L-AP4 infusion on tyrosine hydroxylase positive 
cells in the substantia nigra pars compacta 
 
Within the SNpc, the mean sum of TH-positive cells in triplicate sections obtained 
across three rostrocaudal levels declined from 307.4 ± 19.1 in the intact hemisphere, 
to 36.9 ± 16.1 in the lesioned hemisphere of vehicle-treated 6-OHDA lesioned 
animals, a reduction of approximately 87%. Supranigral infusion of a low dose of L-
AP4 (3nmol), 1 hour prior and for 7 days after 6-OHDA infusion demonstrated 
noticeable preservation of nigral TH-positive cells in the lesioned hemisphere. 
Following L-AP4 (3nmol) treatment the number of TH-positive cells remaining in the 
lesioned hemisphere amounted to 53.7 ± 4.4% of the intact hemisphere, compared to 
an equivalent 12.6 ± 5.6% remaining in vehicle-treated animals (P<0.05; 1-way 
ANOVA with Bonferroni’s post-hoc test; figure 3.6A). Using a higher dose of L-AP4 
(30nmol), preservation of nigral TH-positive cells was lost completing a bell-shaped 
dose response profile following sub-chronic supranigral infusion of L-AP4.  
 
Representative nigral sections demonstrating immunoreactive TH-positive cells in the 
6-OHDA lesioned animals treated with sub-chronic L-AP4 (1-30nmol) are shown in 
figure 3.6B. The photomicrographs demonstrate supranigral infusion of L-AP4 
(3nmol) clearly provides noticeable preservation of TH-positive cells in the lesioned 
hemisphere.  This effect appeared to be lost at the lower (1nmol) and higher (30nmol) 






Figure 3.6: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on tyrosine hydroxylase (TH)-positive cell counts 
in nigral sections of unilaterally 6-OHDA lesioned rats. 
 
                     
Figure 3.6. (A) The effects of sub-chronic supranigral infusion of L-AP4 (1-30nmol in 4µl) or vehicle 
(4µl 1x PBS) on the 6-OHDA induced loss of TH-positive cells in the SNpc on the lesioned side 
expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle, n=7 for 1 
and 3nmol L-AP4, n=8 for 30nmol L-AP4). * (P <0.05) and *** (P < 0.001) indicate significant 
differences compared to vehicle treated animals (1-way ANOVA with Bonferroni’s post-hoc test). F = 
15.33; degrees of freedom (df) = 3 (treatment), 26 (residual). (B) Representative photomicrographs 
show the levels of TH immunoreactivity in nigral sections from 6-OHDA-lesioned animals following 
sub-chronic L-AP4 treatment. Fixed coronal sections shown here are at -5.30mm AP from bregma, 
(Paxinos, 1998). Lesion side on the right; scale bar: 200µm 























































3.3.1.2 Effects of sub-chronic L-AP4 infusion on tyrosine hydroxylase levels in 
the striatum 
 
The optical density measurements of TH immunoreactivity in striatal sections from 
animals treated supranigrally with sub-chronic L-AP4 (1-30nmol) and those treated 
with vehicle is quantified in figure 3.7. When the combined mean striatal TH optical 
density was quantified, TH levels declined in the lesioned striatum of subsequent 
vehicle-treated animals to 7.7 ± 1.9% of the intact side. Supranigral infusion of all 
doses tested of L-AP4 (1-30nmol, 1 hour prior and for 7 days after 6-OHDA infusion 
considerably preserved striatal immunoreactivity in the lesioned hemisphere. TH 
levels remained significantly higher (>63% of intact side) in all L-AP4 treatment 
groups (n=7-8; P<0.01 versus vehicle treatment; 1-way ANOVA with Bonferroni’s 
post-hoc test; figure 3.7A). Maximum protection was observed following 30nmol L-
AP4 where the overall mean optical density in the lesioned striatum amounted to 79.2 
± 5.9% of the intact hemisphere, suggesting considerable preservation of 
dopaminergic striatal nerve terminals in these animals.  
 
When the individual quadrants of the striatum were quantified, each group showed a 
comparable level of TH immunoreactivity between quadrants (P >0.05) and again the 
levels were significantly preserved following L-AP4 treatment at each dose tested 
(figure 3.7B). Although assessment of TH in quadrants of vehicle treated animals 
revealed a tendency for greater loss of TH immunoreactivity in the dorsolateral and 
ventrolateral quadrants i.e. 96% and 98% loss in comparison to 92% and 80% loss in 
the dorsomedial and ventromedial quadrants respectively, this difference was not 
statistically significant (p >0.05; 1-way ANOVA with Bonferroni’s post-hoc test).  
 
Representative striatal sections showing TH immunoreactivity in the 6-OHDA 
lesioned animals treated with sub-chronic L-AP4 (1-30nmol) are shown in figure 3.8. 
The photomicrographs demonstrate L-AP4 at each of the doses tested here provides 





Figure 3.7: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on tyrosine hydroxylase (TH) immunoreactivity in 
striatal sections of unilaterally 6-OHDA lesioned rats.   
 
Figure 3.7. The effects of sub-chronic supranigral infusion of L-AP4 (1-30nmol in 4µl) or vehicle (4µl 
PBS) on the 6-OHDA induced loss of TH immunoreactivity in the whole striatum (A) and individual 
quadrants (B) on the lesioned side expressed as a percentage of the intact side. In (A), ** (P <0.01) and 
*** (P <0.001) indicates significant difference compared to vehicle treated animals (1-way ANOVA 
with Bonferroni’s post- hoc test). F = 15.33; df = 3,26. In (B) ** (P < 0.01) and *** (P < 0.001) 
indicate significant differences compared to vehicle treated animals (2-way ANOVA with Bonferroni’s 
post-hoc test). For treatment factor, F = 43.15, df = 3,104; for quadrant factor F= 2.575, df = 3,104. 
DL: Dorsolateral; DM: Dorsomedial; VL: Ventrolateral; VM: Ventromedial. For (A) and (B) values 
represent mean ± s.e.m. (n=8 for vehicle, n=7 for 1 and 3nmol L-AP4, n=8 for 30nmol L-AP4).   










































































































Figure 3.8: Tyrosine hydroxylase immunoreactivity in representative striatal sections 
from 6-OHDA-lesioned rats following sub-chronic treatment with the broad spectrum 





Figure 3.8. Representative photomicrographs showing the levels of TH immunoreactivity in striatal 
sections from 6-OHDA-lesioned animals following sub-chronic L-AP4 treatment. Fixed coronal 
sections (shown here + 0.20mm AP from bregma, Paxinos, 1998) were reacted with antibodies raised 













3.3.1.3 Effects of sub-chronic L-AP4 infusion on dopa decarboxylase in the 
striatum of 6-OHDA lesioned rats 
 
The optical density of DDC immunoreactivity in striatal sections from animals treated 
supranigrally with sub-chronic L-AP4 (1-30nmol) and those treated with vehicle are 
quantified in figure 3.9A. When the combined mean striatal DDC optical density was 
quantified, DDC levels declined in the lesioned striatum of subsequent vehicle-treated 
animals to 7.9 ± 2.4% of the intact side. Supranigral infusion of all doses tested of L-
AP4 (1-30nmol, 1 hour prior and for 7 days after 6-OHDA infusion considerably 
preserved striatal immunoreactivity in the lesioned hemisphere. DDC levels remained 
significantly higher (>54% of intact side) in all L-AP4 treatment groups (n=7-8; 
P<0.01 versus vehicle treatment; 1-way ANOVA with Bonferroni’s post-hoc test; 
figure 3.9A). Maximum protection was observed following 3nmol L-AP4 where the 
overall mean optical density in the lesioned striatum amounted to 60.8 ± 9.2% of the 
intact hemisphere, demonstrating striatal DDC immunoreactivity was also 
significantly preserved with respect to vehicle-treated animals. This finding 
confirmed preservation of dopaminergic striatal nerve terminals in these animals and 
that preserved levels of TH was not a mere reflection of increased expression of the 
marker.  
 
Representative striatal sections showing DDC immunoreactivity in the 6-OHDA 
lesioned animals treated with sub-chronic L-AP4 (1-30nmol) are shown in figure 
3.9B. The photomicrographs demonstrate supranigral infusion of L-AP4 at each of 
the doses tested, 1 hour and for 7 days after 6-OHDA infusion provided noticeable 










Figure 3.9: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on dopa decarboxylase immunoreactivity in striatal 
sections of unilaterally 6-OHDA lesioned rats.  
 
 
Figure 3.9. (A) The effects of sub-chronic supranigral infusion of L-AP4 (1-30nmol in 4µl) or vehicle 
(4µl PBS) on the 6-OHDA induced loss of DDC in the striatum on the lesioned side expressed as a 
percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle, n=7 for 1 and 3nmol L-
AP4, n=8 for 30nmol L-AP4). ** (P <0.01) and *** (P < 0.001) indicates significant differences 
compared to vehicle treated animals (1-way ANOVA with Dunnett’s post-hoc test). F = 8.283; df = 3, 
26. (B) Representative photomicrographs showing the levels of DDC immunoreactivity in striatal 
sections from 6-OHDA-lesioned animals following sub-chronic L-AP4 treatment. Fixed coronal 
sections (shown here + 0.20mm AP from bregma, Paxinos, 1998) were reacted with antibodies raised 
against DDC and stained with diaminobenzidine (DAB). Lesion side on the right; scale bar: 500µm. 
















































3.3.1.4 Effects of sub-chronic L-AP4 infusion on dopamine content in the 
substantia nigra and striatum 
 
When assayed in a separate study using HPLC, nigral dopamine content was shown 
to be preserved in the lesioned SN of animals treated with L-AP4.  In vehicle-treated 
6-OHDA lesioned animals, nigral dopamine content fell from 3629 ± 912 ng g
-1
 in 
the intact hemisphere to 505 ± 159 ng g
-1
 in the lesioned hemisphere, which 
represented a decline in dopamine to 16.7 ± 5.0% (n=8) of the intact hemisphere 
(figure 3.10A). L-AP4 treatment produced a dose-dependent preservation of nigral 
dopamine content, which reached a maximal significant effect at 3nmol L-AP4, 
where dopamine content in the lesioned hemisphere equated to 80.5 ± 10.2% of the 
intact hemisphere (P <0.001 versus vehicle treatment; 1-way ANOVA with 
Bonferroni’s post-hoc test). At a higher dose of L-AP4 (30nmol), dopamine content 
was no longer significantly preserved in the lesioned SN. 
 
Effects on striatal dopamine content mirrored these seen in the SN. Thus, striatal 
dopamine content was also shown to be preserved in the lesioned hemisphere of 
animals treated with L-AP4.  In vehicle-treated 6-OHDA lesioned animals, striatal 
dopamine content fell from 13450 ± 1351 ng g
-1
 in the intact hemisphere to 1352 ± 
560 ng g
-1
 in the lesioned hemisphere, which represented a decline in dopamine to 
10.3 ± 4.1% (n=8) of the intact hemisphere (figure 3.10B). In tune with nigral 
dopamine content, L-AP4 treatment produced a dose-dependent preservation of 
striatal dopamine content,  reaching a maximal significance effect with 3nmol L-AP4 
(P< 0.01 versus vehicle treatment; 1-way ANOVA with Bonferroni’s post-hoc test), 
where dopamine content in the lesioned hemisphere remained at 78.9 ± 4.1% of the 
intact hemisphere. At a higher dose of L-AP4 (30nmol), preservation of striatal 
dopamine content was reduced with respect to 3nmol L-AP4 yet remained 
significantly preserved (P< 0.05 versus vehicle-treated animals; 1-way ANOVA with 







Figure 3.10: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on dopamine content in the substantia nigra and 
striatum of unilaterally 6-OHDA lesioned rats. 
 
Figure 3.10. The effects of sub-chronic supranigral infusion of L-AP4 (0.1-30nmol in 4µl) or vehicle 
(4µl PBS) on the 6-OHDA induced loss of dopamine content in the SN (A) and striatum (B) on the 
lesioned side expressed as a percentage of the intact side. For both, values represent mean ± s.e.m. 
(n=8 for vehicle, n=6 for 0.1nmol, n=7 for 1, 3 and 30nmol L-AP4). ** (P <0.01) and *** (P < 0.001) 
indicates significant differences compared to vehicle treated animals (1-way ANOVA with 
Bonferroni’s post-hoc test). # (P <0.05) and ## (P<0.01) indicates significance difference compared to 
L-AP4 (0.1nmol) treated animals.  In (A) F = 8.345; df = 4,30, (B) F = 6.194; df = 4,30. 
































































































The effects of sub-chronic supranigral infusion of L-AP4 (0.1-30nmol) on 
spontaneous motor function following a unilateral 6-OHDA lesion of the SNpc in rats 
were assessed using the cylinder test on day 5 post lesion. Ipsilateral, contralateral or 
use of both paws were quantified as a % of total paw use, where naive non-lesioned 
animals demonstrate preference to use both paws (~60%) ahead of ipsilateral (~20%) 
and contralateral (~20%) paws. Since a unilateral 6-OHDA lesion typically induces a 
functional deficit in contralateral paw, use of this paw is illustrated in figure 3.11A. 
As a result of impaired contralateral paw use it is common to observe compensatory 
increases in ipsilateral paw use shown in figure 3.11B.  
 
As expected in vehicle treated animals, there was a significant decrease in use of the 
contralateral paw from 25.9 ± 3.7% pre lesion to 8.1 ± 3.1% post lesion confirming 
that a unilateral 6-OHDA lesion induced a reduction of approximately 69% in 
contralateral paw use (figure 3.11A). In contrast, in animals treated with 0.1, 3 and 
30nmol L-AP4 use of contralateral paw was largely spared following a 6-OHDA 
lesion. For example, following treatment with L-AP4 (3 nmol) contralateral paw use 
equated to 23.7 ± 4.0% of total paw use post-lesion in comparison to 26.6 ± 5.4%  
pre-lesion, demonstrating approximately 89% preservation or 11% reduction in 
contralateral paw use post-lesion following L-AP4 treatment.  
 
Interestingly a marked increase in ipsilateral paw use was observed in vehicle treated 
animals following a 6-OHDA lesion in tune with the significant decrease in 
contralateral paw use. However with increasing doses of L-AP4 this compensatory 
increase in use of ipsilateral paw decreased as use of the contralateral paw was 
preserved following L-AP4 treatment. For example in vehicle treated animals, 
ipsilateral paw use post lesion increased by >230% with respect to pre-lesion score, 
compensating for an impaired contralateral paw. However in L-AP4 treated animals 
(3nmol), ipsilateral paw use post lesion increased by only 25% of pre-lesion score 
confirming the reduced asymmetry in these animals (figure 3.11B).  
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Figure 3.11: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on motor function assessed using the cylinder test 
in unilaterally 6-OHDA lesioned rats.   
 
Figure 3.11. The effects of sub-chronic supranigral infusion of L-AP4 (0.1-30nmol in 4 µl) or vehicle 
(4µl PBS) on contralateral (A) and ipsilateral (B) paw use expressed as a percentage of total paw use 
assessed using the cylinder test at 5 days post a 6-OHDA lesion. For all, values represent mean ± 
s.e.m. (n=8 for vehicle, n=6 for 0.1nmol, n=7 for 1, 3 and 30nmol L-AP4). * (P <0.05), ** (P <0.01) 
and *** (P < 0.001) indicates significant differences compared to pre-lesion score (2-way ANOVA 
with Bonferroni’s post-hoc test). In (A) for pre/post lesion factor, F = 2.135, df = 1,60; for treatment 
factor F = 1.538, df = 4,60.  In (B) for pre/post lesion factor, F = 73.49, df = 1,60; for treatment factor 


















































































The effects of sub-chronic supranigral infusion of L-AP4 (0.1-30nmol) on adjusted 
steps, 3 and 6 days following unilateral 6-OHDA lesioning in rats, are shown as a 
percentage of their pre-lesion scores in figure 3.12. As predicted the contralateral paw 
(lesioned) demonstrated a marked reduction in adjusted steps in the forehand 
direction, from 100% pre-lesion to 58.3 ± 6.1% at 3 days post-lesion and 37.0 ± 7.8% 
at 6 days in the vehicle treated group, indicating unilateral 6-OHDA lesioning 
reduced the number of adjusted steps in this direction (figure 3.12A). Infusion with L-
AP4 protected against the decline in contralateral paw use, again displaying a bell-
shaped dose response profile. For example, use of the contralateral paw increased in a 
dose dependent manner reaching maximal effect with L-AP4 (3nmol) equating to 
81.4 ± 7.5% of pre-lesion scores at 3 days post-lesion and 75.4 ± 4.6% at 6 days, the 
latter of which was a significant effect with respect to vehicle-treated animals (P < 
0.05). However, with a high dose of L-AP4 (30nmol), preservation of contralateral 
paw use was markedly reduced from 79.7 ± 14.2% of pre-lesion score at 3 days post-
lesion and 53.3 ± 11.9% at 6 days.  
 
In the backhand direction, there was also a marked reduction in contralateral paw use 
in vehicle treated animals. This amounted to a decrease in adjusted steps from 100% 
pre-lesion to 61.2 ± 12.1% at 3 days post-lesion and 38.3 ± 8.1% at 6 days confirming 
unilateral 6-OHDA-lesioning also reduced the number of adjusted steps in the 
backhand direction (figure 3.12B). However following L-AP4 treatment use of the 
contralateral paw in the backhand direction was significantly preserved, again 
reaching maximal effect with the 3nmol dose whereby 91.1 ± 8.8% of pre-lesion 
scores at 3 days and 86.2 ± 10.2% at 6 days were obtained. In the high-dose L-AP4 
(30nmol) group there was no significant increase in adjusted steps compared to 
vehicle group consistent with the bell-shaped dose response profile seen in the 
forehand direction. Collectively these findings demonstrate supranigral sub-chronic 
L-AP4 (3nmol) treatment reduced the motor asymmetry induced by a unilateral 6-
OHDA lesion shown here by increasing the contralateral adjusted stepping in both 
forehand and backhand directions, almost restoring contralateral paw use to pre-
lesion levels.    
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As expected the ipsilateral paw (non-lesioned) in both the forehand and backhand 
direction showed no significant deficit in adjusted steps 3 or 6 days post-lesion in 
vehicle treated animals, although there was a tendency for a reduction in adjusted 
steps in the L-AP4 treated groups (figure 3.12C and D). Indeed this effect is similar to 
that seen on assessment of spontaneous motor function in the cylinder test and also 






























Figure 3.12: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on motor function assessed using the adjusted 




Figure 3.12. The effects of sub-chronic supranigral infusion of L-AP4 (0.1-30nmol in 4µl) or vehicle 
(4µl PBS) on contralateral and ipsilateral paw use in the forehand and backhand direction (A-D) 
assessed using the adjusted steps test at 3 and 6 days post a 6-OHDA lesion expressed as a percentage 
of pre-lesion score. Values represent mean ± s.e.m. (n=8 for vehicle, n=6 for 0.1nmol, n=7 for 1, 3 and 
30nmol L-AP4). *(P <0.05) and ** (P <0.01) indicates significant differences compared to vehicle 
treated animals (2-way ANOVA with Bonferroni’s post-hoc test). In (A) for treatment factor, F = 
3.382, df = 4,60 and for days post lesion factor, F = 5.897, df = 1,60. In (B) treatment factor, F = 3.65, 
df = 4,60 and days post lesion factor, F = 2.613, df = 1,60. In (C) treatment factor, F = 4.084, df = 4,60 
and for days post lesion factor, F = 4.275, df = 1,60). In (D) treatment factor, F = 3.806, df = 4,60 and 














































































































































Amphetamine-induced ipsiversive rotations in unilaterally 6-OHDA lesioned rats 
treated with sub-chronic L-AP4 or vehicle are shown in figure 3.13. Both graphs A 
and B show the same vehicle group split with two doses of L-AP4 for clarity. 
Analysis of time-course in vehicle treated animals revealed amphetamine (5mg.kg
-1
) 
induced considerable ipsiversive rotations throughout a 60 min time period. However 
in animals treated with L-AP4 a significant reduction in amphetamine-induced 
ipsiversive rotations was noted. L-AP4 (3nmol) treated animals demonstrated the 
greatest reduction in ipsiversive rotations reaching a significant difference over a 
period of 35 min from 20 to 55 min (P <0.001-0.05, 2-way ANOVA with 
Bonferroni’s post-hoc test) compared to vehicle-treated animals (figure 3.13A). 
Furthermore, figure 3.13B demonstrated L-AP4 (30nmol) also induced a significant 
reduction in ipsiversive rotations at numerous intervals over a 60 min time period (P 
<0.001-0.05, 2 way ANOVA with Bonferroni’s post-hoc test) compared to vehicle-
treated animals.    
 
In figure 3.14, the mean total ipsiversive rotations were quantified over the 60 min 
period. The number of ipsiversive rotations by amphetamine (5mg.kg
-1
) in vehicle 
treated animals was 636 ± 64 60 rotations in 60 min
-1
. L-AP4 dose dependently 
decreased amphetamine-induced ipsiversive rotations reaching maximal effect with 
L-AP4 (3nmol) where the total mean number of rotations equated to 232 ± 72, 
demonstrating a 64% reduction compared to vehicle treated animals (P<0.01, 1-way 
ANOVA with Dunnett’s post-hoc test). A higher dose of L-AP4 (30nmol) also 
significantly reduced the number of rotations to 277 ± 75 rotations in 60 min
-1
 
(P<0.05) however to a lesser extent than L-AP4 (3nmol) consistent with a bell-shaped 
dose response profile reported in previous behavioural tests. Collectively, these 
findings demonstrate L-AP4 mediated functional neuroprotection by effectively 






Figure 3.13: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on motor function assessed following 
amphetamine-induced rotations in unilaterally 6-OHDA lesioned rats.   
 
Figure 3.13. The effects of sub-chronic supranigral infusion of L-AP4 (0.1-30nmol in 4µl) or vehicle 
(4µl PBS) on amphetamine induced rotations in unilaterally 6-OHDA lesioned rats. (A) Time course of 
ipsiversive rotations induced by amphetamine (5mg.kg-1) in vehicle (1x PBS) and L-AP4 (0.1, 3 nmol) 
treated animals. (B) Time course of ipsiversive rotations induced by amphetamine (5mg.kg-1) in 
vehicle (1x PBS) and L-AP4 (1,30nmol) treated animals. Values represent mean ± s.e.m. (n=8 for 
vehicle, n=6 for 0.1nmol, n=7 for 1, 3 and 30nmol L-AP4). (A) * (P <0.05), ** (P <0.01) and *** (P < 
0.001) indicates significant differences between L-AP4 (3 and 30nmol) and vehicle treated animals (2-
way ANOVA with Bonferroni’s post-hoc test). (B) # (P <0.05) indicates significant difference between 
L-AP4 (0.1 and 1nmol) and vehicle treated animals. Treatment factor, F = 25.05, df = 4,450 and for 
time, F = 19.33, df = 14,450. 




























































































Figure 3.14: Effects of sub-chronic supranigral infusion of the broad spectrum group 
III mGlu receptor agonist L-AP4, on motor function assessed following 





Figure 3.14. Total ipsiversive rotations induced by amphetamine in 60 min-1 in vehicle and L-AP4 
treated animals. Values represent mean ± s.e.m. (n=8 for vehicle, n=6 for 0.1nmol, n=7 for 1, 3 and 
30nmol L-AP4). * (P <0.05), ** (P <0.01) indicates a significant difference compared to vehicle 



















































3.3.2 Effects of pre-treatment with group III mGlu receptor antagonist 
CPPG, on L-AP4 mediated neuroprotection in unilaterally 6-OHDA-
lesioned rats 
 
3.3.2.1 Effects of pre-treatment with CPPG on L-AP4 mediated neuroprotection 
with respect to dopamine content in the substantia nigra and striatum 
 
In a separate study, the protective effects of L-AP4 (3nmol) in preserving dopamine 
content in the SN and striatum following a unilateral 6-OHDA lesion were found to 
be significantly inhibited by pre-treatment with CPPG (75nmol). In the lesioned 
hemisphere preservation of nigral dopamine following L-AP4 treatment significantly 
fell from 56.8 ± 8.1% of the intact hemisphere to 18.8 ± 3.4% following pre-treatment 
with CPPG (75nmol) (P < 0.001, 1-way ANOVA with Bonferroni’s post-hoc test). 
Pre-treatment with a low dose of CPPG (7.5nmol) failed to significantly inhibit 
preservation mediated by L-AP4 where 41.9 ± 2.6% of nigral dopamine remained in 
the lesioned hemisphere (figure 3.15A).   
 
L-AP4 mediated preservation of striatal dopamine was also significantly inhibited 
following pre-treatment with CPPG (75nmol) where dopamine content fell from 39.8 
± 10.8% of the intact hemisphere to 4.1 ± 1.9% following pre-treatment with CPPG 
(P <0.01, 1-way ANOVA with Bonferroni’s post-hoc test). Pre-treatment with the 
low dose of CPPG (7.5nmol) also significantly inhibited preservation of striatal 
dopamine mediated by L-AP4 (P<0.05), although to a lesser extent where 14.4 ± 
2.9% of striatal dopamine content remained in the lesioned hemisphere (figure 










Figure 3.15: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of L-AP4, with respect to dopamine content in the substantia nigra 
and striatum of unilaterally 6-OHDA lesioned rats.   
 
Figure 3.15. The effects of sub-chronic supranigral infusion of the broad spectrum group III mGlu 
receptor antagonist CPPG (7.5 or 75nmol in 4µl of 0.1M NaOH) on the protective effect of L-AP4 
(3nmol in 4µl) proceeding 6-OHDA induced loss of dopamine content in (A) the substantia nigra 
(SNpc) and (B) striatum. Values represent mean ± s.e.m. (n=6 for vehicle, n=8 for 7.5nmol CPPG, n=7 
for 75nmol CPPG and 3nmol L-AP4). ** (P<0.01) and *** (P <0.001) indicate a significant difference 
compared to L-AP4 (3nmol) treated animals (1-way ANOVA with Bonferroni’s post-hoc test). ## (P 
<0.01) and ### (P <0.001) indicates a significant difference compared to vehicle-treated animals (1-
way ANOVA with Bonferroni’s post-hoc test). ~ (P <0.05) indicates a significant difference compared 
to L-AP4 (3nmol) treated animals (1-way ANOVA with Bonferroni’s post hoc test). For (A) F = 
17.55; df = 3,24, (B) F = 8.035; df = 3,24.  
































































































 4.3.2.2 Effects of pre-treatment with CPPG on L-AP4 mediated neuroprotection 




The effects of CPPG pre-treatment with L-AP4 (3nmol) on spontaneous motor 
function following a unilateral 6-OHDA lesion of the SNpc in rats was assessed using 
the cylinder test on day 5 post lesion (figure 3.16). As expected in vehicle treated 
animals, there was a significant decrease in use of the contralateral paw from 26.8 ± 
4.9% pre-lesion to 6.4 ± 4.0% post lesion. Consistent with the previous study in this 
chapter, use of the contralateral paw was largely spared with L-AP4 (3nmol) 
following a 6-OHDA lesion. Contralateral paw use equated to 20.8 ± 7.9% of total 
paw use post-lesion in comparison to 24.4 ± 2.8% pre-lesion, demonstrating 
approximately 85% preservation in contralateral paw use post-lesion following L-
AP4 treatment which is in good agreement with our first study in this chapter (89% 
preservation). Pre-treatment with CPPG (75nmol) almost totally inhibited 
preservation of contralateral paw use with L-AP4 from 28.6 ± 4.1% pre-lesion to 8.0 
± 4.9% post-lesion, attaining a similar post-lesion score to that of vehicle treated 
animals (6.4 ± 4.0% post-lesion, figure 3.16A). The lower dose of CPPG (7.5nmol) 
failed to block L-AP4’s actions.  
 
In the previous study, as a result of preserving contralateral paw use, L-AP4 
decreased the compensatory increase in ipsilateral paw use as described in vehicle-
treated animals. Indeed, in this study, ipsilateral paw use in vehicle-treated animals 
post-lesion increased by >236% with respect to pre-lesion score, compensating for an 
impaired contralateral paw. Interestingly in L-AP4 (3nmol) treated animals, the 
ipsilateral paw use post lesion also increased by a similar extent (233% of pre-lesion 
score). However it is likely this is due to a lower pre-lesion score being obtained here 
of 17.34 ± 6.3% in comparison to 36.8 ± 8.3% in the previous study. Nevertheless, in 
CPPG (75nmol) pre-treated animals, use of the ipsilateral paw post-lesion increased 
by 271% (figure 3.16B) confirming impaired motor function in these animals, 




Figure 3.16: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of L-AP4 with respect to motor function assessed using the cylinder 
test in unilaterally 6-OHDA lesioned rats.   
 
Figure 3.16. The effects of sub-chronic supranigral infusion of the broad spectrum group III mGlu 
receptor antagonist CPPG (7.5 or 75nmol in 4µl of NaOH) on the protective effect of L-AP4 (3nmol in 
4µl), with respect to (A) contralateral and (B) ipsilateral paw use assessed using the cylinder test at 5 
days post a 6-OHDA lesion expressed as a percentage of total paw use. For all, values represent mean 
± s.e.m. (n=6 for vehicle, n=8 for 7.5nmol CPPG, n=7 for 75nmol CPPG and L-AP4). * (P <0.05), ** 
(P <0.01) and *** (P < 0.001) indicates significant differences compared to pre-lesion score (2-way 
ANOVA with Bonferroni’s post-hoc test).  In (A) for pre/post lesion factor, F = 13.03, df = 1,48; for 
treatment factor, F = 0.6224, df = 3,48. In (B) for pre/post lesion factor, F = 72.35, df = 1,48 and for 
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The effects of CPPG pre-treatment with L-AP4 (3nmol) on adjusted steps, 3 and 6 
days following unilateral 6-OHDA lesioning in rats, are shown as a percentage of 
their pre-lesion scores in figure 3.17. As predicted, the contralateral paw (lesioned) 
demonstrated a marked reduction in adjusted steps in the forehand direction, from 
100% pre-lesion to 43.9 ± 13.1% at 6 days post-lesion in the vehicle treated group, 
indicating unilateral 6-OHDA lesioning reduced the number of adjusted steps in this 
direction (figure 3.17A). In this study, L-AP4 (3nmol) treatment preserved 
contralateral paw use, equating to 70.0 ± 14.0% of pre-lesion scores at 6 days post-
lesion, with respect to vehicle-treated animals. Following pre-treatment with CPPG 
however, this preservation was reduced to 57.0 ± 9.4% of pre-lesion scores at 6 days 
post-lesion. A similar effect following CPPG pre-treatment was also observed in the 
backhand direction. L-AP4 (3nmol) treatment significantly preserved contralateral 
paw use, equating to 70.9 ± 15.0% of pre-lesion scores at 6 days post-lesion, with 
respect to vehicle-treated animals (P < 0.05). However, following pre-treatment with 
a high dose of CPPG, preservation was reduced, on this occasion to 49.3 ± 12.2% of 
pre-lesion scores at 6 days post-lesion (figure 3.17B). Since the effects of CPPG were 
not significant here, this may suggest the optimal dose of antagonist may not have 
been reached.  
 
As expected the ipsilateral paw (non-lesioned) in the forehand direction showed no 
significant deficit in adjusted steps 3 or 6 days post-lesion in vehicle treated animals, 
although a tendency for an L-AP4 mediated reduction in adjusted steps as previously 
reported was also seen here in both directions (figure 3.17 C,D). This tendency was 
not apparent following pre-treatment with CPPG (75nmol) where scores were similar 
to those obtained to vehicle treated animals. Collectively, these findings demonstrate 
pre-treatment with CPPG inhibited L-AP4 mediated preservation of motor function 








Figure 3.17: Effects of the III mGlu receptor antagonist CPPG on the protective effect 
of L-AP4, with respect to motor function assessed using the adjusted steps test in 




Figure 3.17.The effects of the group III mGlu receptor antagonist CPPG (7.5 or 75nmol in 4µl of 
0.1M NaOH) on the protective effect of L-AP4 (3nmol in 4µl) or vehicle (4µl 0.1M NaOH) with 
respect to contralateral and ipsilateral paw use in the forehand and backhand direction (A-D) assessed 
using the adjusted steps test at 3 and 6 days post a 6-OHDA lesion expressed as a percentage of pre-
lesion score. Values represent mean ± s.e.m. (n=6 for vehicle, n=8 for 7.5nmol CPPG, n=7 for 75nmol 
CPPG and L-AP4). *(P <0.05) indicates a significant difference compared to vehicle-treated animals 
(2-way ANOVA with Bonferroni’s post-hoc test). For (A), treatment factor F = 3.018, df = 3,48 and 
for days post-lesion factor, F = 1.288, df = 1,48. For (B), treatment factor F = 5.074, df = 3,48 and for 
days post-lesion factor, F = 1.036, df = 1,48. For (C), treatment factor F = 2.518, df = 3,48 and for 
days post-lesion factor, F = 7.232, df = 1,48. For (D), treatment factor F = 3.605, df = 3,48 and for 
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Amphetamine-induced ipsiversive rotations in unilaterally 6-OHDA lesioned rats 
treated with sub-chronic L-AP4 following pre-treatment with CPPG are shown in 
figure 3.18. Analysis of time-course in vehicle treated animals revealed amphetamine 
(5mg.kg
-1
) induced considerable ipsiversive rotations throughout a 60 min time 
period. As expected in animals treated with L-AP4 (3nmol) a significant reduction in 
amphetamine-induced ipsiversive rotations were identified, seen here over a period of 
25 min from 15 to 40 min (P <0.001-0.05, 2-way ANOVA with Bonferroni’s post-
hoc test) compared to vehicle-treated animals (figure 3.18A). Pre-treatment with a 
low dose of CPPG failed to inhibit these effects of L-AP4 where a significant 
inhibition of ipsiversive rotations was reported at one time-point only (40 min) 
following amphetamine (P <0.05, 2 way ANOVA with Bonferroni’s post-hoc test) 
compared to L-AP4 treated animals (figure 3.18A). However, pre-treatment with a 
high dose of CPPG (75nmol) revealed considerable inhibition of L-AP4 mediated 
reduction in ipsiversive rotations, reaching significance between 10 to 20 min 
(P<0.01-0.05, 2-way ANOVA with Bonferroni’s post-hoc test, figure 3.18B).     
 
In figure 3.19, the mean total ipsiversive rotations were quantified over the 60 min 
period to identify the effects of CPPG on L-AP4 mediated reduction in ipsiversive 
rotations. L-AP4 (3nmol), as expected, significantly decreased amphetamine-induced 
ipsiversive rotations by up to 69% in comparison to vehicle treated animals (P<0.01, 
1-way ANOVA with Dunnett’s post-hoc test). Pre-treatment with CPPG (75nmol), 
however, significantly inhibited L-AP4 mediated reduction in amphetamine-induced 
rotations. Using this high dose of CPPG the number of rotations equated to 404 ± 73 
in 60 min
-1
 in comparison to 163 ± 77 in L-AP4 treated animals (P<0.05, 1-way 
ANOVA with Dunnett’s post-hoc test). CPPG (7.5nmol) also inhibited the L-AP4 
mediated reduction in ipsiversive rotations, where the number of rotations equated to 
259 ± 42 60 min
-1
, although this effect was not significant. Indeed this response was 
significantly different to vehicle treated animals, suggesting L-AP4 mediated 




Figure 3.18: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of L-AP4, with respect to motor function assessed following 
amphetamine-induced rotations in unilaterally 6-OHDA lesioned rats.   
 
Figure 3.18. Effects of the group III mGlu receptor antagonist CPPG (7.5 or 75nmol in 4µl of 0.1M 
NaOH) on the protective effect of L-AP4 (3nmol in 4µl 1x PBS), with respect to amphetamine induced 
rotations in unilaterally 6-OHDA lesioned rats. (A) Time course of ipsiversive rotations induced by 
amphetamine (5mg.kg-1) in vehicle (0.1M NaOH), L-AP4 (3 nmol) and 7.5nmol CPPG pre-treated 
animals. (B) Time course of ipsiversive rotations induced by amphetamine (5mg.kg-1) in vehicle, L-
AP4 (3nmol) and 75nmol CPPG pre-treated animals. Values represent mean ± s.e.m. (n=6 for vehicle, 
n=8 for 7.5nmol CPPG, n=7 for 3nmol L-AP4 and 75nmol CPPG). (A) * (P <0.05) indicates 
significant difference between L-AP4 and 7.5nmol CPPG pre-treated animals. # (P <0.05), ## (P 
<0.01) and ### (P <0.001) indicate significant difference compared to vehicle treated animals. For 
treatment factor, F = 37.26, df = 2,270 and for time, F = 11.80, df = 14, 270. (B) * (P <0.05) and ** (P 
<0.01) indicate significant difference between L-AP4 and 75nmol CPPG pre-treated animals (2-way 
ANOVA with Bonferroni’s post-hoc test). Treatment factor, F = 40.80, df = 2,255 and for time, F = 
17.27, df = 14, 270.  





























































































Figure 3.19: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of L-AP4, with respect to motor function assessed following 




Figure 3.19. Total ipsiversive rotations induced by amphetamine in 60 min-1 in vehicle, L-AP4 and 
CPPG pre-treated animals. Values represent mean ± s.e.m. (n=6 for vehicle, n=8 for 7.5nmol CPPG, 
n=7 for 75nmol CPPG and L-AP4). * (P <0.05) indicates a significant difference compared to 3nmol 
L-AP4 treated animals (1-way ANOVA with Dunnett’s post-hoc test).  # (P <0.05), ## (P <0.01) 
indicates significant difference compared to vehicle treated animals (1-way ANOVA with Dunnett’s 



















































These studies set out to examine the neuroprotective potential of L-AP4 in a rodent 
model of PD bearing a 6-OHDA lesion. On the basis of producing a sufficiently large 
lesion to offer the maximum potential for protection, as well as the greatest range to 
detect motor behavioural improvements, it was decided a deficit of 80-90% ‘full 
lesion’ would be required for these studies. The dose of 6-OHDA required to achieve 
this lesion size varies widely amongst different laboratories. For example the study of 
Vernon et al., (2005) found an intranigral administration of 12µg of 6-OHDA 
produced a lesion size of 65%, according to loss of TH positive cells in the SNpc 8 
days post-lesion. However a similar study found that 4µg 6-OHDA resulted in an 85-
90% loss of nigral TH positive cells (O'Neill et al., 2004). The discrepancies in lesion 
size are likely a result of different stereotactic coordinates for the SNpc, different 
infusion rates, or even different formulations and batches of 6-OHDA, which is a 
very unstable compound. In our hands 12µg of 6-OHDA was required to produce the 
desired ‘full lesion’ where 83% and 87% loss of nigral dopamine content was 
obtained in vehicle treated animals in studies described in section 3.3.1 and section 
3.3.2 respectively, demonstrating a fairly reproducible lesion. With this in mind and 
to maintain consistency, 12µg of 6-OHDA was used in all subsequent studies 
described in this thesis.  
 
Analysis of striatal TH in individual quadrants following a 6-OHDA lesion in the 
SNpc revealed there was a slight tendency for greater loss of TH staining in the dorsal 
striatum following a 6-OHDA lesion with up to 96% loss in the dorsal lateral region, 
compared to an 80% loss in the ventral medial striatum. This pattern of TH gradient 
loss albeit much more exaggerated has been previously reported by O’Neill et al., 
(2004) who revealed an 80-90% loss of TH staining in the dorsal striatum, whilst 
seeing only a 50-60% loss in the ventral striatum. In the present study however the 
TH loss between quadrants in all treatment groups was not significantly different, 
therefore for all further studies described in this thesis, the mean total striatal TH was 
presented. It is important to emphasise at this point, using a ‘full lesion’ model as 
described here, in which 6-OHDA is injected directly into the SNpc, cell death is 
rapid. Under this paradigm, the majority of cell death occurs within the first 3d of 
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injection (Zuch et al., 2000) and for this reason neuroprotective drug interventions are 
often, as in this case, introduced just prior to toxin injection. Such a design does not 
of course reflect the timing of drug interventions in the clinic and future studies 
should aim to reinforce these findings in a slower retrograde lesion model in which 
there is a sufficient time window to delay treatment.  
 
Accepting this caveat, these studies revealed that L-AP4, administered 1h before and 
for 7 days after 6-OHDA injection protected against a nigrostriatal tract lesion. This 
was evidenced by a preservation of TH-positive cell numbers in the SNpc, 
preservation of the dopaminergic marker dopa decarboxylase (DDC) in the striatum, 
as well as a reduction in 6-OHDA-induced loss of striatal TH immunoreactivity and 
dopamine levels. These effects were maximal at 3 nmol L-AP4 and, in the case of 
TH-positive cell counts and striatal dopamine content, were lost at the highest doses 
tested (L-AP4 30nmol). This bell-shaped dose response relationship is in keeping 
with the findings of Vernon et al, (2007) who found maximal histological and 
neurochemical protection against a 6-OHDA lesion with 10 nmol L-AP4 and a 
similar loss of effect with a higher dose of L-AP4 (50nmol). Furthermore this bell-
shaped response to L-AP4 has been noted in our laboratory for L-AP4 decreased D-
aspartate release in nigral tissue prisms (Austin et al., 2010) and in other 
electrophysiological studies (Valenti et al., 2005) where the inhibitory effects of L-
AP4 were lost at higher concentrations.  
 
Numerous explanations have been suggested to underlie this loss of efficacy at higher 
concentrations. Firstly, loss of efficacy at higher doses of L-AP4 may be caused by 
activation of known mGlu7 receptors residing on GABAergic terminals leading to 
NMDA-induced toxicity. At higher concentrations of L-AP4, activation of mGlu7 
receptors may cause an inhibition of GABA release, consequently removing the 
hyperpolarising influence of GABA on striatal neurones (Lafon-Cazal et al., 1999b). 
However, one would have to question why this effect would predominate only at high 
doses of L-AP4. This could be explained by the relative potency of L-AP4 at the 
group III mGlu receptor subtypes, demonstrating a particularly low potency at mGlu7 
receptors with respect to mGlu4/mGlu8 receptor subtypes (EC50 for L-AP4 at mGlu7 
is 100x > than at mGlu4/8, values are shown in table 3.1). This would suggest 
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activation of mGlu7 receptors on GABAergic terminals would only occur at higher 
concentrations of agonist/L-AP4.  
 
Such a bell-shaped concentration response profile may reflect a loss of 
pharmacological specificity at the higher doses, since L-AP4 is known to activate 
excitatory group I mGlu receptors with an EC50 > 1000 µM in comparison to between 
0.2 and 100 µM at the different group III mGlu receptors (Cartmell & Schoepp, 
2000). However, as group I mGlu receptor activation has been shown to produce a 
similar functional inhibition of excitatory synaptic transmission in the SNpr at least 
(Wittmann et al., 2001), this explanation seems unlikely. The most plausible 
explanation for this loss of efficacy at higher doses of L-AP4 may be a result of 
receptor desensitisation, as suggested to explain the similar bell-shaped nature of 
electrophysiological responses of L-AP4 at the striatopallidal synapse (Valenti et al., 
2003). Moreover, L-AP4 has been shown to cause rapid internalisation of at least two 
members of the group III mGlu receptors in cell lines, mGlu4 (at 100µM; Iacovelli et 
al., 2004) and mGlu7 (at 400µM; Pelkey et al., 2005), suggesting receptor 
desensitisation may be a likely contributing factor.  Finally, our lab has demonstrated 
repeated administration of L-AP4, 4 hours after an intranigral dose, led to a 72% 
reduction in the reversal of akinesia in the reserpine treated rat (Broadstock, 2006, 
PhD Thesis). This suggests desensitisation of group III mGlu receptors may well be a 
consequence of repeated supranigral infusion of L-AP4 perhaps at the higher dose 
reached here. However, given the difficulty of predicting the exact concentration of 
agonist reaching the receptors following intracerebral dosing, such suggestions 
remain speculative at this stage and further studies are required to clarify if 
desensitisation is indeed the root cause for loss of efficacy at the high dose of L-AP4 
tested here (30 nmol).   
 
It is notable in this study that the protection afforded at the striatal level was greater 
and occurred at slightly lower doses than required to give significant protection at the 
nigral level. This outcome was not surprising as the toxin was introduced directly into 
the cell bodies so it may be harder to protect that area compared to the terminals. 
Indeed more robust protection is often seen in the 6-OHDA lesioned rats at the 
striatal level e.g. with AMPA potentiators (Murray et al., 2003) and nicotinic agonists 
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(Visanji et al., 2006). Alternatively, this discrepancy may reflect the different 
parameters being measured in these regions, i.e. cell numbers in the SNpc, versus 
density of terminal staining in the striatum. Given that there is huge compensation in 
the nigrostriatal system, it is possible that small changes at the level of the terminals 
can have effects on function, whereas the level of protection may need to be greater to 
see clear effects on TH-positive cell counts.     
 
In addition to confirming the protective effects of L-AP4 at a neurochemical and 
histological level, this study demonstrated for the first time that the protection 
observed against a 6-OHDA lesion translated to a preservation of motor function. 
According to previous findings, the adjusted steps test requires a lesion of 50-60% to 
show any stepping deficit, with paw akinesia decreasing proportionally for lesion 
sizes 60-100% (Kirik et al., 1998). Following sub-chronic treatment with L-AP4, a 
significant overall preservation of contralateral paw use was shown in adjusted steps, 
whereby 3nmol L-AP4 preserved paw use to ~75%  of pre-lesion score in the 
forehand direction, at 6 days post lesion. To assess spontaneous motor function, the 
cylinder test revealed 3nmol L-AP4 almost totally preserved contralateral paw use 
equating to ~90% of pre-lesion scores. Motor function was also assessed using the 
gold standard amphetamine-induced rotational test whereby robust and proportional 
ipsiversive rotations have been reported for animals with lesion sizes between 50-
100% (Kirik et al., 1998; Moore et al., 2001). Treatment with L-AP4 following a 6-
OHDA lesion mediated a significant decrease (e.g. 64% with 3 nmol L-AP4) in 
amphetamine-induced rotations compared to vehicle treated animals. This data along 
with our neurochemical findings suggest there was an improvement in striatal 
dopamine release from the lesioned hemisphere acting to decrease dopamine 
asymmetry between the lesioned and intact hemispheres.  
 
To confirm that the effects of L-AP4 were mediated by group III mGlu receptor 
activation, in a separate study we examined the ability of the broad spectrum 
antagonist, CPPG, to inhibit the response to L-AP4. CPPG is an orthosteric antagonist 
competing with endogenous glutamate for receptor binding, thus it was predicted to 
remove agonist binding required for group III mGlu receptor activation. Indeed we 
demonstrated here, daily pre-treatment with the selective group III mGlu receptor 
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antagonist, CPPG (75nmol), 30 min prior to L-AP4 administration abolished both 
neurochemical and functional protection mediated by our optimal dose of L-AP4 
(3nmol). For example, preservation of nigral dopamine declined from 57% with 
respect to non-lesioned contralateral hemisphere in L-AP4 (3nmnol) treated animals 
to 81% of non-lesioned hemisphere following pre-treatment with CPPG (75nmol).  
This is consistent with findings from Vernon et al who demonstrated L-AP4 (10nmol) 
responses were inhibited by the group III antagonist, M-SOP (50nmol) confirming a 
receptor mediated response (Vernon et al., 2005).  
 
Having reported L-AP4 mediated a profound neuroprotective effect in our 6-OHDA 
lesion model of PD, it is pertinent to suggest potential mechanisms underlying the 
protection described here. It is thought the neuroprotective nature of L-AP4 may be a 
consequence of presynaptic inhibition of glutamate from the STN, which is known to 
be overactive in the parkinsonian basal ganglia causing degeneration of dopaminergic 
neurons by glutamate-mediated excitotoxicity (Valenti et al., 2005). Our laboratory 
has identified both in vitro using nigral slices and in vivo with microdialysis, L-AP4 
inhibits glutamate release in the SNpr (Austin et al., 2010). Although these studies 
did not focus on the SNpc, STN efferents arborise extensively so that they also 
innervate the SNpc and SNpr (Smith et al., 1990). Thus it is conceivable that L-AP4 
will serve to decrease glutamate release in the SNpc also. In support of this, 
electrophysiological studies have shown L-AP4 inhibits glutamate mediated 
excitatory post-synaptic potentials (EPSPs) in the SNpc (Katayama et al., 2003; 
Wigmore & Lacey, 1998). The most plausible mechanism of neuroprotection by L-
AP4 therefore, would be a reduction in glutamate-mediated excitotoxicity in SNpc 
neurones. However, there are several alternative mechanisms worthy of discussion 
here that may underlie neuroprotection mediated by group III mGlu receptor 
activation. 
  
One such alternative may underlie the contribution of glia to mediate neuroprotection 
either by inhibition of pro-inflammatory cytokines or production of neurotrophic 
factors. Group III mGlu receptors are expressed by glial cells with both cerebellar 
astrocytes and microglia expressing mRNA for all group III mGlu receptors (Taylor 
et al., 2003; Wroblewska et al., 1998). Although an induction of neurotrophic factors 
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has not been demonstrated experimentally by activation of group III mGlu receptors, 
there is considerable evidence that activation of the similar Gi/o coupled group II 
mGlu receptors induce the release of neurotrophic factors. For example in mixed 
cortical cultures, the group II mGlu agonists have been shown to cause an induction 
of the neurotrophic factor TGF-β in response to reactive astrocytes and microglia 
(Bruno et al., 1998). In addition, group II mGlu receptor activation in 6-OHDA 
lesioned and MPP
+
 treated mice has been shown to lead to a significant induction of 
BDNF and TGF-β by reactive glia (Matarredona et al., 2001; Murray et al., 2002). 
This suggests a neurotrophic role for the closely related group III mGlu receptors may 
yet to be disclosed.   
 
The anti-inflammatory role of group III mGlu receptor agonists is more widely 
reported. For example, in mircoglial conditioned medium or in mixed cultures, L-
AP4 can reduce activation of microglia and subsequent neurotoxicity, following 
stimulation with an inflammatory insult such as LPS or chromagranin A (Taylor et 
al., 2003). It is unclear at this point if this is due to an inhibition of neurotrophic 
factors or reduction in pro-inflammatory cytokine production. In support of the latter, 
group III mGlu receptor activation with L-AP4 has been demonstrated to decrease 
reactive gliosis in glial cultures, by inhibiting the chemokine, Regulated upon 
Activation, Normal T-cell Expressed, and Secreted (RANTES) (Besong et al., 2002). 
RANTES is a pro-inflammatory cytokine, activating T cells, eosinophils and 
basophils. Therefore it’s inhibition by group III mGlu receptor activation may 
contribute to neuroprotection mediated by L-AP4, by inhibiting the 
neuroinflammatory response and reactive gliosis which occurs following cell death 
induced by 6-OHDA (as described in section 1.4.2.1). An additional glial-related 
mechanism may involve an increase in glutamate uptake by glial cells. L-AP4 has 
been shown to inhibit neurotoxicity induced by the complex I inhibitor MPP
+
 
restoring levels of glutamate uptake by cultured astrocytes to control levels thereby 
attenuating glutamate mediated excitotoxicity (Yao et al., 2005). Furthermore the 
closely related group II mGlu receptors have been shown to produce an up-regulation 
of the glial glutamate transporters GLT-1 and GLAST through mitogen-activated 
protein (MAP) kinase and phosphatidyl-inositol-3 (PI-3) kinase-dependent pathway 
(Aronica et al., 2003). Since considerable microglial activation occurs in the 6-
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OHDA lesion model of PD (Marinova-Mutafchieva et al., 2009), it is conceivable 
that glial-mediated actions may contribute to the neuroprotection observed here with 
L-AP4.  
 
L-AP4 mediated stimulation of group III mGlu receptors has been shown to stimulate 
MAP kinase and PI-3 kinase pathways in cultured cerebellar granule cells (Iacovelli 
et al, 2004). These pathways are involved in numerous processes such as cell growth, 
proliferation and survival which may also lead to neuroprotective effects. In support 
of this, using specific inhibitors of these pathways, it was demonstrated these were 
necessary to provide neuroprotection against apoptosis induced by trophic deprivation 
(Iacovelli et al., 2004). However, the exact mechanism in which these pathways 
mediate neuroprotection is still unknown.  
 
Finally, a further mechanistic implication has derived from a study demonstrating L-
AP4 could protect TH-positive neurones in rat embryonic midbrain cultures against 
the toxicity of rotenone (Jiang et al., 2006). Rotenone is known to inhibit 
mitochondrial complex I and cause depolymerisation of microtubules, the latter of 
which is thought to be a key mechanism underlying rotenone’s toxicity on 
dopaminergic neurones (Ren et al., 2005). The protective effects of L-AP4 against 
rotenone toxicity are also thought to involve activation of the MAP kinase pathway, 
since L-AP4 increased activation of the MAP kinase extracellular signal-regulated 
kinase in midbrain TH-positive neurone cultures and protection against rotenone 
toxicity was blocked by pharmacological inhibition of MAP kinase kinase (Jiang et 
al., 2006).  Inhibition of MAP kinase kinase also prevented L-AP4-mediated 
attenuation of rotenone-induced microtubule depolymerisation, suggesting L-AP4 
provided protection of TH-positive neurones through activation of the MAP kinase 
pathway to stabilize microtubules (Jiang et al., 2006). Therefore, whilst 
neuroprotection with L-AP4 (3nmol), is considered to be largely mediated by a 
reduction of glutamate release from subthalamonigral terminals to prevent glutamate-
mediated excitotoxicity, a role for glial cells must also be considered. Indeed, glial-
mediated increases in glutamate uptake and inhibition of reactive gliosis, as well as 
activation of MAP kinase and PI3 kinase pathways may all be implicated in affording 
neuroprotective effects. The likely contribution from multiple mechanisms may 
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explain why protection with L-AP4 was maximal with a relatively low dose (3nmol) 
compared to that required to produce maximal reversal of reserpine-induced akinesia 
(300 nmol), which most probably relies on inhibition of glutamate release alone 
(Austin et al., 2010). Although there is little in the way of changed expression of 
group III mGlu receptors following a 6-OHDA lesion (Messenger et al., 2002), a 
post-lesion increase in sensitivity of the receptors may also explain why lower doses 
of L-AP4 were required in this model compared to the acute reserpine model. 
 
In conclusion, the in vivo studies in this chapter confirm activation of group III mGlu 
receptors using the broad spectrum agonist L-AP4 mediated neuroprotection of the 
nigrostriatal tract in 6-OHDA lesioned rats. Furthermore these studies revealed for 
the first time, neuroprotection at the histological and neurochemical level translated 
to functional improvements in both forced and habitual behavioural tests indicating 
normalisation of dopamine asymmetry. In a separate study, pre-treatment with the 
broad spectrum antagonist CPPG significantly inhibited protection mediated by L-
AP4 at the neurochemical and functional level confirming effects are group III mGlu 
receptor driven. Studies in the next two chapters seek to elucidate which group III 
mGlu receptors mediate neuroprotection by L-AP4. Recent findings would indicate 
mGlu4 as the lead candidate since the positive allosteric modulator (PAM) N-phenyl-
7-(hydroxyimino)cyclopropa[b]-chromen-1a-carboxmide (PHCCC) has been shown 
to reduce dopaminergic neuron degeneration in the MPTP model of PD (Battaglia et 
al., 2006). However, no mGlu4 selective agents have yet been examined in the 6-
OHDA lesion model of PD. Furthermore, the contribution of mGlu7 or mGlu8 in 
mediating functional neuroprotection has not yet been explored so a full 
pharmacological evaluation of the potential of these different group III mGlu 
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In the previous chapter we demonstrated the broad spectrum group III mGlu receptor 
agonist L-AP4 (which activates mGlu4, 7 and 8 receptors), significantly protects 
against 6-OHDA-induced nigrostriatal tract degeneration in rats and mediates 
preservation of motor behaviour in these animals. To begin to elucidate the 
pharmacological identity of the group III mGlu receptor(s) mediating this protective 
effect, studies in this chapter sought to examine whether mGlu4 receptor activation 
alone could provide functional neuroprotection in the same experimental paradigm.  
 
In Chapter 2 of this thesis, we demonstrated a particularly high intensity of 
immunoreactivity for mGlu4 in the SNpc. Furthermore electrophysiological studies 
have confirmed the function of these receptors, showing activation of mGlu4 using 
the positive allosteric modulator (PAM) PHCCC inhibits STN-evoked EPSCs in 
dopaminergic neurones of the SNpc (Valenti et al., 2005).  In addition, our lab have 
recently demonstrated activation of mGlu4 receptors in the SN using PHCCC 
(30µM), reduced glutamate release (shown by inhibition of [
3
H]-D-aspartate release) 
from nigral slices in vitro (Broadstock et al., 2011). Collectively, these findings 
propose activation of mGlu4 receptors in the SNpc could be predicted to inhibit 
glutamate-mediated excitotoxicity and thus provide protection against a 6-OHDA-
induced lesion. In support of this notion, a previous report has demonstrated that a 
systemic injection of PHCCC (3mg kg
-1
), given 30 min prior to toxin injection, 
provided approximately 50% protection against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced loss of striatal dopamine content and reduction in 
TH-positive cell numbers in the SNpc in mice (Battaglia et al., 2006). Moreover these 
neuroprotective effects of PHCCC were lost in mGlu4 knockout mice, confirming 
these effects were mGlu4-mediated. While these results with PHCCC are 
encouraging, the compound suffers from low potency (approximately 4 µM in vitro), 
and poor aqueous solubility requiring DMSO which is known to be neurotoxic. 
Indeed in the study by Battaglia et al., (2006) the vehicle for PHCCC, 50% DMSO 
injected alone led to an increase in MPTP toxicity. Furthermore, the pharmacology of 
PHCCC has also been questioned by demonstrating antagonism at the mGlu1 
receptor at a potency similar to that of mGlu4 (Marino et al., 2003). This property is 
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particularly undesired as antagonism of mGlu1 also leads to an inhibition of 
glutamate release, therefore any effects mediated by PHCCC likely implicate group I 
mGlu receptors limiting its utility as an mGlu4 selective PAM. 
 
Accepting these shortcomings, the more recent mGlu4 PAM (±)-cis-2-(3,5,-
dichlorphenylcarbamoyl)cyclo-hexanecarboxylic acid sodium salt (VU0155041) 
offers a far more attractive alternative to investigate the neuroprotective potential of 
targeting mGlu4 receptors. Discovered by high-throughput screening, this lead 
compound was shown to be approximately 8-fold more potent than PHCCC at the 
mGlu4 receptor (EC50 of 0.7µM at rat mGlu4) assessed using thallium flux through 
G-protein regulated inwardly rectifying potassium channels (GIRK) (Niswender et 
al., 2008a). In addition, VU0155041 did not demonstrate any significant potentiator 
or antagonist activity at other mGlu receptor subtypes (i.e. mGlu1, 2, 3, 5, 7 and 8), 
and is more readily soluble in aqueous vehicle (i.e. PBS) avoiding toxicity issues with 
DMSO (Niswender et al., 2008). VU0155041 has also shown robust symptomatic 
activity in two rodent models of PD. Following intracerebroventricular (i.c.v.) 
administration of 31 and 316 nmol, VU0155041 dose dependently decreased 
haloperidol-induced catalepsy and reserpine-induced akinesia in rats (Niswender et 
al., 2008). Therefore in the studies described in this chapter, we seek to investigate 
the contribution of mGlu4 in mediating neuroprotective effects, using the selective 
PAM VU0155041 in 6-OHDA lesioned rats.  
 
In addition to showing enhanced glutamatergic signalling comparable to that in PD 
(Breit et al., 2006; Hassani et al., 1996), the 6-OHDA model also displays a 
pronounced inflammatory response including microglial activation in the striatum and 
SNpc and elevated striatal levels of inflammatory markers such as TNF-α (Cicchetti 
et al., 2002; Duty & Jenner, 2011; Mogi et al., 2000). Furthermore drugs with anti-
inflammatory properties have been shown to provide neuroprotective effects in 
models of PD. Among these compounds, agonists of the peroxisome proliferator-
activated receptor γ( PPARγ) such as pioglitazone, have been shown in pre-clinical 
studies to prevent dopaminergic cell loss induced by MPTP in mice (Breidert et al., 
2002; Dehmer et al., 2004) and protect against inflammation-induced dopaminergic 
neurodegeneration by intrastriatal lipopolysaccharide (LPS) in rats (Hunter et al., 
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2007). The antibiotic Minocycline has also been reported to attenuate MPTP-induced 
dopaminergic neurodegeneration by inhibiting MPTP-induced microglial activation, 
preventing the production of microglia-derived proinﬂammatory factors such as IL-
1β, ROS and NO (Wu et al., 2002). Taken together these findings suggest any 
neuroprotective effects mediated by mGlu4 receptors could involve an anti-
inflammatory action. Furthermore, given that mGlu4 receptors have been identified 
on primary cultured rat astrocytes (Taylor et al., 2003; Yao et al., 2005), it is possible 
that these receptors may also reside on astrocytes in the rodent brain. These findings 
open up the possibility that glial-mediated anti-inflammatory actions in particular, 
may contribute to any protective effects mediated by mGlu4 receptor stimulation. 
Therefore in this chapter we also seek to establish the expression of mGlu4 receptors 
on both neuronal and astroglial cell types in rodent SNpc, and elucidate any potential 
effects of VU0155041 treatment on both astroglial and microglial activation in the 6-



















The overall aim of the studies described here was to examine whether selective 
activation of mGlu4 receptors using the selective mGlu4 PAM VU0155041 was 
sufficient to bring about functional neuroprotection in the 6-OHDA-lesion rat model 
of PD. In addition, studies were undertaken to begin to determine the potential 
mechanisms underlying this response, focussing especially on potential ant-
inflammatory actions of VU0155041.  
 
The primary aims of the studies outlined here were: 
 
1. to determine if VU0155041 provided neuroprotective effects against a 6-
OHDA lesion of the SNpc in rats, determined by immunohistochemical and 
neurochemical analysis 
2. to ascertain whether neuroprotective effects of VU0155041 translated to 
functional preservation of motor function in both forced and habitual 
behavioural tasks 
3. to determine if functional neuroprotection achieved with VU1055041 was lost 
on pre-treatment with a selective group III mGlu receptor antagonist CPPG 
4. to delineate potential co-localisation of mGlu4 receptor subtypes on both 
neurones and astrocytes in naїve rat brain to begin to ascertain neuroprotective 
mechanisms 
5. to investigate the effects of VU0155041 treatment on astrocytic and microglial 


















Male Sprague Dawley rats (B & K or Harlan, U.K.) weighing 270 – 300 g were used 
in these studies. Food and water were provided ad libitum. Animals were housed in a 
temperature- and humidity-controlled environment with a 12-h light / dark cycle. All 
procedures conformed to the U.K. Animals (Scientific Procedures) Act, 1986 and 
every effort was made to minimise animal numbers and suffering. 
 
4.3.1.2 Surgical cannulation  
 
Animals were bilaterally cannulated in the same manner as previously described in 
section 3.3.2.4 whereby cannulae were implanted bilaterally 2mm above the SNpc 
using the following co-ordinates; anterioposterior (AP), -4.8mm, mediolateral (ML), 
± 2.0mm; dorsoventral (DV), -6.3mm from bregma (Paxinos & Watson, 1998).  
 
4.3.1.3 Supranigral drug administration 
 
A minimum of 5 days following cannulae implantation, the neuroprotection study 
commenced. Animals received their first dose of VU0155041 (10-100nmol, dissolved 
in 4µl PBS) or vehicle (4µl 1x PBS) 1 hour prior to 6-OHDA infusion (detailed in 
4.3.1.4). Animals received unilateral drug infusions at a flow rate of 2µl min
-1
 into the 
right cannulae (or left on occasions when the right was blocked) for a further 7 days 
post-lesion as previously described in section 3.3.2.3.  
 
There are currently no mGlu4 selective antagonists available at this time therefore the 
broad spectrum antagonist CPPG was utilised to confirm neuroprotection mediated 
by VU0155041 was a receptor driven process. To investigate the effects of CPPG on 
neuroprotection mediated by VU0155041, CPPG (75 nmol; dissolved in 4μl 0.1M 
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NaOH) or its corresponding vehicle (4µl 0.1M NaOH) were infused at a rate of 2µl 
min
-1
 unilaterally above the SNpc 30 min prior to each injection of VU0155041 
(100nmol) using the same method described above. 
 
4.3.1.4 Intranigral 6-OHDA lesioning 
 
A minimum of 5 days following bilateral cannulation above the SNpc, animals 
received a single, unilateral injection of 6-OHDA into the same side of the SNpc as 
the drug infusions. 30 min prior to 6-OHDA injection, rats were pre-treated with 
desipramine (25 mg kg
-1
 i.p.) and pargyline (5 mg kg
-1
 i.p.). Animals were then 
anaesthetised briefly whilst 6-OHDA (12 μg in 2.5 μl of 0.2% ascorbic acid in 0.9% 
saline) was injected at a rate of 1.25 μl min-1 into the SNpc (2 mm below the guide 
cannula) as previously described in section 3.3.2.4. Animals were placed in cages on 
thermostatically heated mats until fully conscious.  
 
4.3.1.5 Behavioural assessment  
 
The extent of motor impairment following a unilateral lesion to the SNpc was 
assessed at intervals using three behavioural tests. Animal behaviour was assessed 
using the adjusted steps test on day 3 and 6 post-lesion, cylinder test on day 5 post-
lesioning, (both tests also required a baseline assessment one day prior to lesioning) 
and amphetamine induced rotations on day 7 post-lesion. Full details of these tests are 
given earlier in section 3.3.2.5. 
 
4.3.1.6 Data analysis for behavioural tests 
 
Only behavioural data from animals showing correct cannula placement were 
included for data analysis presented in these studies. All behavioural analyses were 
assessed in a similar manner to those described in section 3.3.2.6. Briefly, in the 
adjusted stepping test, use of the contralateral and ipsilateral paw in both forehand 
and backhand directions post lesion were expressed as a % of pre-lesion use. 
Adjusted stepping scores between treatment groups were then compared using a 2-
way ANOVA with Dunnett’s post-hoc test at both 3 and 6 days post-lesion. Use of 
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the contralateral and ipsilateral paw in the cylinder test, expressed as a % of total 
reaches, was also compared pre and post lesion between different treatment groups 
using a 2-way ANOVA with Bonferroni’s post-hoc test. Finally, the number of 
amphetamine-induced rotations was plotted as both time course (5 min intervals) or 
total rotations between 15-45 min (when stable locomotor behaviour was achieved) 
and compared between treatment groups using a 2 or 1-way ANOVA respectively 
with a Bonferroni’s post-hoc test. In all cases, data are expressed as mean ± s.e.m. 
where P<0.05 was taken to be significant, with all statistical analysis performed using 
GraphPad Prism version 5. 
 
4.3.1.7 Immunohistochemical and HPLC protocols 
 
In the initial dose finding study in which behavioural tests were not undertaken, on 
the final day of VU0155041 dosing (day 8), a sub-set of animals were killed by CO2 
asphyxiation and brains were quickly removed for dissection of striatum and SN.  
Both SN and striatal tissue samples were then prepared for HPLC as previously 
described in section 3.3.2.9. 
 
For the larger full study, on the final day of dosing (day 8), animals were killed by 
CO2 asphyxiation, the brains removed and segmented into rostral (striatum) and 
caudal (SN) segments. The striata from these animals were immediately dissected 
from the rostral segment and snap frozen on card-ice before storing at -80
o
C until 
further processing for HPLC measurement of dopamine levels. The SN segment on 
the other hand, was placed in 4% formalin for a period of at least 2 days to ensure 
fixation before processing for immunohistochemistry. Once required, the nigral 
segment of the brain was dehydrated, defatted and then paraffin embedded. 6µm 
coronal sections were taken through the SN at -4.8, -5.3, and -5.8mm AP from 
bregma (Paxinos & Watson, 1986) as described in section 2.3.2.2.  
  
TH and DDC immunohistochemistry in the SNpc was performed exactly as described 
in section 3.3.2.7. As before, staining results in the SN were viewed on a Zeiss 




To investigate the effects of VU1055041 treatment on microglia and astrocytes, 
immunohistochemistry was performed on their respective markers ionised calcium 
binding adaptor molecule 1 (IBA-1) and glial fibrillary acidic protein (GFAP).  Using 
6µm sections from a central region of the SNpc in triplicate (-5.3mm AP from 
bregma, Paxinos & Watson, 1998) were deparaffinised and rehydrated as previously 
described in section 2.3.2.2. Sections were then immersed for 10min in 3% hydrogen 
peroxide to block endogenous peroxide activity. Following this, slides were placed in 
pepsin (0.2 g Sigma-p-7000 pepsin in 50 ml 0.01 M HCl) for 30 min at RT, washed 
and nonspecific binding was blocked for 20 min with 1.5% normal goat serum 
(Vectastatin rabbit IgG ABC kit; Vector Laboratories, UK) diluted in PBS at RT. 
Sections were then incubated with primary rabbit polyclonal anti IBA-1 (1:5000; 
Wako Chemicals, USA) or anti- GFAP (pre-diluted neat solution; BioGenex 
Laboratories, USA) for 18 h at RT. After washing in PBS (3 X 5 min), sections were 
incubated with a biotinylated secondary antibody (Vectastatin rabbit IgG ABC kit) 
for 30 min at RT followed by 3 x 5 min washes with PBS. The horseradish 
peroxidase conjugate (Vectastatin rabbit IgG ABC kit) was then applied for 30 min 
followed by 3 x 5 min PBS rinses all at RT. Antibody binding was visualised by 
incubating sections with the chromagen 3, 3V-diaminobenzidine (DAB substrate kit, 
Vector SK-4100) for 10 min at RT. Sections were finally dehydrated in 100% IMS, 
cleared in xylene, cover-slipped with DPX mountant and allowed to dry before being 
analysed using light microscopy. Digital images of the SN were captured using an 
Aperio ScanScope XT scanner and analysed using Scion Image Software (Scion 
Corporation, USA). 
 
Dopamine content of frozen striata was assessed using HPLC, exactly as described in 










4.3.1.8 Image and data analysis for immunohistochemistry and HPLC studies  
 
For TH immunohistochemistry in the SNpc, the average number of TH-positive cells 
in three adjacent sections for each animal across the three rostrocaudal levels (-4.8, -
5.3, -5.8mm AP from bregma) were obtained as previously described in section 
3.3.2.8, and the mean of these values taken per treatment group.  Statistical 
comparisons were made between VU0155041 and vehicle-treated animals of mean 
TH-positive cell counts in the 6-OHDA lesioned side, expressed as % of the 
contralateral, intact hemisphere, using a 1-way ANOVA with Dunnett’s post-hoc test. 
For IBA-1 staining, the density of IBA-1-positive cells demonstrating amoeboid 
morphology typical of activated microglia, was assessed in the contralateral and 
ipsilateral hemispheres of the SNpc. GFAP positive cells demonstrating the hallmark 
star-shaped characteristic of an activated astrocyte were also compared between 
adjacent hemispheres at a central region of the SNpc (-5.3 mm AP from bregma). For 
each animal, three adjacent sections from the SNpc were counted and then pooled to 
give a total mean density/cell count for the ipsilateral and contralateral hemispheres. 
Statistical comparisons of mean IBA-1 density measures or GFAP-positive cell 
counts in the 6-OHDA lesioned hemisphere, expressed as a % of the contralateral, 
intact hemisphere were made between drug and vehicle-treated animals using a 1-way 
ANOVA with Dunnett’s post-hoc test. For HPLC analyses, dopamine content of 
striatal and nigral samples were converted from peak areas of the chromatogram 
using a calibration curve of pure reference standards and expressed as ng.g
-1
 protein. 
A 1-way ANOVA with Dunnett’s post-hoc test was used to compare dopamine 
content of the 6-OHDA lesioned side, expressed as a % of the contralateral intact side 
between treatment groups. In all cases, data are expressed as mean ± standard error of 
the mean (s.e.m.), where n represents the number of animals in each experimental 
group. Statistical analyses were performed using GraphPad Prism (version 5.0) and 
P<0.05 was taken to indicate significance. 
 
4.3.1.9 Immunofluorescence co-localisation protocol 
 
Immunohistochemical experiments using fluorescence were carried out to investigate 
co-localisation of mGlu4 with TH and GFAP. In each case mGlu4 receptors were 
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visualised using a three step indirect immunofluorescence method employing a 
biotinylated secondary antibody conjugated to a 594 fluorophore-streptavdin 
complex.  
 
Two naїve rats were deeply anaesthetised using pentobarbital (100mg kg-1, i.p.) and 
transcardially perfused with 200ml 100mM PBS followed by 200ml 4% 
paraformaldehyde (PFA) in PBS. Brains were quickly removed and placed in fixative 
overnight to ensure complete fixation. The brain was then cut into a rostral (striatal) 
and caudal (SN) segment, dehydrated and defatted before being manually embedded 
into paraffin wax. Coronal sections (6µm) at a central region of the SNpc (-5.3mm 
AP from bregma), according to the rat brain atlas (Paxinos & Watson., 1998) were 
cut on a microtome and taken up onto slides as previously described in section 
2.3.2.2. 
 
For each immunofluorescence co-localisation study, three adjacent sections 
containing the SN (-5.3mm AP) were de-paraffinised in xylene and 100% industrial 
methylated spirit (IMS) before a 10-min incubation in 3% hydrogen peroxide to block 
endogenous peroxide activity. Following standard antigen retrieval with 1mM citric 
acid then a 10-min incubation with blocking buffer (1% BSA in 0.1M PBS and 10% 
sodium azide), sections were incubated with the primary antibody rabbit polyclonal 
anti-mGlu4 primary antibody (Abcam, 1:50) at RT overnight to localise mGlu4 
receptors. Sections were then washed in TBS, and then incubated for 1 hour with a 
goat anti-rat biotinylated secondary antibody (Sigma). Thereafter, sections were 
washed with TBS and incubated for 1 hour at room temperature with a fluorescent 
AlexaFluor 594 streptavidin complex (Invitrogen, USA).   
 
To assess co-localisation with TH or GFAP, sections were then washed with TBS and 
subsequently incubated with a mouse monoclonal anti-TH (MAB318, Chemicon, 
1:1000), or anti-GFAP (Sigma, G3893, 1:1000), primary antibody for 1 hour at RT. 
Thereafter, sections were washed with TBS, and then incubated for 1 hour at RT with 
a goat anti-mouse-488 fluorescent antibody (Alexa Fluor, Invitrogen, 1:1000) 
solution containing Hoechst (Sigma, 33258, 1: 5000). The immunofluorochemically 
stained rat brain sections were then washed in TBS, and immediately mounted with 
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glass cover slips using the hydrophilic anti-fade mountant, mowiol 4-88. Fluorescent 
images of sections were captured using a Zeiss Apotome fluorescent microscope and 
analysed for co-localisation using Mosaic and Z-stack multicolour functions using 
Axiovision image analysis software.  
 
4.3.2.10 Materials and suppliers 
 

























4.4 Results  
 
4.4.1 Initial dose finding study to investigate the effects of sub-chronic 
supranigral infusion of the selective mGlu4 positive allosteric modulator, 
VU0155041, in unilaterally 6-OHDA-lesioned rats 
 
4.4.1.1 Effects of sub-chronic VU0155041 infusion on dopamine content in the 
substantia nigra and striatum 
 
In an initial dose finding study using HPLC, nigral dopamine content was shown to 
be preserved in the lesioned SN of animals treated with VU0155041 (figure 4.1).  In 
vehicle-treated 6-OHDA lesioned animals, nigral dopamine content fell from 2430 ± 
109 ng g
-1
 in the intact hemisphere to 750 ± 180 ng g
-1
 in the lesioned hemisphere, 
which represented a decline in dopamine to 31.2 ± 7.6% (n=6) of the intact 
hemisphere (figure 4.1A). VU0155041 treatment produced a dose-dependent 
preservation of nigral dopamine content, reaching a maximal significant effect with 
100nmol VU0155041, where dopamine content in the lesioned hemisphere equated to 
68.3 ± 5.3% of the intact hemisphere (P <0.05 versus vehicle treatment; 1-way 
ANOVA with Dunnett’s post-hoc test).  
 
A more profound neuroprotective effect was observed on assessment of striatal 
dopamine following VU0155041 treatment. In vehicle-treated 6-OHDA lesioned 
animals, striatal dopamine content fell from 17144 ± 758 ng g
-1
 in the intact 
hemisphere to 2680 ± 1578 ng g
-1
 in the lesioned hemisphere, which represented a 
decline in dopamine to 16.0 ± 9.1% (n=6) of the intact hemisphere (figure 4.1B). 
VU0155041 treatment at the lowest dose tested (25nmol) significantly preserved 
levels of striatal dopamine content equating to 52.1 ± 11.3% (n=6) of the intact 
hemisphere. A subsequent dose-dependent increase in preservation of striatal 
dopamine content was observed reaching maximal effect with 100nmol VU0155041, 
where dopamine content in the lesioned hemisphere remained at 76.0 ± 4.2% of the 
intact hemisphere (P< 0.001 versus vehicle treatment; 1-way ANOVA with Dunnett’s 
post-hoc test).  
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Figure 4.1: Effects of sub-chronic supranigral infusion of the selective mGlu4 
positive allosteric modulator, VU0155041, on dopamine content in the substantia 
nigra and striatum of unilaterally 6-OHDA lesioned rats. 
 
 
Figure 4.1. The effects of sub-chronic supranigral infusion of VU0155041 (25-100nmol in 4µl) or 
vehicle (4µl PBS) on the on the 6-OHDA induced loss of dopamine content in the SN (A) and striatum 
(B) on the lesioned side expressed as a percentage of the intact side. For both, values represent mean ± 
s.e.m. (n=6 for all treatment groups). * (P<0.05), ** (P <0.01) and *** (P < 0.001) indicates significant 
differences compared to vehicle treated animals (1-way ANOVA with Dunnett’s post-hoc test). For 
(A) F = 2.640, df = 3,20 and for (B) F = 10.99, df = 3,20. 


























































































4.4.2 Full neuroprotection study to investigate effects of sub-chronic 
supranigral infusion of the selective mGlu4 positive allosteric modulator, 
VU0155041, in unilaterally 6-OHDA-lesioned rats 
 
4.4.2.1 Effects of sub-chronic VU0155041 infusion on tyrosine hydroxylase 
positive cells in the substantia nigra pars compacta 
 
In a separate follow-up full neuroprotection study, the effects of VU0155041 were 
assessed using TH immunohistochemistry. In the SNpc, the mean sum of TH-positive 
cells in triplicate sections obtained across three rostrocaudal levels declined from 
306.3 ± 7.4 in the intact hemisphere to 26.5 ± 5.7 in the lesioned hemisphere of 
vehicle-treated 6-OHDA lesioned animals (n=8), demonstrating a full lesion with a 
deficit > 90%. Owing to the considerable preservation of dopamine content observed 
following 25nmol VU0155041 in the initial study, a lower (10nmol) dose of 
VU0155041 was investigated here to achieve a fuller neuroprotective dose response 
profile. Supranigral treatment with VU0155041 significantly protected against TH-
positive cell loss whereby maximal protection was reached with a 100nmol dose of 
VU0155041. The number of TH-positive cells remaining in the lesioned hemisphere 
following 100nmol VU0155041 treatment (n=6), was 131.3 ± 11.6 equivalent to 40.9 
± 3.1% of the intact hemisphere in contrast to 8.6 ± 3.5% remaining in the vehicle-
treated animals (n=8, P< 0.001; one-way ANOVA with a Dunnett’s post- hoc test; 
figure 4.2A).  
 
Representative nigral sections demonstrating immunoreactivity to TH-positive cells 
in the 6-OHDA lesioned animals treated with sub-chronic VU0155041 (10-100nmol) 
are shown in figure 4.2B. The photomicrographs demonstrate supranigral infusion of 
VU0155041 (100nmol) clearly provides noticeable preservation of TH-positive cells 
in the lesioned hemisphere.  Little effect on TH-positive cells was observed with a 
low dose of VU0155041 (10nmol), however a degree of preservation was observed 
on increasing the dose of VU0155041 (75nmol) compared to vehicle treated animals, 





Figure 4.2 Effects of sub-chronic supranigral infusion of the selective mGlu4 positive 
allosteric modulator VU0155041, on tyrosine hydroxylase-positive cell counts in 
nigral sections of unilaterally 6-OHDA lesioned rats. 
 
                    
Figure 4.2. (A) The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on the 6-OHDA induced loss of TH-positive cells in the SNpc on the lesioned side 
expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle and 
75nmol VU0155041, n=7 for 10nmol VU0155041, n=6 for 100nmol VU0155041). *** (P < 0.001) 
indicate significant differences compared to vehicle treated animals (1-way ANOVA with Dunnett’s 
post-hoc test). F = 16.66; df = 3,25. (B) Representative photomicrographs showing the levels of TH 
immunoreactivity in nigral sections from 6-OHDA-lesioned animals following sub-chronic 
VU0155041 treatment. Arrow delineates SNpc. Lesion side on the right; scale bar: 200µm. 






















































4.4.2.2 Effects of sub-chronic VU0155041 infusion on tyrosine hydroxylase levels 
in the striatum of 6-OHDA lesioned rats 
 
The optical density measurements of TH immunoreactivity in striatal sections from 
animals treated supranigrally with sub-chronic VU0155041 (10-100nmol) and those 
treated with vehicle is quantified in figure 4.3. When the combined mean striatal TH 
optical density was quantified, TH levels declined in the lesioned striatum of 
subsequent vehicle-treated animals to 5.3 ± 3.7% of the intact side. Supranigral 
infusion of VU0155041 (10-100nmol), 1 hour prior and for 7 days after 6-OHDA 
infusion dose dependently preserved striatal TH immunoreactivity in the lesioned 
hemisphere obtaining maximal effect with the highest dose of VU0155041 (100nmol) 
tested. Following 100nmol VU0155041, significant preservation of TH 
immunoreactivity was observed where the overall mean optical density in the 
lesioned striatum amounted to 44.8 ± 4.7% of the intact hemisphere, suggesting 
dopaminergic striatal nerve terminals were considerably protected in these animals 
(n=6-8; P<0.001 versus vehicle treatment; 1-way ANOVA with Dunnett’s post-hoc 
test; figure 4.3A).  
 
Representative striatal sections showing TH immunoreactivity in the 6-OHDA 
lesioned animals treated with sub-chronic VU0155041 (10-100nmol) are shown in 
figure 4.3B. The photomicrographs demonstrate VU0155041 at the highest dose 
tested (100nmol), provides extensive preservation of striatal immunoreactivity in 












Figure 4.3: Effects of sub-chronic supranigral infusion of the selective mGlu4 
positive allosteric modulator, VU0155041, on tyrosine hydroxylase immunoreactivity 
in striatal sections of unilaterally 6-OHDA lesioned rats.   
 
 
Figure 4.3. (A) The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on the 6-OHDA induced loss of TH immunoreactivity in the striatum expressed as a 
percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle and 75nmol VU0155041, 
n=7 for 10 and n= 6 for 100nmol VU0155041) *** (P <0.001) indicates significant differences 
compared to vehicle treated animals (1-way ANOVA with Dunnett’s post- hoc test). F = 9.475; df = 
3,25. (B) Representative photomicrographs showing the levels of TH immunoreactivity in striatal 
sections from 6-OHDA-lesioned animals following sub-chronic VU0155041 treatment. Lesion side on 
the right; scale bar: 500µm. 














































4.4.2.3 Effects of sub-chronic VU0155041 infusion on dopa decarboxylase in the 
striatum of 6-OHDA lesioned rats 
 
The optical density of DDC immunoreactivity in striatal sections from animals treated 
supranigrally with sub-chronic VU0155041 (10-100nmol) and those treated with 
vehicle are shown in figure 4.4. When the combined mean striatal DDC optical 
density was quantified, DDC levels declined in the lesioned striatum of subsequent 
vehicle-treated animals to 11.7 ± 4.9% of the intact side. Supranigral infusion of 
VU0155041, 1 hour prior and for 7 days after 6-OHDA infusion, dose dependently 
preserved striatal immunoreactivity in the lesioned hemisphere. Maximum protection 
was observed following 100nmol VU0155041 where the overall mean optical density 
in the lesioned striatum amounted to 44.3 ± 4.9% of the intact hemisphere, 
demonstrating striatal DDC immunoreactivity was also significantly preserved with 
respect to vehicle-treated animals (n=6-8; P<0.05; 1-way ANOVA with Dunnett’s 
post-hoc test; figure 4.4A). This finding confirmed VU0155041 treatment preserved 
dopaminergic striatal nerve terminals in these animals and that preserved levels of TH 
was not a mere reflection of increased expression of the marker.  
 
Representative striatal sections showing DDC immunoreactivity in the 6-OHDA 
lesioned animals treated with sub-chronic VU0155041 (10-100nmol) are shown in 
figure 4.4B. The photomicrographs demonstrate supranigral infusion of VU0155041 
at the highest dose tested (100nmol), provided noticeable protection of striatal 












Figure 4.4: Effects of sub-chronic supranigral infusion of the selective mGlu4 
receptor positive allosteric modulator, VU0155041, on dopa decarboxylase 
immunoreactivity in striatal sections of unilaterally 6-OHDA lesioned rats.  
 
 
Figure 4.4. (A) The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on the 6-OHDA induced loss of DDC in the striatum on the lesioned side expressed 
as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle and 75nmol 
VU0155041, n=7 for 10nmol VU0155041, n=6 for 100nmol VU0155041). * (P <0.05) indicates 
significant differences compared to vehicle treated animals (1-way ANOVA with Dunnett’s post-hoc 
test). F = 5.738; df = 3,25. (B) Representative photomicrographs showing the levels of DDC 
immunoreactivity in striatal sections from 6-OHDA-lesioned animals following sub-chronic 
VU0155041 treatment. Lesion side on the right; scale bar: 500µm. 















































4.4.2.4 Effects of sub-chronic VU0155041 infusion on levels of calcium binding 
adaptor molecule 1 in the substantia nigra pars compacta 
 
Analysis of IBA-1, revealed a unilateral injection of 6-OHDA markedly increased 
microglial activation in the lesioned SNpc compared to the intact non-lesioned 
hemisphere (figure 4.5A). Following a unilateral 6-OHDA lesion, the mean total 
IBA-1 density at a central region of the SNpc increased to ~ 289% of the intact 
hemisphere in vehicle treated animals (n=8). However, following VU0155041 
treatment (100nmol, n=6) this increase in IBA-1 density was significantly reduced 
compared to vehicle treated animals, whereby only a 161% increase in IBA-1 
immunoreactivity was observed with respect to the intact hemisphere (p<0.05; one-
way ANOVA with Dunnett’s post-hoc test). 
 
Representative nigral sections showing IBA-1 immunoreactivity in the 6-OHDA 
lesioned animals treated with sub-chronic VU0155041 (10-100nmol) are shown in 
figure 4.5B. Qualitative analysis revealed IBA-1-positive cells in the intact 
hemisphere displayed morphology typical of resting or quiescent cells. By contrast in 
the lesioned hemisphere a marked increase in IBA-1-positve cells was observed, with 
a switch from ramified to amoeboid morphology. The photomicrographs demonstrate 
supranigral infusion of VU0155041 dose-dependently reduced levels of IBA-1 














Figure 4.5: Effects of sub-chronic supranigral infusion of the selective mGlu4 
positive allosteric modulator, VU0155041, on ionised calcium binding adaptor 
molecule 1 immunoreactivity in striatal sections of unilaterally 6-OHDA lesioned 
rats.                     
   
                 
Figure 4.5. (A) The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on the 6-OHDA induced elevation of IBA-1 density in the SNpc on the lesioned side 
expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle and 
75nmol VU0155041, n=7 for 10nmol VU0155041, n=6 for 100nmol VU0155041). * (P <0.05) 
indicates significant differences compared to vehicle treated animals (1-way ANOVA with Dunnett’s 
post-hoc test). F = 3.345; df = 3,25. (B) Representative photomicrographs demonstrating IBA-1 
immunoreactivity in nigral sections from 6-OHDA-lesioned animals following sub-chronic 
VU0155041 treatment. Lesion side on the right; scale bar: 200µm on main panel, 50µm on higher 
magnification images. Arrows indicate the dorsal border of the SNpc. 


















































4.4.2.5 Effects of sub-chronic VU0155041 infusion on levels of glial fibrillary 
acidic protein in the substantia nigra pars compacta 
 
A marked increase in the astrocytic marker and hallmark of neurotoxicity, GFAP, 
was also observed in the lesioned SNpc compared to the intact non-lesioned 
hemisphere in vehicle-treated animals (figure 4.6A). Following a unilateral 6-OHDA 
lesion, the mean total number of GFAP- positive cells increased to 442% of the intact 
hemisphere in vehicle treated animals (n=8). Following VU0155041 treatment 
(100nmol, n=6), the increase in GFAP immunoreactivity in the lesioned SNpc was 
markedly reduced on comparison to vehicle treated animals, where a 327% increase 
in GFAP-positive cells was observed with respect to the intact hemisphere. This 
effect however was not significant (p > 0.05; one-way ANOVA with Dunnett’s post-
hoc test). 
 
Representative nigral sections demonstrating immunoreactivity to GFAP-positive 
cells in the 6-OHDA lesioned animals treated with sub-chronic VU0155041 (10-
100nmol) are shown in figure 4.6B. Qualitative analysis revealed GFAP-positive 
cells in the intact hemisphere displayed morphology typical of resting or quiescent 
cells. By contrast in the lesioned hemisphere a marked increase in GFAP-positive 
cells displaying thickened star-shaped morphology was observed. The 
photomicrographs confirm what was noted above, that supranigral infusion of 
VU0155041 (100nmol) provided a marked reduction in GFAP activation compared to 












Figure 4.6: Effects of sub-chronic supranigral infusion of the selective mGlu4 
receptor positive allosteric modulator VU0155041, on glial fibrillary acidic protein 
cell counts in nigral sections of unilaterally 6-OHDA lesioned rats. 
           
         
Figure 4.6. (A) The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on GFAP-positive cell number in the SNpc following a 6-OHDA lesion expressed 
as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle and 75nmol 
VU0155041, n=7 for 10nmol VU0155041, n=6 for 100nmol VU0155041). * (P <0.05) indicates 
significant differences compared to vehicle treated animals (1-way ANOVA with Dunnett’s post-hoc 
test). F = 0.9321; df = 3,25. (B) Representative photomicrographs demonstrating GFAP 
immunoreactivity in nigral sections from 6-OHDA-lesioned animals following sub-chronic 
VU0155041 treatment. Lesion side on the right; scale bars: 200µm on main panel, 50µm on higher 
magnification images. Arrows indicate the dorsal border of the SNpc. 

















































4.4.2.6 Effects of sub-chronic VU0155041 infusion on motor behaviour in 6-




The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol) on 
spontaneous motor function following a unilateral 6-OHDA lesion of the SNpc in rats 
were assessed using the cylinder test on day 5 post lesion.  
 
As expected in vehicle treated animals, there was a significant decrease in use of the 
contralateral paw from 35.7 ± 3.7% pre-lesion to 11.9 ± 3.5% post-lesion confirming 
that a unilateral 6-OHDA lesion induced a reduction of approximately 68% in 
contralateral paw use (figure 4.7A). VU0155041 (10-75nmol) failed to significantly 
protect contralateral paw use although improvements in post-lesion scores were 
observed following 75nmol VU0155041. Pre-lesion scores in animals subsequently 
treated with 100nmol VU0155041 (~20%) were below that normally expected 
(~30%). However, in these animals subsequent assessment of post-lesion scores alone 
revealed a marked improvement in contralateral paw use following this high dose of 
VU0155041 with respect to vehicle-treated animals. Furthermore in VU0155041 
(100nmol) treated animals, use of the contralateral paw was almost equivalent to that 
observed prior to a 6-OHDA lesion demonstrating total preservation. Contralateral 
paw use equated to 25.0 ± 2.5% of total paw use post-lesion in comparison to 20.4 ± 
2.5% pre-lesion, demonstrating approximately an 18% increase in contralateral paw 
use post-lesion following treatment with 100nmol VU0155041.  
 
A marked increase in ipsilateral paw use was also observed in vehicle treated animals 
following a 6-OHDA lesion in tune with the significant decrease in contralateral paw 
use. However with increasing doses of VU0155041 and subsequent increases in use 
of contralateral paw (as described above) use of the ipsilateral paw decreased. For 
example in vehicle treated animals, ipsilateral paw use post lesion increased by 
>150% with respect to pre-lesion score, compensating for an impaired contralateral 
paw. However in VU0155041 treated animals (100nmol), ipsilateral paw use post 
lesion increased by < 120% of pre-lesion score confirming the reduced asymmetry in 
these animals (figure 4.7B).  
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Figure 4.7: Effects of sub-chronic supranigral infusion of the selective mGlu4 
receptor positive allosteric potentiator VU0155041, on motor function assessed using 
the cylinder test in unilaterally 6-OHDA lesioned rats.   
 
 
Figure 4.7. The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on contralateral (A) and  ipsilateral (B) paw use expressed as a percentage of total 
paw use assessed using the cylinder test at 5 days post a 6-OHDA lesion. For all, values represent 
mean ± s.e.m. (n=8 for vehicle and 75nmol VU0155041, n=7 for 10nmol VU0155041, n=6 for 
100nmol VU0155041) * (P <0.05) and *** (P < 0.001) indicates significant differences compared to 
pre-lesion score (2-way ANOVA with Bonferroni’s post-hoc test). In (A) pre/post lesion factor, F = 
18.73, df = 1,50 and for treatment factor, F = 1.120, df = 3,50. In (B) pre/post lesion factor, F = 94.87, 


















































































The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol) on 
adjusted steps, 3 and 6 days following unilateral 6-OHDA lesioning in rats, are shown 
as a percentage of their pre-lesion scores in figure 4.8. As expected, the contralateral 
paw (lesioned) demonstrated a marked reduction in adjusted steps in the forehand 
direction, from 100% pre-lesion to 48.7 ± 6.7% at 3 days post-lesion and 52.9 ± 5.2% 
at 6 days in the vehicle treated group, indicating unilateral 6-OHDA lesioning 
reduced the number of adjusted steps in this direction (figure 4.8A). Infusion of the 
two lower doses of VU0155041 failed to significantly modify this loss of 
contralateral paw stepping. However, VU0155041 (100nmol) almost totally 
preserved the decline in contralateral paw use where scores  equated to 93.8 ± 14.5% 
of pre-lesion scores at 3 days post-lesion and 86.5 ± 13.9% at 6 days, both of which 
were a significant effect with respect to vehicle-treated animals (P < 0.001 and P < 
0.01 respectively).  
 
In the backhand direction, there was also a marked reduction in contralateral paw use 
in vehicle treated animals. This amounted to a decrease in adjusted steps from 100% 
pre-lesion to 38.2 ± 6.3% at 3 days post-lesion and 42.6 ± 2.3% at 6 days confirming 
unilateral 6-OHDA-lesioning also reduced the number of adjusted steps in the 
backhand direction (figure 4.8B). However following VU0155041 treatment use of 
the contralateral paw in the backhand direction was also significantly preserved, 
attaining maximal effect with the 100nmol dose, whereby 90.9 ± 13.5% of pre-lesion 
scores at 3 days and 112.1 ± 13.1% at 6 days were obtained. Collectively these 
findings demonstrate supranigral sub-chronic VU0155041 (100nmol) treatment 
reduced the motor asymmetry induced by a unilateral 6-OHDA lesion shown here by 
preserving contralateral adjusted stepping in both forehand and backhand directions. 
In the case of the backhand direction, the effect of VU0155041 treatment was of such 
magnitude to restore contralateral paw use to pre-lesion levels.    
 
In the ipsilateral (non-lesioned) paw in both the forehand and backhand direction no 
significant changes in adjusted steps 3 or 6 days post-lesion with respect to vehicle 
treated animals was observed (figure 4.8C and D).  
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Figure 4.8: Effects of sub-chronic supranigral infusion of the selective mGlu4 
receptor positive allosteric potentiator VU0155041, on motor function assessed using 




Figure 4.8. The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on contralateral and ipsilateral paw use in the forehand and backhand direction (A-
D) assessed using the adjusted steps test at 3 and 6 days post a 6-OHDA lesion expressed as a 
percentage of pre-lesion score. Values represent mean ± s.e.m. (n=8 for vehicle and 75nmol 
VU0155041, n=7 for 10nmol VU0155041, n=6 for 100nmol VU0155041). *(P <0.05), ** (P <0.01) 
and *** (P <0.001) indicates significant differences compared to vehicle treated animals (2-way 
ANOVA with Bonferroni’s post-hoc test). In (A) for treatment factor, F = 9.676, df = 3,50 and for days 
post lesion factor, F = 0.7086, df = 1,50. In (B) treatment factor, F = 22.62, df = 3,50 and for days post 
lesion factor, F = 8.591, df = 1,50. In (C) treatment factor, F = 4.112, df = 3, 50 and for days post 
lesion factor, F = 0.5964, df = 1,50. In (D) treatment factor, F= 1.245, df = 3, 50 and for days post 













































































































































Amphetamine-induced ipsiversive rotations in unilaterally 6-OHDA lesioned rats 
treated with sub-chronic VU0155041 or vehicle are shown in figure 4.9. Both graphs 
A and B show the same vehicle group alongside varying doses of VU0155041 for 
clarity, but all groups were analysed together. Analysis of time-course in vehicle 
treated animals revealed amphetamine (5mg.kg
-1
) induced considerable ipsiversive 
rotations throughout a 60 min time period. However, in animals treated with 
VU0155041 a marked reduction in amphetamine-induced ipsiversive rotations was 
noted. Figure 4.9A demonstrated 10 and 75nmol doses of VU0155041 induced a 
moderate reduction in ipsiversive rotations between 15 and 35 min post injection of 
amphetamine, although neither effect was significant compared to vehicle-treated 
animals (P >0.05; 2-way ANOVA with Bonferroni’s post-hoc test). VU0155041 
(100nmol) treated animals demonstrated the greatest reduction in ipsiversive rotations 
reaching a significant difference at 20 and 25 min post injection of amphetamine (P 
<0.01-0.05, 2-way ANOVA with Bonferroni’s post-hoc test) compared to vehicle-
treated animals (figure 4.9B).  
 
In figure 4.10, the mean total ipsiversive rotations were quantified over a 30 min 
period (15-45 min). The number of ipsiversive rotations by amphetamine (5mg.kg
-1
) 
in vehicle treated animals was 333 ± 24 rotations in 30 min
-1
. VU0155041 markedly 
decreased amphetamine-induced ipsiversive rotations where at 100nmol VU0155041, 
the total mean number of rotations equated to 202 ± 44, demonstrating a 39% 
reduction compared to vehicle-treated animals, however this result was not significant 










Figure 4.9: Effects of sub-chronic supranigral infusion of the selective mGlu4 
receptor positive allosteric modulator VU0155041, on motor function assessed 
following amphetamine-induced rotations in unilaterally 6-OHDA lesioned rats.   
 
Figure 4.9. The effects of sub-chronic supranigral infusion of VU0155041 (10-100nmol in 4µl) or 
vehicle (4µl PBS) on amphetamine induced rotations in unilaterally 6-OHDA lesioned rats. (A) Time 
course of ipsiversive rotations induced by amphetamine (5mg.kg-1) in vehicle and VU0155041 (10, 
75nmol) treated animals. (B) Time course of ipsiversive rotations induced by amphetamine (5mg.kg-1) 
in vehicle and VU0155041 (100 nmol) treated animals. Values represent mean ± s.e.m. (n=8 for 
vehicle and 75nmol VU0155041, n=7 for 10nmol VU0155041, n=6 for 100nmol VU0155041). * (P 
<0.05), ** (P <0.01) indicates significant differences between VU0155041 (100nmol) and vehicle 
treated animals (2-way ANOVA with Bonferroni’s post-hoc test). For treatment factor F = 2.546; df = 
3, 375 and for time F = 8.129; df = 14, 375.   















































































Figure 4.10: Effects of sub-chronic supranigral infusion of the selective mGlu4 
receptor positive allosteric modulator VU0155041, on motor function assessed 





Figure 4.10. Total ipsiversive rotations induced by amphetamine in 30 min-1 (15-45 min) in vehicle 
and VU0155041 treated animals. Values represent mean ± s.e.m. (n=8 for vehicle and 75nmol 


















































4.4.3 Effects of pre-treatment with group III mGlu receptor antagonist 
CPPG, on VU0155041 mediated neuroprotection in unilaterally 6-OHDA-
lesioned rats 
 
4.4.3.1 Effects of pre-treatment with CPPG on VU0155041 mediated 
preservation of tyrosine hydroxylase positive cells in the substantia nigra pars 
compacta 
 
The protective effects of VU0155041 (100nmol) in preserving TH-positive cells in 
the SNpc following a unilateral 6-OHDA lesion were found to be significantly 
inhibited by pre-treatment with CPPG (75nmol). In this study, 100nmol VU0155041 
mediated significant preservation of TH-positive cells in the lesioned SNpc 
amounting to 46.1 ± 4.4% of the intact hemisphere effectively reproducing the level 
of preservation achieved in the previous study (44.8 ± 4.7% of the intact hemisphere; 
figure 4.11A). However, this preservation of TH-positive cells in the SNpc following 
VU0155041 treatment was significantly inhibited following pre-treatment with CPPG 
(75nmol), whereby levels of TH fell to 32.3 ± 1.6% of the intact hemisphere (P < 
0.01, 1-way ANOVA with Dunnett’s post-hoc test). As anticipated, no significant 
difference between CPPG and vehicle-treated groups was observed. 
 
Representative nigral sections demonstrating the effects of pre-treatment with CPPG 
on VU0155041 (100nmol) mediated preservation of TH-positive cells in 6-OHDA 
lesioned animals are shown in figure 4.11B. The photomicrographs clearly 
demonstrate supranigral infusion of VU0155041 (100nmol) provided noticeable 
preservation of TH-positive cells in the lesioned hemisphere. Following pre-treatment 








Figure 4.11: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of VU0155041, with respect to tyrosine hydroxylase positive cells in 
the substantia nigra pars compacta of unilaterally 6-OHDA lesioned rats.   
 
 
               
Figure 4.11. (A) The effects of sub-chronic supranigral infusion of the broad spectrum antagonist 
CPPG (75nmol in 4µl of 0.1M NaOH) on the protective effect of VU0155041 (100nmol in 4µl)  
proceeding 6-OHDA induced loss of TH-positive cells in the SNpc. Values represent mean ± s.e.m. 
(n=7 for all treatment groups). ** (P <0.01) indicates significant difference compared to VU0155041 
(100nmol) treated animals. ### (P <0.001) indicates significant difference compared to vehicle treated 
animals (1-way ANOVA with Dunnett’s post-hoc test). F = 17.76; df = 3,23. (B) Representative 
photomicrographs show the levels of TH immunoreactivity in nigral sections of VU0155041 
(100nmol) treated 6-OHDA-lesioned animals following pre-treatment with CPPG. Fixed coronal 
sections shown here are at -5.30cm AP from bregma, (Paxinos, 1998). Arrow delineates SNpc. Lesion 
side on the right; scale bar: 200µm. 




























































4.4.3.2 Effects of pre-treatment with CPPG on VU0155041 mediated 
preservation of striatal dopamine content 
 
VU0155041 (100nmol) mediated preservation of striatal dopamine was also markedly 
inhibited following pre-treatment with CPPG (75nmol). As expected, the level of 
protection was significant in absence of CPPG where VU0155041 (100nmol) alone 
significantly preserved striatal dopamine following a 6-OHDA lesion, amounting to 
37.0 ± 6.8% of the intact hemisphere with respect to vehicle-treated animals (P< 0.01, 
figure 4.12). However, this preservation following pre-treatment with CPPG was no 
longer significant where striatal dopamine content fell to 23.9 ± 1.1% of the intact 
hemisphere, demonstrating CPPG had blocked this response (P >0.05, 1-way 
ANOVA with Bonferroni’s post-hoc test). Consistent with previous findings, no 




















Figure 4.12: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of VU0155041, with respect to dopamine content in the striatum of 





Figure 4.12. The effects of sub-chronic supranigral infusion of the broad spectrum group III mGlu 
receptor antagonist CPPG (75nmol in 4µl of 0.1M NaOH) on the protective effect of VU0155041 
(100nmol in 4µl), with respect to dopamine content in the striatum of unilaterally 6-OHDA lesioned 
rats. Values represent mean ± s.e.m. (n=7 for all treatment groups). ** (P <0.01) indicates a significant 
difference compared to vehicle treated animals (1-way ANOVA with Bonferroni’s post-hoc test). F = 


























































4.4.3.3 Effects of pre-treatment with CPPG on VU0155041 mediated 




The effects of CPPG pre-treatment with VU0155041 (100nmol) on spontaneous 
motor function following a unilateral 6-OHDA lesion of the SNpc in rats was 
assessed using the cylinder test on day 5 post lesion (figure 4.13). As expected in 
vehicle treated animals, there was a significant decrease in use of the contralateral 
paw from 30.1 ± 3.7% pre-lesion to 14.7 ± 3.0% post lesion (P <0.05, 2-way 
ANOVA with Bonferroni’s post-hoc test). Consistent with our previous findings in 
this chapter, use of the contralateral paw was largely spared with VU155041 
(100nmol) following a 6-OHDA lesion (figure 4.13A). Contralateral paw use equated 
to 23.3 ± 3.0% of total paw use post-lesion in comparison to 27.9 ± 3.4% pre-lesion, 
demonstrating approximately 84% preservation in contralateral paw use post-lesion 
following VU1055041 treatment, which is in very close agreement with our first 
study in this chapter (85% preservation). Pre-treatment with CPPG (75nmol) reduced 
the degree of preservation of contralateral paw use with VU0155041 from 28.7 ± 
3.6% pre-lesion to 19.8 ± 2.5% post-lesion, although this effect was not significant (P 
>0.05, 2-way ANOVA with Bonferroni’s post-hoc test).  
 
Ipsilateral paw use in vehicle-treated animals increased post-lesion by >160% with 
respect to pre-lesion score, compensating for an impaired contralateral paw although 
to a lesser extent than previously described. As a result, in VU0155041 (100nmol) 
treated and in CPPG pre-treated animals, use of the ipsilateral paw post-lesion 
revealed similar post-lesion scores to the vehicle-treated group which was not 








Figure 4.13: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of VU0155041, with respect to motor function assessed using the 
cylinder test in unilaterally 6-OHDA lesioned rats.   
 
Figure 4.13. The effects of sub-chronic supranigral infusion of the broad spectrum group III mGlu 
receptor antagonist CPPG (75nmol in 4µl of 0.1M NaOH) on the protective effect of VU0155041 
(100nmol in 4µl), with respect to (A) contralateral and (B) ipsilateral paw use assessed using the 
cylinder test at 5 days post a 6-OHDA lesion, expressed as a percentage of total paw use. For all, 
values represent mean ± s.e.m. (n=7 for all treatment groups). * (P <0.05), ** (P <0.01) and *** (P < 
0.001) indicates significant differences compared to pre-lesion score (2-way ANOVA with 
Bonferroni’s post-hoc test). In (A) for pre/post lesion factor, F = 12.48, df = 1,34; for treatment factor 
F = 0.4066, df = 2,34. In (B) for pre/post lesion factor, F = 42.77, df = 1,34; treatment factor F = 1.019, 













































































The effects of CPPG pre-treatment with VU0155041 (100nmol) on adjusted steps, 3 
and 6 days following unilateral 6-OHDA lesioning in rats, are shown as a percentage 
of their pre-lesion scores in figure 4.14. As expected, the contralateral paw (lesioned) 
demonstrated a marked reduction in adjusted steps in the forehand direction, from 
100% pre-lesion to 47.6 ± 4.8% at 6 days post-lesion in the vehicle treated group 
(figure 4.14A). In this study, VU0155041 (100nmol) treatment significantly 
preserved contralateral paw use with respect to vehicle-treated animals, equating to 
86.3 ± 5.6% of pre-lesion scores at 6 days post-lesion (P < 0.001, 2-way ANOVA 
with Bonferroni’s post hoc test). However, following pre-treatment with CPPG, this 
preservation was significantly reduced to 64.1 ± 4.6% of pre-lesion scores at 6 days 
post-lesion (P<0.05). A similar effect following CPPG pre-treatment was observed in 
the backhand direction. VU0155041 (100nmol) treatment significantly preserved 
contralateral paw use with respect to vehicle-treated animals, equating to 76.7 ± 6.3% 
of pre-lesion scores at 6 days post-lesion (P < 0.01). However, following pre-
treatment with CPPG, this preservation was significantly reduced to 56.2 ± 5.6% of 
pre-lesion scores at 6 days post-lesion (P<0.05, figure 4.14B). 
 
As expected the ipsilateral paw in the forehand direction showed no significant deficit 
in adjusted steps 3 or 6 days post-lesion in vehicle treated animals. However, a 
significant VU0155041 mediated reduction in adjusted steps as previously reported 
was seen here in the backhand direction (P<0.01, figure 4.14C, D). This effect was 
totally abolished following pre-treatment with CPPG (75nmol) where post-lesion 
scores were above those obtained in vehicle treated animals. Collectively these 
findings demonstrate pre-treatment with CPPG inhibited VU0155041 mediated 
preservation of motor function shown here by significantly reducing contralateral 







Figure 4.14: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of VU0155041, with respect to motor function assessed using the 




Figure 4.14. The effects of sub-chronic supranigral infusion of the broad spectrum group III mGlu 
receptor antagonist CPPG (75nmol in 4µl of 0.1M NaOH) on the protective effect of VU0155041 
(100nmol in 4µl), with respect to contralateral and ipsilateral paw use in the forehand and backhand 
direction (A-D) assessed using the adjusted steps test at 3 and 6 days post a 6-OHDA lesion, expressed 
as a percentage of pre-lesion score. Values represent mean ± s.e.m. (n=7 for all treatment groups). *(P 
<0.05) and ***(P<0.001) indicates significant differences compared to VU0155041 treated animals. ## 
(P<0.01) and ### (P<0.001) indicates significant differences compared to vehicle-treated animals (both 
2-way ANOVA with Bonferroni’s post-hoc test).  In (A), for treatment factor, F = 4.765, df = 3,46 and 
for days post lesion factor F = 5.116, df = 1,46. In (B), treatment factor, F = 4.588, df = 3,46 and for 
days post lesion factor F = 6.034, df = 1,46. In (C), treatment factor, F = 2.859, df = 3, 46 and for days 
post lesion factor F = 2.531, df = 1,46. In (D), treatment factor, F = 7.985, df = 3,46 and for days post 






















































































































































Amphetamine-induced ipsiversive rotations in unilaterally 6-OHDA lesioned rats 
treated with sub-chronic VU0155041 following pre-treatment with CPPG are shown 
in figure 4.15. Analysis of time-course in vehicle treated animals revealed 
amphetamine (5mg.kg
-1
) induced considerable ipsiversive rotations throughout a 60 
min time period. As expected, in animals treated with VU0155041 (100nmol) a 
marked reduction in amphetamine-induced ipsiversive rotations was observed, 
reaching significance at 15, 20 and 25 min post injection of amphetamine compared 
to vehicle-treated animals (P<0.01, 2-way ANOVA with Bonferroni’s post-hoc test; 
figure 4.15A). Pre-treatment of CPPG markedly inhibited VU0155041 mediated 
reduction in ipsiversive rotations, reaching significance at 15 and 20 min post 
injection of amphetamine (P<0.001, 2-way ANOVA with Bonferroni’s post-hoc test).     
 
In figure 4.15B, the mean total ipsiversive rotations were quantified over a 30 min 
(15-45) period to identify the effects of CPPG on VU0155041 mediated reduction in 
ipsiversive rotations. As expected, VU0155041 (100nmol), markedly decreased 
amphetamine-induced ipsiversive rotations, shown here, by up to 44% in comparison 
to vehicle treated animals, however this effect was not significant (P>0.05). 
Importantly for this study, pre-treatment with CPPG (75nmol), inhibited a 
VU0155041 mediated reduction in amphetamine-induced rotations where the number 
of rotations equated to 281 ± 28 in 30 min
-1
 in comparison to 209 ± 61 30 min
-1
 in 












Figure 4.15: Effects of the group III mGlu receptor antagonist CPPG on the 
protective effect of VU0155041, with respect to motor function assessed following 
amphetamine-induced rotations in unilaterally 6-OHDA lesioned rats.   
 
 
Figure 4.15. Effects of the group III mGlu receptor antagonist CPPG (75nmol in 4µl of 0.1M NaOH) 
on the protective effect of VU0155041 (100nmol in 4µl), with respect to amphetamine induced 
rotations in unilaterally 6-OHDA lesioned rats. (A) Time course of ipsiversive rotations induced by 
amphetamine (5mg.kg-1) in vehicle, VU0155041 and CPPG pre-treated animals. (A) * (P<0.05), *** 
(P<0.001) indicate significance compared to CPPG pre-treated animals. # (P<0.05), ## (P<0.01) 
indicate significant difference compared to vehicle-treated animals (2-way ANOVA with Bonferroni’s 
post-hoc test). For treatment factor, F = 7.937, df = 2, 270 and for time, F = 15.06, df = 14, 270. (B) 
Total ipsiversive rotations induced by amphetamine in 30 min-1 in vehicle, VU0155041 and CPPG pre-
treated animals. F = 2.933, df = 2,18. Values represent mean ± s.e.m. (n=7 for all treatment groups).  















































































4.4.4 Preliminary study to determine localisation of mGlu4 receptors on 
dopaminergic neurons and astrocytes in the SNpc of naїve rats 
 
4.4.4.1 Co-localisation of mGlu4 receptors with tyrosine hydroxylase 
 
This final study set out to investigate whether mGlu4 receptors were co-localised on 
dopaminergic neurons in the SNpc of naїve rat brain using fluorescence microscopy. 
The results from a representative set of sections in the SNpc are shown in figure 4.16. 
 
Assessment of mGlu4 receptors alone revealed diffuse homogenous staining 
throughout the SNpc consistent with previous findings in Chapter 2, suggesting a 
likely pre-synaptic axon terminal location. Interestingly, shown here, 
immunoreactivity to mGlu4 was punctate, indicating some mGlu4 receptors in the 
SNpc may also be post-synaptic in origin (figure 4.16A). This punctate staining for 
mGlu4 was not co-localised with resident nuclei demonstrating no overlap with the 
nuclear stain Hoechst, implying antibody binding was specific to mGlu4 receptors 
(figure 4.16B). Analysis of TH in the same region of the SNpc, as expected, revealed 
wide distribution of TH-positive cells throughout (figure 4.16C). On merging all three 
images, a number but not all of the presumed post-synaptic mGlu4 receptors were 
shown to be co-localised with TH positive cells (figure 4.16D). This would suggest 
post-synaptic mGlu4 receptors are localised on dopaminergic neurons within the 
SNpc.        













Figure 4.16: Co-localisation of mGlu4 receptors with tyrosine hydroxylase in the 




Figure 4.16. Photomicrographs of immunofluorescence for (A) mGlu4 receptors [red], (B) nuclei 
(Hoechst) [blue], (C) TH-positive cells [green] and (D) merged image of all three markers in a region 
of the SNpc in naїve rat brain. In D, white arrows indicate co-localisation of mGlu4 receptors with TH-












4.4.4.2 Co-localisation of mGlu4 receptors with glial fibrillary acidic protein 
 
Immunofluorescence microscopy was utilised to investigate co-localisation of mGlu4 
receptors on astrocytes in the SNpc of naїve rat brain. The results from a 
representative set of sections in the SNpc are shown in figure 4.17. 
 
Immunoreactivity for mGlu4 receptors in the SNpc again appeared predominantly of 
a diffuse fibrous nature consistent with the notion of a pre-synaptic axon terminal 
location. In addition, mGlu4 immunoreactivity was also punctate, suggesting mGlu4 
receptors may also reside post-synaptically in the SNpc as previously described 
(figure 4.17A). The punctate staining for mGlu4 largely appeared not to be co-
localised with resident nuclei using the nuclear stain Hoechst. However, on closer 
visual inspection, co-localisation was observed, suggesting a degree of non-specific 
binding with this antibody (figure 4.16B). Staining for GFAP in the same region of 
the SNpc, revealed wide distribution of GFAP-positive cells demonstrating 
morphology reminiscent of both quiescent and activated (star-shaped characteristic) 
astrocytes (figure 4.17C). On merging all three images, very little co-localisation of 
mGlu4 receptors with GFAP-positive cells was observed in the SNpc. However in 
one instance in figure 4.16D, co-localisation of mGlu4 with GFAP was clearly 
apparent. These findings suggest post-synaptic mGlu4 receptors may be localised on 
astrocytes, however likely account for a minority of mGlu4 receptors in the SNpc. 
Thus, owing to the limited co-localisation observed here, post-synaptic mGlu4 













Figure 4.17: Co-localisation of mGlu4 receptors with glial fibrillary acidic protein in 




Figure 4.17. Photomicrographs of immunofluorescence for (A) mGlu4 receptors [red], (B) nuclei 
(Hoechst) [blue], (C) GFAP-positive cells [green] and (D) merged image of all three markers in a 
region of the SNpc in naїve rat brain. In D, white arrow indicates co-localisation of mGlu4 receptor 













In this chapter we demonstrate for the first time, using the selective positive allosteric 
modulator (PAM) VU0155041, that mGlu4 receptor activation provides functional 
neuroprotection in the 6-OHDA rat model of PD. In addition, the effects of 
VU0155041 were inhibited by pre-treatment with the group III mGlu receptor 
antagonist CPPG, confirming responses were mediated by activation of the mGlu4 
receptor. Furthermore, protection mediated by VU0155041 was accompanied by a 
reduction in inflammatory markers, suggesting that a reduced inflammatory response 
may contribute in part to this neuroprotective effect.   
 
The studies presented in this chapter, demonstrate the mGlu4 selective PAM 
VU0155041 administered 1h before and for 7 days post a 6-OHDA lesion 
significantly protected the nigrostriatal tract. This was evidenced by the dose-
dependent preservation of TH-positive cells in the SNpc and reduction in 6-OHDA-
induced loss of striatal TH and DDC immunoreactivity.  These preserved makers of 
nigrostriatal tract integrity were reflected in elevated dopamine content in both the 
SN and striatum of VU0155041 versus vehicle-treated animals, as measured by 
HPLC. This finding is consistent with those of Battaglia et al., (2006), who found that 
systemic injections of the mGlu4 PAM PHCCC, given 30 min before toxin injection, 
offered approximately 50% protection against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced loss of striatal dopamine content and reduction in 
TH-positive cell numbers in the SNc in mice.   
 
 In addition to confirming a neuroprotective effect at the neurochemical and 
immunohistochemical level following treatment with the mGlu4 PAM VU0155041, 
we demonstrate here protection led to a preservation of motor function following a 
unilateral injection of 6-OHDA. Significant preservation of contralateral paw use was 
shown in both the cylinder and adjusted stepping test following VU0155041 
treatment in addition to a reduction in amphetamine-induced ipsiversive rotations 
reflecting reduced asymmetry between the lesion and intact hemispheres in this 
hemiparkinsonian model. Furthermore in a separate study, treatment with the broad 
spectrum antagonist CPPG prior to VU0155041 markedly attenuated both the 
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behavioural end-points and the post-mortem indices of preserved nigrostriatal tract 
function, confirming VU0155041 produced these effects via a receptor mediated 
process. In certain instances the effects of CPPG to inhibit responses at the 
behavioural level were not significant therefore it remains to be determined whether 
higher doses of CPPG would have inhibited the residual responses of VU0155041.  
 
In the initial dose finding study, preservation of dopamine content in both the 
striatum and SN (~70% of intact hemisphere) following treatment with VU0155041 
was greater than that in the follow-up study investigating preservation of TH (~45%). 
These contrasting levels of protection are likely due to the variability in lesion size, 
where in the initial study only a ~70% lesion in the SN was obtained compared to the 
desired ~90% in the full study. Therefore the larger investigation offers a more valid 
assessment of the neuroprotective potential of mGlu4 receptor activation in this 
experimental paradigm.  
 
The degree of protection seen with VU0155041 according to levels of TH in the SN 
(45% preservation) was slightly less than that achieved in the previous chapter using 
the broad spectrum agonist L-AP4 (~60% preservation of TH). Nevertheless, this 
indicates that a large proportion of L-AP4’s effects were likely attributable to mGlu4 
receptor activation.  The maximal dose of VU0155041 tested here (100 nmol) was 
based on that used i.c.v. by Niswender et al (2008) against haloperidol-induced 
catalepsy and reserpine-induced akinesia. However, a recent study has shown doses 
of 500 nmol can be tolerated intrathecally (Wang et al., 2011), paving the way for 
examination of higher doses in the future that may afford a greater degree of 
protection, akin to that seen with L-AP4. The lack of comparable protection with L-
AP4 seen here with VU0155041 may also suggest a contribution from activation of 
additional group III mGlu receptors, a possibility explored in the next chapter of this 
thesis. The protective effects of VU0155041 are certainly consistent with the intense 
staining for mGlu4 in the SNpc described in Chapter 2 of this thesis. Some of this 
immunoreactivity most likely represents mGlu4 receptors located on excitatory 
(glutamatergic) terminals, as has been specifically demonstrated in the neighbouring 
SNpc (Corti et al., 2002; Kosinski et al., 1999). However, the precise anatomical 
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location of mGlu4 receptors on other neurones or additional cell types in this region 
remains to be examined.  
  
Interestingly, previous reports using group III mGlu receptor broad spectrum agonists 
in electrophysiological responses in-vitro, through to the behavioural and 
neuroprotective findings with L-AP4 in-vivo discussed in chapter 3, have shown 
effects tail off at the higher concentrations or doses tested (MacInnes et al., 2004; 
Valenti et al., 2003; Vernon et al., 2007b) thought to be a result of receptor 
desensitisation/ internalisation. This effect was not apparent in our studies using 
VU0155041 suggesting targeting the allosteric site of the receptor may be an 
effective strategy to reduce the likelihood of receptor desensitisation (Kew, 2004). 
Indeed, pharmacological modulation of an allosteric site over a highly conserved 
orthosteric binding site may offer numerous advantages in addition to a lack of 
desensitisation and internalization, such as higher subtype selectivity and lack of 
downregulation along with reduced side effects (Wood et al., 2011). Taken together, 
these facets likely explain the recent emphasis on developing further mGlu4 receptor 
PAMs (East et al., 2010; Engers et al., 2010; Niswender et al., 2008b; Williams et al., 
2009) to probe the functional involvement of these receptors. 
 
Owing to the positive effect of VU0155041 in these studies, it is pertinent at this 
stage to consider potential mechanisms underlying this protection. Whilst numerous 
mechanisms have been proposed to underlie mGlu4 receptor-mediated 
neuroprotection (reviewed in Duty, 2010), the two most likely mechanisms include 
inhibition of glutamate release in the SNpc to facilitate protection from glutamate-
mediated excitotoxicity, or reduced inflammatory actions. Previous data from this and 
other laboratories already provides some support for the glutamate hypothesis, while 
the findings presented in this chapter has provided new evidence in support of a 
potential anti-inflammatory contribution.  
 
In relation to the glutamate hypothesis, electrophysiological findings have shown the 
broad spectrum agonist L-AP4 depresses STN-evoked EPSCs in the SNpr (Wittmann 
et al., 2001; Wittmann et al., 2002), and inhibits EPSPs in dopaminergic neurones of 
the SNpc (Wigmore & Lacey, 1998), most likely reflecting inhibition of glutamate 
235 
 
release from STN terminals in these regions. In support of this, we found that L-SOP 
and L-AP4 inhibited depolarisation-evoked release of [
3
H]-D-aspartate from slices of 
rat SN in-vitro and that local intranigral infusion of L-SOP reduced glutamate release 
in the SNpr in- vivo (Austin et al., 2010). Furthermore mGlu4 receptors have been 
identified as key functional subtypes involved, since STN-evoked EPSCs in 
dopaminergic neurones of the SNpc were inhibited by the mGlu4 PAM,  PHCCC 
(Valenti et al., 2005).  Indeed, this is consistent with findings in our laboratory that 
show L-SOP and L-AP4 inhibit depolarisation-evoked release of [
3
H]-D-aspartate 
from slices of rat SN in-vitro while local intranigral infusion of L-SOP reduces 
glutamate release in the SNpr in- vivo (Austin et al., 2010).  These effects of L-AP4 
in vitro were potentiated by PHCCC which further supports involvement of mGlu4 
receptors in restricting glutamate release in the SN in general (Broadstock et al., 
2011). Further microdialysis studies would be of real worth here to support the notion 
that inhibition of glutamate release in the SNpc contributes to the neuroprotective 
effects following mGlu4 receptor potentiation. In the MPTP study of Battaglia et al., 
(2006), protection against MPTP-induced degeneration was seen following injection 
of PHCCC directly into the globus pallidus which lies upstream of the SNpc in the 
indirect basal ganglia circuit. This finding implies that mGlu4 receptor-mediated 
normalisation of glutamatergic drive to the SNpc, either directly by actions in the 
SNpc itself or indirectly via correction of pallidosubthalamic firing and subsequent 
downstream reductions in STN glutamatergic drive to the SNpc, might provide 
effective neuroprotection in these toxin-induced animal models of PD.  
 
The presence of mGlu4 receptors on both astrocytes and microglia in culture (Taylor 
et al., 2003; Yao et al., 2005), raises the possibility that a further glial component 
may contribute to the overall protective actions of mGlu4 modulators. Certainly, 
inflammation is believed to play a key role in PD pathogenesis (Gerhard et al., 2006; 
Mogi et al., 2000; Tansey & Goldberg, 2010; Whitton, 2007) and microglial 
activation and elevated inflammatory markers are similarly seen in the striatum and 
SNpc of rats following a 6-OHDA lesion (Cicchetti et al., 2002; Mogi et al., 2000). It 
is thought that following a pathologic stimulus of this kind, substantial increases in 
pro-inflammatory cytokines and cell adhesion molecules occur, whereupon the 
activated microglia cluster around dopaminergic neurones and become phagocytic 
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(Banati et al., 1998; Bronstein et al., 1995). The progressive degeneration is 
worsened by the release of chemo-attractants from the dying neurones which leads to 
further activated microglia infiltrating the region. L-AP4 treatment of astrocytes has 
been shown to reduce the production of such pro-inflammatory chemokines (Besong 
et al., 2002) and more importantly, this effect was abolished in astrocyte cultures 
from mGlu4 -/- mice, implicating astroglial mGlu4 receptors in mediating potential 
anti-inflammatory actions. The marked decrease in GFAP-positive cells observed 
here following VU0155041 treatment is certainly supportive of a role for mGlu4 
receptor activation in restricting 6-OHDA-induced astroglial-driven neurotoxicity in 
vivo. Treatment with the mGlu4 PAM also lead to significant reduction in activation 
of microglia in the SNpc of 6-OHDA rats, as shown by the reduced levels of IBA-1 in 
the lesioned hemisphere of VU0155041-treated animals compared to that of vehicle 
treated animals.  
 
Whilst the presence of mGlu4 receptors has been shown on astrocytes and microglia 
in culture, despite much speculation, no study to our knowledge has confirmed such a 
presence in the rodent brain. To investigate this possibility, a final co-localisation 
study was performed to determine the presence of mGlu4 receptors on astrocytes in 
the rat SNpc. Interestingly very little co-localisation of mGlu4 with GFAP was 
observed in the SNpc suggesting mGlu4 receptors are in fact unlikely to reside on 
astrocytes. Whilst localisation of mGlu4 receptors on microglia has not been 
investigated, these findings would suggest the anti-inflammatory effects of 
VU0155041 most likely reflect an indirect effect via stimulation of neuronal mGlu4 
receptors. However further studies particularly in vivo, are no doubt required to 
elucidate the contribution of an anti-inflammatory action in mediating 
neuroprotective effects. These preliminary studies also revealed a degree of co-
localisation of likely post-synaptic mGlu4 receptors on dopaminergic neurons (shown 
by TH-positive cells), raising the possibility of a post-synaptic action of mGlu4 
receptors in mediating neuroprotection. Currently however, there is little evidence in 
favour of a post-synaptic action of mGlu4 receptors in the SNpc. Indeed, Wigmore & 
Lacey (1998) failed to detect any direct post-synaptic effects of L-AP4 on SNpc 
neurones however mGlu4 selective agents were not investigated. Therefore additional 
studies are required to clarify whether mGlu4 receptors may mediate any post-
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synaptic action, distinct from modulation of neuronal excitability which may relate to 
a potential neuroprotective effect.   
 
Nonetheless, the notion that multiple mechanisms are involved in mediating 
functional neuroprotection may explain why considerably lower doses of VU0155041 
(100nmol) are required in the 6-OHDA model compared to that required to produce 
reversal of reserpine-induced akinesia (316nmol) which largely relies on inhibition of 
glutamate release alone (Niswender et al., 2008). However, despite little change in 
receptor expression following a 6-OHDA lesion (Messenger et al., 2002), we cannot 
rule out a post-lesion increase in sensitivity of these receptors which could also 
underlie the lower doses of VU0155041 required in this model of PD. 
 
To conclude, the studies reported here demonstrate selective activation of mGlu4 
receptors using the selective PAM V0155041 can provide functional neuroprotection 
in the 6-OHDA rat model of PD. The notion that several mechanisms, including 
restricting glutamate release and provision of an anti-inflammatory component, may 
be involved in mediating this protection is particularly appealing given the likelihood 
that multiple pathogenic events lead to PD. It is hoped by implementing multiple 
mechanisms, mGlu4 receptor activation may offer improved translation in additional 
animal models of PD as a neuroprotective or disease modifying strategy which has in 
the past so often failed when targeting one mechanism alone (as described in Duty & 
Jenner, 2011). Finally, with the degree of protection seen with VU0155041 being 
slightly less than that achieved with the broad spectrum agonist L-AP4, it is 
encouraging to suggest the additional group III mGlu receptor subtypes mGlu7 and 8 














Chapter 5: Potential of targeting metabotropic 
glutamate receptor 7 and 8 to provide functional 

































In chapter 4 of this thesis we demonstrated that activation of mGlu4 receptors using 
the selective positive allosteric modulator VU0155041 significantly protects against 
6-OHDA-induced nigrostriatal tract degeneration in rats and mediates preservation of 
motor behaviour in these animals. These findings confirmed for the first time that 
neuroprotection could be mediated exclusively upon activation of a single group III 
mGlu receptor subtype in the 6-OHDA rat model of PD. In this chapter we seek to 
determine the ability of mGlu7 and mGlu8 receptors to similarly provide functional 
neuroprotection in the 6-OHDA rat model of PD. 
 
Assessment of group III mGlu receptor distribution, in Chapter 2 of this thesis 
revealed high intensity staining for mGlu7 receptors in the dorsal tier of the SNpc, 
SNpr and STN and moderate intensity staining in the striatum and GP (internal and 
external segments). Indeed additional studies have confirmed the presence of mGlu7 
receptors in numerous basal ganglia nuclei demonstrating particularly high expression 
in the striatum and the SN (Bradley et al., 1999; Kosinski et al., 1999). Furthermore 
in the striatum, mGlu7 receptors have been shown to be localized presynaptically on 
the corticostriatal glutamatergic synapses, where they are found to decrease the 
glutamatergic tone and attenuate transmission in cholinergic interneurons (Bonsi et 
al., 2007; Pisani et al., 1997). Thus mGlu7’s wide distribution in the basal ganglia 
circuit suggests that it may display a fundamental role in the control of normal and 
abnormal motor activity (Kinoshita et al., 1996; Kosinski et al., 1999). In particular, 
expression of mGlu7 receptors in the subthalamonigral terminal regions would 
suggest these group III mGlu receptor subtypes could hold promise as potential 
candidates to mediate functional neuroprotection. 
 
There is limited evidence to date to supporting a neuroprotective role of mGlu7 
receptors. However, early in vitro studies which showed activation of group III mGlu 
receptors using L-AP4 could protect against NMDA-induced toxicity in mixed 
cultures of mouse cerebellar granule neurones offers some support. This stems from 
the fact that high concentrations of L-AP4 (1-3mM) used in these studies would 
suggest mGlu7 may mediate this effect since the EC50 of L-AP4 at mGlu7 is greater 
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than 100µM, 100-fold higher than at mGlu4 or 8 (Lafon-Cazal et al., 1999a). 
Furthermore this effect was not apparent at lower concentrations of L-AP4 supporting 
a lack of involvement of mGlu4 and mGlu8 receptors. 
 
Progress in elucidating a neuroprotective role for mGlu7 receptors in PD has been 
hampered by a lack of selective pharmacological tools. However the relatively recent 
discovery of an orally active, brain-penetrable and selective allosteric activator of 
mGlu7 receptors, N,N’-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082) 
(Mitsukawa et al., 2005), has opened up the possibility in establishing a role for 
mGlu7 in PD. AMN082 directly activates receptor signalling via an allosteric site in 
the transmembrane domain demonstrating little effect on the potency of orthosteric 
ligands. In transfected mammalian cells expressing mGlu7, AMN082 potently 
inhibits cAMP accumulation and stimulates GTPγS binding (EC50-values, 64-290nM; 
Mitsukawa et al., 2005) with agonist efficacies comparable to those of L-AP4 and 
superior to those of glutamate (EC50 values are documented in Table 3.1). Selectivity 
profiling of AMN082 assessed using the GTPγS binding radioligand displacement 
assay in CHO cells revealed no  activating or inhibitory effect at other mGlu receptor 
subtypes and selected iGlu receptors with concentrations less than or equal to 10µM 
(Mitsukawa et al., 2005). Furthermore no significant binding interaction of 1µM 
AMN082 with 30 additional nervous system targets including receptors for 
adrenaline, dopamine, GABA, histamine, acetylcholine, opiates, serotonin and 
substance P was reported in this initial study. However the specific receptor subtypes 
of these transmitter systems examined in these studies are not described so activity at 
all subtypes cannot categorically be ruled out.   
 
Following the discovery of AMN082, a recent study has attempted to examine the 
antiparkinsonian effects following mGlu7 receptor activation in vivo. Intrastriatal 
administration (0.1 and 0.5nmol) of AMN082 was shown to reverse haloperidol-
induced catalepsy in rats. Furthermore this reduction in catalepsy was not apparent in 
mGlu7 receptor knockout mice suggesting that these antiparkinsonian effects could 
be mediated by activation of (assumed pres-synaptic) mGlu7 receptors on the 
glutamatergic corticostriatal synapses (Greco et al., 2010). This study also went on to 
show AMN082 (2.5 and 5mg/kg i.p.) reduced apomorphine-induced rotations in 
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unilateral 6-OHDA lesioned rats and in a more complex task commonly used to 
evaluate major akinetic symptoms of PD patients, AMN082 (5mg/kg) was shown to 
reverse the increased reaction time to respond to a cue in bilateral 6-OHDA lesioned 
rats. The low doses used for intrastriatal administration of AMN082 in these studies 
(0.1-0.5nmol) are likely an attempt to adhere to the narrow window of selectivity 
initially reported for AMN082 at mGlu7 (≤ 10µM, Mitsukawa et al., 2005). 
Furthermore, studies in this laboratory have recently demonstrated intranigral 
administration of AMN082 is also able to reverse parkinsonian-like symptoms in the 
reserpine-treated rat model (Broadstock et al., 2011). Although these effects were 
presumed to reflect inhibition of glutamate release following activation of mGlu7 
receptors on subthalamonigral terminals, this mechanism of action remains to be 
confirmed. However, in this same study AMN082 was shown to significantly inhibit 
KCl-evoked [
3
H]-D-aspartate release in nigral slices in vitro (Broadstock et al., 2011) 
suggesting activation of mGlu7 receptors could mediate this desired outcome. 
Therefore, these findings point to a strong likelihood that activation of mGlu7 
receptors in the SNpc, may well provide some degree of neuroprotection.   
 
As for assessing the potential of targeting mGlu8, distribution studies described in 
chapter 2 of this thesis revealed widespread expression throughout the basal ganglia 
although to a much lesser degree than that seen for both mGlu4 and 7. This pattern is 
in agreement with in-situ hybridisation studies performed previously in our 
laboratory, which reported particularly low levels of mGlu8 mRNA in the GPe, GPi 
and the SNpr (Messenger et al., 2002). The distribution of mGlu8 receptors in the 
basal ganglia is the least well characterised of all the group III mGlu receptor 
subtypes, therefore no additional studies supplement these preliminary findings. 
However, expression of mRNA encoding mGlu8 receptors has been reported in the 
cortex, striatum and STN (Messenger et al., 2002), suggesting the possibility that 
mGlu8 receptors are found on pre-synaptic terminals of corticostriatal, striatonigral 
and subthalamonigral pathways. The presence particularly in the subthalamonigral 
pathway would favour a potential role for mGlu8 receptors to provide 




Autoradiographic studies also offer some support for the presence of mGlu8 in the 
basal ganglia. Visualisation of group III mGlu receptors, using [
3
H]-L-AP4, has 
shown high levels of binding within the globus pallidus (GP) and SNpr, moderate 
levels in the striatum, and low levels within the STN and SNpc in rat brain (Hudtloff 
& Thomsen, 1998). Furthermore, studies comparing [
3
H]-L-AP4 (30nM) binding in 
wild-type and mGlu4 knock-out mice revealed 28% of specific binding remains in the 
SNpr of the knock-out mice (Thomsen & Hampson, 1999). Although these results 
confirm a significant proportion of L-AP4 binding is due to mGlu4 in this region, the 
remaining high-affinity specific binding could be due to mGlu8 binding, rather than 
mGlu7 which requires, as noted above higher (µM range) concentrations for 
activation (Cartmell & Schoepp, 2000). However no mGlu8 knock-out studies have 
been used to confirm this notion.  
 
As previously mentioned, very few selective pharmacological agents have been 
identified for group III mGlu receptors. Currently, the mGlu8 receptor agonist (S)-
3,4-dicarboxyphenylglycine (DCPG) remains the only selective pharmacological tool 
to probe the involvement of mGlu8 receptors. Initially described by Thomas et al., 
(2001), (S)-3,4-DCPG has been characterised on cloned human mGlu1–8 receptors 
individually expressed in AV12-664 cells co-expressing a rat glutamate/aspartate 
transporter. Data from the assays on each of the eight mGlu receptor subtypes 
demonstrated (S)-3,4-DCPG is at least 100-fold more selective at mGlu8 (EC50 of 
31nM) than additional mGlu receptor subtypes (EC50 values  >3.5 mM on mGlu1–7). 
This study further identified the (S)-isomer to be more potent and selective than the 
(R)-isomer of 3,4-DCPG which demonstrated antagonist activity at AMPA receptors 
on rat motor neurons (Thomas et al., 2001). Thus the (S)-isomer is favoured to probe 
involvement of mGlu8 receptors and all further reference to DCPG in this thesis 
refers to this isomer.   
 
To determine the ability of mGlu8 to inhibit glutamate release in vitro, previous 
findings in our laboratory have shown selective activation of mGlu8 receptors using 
DCPG over a wide concentration range (0.03 – 10 μM) spanning the estimated EC50 
of 31 nM (Thomas et al., 2001), had no significant effects on either basal or 25mM 
KCl-evoked [3H]-D-aspartate release in nigral slices in vitro (Broadstock et al., 
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2011). This would suggest mGlu8 receptors may well be less prominent in inhibiting 
glutamate release from overactive glutamatergic projections in the basal ganglia in a 
rat model of PD. Nonetheless, an interesting observation from the neuroprotection 
studies using VU0155041 in Chapter 3 of this thesis, is that the level of protection 
achieved following mGlu4 receptor activation was below that seen with the broad 
spectrum agonist L-AP4. For example in the striatum, preservation of TH equated to 
~45% of the intact hemisphere following treatment with VU0155041, yet > 63% of 
TH was preserved in L-AP4 treated rats following a 6-OHDA lesion. Whilst these 
findings would suggest mGlu4 receptors are largely responsible for the protection 
observed with L-AP4, the additional protective effect may arise from other group III 
mGlu receptor subtypes, namely mGlu7 or mGlu8. Based on the literature described 
thus far, mGlu7 is likely involved in this residual response, however a role for mGlu8 
cannot be ruled out.    
 
The studies described in this chapter seek to further our quest in elucidating the 
potential of targeting group III mGlu receptors as an alternative, non-dopaminergic, 
therapy to provide neuroprotection in the treatment of PD. In particular the main 
objectives to be addressed in this chapter was to examine the potential of targeting 
mGlu7 and mGlu8 receptors using the respective selective ligands AMN082 and 
DCPG to provide functional neuroprotection in the 6-OHDA rat model of PD. 
Although both these agents are thought to demonstrate a degree of systemic activity, 
the studies described here seek to assess the efficacy of both agents following site-
directed injections directly into the SNpc using the same experimental paradigm 
described in the previous chapter. Through direct injection of agents into the SNpc, 
we can be sure that any effects seen are the result of targeting receptors in this region 
alone; such information is valuable not only in teasing out the role of receptors within 











The overall aim of the studies described in this chapter was to investigate whether 
activation of mGlu7 or mGlu8 receptors provides functional neuroprotection in the 6-
OHDA rat model of PD.  
 
More specifically the key objectives here were: 
 
1. to determine if the mGlu7 selective positive allosteric agonist AMN082 and 
mGlu8 selective agonist DCPG provide neuroprotective effects against a 6-
OHDA lesion of the SNpc in rats, determined by immunohistochemical and 
neurochemical analysis 
2. to ascertain whether any neuroprotective effects of AMN082 and DCPG 
translate to functional restoration of motor function as assessed in both forced 
and habitual behavioural tasks 
3. to establish the effective dose range of AMN082 and DCPG to provide 
neuroprotection as determined by behavioural and immunohistochemical 
assessment 
4. to investigate whether AMN082 or DCPG treatment leads to astrocytic and 






















Male Sprague Dawley rats (B & K or Harlan, U.K.) weighing 270 – 300 g were used 
in these studies. Food and water were provided ad libitum. Animals were housed in a 
temperature- and humidity-controlled environment with a 12-h light / dark cycle. All 
procedures conformed to the U.K. Animals (Scientific Procedures) Act, 1986 and 
every effort was made to minimise animal numbers and suffering. 
 
5.3.1.2 Surgical cannulation  
 
Animals were bilaterally cannulated in the same manner as previously described in 
section 3.3.2.4 whereby cannulae were implanted bilaterally 2mm above the SNpc 
using the following co-ordinates; anterioposterior (AP), -4.8mm, mediolateral (ML), 
± 2.0mm; dorsoventral (DV), -6.3mm from bregma (Paxinos & Watson, 1998).  
 
5.3.1.3 Supranigral drug administration 
 
A minimum of 5 days following cannulae implantation, the neuroprotection study 
commenced. Animals received their first dose of AMN082, DCPG or vehicle 1 hour 
prior to 6-OHDA infusion (detailed in 5.3.1.4). AMN082 was administered at doses 
of 0.5, 1, 10 and 100nmol, dissolved in 4µl PBS with 10% DMSO, while DCPG was 
administered at 1, 10 and 30nmol in 4µl PBS. Animals received unilateral drug 
infusions at a flow rate of 2µl min
-1
  into the right cannulae (or left on occasions when 
the right was blocked) for a further 7 days post-lesion as previously described in 






5.3.1.4 Intranigral 6-OHDA lesioning 
 
A minimum of 5 days following bilateral cannulation above the SNpc, animals 
received a single, unilateral injection of 6-OHDA into the same side of the SNpc as 
the drug infusions. 30 min prior to 6-OHDA injection, rats were pre-treated with 
desipramine (25 mg kg
-1
 i.p.) and pargyline (5 mg kg
-1
 i.p.). Animals were then 
anaesthetised briefly whilst 6-OHDA (12 μg in 2.5 μl of 0.2% ascorbic acid in 0.9% 
saline) was injected at a rate of 1.25 μl min-1 into the SNpc (2 mm below the guide 
cannula) as previously described in section 3.3.2.4. Animals were placed in cages on 
thermostatically heated mats until fully conscious.  
 
5.3.1.5 Behavioural assessment  
 
The extent of motor impairment following a unilateral lesion to the SNpc was 
assessed at intervals using three behavioural tests. Animal behaviour was assessed 
using the adjusted steps test on day 3 and 6 post-lesion, cylinder test on day 5 post-
lesioning, (both tests also required a baseline assessment one day prior to lesioning) 
and amphetamine induced rotations on day 7 post-lesion. Full details of these tests are 
given earlier in section 3.3.2.5. 
 
5.3.1.6 Data analysis for behavioural tests 
 
Only behavioural data from animals showing correct cannula placement were 
included for data analysis presented in these studies. All behavioural analyses were 
assessed in a similar manner to those described in section 3.3.2.6. Briefly, in the 
adjusted stepping test, use of the contralateral and ipsilateral paw in both forehand 
and backhand directions post lesion were expressed as a % of pre-lesion use. 
Adjusted stepping scores between treatment groups were then compared using a 2-
way ANOVA with Dunnett’s post-hoc test at both 3 and 6 days post-lesion. Use of 
the contralateral and ipsilateral paw in the cylinder test, expressed as a % of total 
reaches, was also compared pre and post lesion between different treatment groups 
using a 2-way ANOVA with Bonferroni’s post-hoc test. Finally, the number of 
amphetamine-induced rotations was plotted as both time course (5 min intervals) or 
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total rotations between 15-45 min and compared between treatment groups using a 2 
or 1-way ANOVA respectively with a Bonferroni’s post-hoc test. In all cases, data 
are expressed as mean ± s.e.m. where P<0.05 was taken to be significant, with all 
statistical analysis performed using GraphPad Prism version 5. 
 
5.3.1.7 Immunohistochemical and HPLC protocols 
 
On the final day of dosing (day 8), animals were killed by CO2 asphyxiation, the 
brains removed and segmented into rostral (striatum) and caudal (SN) segments. The 
striata from these animals were immediately dissected from the rostral segment and 
snap frozen on card-ice before storing at -80
o
C until further processing for HPLC 
measurement of dopamine levels. The SN segment on the other hand, was placed in 
4% formalin for a period of at least 2 days to ensure fixation before processing for 
immunohistochemistry. 
  
TH immunohistochemistry in the SNpc was performed exactly as described in section 
3.3.2.7. Ionised calcium binding adaptor molecule 1 (IBA-1) and glial fibrillary acidic 
protein (GFAP) immunocytochemistry in the SNpc were performed exactly as 
described in section 4.3.1.7 Staining results in the SN were viewed on a Zeiss 
apotome microscope and recorded using Axiovision LE software (Carl Zeiss Ltd., 
UK).  
 
Dopamine content of frozen striata was assessed using HPLC, exactly as described in 
section 3.3.2.9.  
 
5.3.1.8 Image and data analysis for immunohistochemistry and HPLC studies  
 
For TH immunohistochemistry in the SNpc, the average number of TH-positive cells 
in three adjacent sections for each animal across the three rostrocaudal levels (-4.8, -
5.3, -5.8mm AP from bregma) were obtained as previously described in section 
3.3.2.8, and the mean of these values taken per treatment group. Statistical 
comparisons were made between drug and vehicle-treated animals of mean TH-
positive cell counts in the 6-OHDA lesioned side, expressed as % of the contralateral, 
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intact hemisphere, using a 1-way ANOVA with Dunnett’s post-hoc test. For IBA-1 
and GFAP staining in the SN, the average density or number of GFAP-positive cells 
between the contralateral and intact hemispheres in three adjacent sections at a central 
region of the SNpc (-5.3mm AP from bregma) were obtained, and the mean of these 
values taken per treatment group. Statistical comparisons of mean IBA-1 density 
measures or GFAP-positive cell counts in the 6-OHDA lesioned hemisphere, 
expressed as a % of the contralateral, intact hemisphere were made between drug and 
vehicle-treated animals using a 1-way ANOVA with Dunnett’s post-hoc test. For 
HPLC analyses, dopamine content of striatal samples were converted from peak areas 
of the chromatogram using a calibration curve of pure reference standards and 
expressed as ng.g
-1
 protein. A 1-way ANOVA with Dunnett’s post-hoc test was used 
to compare dopamine content of the 6-OHDA lesioned side, expressed as a % of the 
contralateral intact side between treatment groups. In all cases, data are expressed as 
mean ± standard error of the mean (s.e.m.), where n represents the number of animals 
in each experimental group. Statistical analyses were performed using GraphPad 
Prism (version 5.0) and P<0.05 was taken to indicate significance. 
 
5.3.1.9 Materials and suppliers 
 

















5.4.1 Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist, AMN082, in unilaterally 6-OHDA-lesioned rats 
 
5.4.1.1 Effects of sub-chronic AMN082 infusion on tyrosine hydroxylase positive 
cells in the substantia nigra pars compacta 
 
The number of TH-positive cells in nigral sections from animals treated supranigrally 
with sub-chronic AMN082 (0.5-100nmol) and those treated with vehicle (10% 
DMSO in PBS) are quantified in figure 5.1A. In the SNpc, the mean sum of TH-
positive cells in triplicate sections obtained across three rostrocaudal levels declined 
from 317.6 ± 22.8 in the intact hemisphere to 66.0 ± 15.1 in the lesioned hemisphere 
of vehicle-treated 6-OHDA lesioned animals, (n=8). This equated to a deficit ~ 79% 
which was markedly smaller than previous studies highlighting the variability in 
lesion size in response to 6-OHDA. Supranigral treatment with AMN082 dose-
dependently protected against TH-positive cell loss whereby maximal and significant 
protection was reached with a 100nmol dose of AMN082. The number of TH-
positive cells remaining in the lesioned hemisphere following 100nmol AMN082 
treatment (n=8), was 150.3 ± 9.3 equivalent to 46 ± 3.4% of the intact hemisphere, in 
contrast to 21.5 ± 4.2% remaining in vehicle-treated animals (P< 0.01; one-way 
ANOVA with Bonferroni’s post- hoc test).  
 
Representative nigral sections demonstrating immunoreactive TH-positive cells in the 
6-OHDA lesioned animals treated with sub-chronic AMN082 (0.5-100nmol) are 
shown in figure 5.1B. The photomicrographs demonstrate supranigral infusion of 
AMN082 (100nmol) provides noticeable preservation of TH-positive cells in the 
lesioned hemisphere compared to vehicle-treated animals suggesting protection of 






Figure 5.1 Effects of sub-chronic supranigral infusion of the selective mGlu7 receptor 
allosteric agonist AMN082, on tyrosine hydroxylase-positive cell counts in nigral 
sections of unilaterally 6-OHDA lesioned rats. 
 
                                
Figure 5.1 (A) The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol in 4µl) or 
vehicle (4µl 10% DMSO in PBS) on the 6-OHDA induced loss of TH-positive cells in the SNpc on the 
lesioned side expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for 
vehicle, 0.5, 10 and 100nmol AMN082, n=7 for 1nmol AMN082). ** (P < 0.01) indicates a significant 
difference compared to vehicle treated animals. ## (P<0.01) indicates significant difference compared 
to AMN082 (0.5nmol) treated animals (1-way ANOVA with Bonferroni’s post-hoc test). F = 4.986; df 
= 4,34. (B) Representative photomicrographs showing the levels of TH immunoreactivity in nigral 
sections from 6-OHDA-lesioned animals following sub-chronic AMN082 treatment. Arrow indicates 
SNpc. Lesion side on the right; scale bar: 200µm. 























































5.4.1.2 Effects of sub-chronic AMN082 infusion on dopamine content in the 
striatum 
 
Using HPLC, assessment of striatal dopamine content was shown to be preserved in 
the lesioned striatum of animals treated with AMN082.  In vehicle-treated 6-OHDA 
lesioned animals, striatal dopamine content fell from 18427 ± 789 ng g
-1
 in the intact 
hemisphere to 3620 ± 899 ng g
-1
 in the lesioned hemisphere, which represented a 
decline in dopamine to 19.4 ± 4.7% (n=8) of the intact hemisphere (figure 5.2). As 
with assessment of nigral TH, AMN082 treatment produced a dose-dependent 
preservation of striatal dopamine content, also reaching maximal effect with 100nmol 
AMN082 (P< 0.05 versus vehicle treatment; 1-way ANOVA with Dunnett’s post-hoc 
test), where dopamine content in the lesioned hemisphere remained at 34.1 ± 3.1% of 
the intact hemisphere. At the lowest dose tested, AMN082 appeared to cause a 





















Figure 5.2: Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist, AMN082, on dopamine content in the striatum of 




Figure 5.2. The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol in 4µl) or 
vehicle (4µl 10% DMSO in PBS) on the 6-OHDA induced loss of dopamine content in the lesioned 
striatum expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle, 
0.5, 10 and 100nmol AMN082, n=7 for 1nmol AMN082). * (P<0.05) indicates a significant difference 
compared to vehicle treated animals (1-way ANOVA with Dunnett’s post-hoc test). F = 6.950; df = 
4,34. # (P<0.05) and ## (P<0.01) indicate significant difference compared to 0.5nmol AMN082 treated 






























































5.4.1.3 Effects of sub-chronic AMN082 infusion on levels of calcium binding 
adaptor molecule 1 in the substantia nigra pars compacta 
 
As previously shown in Chapter 3, analysis of IBA-1, revealed a unilateral injection 
of 6-OHDA markedly increased microglial activation in the lesioned SNpc compared 
to the intact non-lesioned hemisphere (figure 5.3A). Following a unilateral 6-OHDA 
lesion, the mean total IBA-1 density at a central region of the SNpc increased to ~ 
217% of the intact hemisphere in vehicle-treated animals (n=8). However, following 
treatment with AMN082, a graded decline in IBA-1 activation was observed with 
increasing doses of AMN082. Maximal effect was achieved with 100nmol AMN082 
(n=8) whereby the increase in IBA-1 density was significantly reduced compared to 
vehicle treated animals, equating to a 166% increase in IBA-1 immunoreactivity with 
respect to the intact hemisphere (p<0.01; one-way ANOVA with Bonferroni’s post-
hoc test). 
 
Representative nigral sections showing IBA-1 immunoreactivity in the 6-OHDA 
lesioned animals treated with sub-chronic AMN082 (0.5-100nmol) are shown in 
figure 5.3B. Qualitative visual inspection revealed IBA-1-positive cells in the intact 
hemisphere displayed morphology typical of resting or quiescent cells. By contrast in 
the lesioned hemisphere a marked increase in IBA-1-positve cells was observed, with 
a switch to ramified and amoeboid morphology. The photomicrographs demonstrate 
supranigral infusion of AMN082 (100nmol) clearly reduced levels of IBA-1 
compared to the vehicle group in tune with the notion of a decreased inflammatory 











Figure 5.3: Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist, AMN082, on ionised calcium binding adaptor molecule 1 
immunoreactivity in striatal sections of unilaterally 6-OHDA lesioned rats.  
 
            
Figure 5.3 (A) The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol in 4µl) or 
vehicle (4µl of 10% DMSO in PBS) on the 6-OHDA induced elevation of IBA-1 density in the 
lesioned SNpc expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for 
vehicle, 0.5, 10 and 100nmol AMN082, n=7 for 1nmol AMN082). * (P <0.05) and ** (P <0.01) 
indicate significant differences compared to vehicle treated animals (1-way ANOVA with Bonferroni’s 
post-hoc test). F = 6.301; df = 4,34. (B) Representative photomicrographs demonstrating IBA-1 
immunoreactivity in nigral sections from 6-OHDA-lesioned animals following sub-chronic AMN082 
treatment. Arrows indicate boundary of SNpc. Lesion side on the right; scale bar: 200µm. 















































5.4.1.4 Effects of sub-chronic AMN082 infusion on levels of glial fibrillary acidic 
protein in the substantia nigra pars compacta 
 
A marked increase in the astrocytic marker, GFAP, was also observed in the lesioned 
SNpc compared to the intact non-lesioned hemisphere in vehicle-treated animals 
(figure 5.4A). Following a unilateral 6-OHDA lesion, the mean total number of 
GFAP- positive cells increased to 418% of the intact hemisphere in vehicle-treated 
animals (n=8). Interestingly in comparison to findings with IBA-1, treatment with 
AMN082, at each dose tested, revealed no decline in GFAP immunoreactivity in the 
lesioned SNpc in comparison to vehicle-treated animals. Indeed, following AMN082 
(100nmol) a 421% increase in GFAP-positive cells was observed with respect to the 
intact hemisphere attributing to a comparable level obtained in vehicle-treated 
animals. 
 
Representative nigral sections demonstrating immunoreactivity to GFAP-positive 
cells in the 6-OHDA lesioned animals treated with sub-chronic AMN082 (0.5-
100nmol) are shown in figure 5.4B. Qualitative analysis revealed GFAP-positive 
cells in the intact hemisphere displayed morphology typical of resting or quiescent 
cells. By contrast in the lesioned hemisphere a marked increase in GFAP-positive 
cells displaying thickened star-shaped morphology was observed. The 
photomicrographs confirm findings noted above that animals supranigrally infused 
with AMN082 (100nmol) demonstrated a comparable level of GFAP activation in the 











Figure 5.4: Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist AMN082, on glial fibrillary acidic protein cell counts in 
nigral sections of unilaterally 6-OHDA lesioned rats. 
 
           
Figure 5.4. (A) The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol in 4µl) or 
vehicle (4µl 10% DMSO in PBS) on GFAP-positive cell number in the SNpc following a 6-OHDA 
lesion expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for vehicle, 
0.5, 10 and 100nmol AMN082, n=7 for 1nmol AMN082). F = 0.2722; df = 4,34. (B) Representative 
photomicrographs demonstrating GFAP immunoreactivity in nigral sections from 6-OHDA-lesioned 
animals following sub-chronic AMN082 treatment. Arrows indicate boundary of SNpc. Lesion side on 
the right; scale bar: 200µm. 
























































The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol) on 
spontaneous motor function following a unilateral 6-OHDA lesion of the SNpc in rats 
were assessed using the cylinder test on day 5 post lesion.  
 
As expected in vehicle-treated animals, there was a significant decrease in use of the 
contralateral paw from 29.6 ± 2.0% pre-lesion to 14.7 ± 2.6% post-lesion confirming 
that a unilateral 6-OHDA lesion induced a reduction of approximately 50% in 
contralateral paw use (figure 5.5A). Interestingly, 100 nmol AMN082, failed to 
preserve use of contralateral paw despite the observed preservation in post-mortem 
indices, demonstrating only a marginal improvement in post-lesion scores with 
respect to vehicle-treated animals. However, following treatment with both 1 and 
10nmol AMN082 use of the contralateral paw was considerably preserved, failing to 
show a significant decline in use post-lesion. For example in 10nmol AMN082 
treated animals, contralateral paw use equated to 21.2 ± 2.4% of total paw use post-
lesion in comparison to 27.1 ± 3.5% pre-lesion equating to 78% preservation in 
contralateral paw use post-lesion following AMN082 treatment. 
 
As previously described, a marked increase in ipsilateral paw use was observed in 
vehicle-treated animals following a 6-OHDA lesion in tune with the significant 
decrease in contralateral paw use. For example in vehicle-treated animals, ipsilateral 
paw use post lesion increased by ~73% with respect to pre-lesion score, 
compensating for an impaired contralateral paw. This effect was also apparent 
following treatment with AMN082, albeit to a lesser extent to that described in 
vehicle-treated animals (~62% increase in 10nmol AMN082 treatment group, figure 
5.5B). Taken together, these findings suggest AMN082 can mediate some 
preservation of contralateral paw use following a 6-OHDA lesion, however the 
comparable increase in ipsilateral paw use post-lesion would suggest a degree of 
asymmetry remains in these treated animals.   
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Figure 5.5: Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist AMN082, on motor function assessed using the cylinder 
test in unilaterally 6-OHDA lesioned rats.   
 
Figure 5.5. The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol in 4µl) or 
vehicle (4µl 10% DMSO in PBS) on contralateral (A) and  ipsilateral (B) paw use expressed as a 
percentage of total paw use assessed using the cylinder test at 5 days post a 6-OHDA lesion. For all, 
values represent mean ± s.e.m. (n=8 for vehicle, 0.5, 10 and 100nmol AMN082, n=7 for 1nmol 
AMN082) * (P <0.05), ** (P <0.01) and *** (P < 0.001) indicates significant differences compared to 
pre-lesion score (2-way ANOVA with Bonferroni’s post-hoc test). In (A) pre/post lesion factor, F = 
35.59, df = 1,68 and for treatment factor, F = 1.805, df = 4,68. In (B) pre/post lesion factor, F = 354.4, 






















































































The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol) on 
adjusted steps, 3 and 6 days following unilateral 6-OHDA lesioning in rats, are shown 
as a percentage of their pre-lesion scores in figure 5.6. As predicted the contralateral 
paw demonstrated a marked reduction in adjusted steps in the forehand direction, 
from 100% pre-lesion to 56.2 ± 5.7% at 6 days post-lesion in vehicle-treated animals, 
indicating unilateral 6-OHDA lesioning reduced the number of adjusted steps in this 
direction (figure 5.6A). Interestingly in contrast to the cylinder test, infusion of 
AMN082 failed to show any improvements in contralateral paw use with each of the 
doses tested. 
 
In the backhand direction, there was also a marked reduction in contralateral paw use 
in vehicle-treated animals. This amounted to a decrease in adjusted steps from 100% 
pre-lesion to 42.3 ± 4.3% at 6 days post-lesion confirming unilateral 6-OHDA-
lesioning also reduced the number of adjusted steps in the backhand direction (figure 
5.6B). However, similar to that observed in the forehand direction, no significant 
improvements in adjusted steps in any of the AMN082 treatment groups was 
observed.  
 
As expected the ipsilateral paw (non-lesioned) in both the forehand and backhand 
direction showed no significant deficit in adjusted steps 3 or 6 days post-lesion in 
vehicle and AMN082 treated animals (figure 5.6C and D). Significant reductions in 
ipsilateral paw use were seen in AMN082 (0.5nmol) treated animals which may 
suggest animals in this treatment group were less responsive compared to vehicle-
treated animals. Collectively these findings demonstrate supranigral sub-chronic 
AMN082 (0.5-100nmol) treatment does not significantly alter the number of adjusted 
steps in the contralateral paw, indicating that AMN082 does not improve motor 







Figure 5.6: Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist AMN082, on motor function assessed using the adjusted 




Figure 5.6. The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol in 4µl) or 
vehicle (4µl of 10% DMSO in PBS) on contralateral and ipsilateral paw use in the forehand and 
backhand direction (A-D) assessed using the adjusted steps test at 3 and 6 days post a 6-OHDA lesion 
expressed as a percentage of pre-lesion score. Values represent mean ± s.e.m. (n=8 for vehicle, 0.5, 10 
and 100nmol AMN082, n=7 for 1nmol AMN082). *(P <0.05), ** (P <0.01) and *** (P <0.001) 
indicates significant differences compared to vehicle treated animals (2-way ANOVA with 
Bonferroni’s post-hoc test). In (A) for treatment factor, F = 1.150, df = 4,68 and for days post lesion 
factor, F = 0.5041, df = 1,68. In (B) treatment factor, F = 1.611, df = 4,68 and for days post lesion, F = 
0.5662, df = 1,68. In (C) treatment factor, F = 3.110, df = 4, 68 and for days post lesion, F = 0.1078, df 









































































































































Amphetamine-induced ipsiversive rotations in unilaterally 6-OHDA lesioned rats 
treated with sub-chronic AMN082 or vehicle are shown in figure 5.7. Both graphs A 
and B show the same vehicle group split with varying doses of AMN082 for clarity. 
Analysis of time-course in vehicle treated animals revealed amphetamine (5mg.kg
-1
) 
induced considerable ipsiversive rotations throughout a 60 min time period. Animals 
treated with 0.5nmol AMN082 demonstrated an unexpected initial increase in 
ipsiversive rotations (10 min post-injection, P<0.001) although no further significant 
effects with respect to vehicle-treated animals were reported. Following treatment 
with 1nmol AMN082, small decreases in ipsiversive rotations were observed, 
reaching significance at 10 min post injection of amphetamine (P <0.01, 2-way 
ANOVA with Bonferroni’s post-hoc test, figure 5.7A). Furthermore, figure 5.7B 
demonstrated 10 and 100nmol doses of AMN082 induced a moderate reduction in 
ipsiversive rotations particularly within the first 20 min following injection of 
amphetamine, with both doses reaching a  significant reduction in rotations compared 
to vehicle-treated animals at 15 min post amphetamine (P <0.01, 2-way ANOVA 
with Bonferroni’s post-hoc test).   
 
In figure 5.8, the mean total ipsiversive rotations were quantified over a 30 min 
period (15-45 min). The number of ipsiversive rotations by amphetamine (5mg.kg
-1
) 
in vehicle treated animals was 414 ± 46 rotations in 30 min
-1
. AMN082 dose 
dependently decreased amphetamine-induced ipsiversive rotations reaching maximal 
effect with 100nmol AMN082. The total mean number of rotations equated to 220 ± 
45, demonstrating a 47% reduction compared to vehicle treated animals, however this 
result was not significant (P>0.05, 1-way ANOVA with Dunnett’s post-hoc test). 
Nevertheless, this marked reduction suggests AMN082 treatment to an extent acts to 







Figure 5.7: Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist AMN082, on motor function assessed following 
amphetamine-induced rotations in unilaterally 6-OHDA lesioned rats.   
 
Figure 5.7. The effects of sub-chronic supranigral infusion of AMN082 (0.5-100nmol in 4µl) or 
vehicle (4µl 10% DMSO in PBS) on amphetamine induced rotations in unilaterally 6-OHDA lesioned 
rats. (A) Time course of ipsiversive rotations induced by amphetamine (5mg.kg-1) in vehicle and 
AMN082 (0.5, 1nmol) treated animals. (B) Time course of ipsiversive rotations induced by 
amphetamine (5mg.kg-1) in vehicle and AMN082 (10, 100nmol) treated animals. Values represent 
mean ± s.e.m. (n=8 for vehicle, 0.5, 10 and 100nmol AMN082, n=7 for 1nmol AMN082). (A) ** (P 
<0.01; 0.5nmol AMN082) and ### (P <0.001; 1nmol AMN082) indicates significant difference 
compared to vehicle treated animals (2-way ANOVA with Bonferroni’s post-hoc test). (B) ## (P 
<0.01; 10nmol AMN082) and ** (P <0.01; 100nmol AMN082) indicates significant difference 
compared to vehicle treated animals (2-way ANOVA with Bonferroni’s post-hoc test). For treatment 
factor F = 6.552; df = 4,510 and for time F = 20.26; df = 14, 510.  





















































































Figure 5.8: Effects of sub-chronic supranigral infusion of the selective mGlu7 
receptor allosteric agonist AMN082, on motor function assessed following 





Figure 5.8. Total ipsiversive rotations induced by amphetamine in 30 min-1 (15-45 min) in vehicle and 
AMN082 treated animals. Values represent mean ± s.e.m. (n=8 for vehicle, 0.5, 10 and 100nmol 




















































5.4.2 Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist, DCPG, in unilaterally 6-OHDA-lesioned rats 
 
5.4.2.1 Effects of sub-chronic DCPG infusion on tyrosine hydroxylase positive 
cells in the substantia nigra pars compacta 
 
In the SNpc, the mean sum of TH-positive cells in triplicate sections obtained across 
three rostrocaudal levels declined from 257.6 ± 17.2 in the intact hemisphere to 24.6 
± 4.2 in the lesioned hemisphere of vehicle-treated 6-OHDA lesioned animals (n=8), 
demonstrating a full lesion with a deficit ~ 90%.  Supranigral treatment with DCPG 
(1-30nmol) failed to significantly protect TH-positive cells at each of the doses tested 
compared to vehicle treated animals. For example, the number of TH-positive cells 
remaining in the lesioned hemisphere following DCPG treatment (30nmol, n=8), was 
40.4 ± 7.1 equivalent to 16.6 ± 9.3% of the intact hemisphere in contrast to 9.6 ± 
2.5% remaining in the vehicle-treated animals (figure 5.9A).  
 
Representative nigral sections demonstrating immunoreactive TH-positive cells in the 
6-OHDA lesioned animals treated with sub-chronic DCPG (1-30nmol) are shown in 
figure 5.9B. The photomicrographs demonstrate following supranigral infusion of 
30nmol DCPG a small number of TH-positive cells were present in the lesioned 
SNpc suggesting minor preservation in these treated animals. At the other doses 
tested, no noticeable preservation of TH-positive cells in the lesioned hemisphere was 











Figure 5.9: Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist DCPG, on tyrosine hydroxylase-positive cell counts in nigral 
sections of unilaterally 6-OHDA lesioned rats. 
 
 
               
Figure 5.9. (A) The effects of sub-chronic supranigral infusion of DCPG (1-30nmol in 4µl) or vehicle 
(4µl 1x PBS) on the 6-OHDA induced loss of TH-positive cells in the SNpc on the lesioned side 
expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for all treatment 
groups). F = 0.3554; df = 3,28.  (B) Representative photomicrographs showing the levels of TH 
immunoreactivity in nigral sections from 6-OHDA-lesioned animals following sub-chronic DCPG 
treatment. Arrow indicates SNpc. Lesion side on the right; scale bar: 200µm. 





















































5.4.2.2 Effects of sub-chronic DCPG infusion on dopamine content in the 
striatum 
 
In vehicle-treated 6-OHDA lesioned animals, striatal dopamine content fell from 
16097 ± 1099 ng g
-1
 in the intact hemisphere to 3524 ± 748 ng g
-1
 in the lesioned 
hemisphere, which represented a decline in dopamine to 21.1 ± 3.8% (n=8) of the 
intact hemisphere (figure 5.10). DCPG treatment at the lower doses tested (1-10nmol) 
failed to significantly preserve striatal dopamine content with respect to vehicle-
treated animals. However, a more profound neuroprotective effect was observed with 
a high dose of DCPG (30nmol, P<0.05 versus vehicle treatment; 1-way ANOVA with 
Dunnett’s post-hoc test), where dopamine content in the lesioned hemisphere 





















Figure 5.10: Effects of sub-chronic supranigral infusion of the selective mGlu8 






Figure 5.10. The effects of sub-chronic supranigral infusion of DCPG (1-30nmol in 4µl) or vehicle 
(4µl PBS) on the 6-OHDA induced loss of dopamine content in the striatum in the lesioned side 
expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for all treatment 
groups). * (P<0.05) indicates a significant difference compared to vehicle treated animals (1-way 

























































5.4.2.3 Effects of sub-chronic DCPG infusion on levels of calcium binding 
adaptor molecule 1 in the substantia nigra pars compacta 
 
Analysis of IBA-1, revealed a unilateral injection of 6-OHDA markedly increased 
microglial activation in the lesioned SNpc compared to the intact non-lesioned 
hemisphere (figure 5.11A). Following a unilateral 6-OHDA lesion, the mean total 
IBA-1 density at a central region of the SNpc increased to ~ 264% of the intact 
hemisphere in vehicle-treated animals (n=8). However, following DCPG treatment 
this increase in IBA-1 density was significantly reduced compared to vehicle-treated 
animals. Maximal reduction was achieved with a 10nmol dose of DCPG where only a 
170% increase in IBA-1 immunoreactivity was observed with respect to the intact 
hemisphere (p<0.05; one-way ANOVA with Dunnett’s post-hoc test). 
 
 
Representative nigral sections showing IBA-1 immunoreactivity in the 6-OHDA 
lesioned animals treated with sub-chronic DCPG (10nmol) or vehicle are shown in 
figure 5.11B. Qualitative analysis revealed IBA-1-positive cells in the intact 
hemisphere displayed morphology typical of resting or quiescent cells. By contrast in 
the lesioned hemisphere a marked increase in IBA-1-positve cells was observed, with 
a switch to amoeboid morphology. The photomicrographs demonstrate supranigral 
infusion of DCPG (10nmol) markedly reduced levels of IBA-1 compared to vehicle-














Figure 5.11: Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist, DCPG, on ionised calcium binding adaptor molecule-1 
immunoreactivity in striatal sections of unilaterally 6-OHDA lesioned rats.  
 
                 
Figure 5.11. (A) The effects of sub-chronic supranigral infusion of DCPG (1-30nmol in 4µl) or 
vehicle (4µl 1x PBS) on the 6-OHDA induced elevation of IBA-1-density in the SNpc on the lesioned 
side expressed as a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for all treatment 
groups). * (P <0.05) indicates significant difference compared to vehicle treated animals (1-way 
ANOVA with Dunnett’s post-hoc test) F = 3.042; df = 3,28. (B) Representative photomicrographs 
demonstrating IBA-1 immunoreactivity in nigral sections from 6-OHDA-lesioned animals following 
sub-chronic vehicle and DCPG (10nmol) treatment. Arrows indicate boundary of SNpc. Lesion side on 
the right; scale bar: 200µm. 
















































5.4.2.4 Effects of sub-chronic DCPG infusion on levels of glial fibrillary acidic 
protein in the substantia nigra pars compacta 
 
A marked increase in the astrocytic marker GFAP was also observed in the lesioned 
SNpc compared to the intact non-lesioned hemisphere in vehicle-treated animals 
(figure 5.12A). Following a unilateral 6-OHDA lesion, the mean total number of 
GFAP- positive cells increased to 447% of the intact hemisphere in vehicle-treated 
animals (n=8). Following DCPG treatment (1-30nmol), no significant difference in 
GFAP immunoreactivity in the lesioned SNpc was observed on comparison to 
vehicle-treated animals. However, a marked decrease in GFAP-positive cells was 
seen following 10nmol DCPG equating to a 322% increase in GFAP-positive cell 
activation with respect to the intact hemisphere although this effect was not 
significant (p > 0.05; one-way ANOVA with Dunnett’s post-hoc test). 
 
Representative nigral sections demonstrating immunoreactivity to GFAP-positive 
cells in 6-OHDA lesioned animals treated with sub-chronic DCPG (10nmol) or 
vehicle are shown in figure 5.12B. Qualitative analysis revealed GFAP-positive cells 
in the intact hemisphere displayed morphology typical of resting or quiescent cells. 
By contrast in the lesioned hemisphere a marked increase in GFAP-positive cells 
displaying thickened star-shaped morphology was observed. The photomicrographs 
demonstrate supranigral infusion of DCPG (10nmol) provided a clear reduction in 
GFAP activation compared to vehicle-treated animals consistent with the reduced 











Figure 5.12 Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist DCPG, on glial fibrillary acidic protein cell counts in nigral sections 
of unilaterally 6-OHDA lesioned rats. 
 
            
Figure 5.12. (A) The effects of sub-chronic supranigral infusion of DCPG (1-30nmol in 4µl) or 
vehicle (4µl PBS) on GFAP positive cell number in the SNpc following a 6-OHDA lesion expressed as 
a percentage of the intact side. Values represent mean ± s.e.m. (n=8 for all treatment groups) F = 
0.8098; df = 3,28. (B) Representative photomicrographs demonstrating GFAP immunoreactivity in 
nigral sections from 6-OHDA-lesioned animals following sub-chronic DCPG (10nmol) treatment or 
vehicle. Arrows indicate boundary of SNpc. Lesion side on the right; scale bar: 200µm. 


























































The effects of sub-chronic supranigral infusion of DCPG (1-30nmol) on spontaneous 
motor function following a unilateral 6-OHDA lesion of the SNpc in rats were 
assessed using the cylinder test on day 5 post lesion.  
 
As expected in vehicle treated animals, there was a significant decrease in use of the 
contralateral paw from 30.4 ± 2.2% pre-lesion to 9.6 ± 4.2% post-lesion confirming 
that a unilateral 6-OHDA lesion induced a reduction of approximately 68% in 
contralateral paw use (figure 5.13A). In animals treated with DCPG (1-30nmol), 
assessment of post-lesion scores alone revealed use of contralateral paw was not 
significantly preserved at any of the doses tested, demonstrating only a marginal 
improvement with a high dose of DCPG (30nmol) compared to vehicle-treated 
animals. However 1 and 30nmol DCPG did not demonstrate a significant decline in 
contralateral paw use with respect to pre-lesion scores (2-way ANOVA with 
Bonferroni’s post-hoc test) suggesting a degree of preservation in these animals.  
 
As predicted, a marked increase in ipsilateral paw use was observed in vehicle treated 
animals following a 6-OHDA lesion in tune with the significant decrease in 
contralateral paw use. For example in vehicle treated animals, ipsilateral paw use 
post-lesion increased by ~81% with respect to pre-lesion score, compensating for an 
impaired contralateral paw. This effect was also apparent following treatment with 
DCPG in which a ~75% increase in ipsilateral paw use with respect to pre-lesion 
score was obtained (30nmol DCPG, figure 5.13B). These findings taken together with 
contralateral paw use confirms DCPG provides only a modest improvement in motor 







Figure 5.13: Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist DCPG, on motor function assessed using the cylinder test in 
unilaterally 6-OHDA lesioned rats.   
 
Figure 5.13. The effects of sub-chronic supranigral infusion of DCPG (1-30nmol in 4 µl) or vehicle 
(4µl PBS) on contralateral (A) and  ipsilateral (B) paw use expressed as a percentage of total paw use 
assessed using the cylinder test at 5 days post a 6-OHDA lesion. For all, values represent mean ± 
s.e.m. (n=8 for all treatment groups) * (P <0.05) and *** (P < 0.001) indicates significant differences 
compared to pre-lesion score (2-way ANOVA with Bonferroni’s post-hoc test). In (A) pre/post lesion 
factor, F = 28.48, df = 1,56 and for treatment factor, F = 0.6486, df = 3,56. In (B) pre/post lesion 



















































































The effects of sub-chronic supranigral infusion of DCPG (1-30nmol) on adjusted 
steps, 3 and 6 days following unilateral 6-OHDA lesioning in rats, are shown as a 
percentage of their pre-lesion scores in figure 5.14. As predicted the contralateral paw 
(lesioned) demonstrated a marked reduction in adjusted steps in the forehand 
direction, from 100% pre-lesion to 36.7 ± 2.6% at 6 days post-lesion in the vehicle 
treated group, indicating unilateral 6-OHDA lesioning reduced the number of 
adjusted steps in this direction (figure 5.14A). Infusion of DCPG (1-10nmol) did not 
significantly preserve contralateral paw use at day 6 post-lesion. A small but 
significant preservation of contralateral paw use was observed at 3 days post-lesion 
following 1nmol DCPG (P<0.05 with respect to vehicle-treated animals), however 
this effect was lost at 6 days post-lesion. A degree of preservation of contralateral 
paw use was observed following 30nmol DCPG at 6 days post-lesion, equating to 
47.8 ± 6.2% of pre-lesion score, however this effect was not significant with respect 
to vehicle-treated animals.  
 
In the backhand direction, there was also a marked reduction in contralateral paw use 
in vehicle-treated animals. This amounted to a decrease in adjusted steps from 100% 
pre-lesion to 45.0 ± 6.3% at 6 days post-lesion confirming unilateral 6-OHDA-
lesioning also reduced the number of adjusted steps in the backhand direction (figure 
5.14B). Following DCPG treatment (1-30nmol) no significant preservation in use of 
the contralateral paw in the backhand direction was observed in any of the DCPG 
treated groups compared to vehicle-treated animals. As expected the ipsilateral paw 
(non-lesioned) in both the forehand and backhand direction showed no significant 
deficit in adjusted steps 3 or 6 days post-lesion in vehicle-treated animals (figure 
5.14C and D).  
 
Taken together, these findings demonstrate supranigral sub-chronic DCPG (1-
30nmol) treatment does not significantly preserve contralateral paw use indicating 
DCPG, does not reduce the motor asymmetry induced by a unilateral 6-OHDA lesion 




Figure 5.14: Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist DCPG, on motor function assessed using the adjusted stepping test in 




Figure 5.14. The effects of sub-chronic supranigral infusion of DCPG (1-30nmol in 4µl) or vehicle 
(4µl PBS) on contralateral and ipsilateral paw use in the forehand and backhand direction (A-D) 
assessed using the adjusted steps test at 3 and 6 days post a 6-OHDA lesion expressed as a percentage 
of pre-lesion score. Values represent mean ± s.e.m. (n=8 for all treatment groups). * (P <0.05) 
indicates significant differences compared to vehicle treated animals (2-way ANOVA with 
Bonferroni’s post-hoc test). In (A) for treatment factor, F = 2.327, df = 3,56 and for days post lesion 
factor, F = 0.5449, df = 1,56. In (B) treatment factor, F = 0.2001, df = 3,56 and for days post lesion, F 
= 2.285, df = 1,56. In (C) treatment factor, F = 1.579, df = 3, 56 and for days post lesion, F = 3.802, df 




































































































































Amphetamine-induced ipsiversive rotations in unilaterally 6-OHDA lesioned rats 
treated with sub-chronic DCPG or vehicle are shown in figure 5.15. Both graphs A 
and B show the same vehicle group split with varying doses of DCPG for clarity. 
Analysis of time-course in vehicle-treated animals revealed amphetamine (5mg.kg
-1
) 
induced considerable ipsiversive rotations throughout a 60 min time period. However 
in animals treated with DCPG (1-10nmol) no significant difference between DCPG 
and vehicle-treated animals was observed from 0-60 min (figure 5.15A).  A marked 
reduction in ipsiversive rotations between 15 and 20 min post injection of 
amphetamine was observed following 30nmol DCPG (figure 5.15B), however this 
effect was not significant when compared to vehicle-treated animals (P >0.05; 2-way 
ANOVA with Bonferroni’s post-hoc test).   
 
In figure 5.16, the mean total ipsiversive rotations were quantified over a 30 min 
period (15-45 min). The number of ipsiversive rotations by amphetamine (5mg.kg
-1
) 
in vehicle-treated animals was 334 ± 37 rotations in 30 min
-1
. A dose dependent 
reduction in ipsiversive rotations was observed following treatment with DCPG 
treatment reaching maximal effect with 30nmol DCPG. At this dose the mean total 
number of rotations equated to 240 ± 64, demonstrating a 28% reduction compared to 
vehicle-treated animals, but again this result was not significant (P>0.05, 1-way 
ANOVA with Dunnett’s post-hoc test). This effect may reflect the small degree of 












Figure 5.15: Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist DCPG, on motor function assessed following amphetamine-induced 
rotations in unilaterally 6-OHDA lesioned rats.   
 
Figure 5.15. The effects of sub-chronic supranigral infusion of DCPG (1-30nmol in 4µl) or vehicle 
(4µl 1x PBS) on amphetamine induced rotations in unilaterally 6-OHDA lesioned rats. (A) Time 
course of ipsiversive rotations induced by amphetamine (5mg.kg-1) in vehicle and DCPG (1, 10nmol) 
treated animals. (B) Time course of ipsiversive rotations induced by amphetamine (5mg.kg-1) in 
vehicle and DCPG (30nmol) treated animals. Values represent mean ± s.e.m. (n=8 for all treatment 
groups). For treatment factor F = 0.5506; df = 3,420 and for time F = 9.636; df = 14, 420.  
 
















































































Figure 5.16: Effects of sub-chronic supranigral infusion of the selective mGlu8 
receptor agonist DCPG, on motor function assessed following amphetamine-induced 





Figure 5.16. Total ipsiversive rotations induced by amphetamine in 30 min-1 (15-45 min) in vehicle 
and DCPG treated animals. Values represent mean ± s.e.m. (n=8 for all treatment groups). F = 0.6341; 





















































In this chapter we demonstrate for the first time, using the selective allosteric agonist 
AMN082, that mGlu7 receptor activation mediates neuroprotection and preservation 
of motor function in the 6-OHDA rat model of PD. In addition, the effects of 
AMN082 were complemented by a reduction in an inflammatory marker, suggesting 
a reduced inflammatory response may contribute in part to this protective effect. In 
contrast, activation of mGlu8 receptors using the selective agonist DCPG was less 
promising revealing modest protection in post-mortem indices with little to no 
preservation in motor function. DCPG did, however, reduce indices of microglial 
activation, suggesting it too may confer some degree of anti-inflammatory action. 
 
To investigate the potential of targeting mGlu7 receptors to mediate functional 
neuroprotection, the selective allosteric agonist AMN082 was tested in 6-OHDA- 
lesioned rats. AMN082 administered 1h before and for 7 days post a 6-OHDA lesion 
significantly protected the nigrostriatal tract. This was shown by the preservation of 
TH-positive cells in the SNpc and the reduction in 6-OHDA-induced loss of striatal 
dopamine content, whereby maximal effect was achieved with a 100nmol dose of 
AMN082. In addition these studies revealed that the degree of neuroprotection was 
sufficient to preserve certain motor functions or symmetries that would otherwise be 
lost following a unilateral injection of 6-OHDA. Thus, marked preservation of 
contralateral paw use was shown in the cylinder test following AMN082 treatment in 
addition to a reduction in amphetamine-induced ipsiversive rotations. However, not 
all behavioural tests gave a positive outcome; in the adjusted steps test AMN082 did 
not combat the loss of contralateral paw stepping induced by 6-OHDA. Furthermore, 
there is some degree of mismatch between the effective doses of AMN082. While 
significant preservation of TH-positive cells in the SNpc was only seen at the highest 
dose of 100nmol, striatal dopamine content was significantly preserved at all three 
doses examined. Similarly, efficacy in the cylinder test was noted with 1 and 10nmol 
doses, but not the 100nmol dose which did, conversely provide a significant reduction 
in amphetamine-induced rotations. The reasons behind this mismatch are not clear, 
although the behavioural outcomes generally are well allied with striatal dopamine 
suggesting preservation of dopamine in the terminal regions of the nigrostriatal tract 
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is a more essential requirement for improved motor function than protection at the 
level of the nigra. Furthermore it is not surprising greater preservation was observed 
in the striatum since the toxin was introduced directly into the cell bodies so it may be 
more difficult to protect at the nigral level compared to the terminals.  Indeed, more 
robust protection is often seen in the 6-OHDA lesioned rats at the striatal level, 
reported using AMPA potentiators (Murray et al., 2003) and nicotinic agonists 
(Visanji et al., 2006). Nonetheless, overall, these studies are clearly indicative of a 
protective effect afforded by this mGlu7 allosteric agonist in the 6-OHDA rat model 
of PD. 
 
The neuroprotective effects of AMN082 are certainly consistent with the distribution 
studies described in Chapter 2 which suggested mGlu7 may be ideally situated to 
mediate preservation of the nigrostriatal system demonstrating high intensity staining 
in the dorsal tier of the SNpc as well as in the striatum. Indeed as with mGlu4, mGlu7 
has been found on excitatory (presumed glutamatergic) terminals in the SNpr 
(Kosinski et al., 1999) which receives excitatory inputs from the STN but also the 
pedunculopontine nucleus and frontal cortex (Carter, 1982; Di Loreto et al., 1992; 
Kita & Kitai, 1987). However the presence of mGlu7 mRNA in the STN (Kosinski et 
al., 1999; Messenger et al., 2002) strongly supports their expression on terminals of 
STN efferents which co-excite both segments of the substantia nigra (SNpr and 
SNpc) via the subthalamonigral pathway (Valenti et al., 2005). Although the majority 
of mGlu7 receptors are assumed pre-synaptic in origin, low levels of mGlu7 
immunoreactivity have been found at post-synaptic dendritic sites in both the GP 
(Bradley et al., 1999; Kosinski et al., 1999) and striatum (Kosinski et al., 1999). 
Electrophysiological studies to date however, have found no evidence for a post-
synaptic action of group III mGlu receptors in the GP (Valenti et al., 2003) although 
such an action in the striatum remains to be determined. Therefore at this moment in 
time, it is most likely that the receptors in the SNpc are similarly pre-synaptic 
receptors. 
 
Having demonstrated a neuroprotective effect of AMN082, this raises the question as 
to what potential mechanisms may underlie this effect. Since this is the first study of 
its kind to demonstrate a neuroprotective role for mGlu7 receptors, there is little 
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published evidence to guide us in this respect. However on the basis of previous work 
undertaken in this laboratory, the likely mechanisms include inhibition of glutamate 
release in the SNpc to facilitate protection from glutamate-mediated excitotoxicity. 
Previous studies in our lab have shown that mGlu7 receptors, using AMN082, 
reduces glutamate release from nigral tissue in vitro. When given alongside a sub-
threshold concentration of L-AP4, AMN082 produced a concentration-dependent 
inhibition of release (Broadstock et al., 2011).  Interestingly, when added to SNpr 
tissue prisms alone, AMN082 (0.01 – 100 μM which extended beyond its EC50 of 
0.064µM) failed to modify [3H]-D-aspartate release. Furthermore in a separate study, 
AMN082 was shown to potentiate L-AP4-mediated inhibition of EPSCs in the rat 
basolateral amygdala (Ugolini et al., 2008) suggesting a potentiating rather than 
direct agonist for this agent. However electrophysiological studies confirming these 
effects in the SNpc are awaited to clarify this notion.  
 
Identification of mGlu7 receptors on primary cultures of rat astrocytes, suggests 
additional non-neuronal mechanisms may also have been involved in mediating 
neuroprotection with AMN082 (Yao et al., 2005). As mentioned in the previous 
chapter,  it is thought that following insult with a pathological stimulus such as 6-
OHDA, substantial increases in pro-inflammatory cytokines and cell adhesion 
molecules occur, whereupon activated microglia are recruited to the site of injury and 
cluster around dopaminergic neurones to be phagocytosed (Banati et al., 1998; 
Bronstein et al., 1995). In astrocyte cultures from mGlu4 knock-out mice, L-AP4 
(300 µM) at a concentration known to occupy mGlu7 receptors was shown to reduce 
the production of a pro-inflammatory chemokine, Regulated upon Activation, Normal 
T-cell Expressed, and Secreted (RANTES) (Besong et al., 2002). This suggests that 
activation of glial mGlu7 receptors may well contribute to the regulation of such pro-
inflammatory chemokines in mediating anti-inflammatory actions. Interestingly 
treatment of AMN082 at all the doses tested did not demonstrate any significant 
effect on GFAP activation, yet a significant reduction in activation of microglia in the 
SNpc was observed supporting the notion of an anti-inflammatory mechanism. 
However the lack of effect on GFAP activation would favour the glutamate 
hypothesis as the predominant mechanism here, in which AMN082 facilitates 
protection from glutamate-mediated excitotoxicity in the SNpc.  
282 
 
An important observation from this study was that the lesion size in vehicle-treated 
animals was approximately 80% which is considerably smaller than the desired ~90% 
seen in previous chapters, suggesting a degree of experimental variability in these 
animals. Whilst it is unlikely a reduced lesion size would affect the ability of 
AMN082 to mediate protection, the reduced behavioural impairment as a result of a 
more partial lesion in vehicle-treated animals may account for the less pronounced 
effect of AMN082 with respect to preservation of motor function. Indeed at the 
immunohistochemical level, AMN082 (100nmol) demonstrated a comparable level of 
protection to that seen with VU0155041 (100nmol, ~45% of intact hemisphere), yet 
in behavioural indices the effects of VU0155041 were far more pronounced. Another 
point worthy of mention when considering the level of protection seen with 
AMN082, is the fact that it was administered supranigrally in 10% DMS0, which is 
known to be neurotoxic. Indeed, in the study of Battaglia et al., (2006) 50% DMSO in 
saline (the vehicle for PHCCC) given i.p. led to an increase in MPTP toxicity. 
However our lab has shown no increase in toxicity in the vehicle (10% DMSO in 
PBS) compared to animals treated only with PBS, assessed by loss of TH in the 
lesioned striatum, suggesting this is unlikely to influence the degree of preservation 
seen here with AMN082 (Austin., 2007, PhD Thesis).  
 
It would have been highly desirable to have confirmed the receptor selectivity of 
AMN082 at mGlu7 in a follow-up study using a selective mGlu7 antagonist. 
However the only currently available compound MMPIP whilst effective in vitro has 
not yet provided compelling antagonism of mGlu7 receptors in vivo. This has been 
exemplified in a recent study where MMPIP was found to block only limited actions 
of mGlu7 signalling and failed to block mGlu7-mediated inhibition of EPSPs across 
the Schaffer collateral CA1 synapse (Niswender et al., 2010). Given this poor profile, 
the use of MMPIP in vivo cannot yet be justified as interpretation of these results 
would still be ambiguous. Thus despite the promising neuroprotective effects 
revealed with AMN082, confirmation of the involvement of the mGlu7 receptor in 
these responses remains to be confirmed. This confirmation is essential for 
interpretation of the effects of AMN082, given recent preliminary reports that 
AMN082 is rapidly metabolised in vivo, with its metabolite displaying binding 
affinity for a wide range of targets including DAT, NAT and SERT (Sukoff-Rizzo et 
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al., 2010). The direct injection into the SNpc in this study most likely circumvents 
many of these issues with metabolite formation, favouring an mGlu7 mediated effect 
with AMN082 using this experimental paradigm. However since completion of these 
experiments, a recent report has suggested a pharmacologically rich profile for 
AMN082. In this study off target effects were assessed by measuring inhibition of 
binding using a screening concentration of 10μM AMN082 at 71 GPCR, transporter, 
ion channel and enzyme targets revealing significant activity at 26 targets including 
DAT (92%), NAT (87%), µ opioid peptide receptor (MOP, 91%) and 
acetylcholinesterase (100%) with potencies likely to exceed that at mGlu7 (Brodbeck 
et al., 2010). Thus owing to the rich pharmacology of AMN082 we cannot be certain 
the neuroprotective effects seen here are mGlu7 mediated until a subtype selective 
antagonist is used or mGlu7 knockout studies are undertaken. Furthermore, these 
findings highlight the need to develop more selective compounds to assess fully the 
potential of targeting mGlu7 receptors.  
 
The final objective of these studies was to investigate the potential of targeting 
mGlu8 receptors to mediate functional neuroprotection, using the selective agonist 
DCPG in the 6-OHDA rat model of PD. The studies described here demonstrate that 
following administration of DCPG 1h before and for 7 days post a 6-OHDA lesion 
failed to demonstrate significant protection of the nigrostriatal tract. This was shown 
by a lack of preservation of TH-positive cells in the SNpc and no significant 
preservation of motor function in these animals. Interestingly, assessment of striatal 
dopamine revealed significant preservation following a high dose of DCPG (30nmol). 
Indeed this greater level of protection afforded at the striatal level was also observed 
in studies with AMN082, again demonstrating preservation at the nigral level is more 
difficult to achieve when 6-OHDA is introduced directly into the cell bodies. 
However what remains unclear here is why protection afforded at the striatal level 
failed to provide any significant preservation of motor function in behavioural 
outcomes, although there was a trend to reduce amphetamine-induced rotations at this 
dose. This may suggest the dopamine present in the lesioned striatum may not be of 
neuronal origin whereby microdialysis experiments have revealed intraneuronal pools 
of dopamine that exist following a 6-OHDA lesion that are insensitive to evoked 
release (Zetterstrom et al., 1988).  Indeed further studies would be required to 
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ascertain the physiological state of the dopamine detected here. For example, a 
microdialysis study would be of worth to examine dopamine efflux following 
stimulation of potassium to confirm neuronal derivation. An additional suggestion is 
that DCPG may alter TH activity thereby increasing dopamine content or act to 
reduce dopamine turnover, although both these possibilities remain speculative at this 
point.   
 
The lack of neuroprotection seen following treatment with DCPG is perhaps not 
surprising since our immunohistochemical studies investigating the distribution of 
group III mGlu receptors (discussed in Chapter 2), revealed generally low intensity 
staining for mGlu8 in the basal ganglia particularly within the SNpc. Furthermore 
previous studies in our lab have reported a lack of efficacy of DCPG to inhibit 
glutamate release from nigral slices (Broadstock et al., 2011). DCPG, failed to inhibit 
release over a wide concentration range (0.03 – 10 µM, spanning the estimated EC50 
of 31 nM) when applied either alone or in combination with L-AP4 (Broadstock et 
al., 2011).  Interestingly in a parallel study, injection of DCPG into the SNpr did 
produce a dose-dependent reversal of akinesia, however, this effect was not inhibited 
by pre-treatment with CPPG, suggesting it was driven through an off-target action of 
DCPG, independent of group III mGlu receptor activation (Broadstock et al., 2011). 
Although the identity of such a target is yet to be identified, an additional low affinity 
non-mGlu, non iGlu receptor target was described for DCPG when it was first 
characterised (Thomas et al., 2001) raising a concern over the selectivity for DCPG at 
mGlu8. 
 
Electrophysiological studies employing whole-cell patch clamp recordings from 
dopaminergic neurones of the rat SNpc, confirmed DCPG had no effect on evoked 
EPSPs in the SNpc (Valenti et al., 2005). Application of 300 nM (S)-3,4-DCPG, a 
concentration 10-fold higher than the EC50 of this compound at recombinant 
mGluR8, produced no effect on the excitatory transmission in the SNpc suggesting 
that mGluR8 does not play a role in modulating transmission on the subthalamonigral 
pathway. Furthermore Lopez et al., (2007) found a similar lack of efficacy of DCPG 
against haloperidol-induced catalepsy following intranigral administration, and to 
reverse 6-OHDA-induced akinesia following intrapallidal injection (Beurrier et al., 
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2009) demonstrating a lack of target potential of mGlu8 receptors to provide 
symptomatic relief in PD.   
 
While a protective role is ruled out, DCPG at a single dose (10nmol) did show a 
significant anti-inflammatory response by decreasing levels of IBA-1. This effect is 
important as it indicates that the protection seen with VU0155041 (in the previous 
chapter) and above with AMN082 are not likely to be solely dependent on reducing 
levels of IBA-1, otherwise DCPG would have also shown clear protection here. 
Whilst this does not rule out an inflammatory mechanism these findings certainly 
suggest this is not the predominant mechanism in mediating neuroprotection which 
may ultimately be driven through an inhibition of glutamate release. Of course it is 
possible neuroprotection implicates multiple mechanisms and an anti-inflammatory 
mechanism may still provide an integral contribution to achieve this desired outcome. 
Taken together, these findings suggest that mGlu8 demonstrates the least promise as a 
potential novel group III mGlu target for the treatment of PD, shown here by its 
failure to provide functional neuroprotection in the 6-OHDA rat model of PD. 
However, it is unclear how the limited pharmacology of DCPG has contributed to this 
supposition. Only when further studies are performed using more selective mGlu8 
agents over a wider dose range confirmed with corresponding antagonist or exclusive 
mGlu8 receptor knockout studies, can a neuroprotective role for mGlu8 be 
definitively ruled out. 
 
To conclude, the studies presented in this chapter demonstrate selective activation of 
mGlu7 receptors using the allosteric agonist AMN082 can mediate neuroprotection 
and preservation of motor function in the 6-OHDA rat model of PD. However a 
degree of uncertainty remains over the potential of targeting mGlu7 receptors owing 
to the recent unearthing of a pharmacologically rich profile for AMN082 and further 
studies are clearly required to address this caveat. As for mGlu8, these studies along 
with findings in the literature reveal little evidence to pursue targeting this group III 
mGlu receptor subtype for disease modification in PD. However it is unclear at this 
stage how the potential of targeting mGlu8 has also been hindered by a lack of 
selective pharmacological ligands. Collectively, the data described here would imply 
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that the mGlu7 group III mGlu receptor subtype, rather than mGlu8 is the more likely 









































































Current treatments for PD to date have relied heavily on reinstating dopaminergic 
transmission either with L-DOPA or dopamine agonists. Whilst this has proven to be 
extremely effective at treating the symptoms of the disease, this approach does little 
to combat the progressive degeneration. This failure affects patients’ long-term health 
because the increasing doses of drug required to stabilize worsening symptoms often 
result in disabling adverse effects, such as L-DOPA induced dyskinesia and psychosis 
(Stocchi et al., 1997). Clearly then the development and use of neuroprotective agents 
for PD represents one of the most important goals for researchers in this field. Indeed, 
the need for such therapies is now stronger than ever since as average human life 
expectancy increases so will the prevalence of PD, and therefore suffering and 
economic burden caused by loss of earning and cost of care will too rise. Thus there 
is a huge medical and economic incentive to find an effective treatment for this 
disorder.  
 
In PD, loss of striatal dopamine evokes numerous downstream changes within the 
basal ganglia, including increased firing of the STN (Vila et al., 1999). The 
subsequent increased release of glutamate in the STN target areas such as the SNpr 
and GPi, leads to inhibition of thalamocortical feedback which contributes to the 
generation of motor deficits associated with PD. Importantly, the STN also sends 
direct projections to the SNpc (Iribe et al., 1999; Smith & Bolam, 1990), which under 
parkinsonian conditions may lead to a parallel increase in glutamate release and 
contribute to the progressive degeneration in the SNpc via an excitotoxic mechanism 
(Rodriguez et al., 1998). Accordingly, reducing STN firing via subthalamotomy or 
deep brain stimulation reduces symptoms in animal models and PD patients (Alvarez 
et al., 2005; Peppe et al., 2004; Windels et al., 2005) while chemical inactivation of 
the STN (through kainic acid lesioning), also reduces nigrostriatal tract damage 
induced by the dopaminergic toxin, 6-hydroxydopamine (6-OHDA) (Piallat et al., 
1996).  Given these surgical procedures are invasive, expensive and available in few 
centres world-wide, alternative strategies for combating the effects of increased STN 
activity are desirable. One such approach may be the pharmacological inhibition of 
glutamate release from STN terminals in the SN and group III mGlu receptors are one 
of a number of possible targets that might achieve this and thereby sequester 
degenerative processes in PD. 
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The Gi / Go – coupled group III mGlu receptors, which in the brain comprise  
mGlu4,7 and 8 are found on pre-synaptic elements of glutamatergic synapses where 
they serve a modulatory role (Conn & Pin, 1997). Of particular relevance here, 
previous in vitro electrophysiological studies have shown that activation of group III 
mGlu receptors using the broad spectrum agonist, L-AP4 inhibits glutamate 
transmission across the subthalamonigral synapse (Wittmann et al., 2001). This 
finding has since been supported by work from our laboratory showing that activation 
of group III mGlu receptors in the SN leads to a reduction of glutamate release both 
in vitro and, more importantly, in vivo (Austin et al., 2010). Armed with this 
knowledge, the studies in this thesis were undertaken to assess whether activation of 
group III mGlu receptors in the SNpc, could offer benefit in PD by protecting 
dopaminergic neurones from 6-OHDA induced toxicity.  
 
In Chapter 2, a preliminary study was conducted to assess group III mGlu receptor 
distribution in the basal ganglia via immunohistochemistry. These studies paid 
particular attention to mGlu8, where expression studies were limited. Previous studies 
have been conducted to assess mGlu4 and mGlu7 receptor distribution and our 
observations were in good agreement with these findings revealing particularly 
intense staining for both receptor subtypes in the SNpc, suggesting these receptors 
may be ideally positioned for pharmacological manipulation. Furthermore, these 
studies revealed the presence of mGlu8 throughout the basal ganglia. Generally, the 
levels of mGlu8 expression seen here appeared to be considerably lower than that 
seen for both mGlu4 and 7 in each of the basal ganglia nuclei with the exception of 
the striatum, although these were not quantifiably compared. These findings therefore 
revealed that all three group III mGlu receptor subtypes are potential pharmacological 
targets for future investigation.  
 
The neuroprotective potential of targeting group III mGlu receptors has already been 
suggested from findings of Vernon et al., (2005), who demonstrated the ability of 
sub-chronic L-AP4, administered intranigrally, to preserve dopaminergic cell bodies 
and terminals of the nigrostriatal tract in 6-OHDA-lesioned rats. This study however, 
did not investigate whether the protection of dopaminergic neurones resulted in 
preservation of motor behaviour. Therefore the initial studies in Chapter 3 of this 
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thesis, aimed to confirm the neuroprotective ability of L-AP4 in 6-OHDA-lesioned 
rats, and additionally investigate whether this protection translated into preservation 
of motor behaviour.  
 
The studies detailed in Chapter 3 confirmed sub-chronic L-AP4, administered 
supranigrally 1 hour before and for 7 days post 6-OHDA-lesioning afforded 
neuroprotection shown by preservation of TH, AADC immunohistochemistry and 
neurochemical assessment of striatal dopamine content. Importantly, this study also 
revealed that the protection observed against a 6-OHDA lesion translated to 
preservation of motor function. This was apparent by a significant preservation of 
contralateral paw use in the adjusted steps test and cylinder test of forelimb akinesia 
following L-AP4 treatment, as well as a reduction in the degree of amphetamine-
induced rotations. These positive behavioural outcomes indicated that the 
improvement in striatal dopamine levels in the lesioned hemisphere reduced striatal 
dopamine asymmetry between this and the intact hemisphere sufficiently to improve 
motor function. Furthermore, in a follow-up study, neuroprotection mediated by L-
AP4 was shown to be significantly inhibited with prior administration of a selective 
group III mGlu receptor antagonist CPPG in both immunohistochemical and 
neurochemical indices. The ability of L-AP4 to improve motor function was also 
significantly compromised following pre-treatment with CPPG in all three 
behavioural measures. The findings confirmed the protective effects mediated by L-
AP4 were driven by a group III mGlu receptor dependent mechanism.  
 
In Chapter 4, studies commenced into identifying which of the known group III mGlu 
receptor subtypes was responsible for mediating this protective effect seen with L-
AP4, firstly by examining mGlu4 receptors. Administration of the novel mGlu4 
selective PAM VU0155041 was found to significantly protect the nigrostriatal tract. 
This was evidenced by a preservation of TH-positive cells in the SNpc and reduction 
in 6-OHDA-induced loss of striatal TH and DDC immunoreactivity. Furthermore, 
these preserved makers of nigrostriatal tract integrity were reflected in elevated 
dopamine content in the striatum of VU0155041 versus vehicle-treated animals. Of 
important functional significance, VU0155041 also preserved motor function post 6-
OHDA lesion. Significant preservation of contralateral forelimb use was shown in 
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both the cylinder and adjusted stepping test following VU0155041 treatment in 
addition to a reduction in amphetamine-induced ipsiversive rotations, reflecting 
reduced asymmetry between the lesion and intact hemispheres in this 
hemiparkinsonian model. Pre-treatment with CPPG prior to VU0155041, markedly 
attenuated both the behavioural end-points and the post-mortem indices of preserved 
nigrostriatal tract function, confirming VU0155041 produced these effects via a 
receptor mediated process.  
 
Numerous mechanisms may underlie this mGlu4 receptor-mediated neuroprotection, 
however following intranigral administration, as undertaken in this study, the two 
most likely mechanisms include inhibition of glutamate release in the SNpc and 
protection thereby from glutamate-mediated excitotoxicity, or reduced inflammatory 
actions. Support for the glutamate hypothesis was already available in the form of 
electrophysiological studies which had revealed that STN-evoked EPSCs in 
dopaminergic neurones of the SNpc were inhibited by the mGlu4 PAM, PHCCC 
(Valenti et al., 2005).  In addition, studies conducted in our laboratory have recently 
shown that PHCCC inhibits depolarisation-evoked release of [
3
H]-D-aspartate from 
slices of rat SN in-vitro (Broadstock et al., 2011). In vivo microdialysis studies using 
VU0155041 would have helped strengthen this in vitro support. Although time did 
not permit undertaking microdialysis during the course of this thesis, such studies are 
currently underway and should help shed further light on whether inhibition of 
glutamate release in the SNpc contributes to the neuroprotective effects seen 
following mGlu4 receptor potentiation.  
 
The studies of Chapter 4 have however, provided new evidence in support of an 
additional, anti-inflammatory contribution potentially mediated by astroglial mGlu4 
receptors. The marked decrease in GFAP-positive cells observed here following 
VU0155041 treatment may suggest a role for mGlu4 receptor activation in restricting 
6-OHDA-induced astroglial-driven neurotoxicity in vivo. Treatment with the mGlu4 
PAM also led to a significant reduction in activation of microglia in the SNpc of 6-
OHDA rats, as shown by the reduced levels of IBA-1 in the lesioned hemisphere of 
VU0155041-treated animals. Therefore, although these mechanisms have only just 
begun to be explored, it is tempting to suggest a component derived from activation 
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of astroglial mGlu4 receptors may contribute to the overall protective potential of 
targeting these receptors in PD. However, these data should be interpreted with an 
element of caution, as decreases in microglial markers may reflect a secondary effect 
to neuroprotection mediated by VU0155041 through alternative mechanisms. 
Furthermore, in the preliminary fluorescent immunohistochemical studies undertaken 
at the close of Chapter 4, there was little evidence for co-localisation of mGlu4 
receptors with GFAP. Therefore any anti-inflammatory component is certainly more 
likely to reflect an indirect effect via stimulation of neuronal mGlu4 receptors, rather 
than a direct effect of stimulating mGlu4 receptors localised on the glial cells 
themselves. Owing to this uncertainty, further studies are no doubt required to probe 
the potential of an mGlu4-derived anti-inflammatory action in mediating 
neuroprotection in rodent models of PD.  
 
Interestingly the level of protection achieved following mGlu4 receptor activation 
alone was below that achieved with L-AP4. This effect may be due to not reaching 
the optimal dose of VU0155041 and higher doses should be considered in future 
studies. However, this finding would also suggest additional group III mGlu receptor 
subtypes i.e. mGlu7 and mGlu8 may too provide neuroprotective effects. Indeed, the 
studies presented in Chapter 5 reveal the mGlu7 allosteric agonist, AMN082, 
administered 1h before and for 7 days post a 6-OHDA lesion significantly protects 
the nigrostriatal tract. This was shown by a preservation of TH-positive cells in the 
SNpc and reduction in 6-OHDA-induced loss of striatal dopamine. Furthermore, this 
study revealed neuroprotection following treatment with AMN082 also led to a 
degree of preservation of motor function post-lesion. This was shown by a marked 
preservation of contralateral paw use in the cylinder test following AMN082 
treatment, in addition to a reduction in amphetamine-induced ipsiversive rotations.  
 
In an attempt to investigate a potential mGlu7-mediated anti-inflammatory 
mechanism, treatment with AMN082 resulted in a significant decline in IBA-1 
activation however no effect on GFAP activation was observed. This would imply an 
astrocytic mGlu7 neuroinflammatory mechanism is unlikely to be mediating the 
neuroprotection observed here and again may reflect an indirect effect via stimulation 
of neuronal mGlu4 receptors. The most likely mechanism for mGlu7-mediated 
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neuroprotection is via inhibition of glutamate release in the SNpc to facilitate 
protection from glutamate-mediated excitotoxicity. From studies in our laboratory, 
AMN082 was shown to inhibit depolarisation-evoked [3H]-D-aspartate from slices of 
rat SN in vitro (Broadstock et al., 2011). Additionally, AMN082 has been shown to 
potentiate L-AP4-mediated inhibition of EPSCs in the rat basolateral amygdala 
(Ugolini et al., 2008) providing further weight to the glutamate hypothesis. 
 
Following treatment with the selective mGlu8 agonist DCPG, whilst displaying 
preservation of striatal dopamine, demonstrated no immunohistochemical protection 
at the level of the SN or preservation of motor behaviour. This overall lack of 
protection seen with DCPG was not too surprising since our immunohistochemical 
studies investigating the distribution of group III mGlu receptors in Chapter 2, 
revealed generally low intensity staining for mGlu8 in the basal ganglia particularly 
within the SNpc. Furthermore, previous studies in our lab have reported a lack of 
efficacy of DCPG to inhibit glutamate release from nigral slices (Broadstock et al., 
2011).  An important observation in this study was that whilst DCPG did not protect 
at the level of the SNpc, significant reductions in IBA-1 activation were observed. 
This mismatch between an anti-inflammatory action and lack of protection would 
suggest an astrocytic-mediated neuroinflammatory response may in fact be 
insufficient on its own to provide neuroprotection or serves more of a secondary role 
here. Thus, in the absence of any inhibition of glutamate release, i.e. following 
mGlu8 receptor activation (Broadstock et al., 2011), this anti-inflammatory action 
alone is insufficient to provide significant protection while when, as in the case of 
mGlu4 and mGlu7, this effect occurs most likely in concert with inhibition of 
glutamate release (Broadstock et al., 2011) to offer protection. Further studies to 
assess the effects of group III mGlu receptor activation on glial responses in vivo are 
clearly warranted to fully gauge the contribution of a neuroinflammatory mechanism 
to mediate functional neuroprotection.   
 
Collectively, the findings presented in this thesis suggest that, of the group III mGlu 
receptors investigated, mGlu4 offers the most potential as a promising target for 
establishing disease modification in PD. It is likely the profound neuroprotective 
effect mediated by mGlu4 with respect to mGu7 and to a lesser degree mGlu8 is due 
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to its greater expression along the subthalamonigral tract. However, an additional 
factor is that the lack of efficacious, selective pharmacological agents for mGlu7 and 
mGlu8 receptors has likely contributed to this outcome and a role at least for mGlu7 
should not be underestimated at this stage. To assess the clinical utility of selectively 
targeting mGlu7 receptors, compounds demonstrating greater efficacy and selectivity 
are eagerly awaited. Furthermore once this goal is achieved, an additional possibility 
may be that a maximal neuroprotective effect requires activation of more than one 
group III mGlu receptor subtypes. A similar parallel can be drawn with the 
neuroprotective effects of nicotine in 6-OHDA lesioned rats, whereby nicotine itself 
shows the ability to preserve striatal dopamine and motor function, yet individual 
nicotine receptor subtype agonists could not (Visanji et al., 2006). Future studies 
should therefore consider the possibility of using a cocktail of group III mGlu 
receptor subtype selective ligands.  
 
However, for the immediate future, the first objective must be to move away from the 
current experimental design in initiating treatment prior to lesion, which demonstrates 
in vivo proof of concept yet does not reflect the timing of drug intervention in a 
clinical setting. The need to follow this paradigm is an attempt to account for the 
rapid degeneration following 6-OHDA insult however it is clearly a far reflection of 
the ongoing progressive degenerative process in PD patients and remains a severe 
limitation of this model. Therefore, future studies must seek to investigate the 
potential of targeting group III mGlu receptors whereby treatment can be delayed 
until after the lesion. This will require a more progressive lesion such as that obtained 
in the striatal 6-OHDA model which leads to nigral cell loss over a period of weeks 
rather than days.  
 
In the long-term it will also be important to investigate the neuroprotective potential 
of group III mGlu receptor ligands in a model which leads to the formation of Lewy 
bodies. In this regard, the 6-OHDA model shares a common failing with many other 
animal models of PD in failing to mimic this pathological hallmark. Whilst the exact 
role of Lewy bodies remains to be established, drugs to reduce aggregate formation 
are considered a potential future strategy for treating PD and animal models must be 
devised to successfully mimic this pathological phenomenon. Early indications 
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suggested the proteasomal models such as PSI had strong face validity in this respect, 
demonstrating progressive loss of nigrostriatal neurones, onset of motor disability and 
crucially proteinous inclusions relating to Lewy bodies. Unfortunately PSI appears to 
be highly variable proving difficult to reproduce between laboratories which is hugely 
frustrating since this could potentially be a valuable model in which to test 
neuroprotective strategies, but nothing has so far appeared in the literature to this 
effect. It is a similar story with regard to the genetic models which successfully 
mimic the mitochondrial dysfunction and subtle abnormalities in dopaminergic 
transmission consistent with PD, yet fail to replicate nigral pathology. However, 
genetic studies will no doubt tell us more about the pathology of PD which can be 
implemented in future improved models. This is urgently awaited considering the fact 
no translation from animal models of PD into a clinically proven neuroprotective or 
disease-modifying strategy has been demonstrated to date.  
 
Numerous potentially neuroprotective compounds from a wide range of 
pharmacological classes that have shown efficacy in rodent and primate models have 
worryingly all proven to be ineffective in the clinic. Dopamine agonists, such as 
ropinirole and pramipexole, have been reported to be neuroprotective in a range of 
animals models of PD, including the MPTP treated mouse and 6‐OHDA lesioned rat 
yet there is no clinical evidence to support such effects. Drugs that modify cell death 
cascades leading to apoptosis have shown to be highly effective in preventing the 
toxicity of a range of toxins in animal models of PD but have later proved to be 
inactive in subsequent clinical trials. In fact many potentially neuroprotective 
compounds ranging from glutamate receptor antagonists, antioxidants, neurotrophic 
factors and anti‐inflammatory agents have all been identified in rodent and primate 
models, yet none have proved effective in man. It is therefore difficult to see how 
proceeding with more of the same is going to lead to a neuroprotective strategy for 
PD.  
 
So where does the problem lie? It may be that selective destruction of dopaminergic 
neurones through toxin use provides excellent animal models for testing the effects of 
symptomatic treatments but does not reflect the pathogenic events occurring in man. 
Indeed, the cause or causes of PD at the molecular level remain unclear, so the target 
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for neuroprotective therapy is unknown. The animal models of PD currently 
employed reflect current understanding on the pathogenesis of PD but this thinking 
may actually be incorrect.  
 
An alternative suggestion may be that the animal models are indeed providing the 
correct answer but the subsequent clinical trials are at fault. The number of dose 
levels used in man is limited and may not result in the concentrations reached in the 
brain of animals. More importantly, it is very likely that there are multiple pathogenic 
events leading to PD and these vary between individuals. While clinical trials 
continue to be based on large patient groups of mixed pathology, it may be 
impossible to detect disease modification that affects small numbers of those 
receiving active treatment against a background demonstrating lack of effect in most. 
Therefore considerable attention needs to be given to sub‐typing patients with PD 
based on genetics or biomarkers to avoid further oversight.  
 
Perhaps the greatest limitation hindering the development of a neuroprotective 
therapy in PD is the identification of a trial design and an outcome 
measure/biomarker that is not confounded by possible symptomatic or 
pharmacological effects of the study, but accurately reflects the underlying disease 
state. It may be necessary to reconsider the study designs and outcome measures that 
have been used in PD trials aimed at detecting disease modification to accomplish 
this goal.  To date, studies have primarily included patients early in the course of PD 
using motor measures such as the UPDRS score as the primary outcome measure. 
However, UPDRS scores are readily confounded by any symptomatic effect of 
putative neuroprotective agents. Furthermore, it is becoming increasingly evident that 
long-term disability in PD patients is not so much associated with the classic motor 
features of the disease (rigidity, bradykinesia, and tremor), which can generally be 
controlled with symptomatic medications, but with the complex motor and non-motor 
problems that develop with advancing PD which do not respond to dopaminergic 
therapies. Indeed, postural instability and freezing (with associated falls and 
fractures), psychiatric disturbances (hallucinations and depression), and cognitive 
impairment (dementia) are the major causes of disability in advanced PD patients and 
the primary reasons for institutionalization. Few trials aimed at disease modification 
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have focused on the prevention of this type of accumulated disability. It may appear a 
far stretch to go from addressing mechanisms responsible for neurodegeneration to 
developing therapies that prevent these generic types of disability, however, the 
ultimate aim of a neuroprotective treatment is precisely the prevention of these 
problems.  
 
In the context of this thesis, considering the lack of translation and numerous 
challenges in store for any ‘hit to lead’, it is far too early to say at this stage whether 
activation of group III mGlu receptors offer any degree of long-term neuroprotective 
potential in the treatment of PD. It is essential far more improved, systemically active 
drugs become available to assess the long-term effectiveness of targeting group III 
mGlu receptors. This will clarify whether receptor desensitization will have a bearing 
on the long-term utility of this approach. Certainly many of the responses reported to 
date with broad spectrum agonists, ranging from electrophysiological studies in vitro 
through to the in vivo studies reported in this thesis demonstrate that responses tail off 
at higher concentrations. These observations are likely a result of receptor 
desensitization since the broad spectrum agonist L-AP4 has been shown to induce 
internalisation of at least two of the group III mGlu receptor subtypes (mGlu4 and 
mGlu7 receptors) as previously discussed in Chapter 3. Targeting the allosteric site of 
the receptor however is likely to reduce the chance of desensitisation becoming a 
problem. Indeed from the studies conducted in Chapter 4 using the mGlu4 PAM 
VU0155041, no such tailing off effect was observed and may help to explain the 
recent emphasis on developing mGlu4 receptor PAMs rather than the classical 
orthosteric agonists (Niswender et al., 2008; Engers et al., 2009; Williams et al., 
2009). 
 
As of yet, investigations in the group III mGlu receptor field have still not progressed 
into the final preclinical model of PD, the MPTP primate. This model is the most 
clinically relevant to monitor the long-term effectiveness of promising agents and 
such studies will provide a valuable indication into the clinical potential of targeting 
group III mGlu receptors in PD as well as revealing any unforeseen side effects that 
may arise from this approach. This is particularly important given that attempts to 
target glutamatergic transmission via ionotropic glutamate receptor antagonists, was 
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predicted to lead to unacceptable cognitive and psychomimetic adverse effects. It will 
therefore be essential to determine if group III mGlu receptors may achieve such 
inhibition of glutamatergic transmission without the occurrence of similar side 
effects. Recent clinical trials conducted with agonists of the closely related group II 
mGlu receptors in patients with schizophrenia have reported good tolerance and 
crucially no major treatment-related adverse effects (Patil et al., 2007). Whilst the 
outcome of longer duration clinical trials is still awaited, these earliest observations of 
targeting group II mGlu receptors in humans provide hope that drugs targeting group 
III mGlu receptors may prove to be equally well tolerated and devoid of unwanted 
adverse effects. Nonetheless, the challenge of producing ‘hit-to-lead’ compounds for 
group III mGlu receptors with the necessary systemic activity may still hinder the 
translational progress in this area. 
 
In closing, it is important to turn our attention back to the advances achieved in this 
thesis. From what begun as a hypothetical proposition, the results presented here 
provide early encouragement to the potential of targeting group III mGlu receptors to 
provide disease modification in PD. In particular, these findings demonstrate mGlu4 
but also mGlu7 can provide functional neuroprotection in an animal model of PD 
which likely attributes to a reduction in glutamate release from subthalamonigral 
terminals. Selectively targeting group III mGlu receptors therefore warrants 
considerable future investigation in additional pre-clinical models of parkinsonism 
such as the MPTP-treated primate, in order to elucidate their likely long-term 
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Phosphate-buffered saline (PBS) 137 mM NaCl, 2.7mM KCl, 1.8mM KH2PO4, 
10mM  Na2HPO4, pH 7.6  
 
Tris-buffered saline (TBS)  50 mM Tris, 150 mM NaCl, pH 7.6 
 
Blocking buffer 1% BSA in 0.5M TBS and 10% sodium azide, 
pH 7.6 
 
Reagents and consumables 
 
Material       Supplier 
ABC        Vector 
Acetic acid, glacial      Sigma 
N,N’-dibenzhydrylethane-1,2-diamine dihydrochloride Tocris Cookson  
(AMN082) 
Ascorbic acid       Sigma 
D-amphetamine      Sigma   
Calcium chloride (CaCl2)     Sigma 
Cannulae tubing      Coopers 
(RS)-alpha-cyclopropyl-4-phosphonophenylglycine  Tocris Cookson 
(CPPG)  
Cresyl  violet       Sigma 
(S)-3,4-dicarboxyphenylglycine ((S)-3,4-DCPG)  Tocris Cookson 
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Dental cement - De Trey ‘Rapid Repair’   Skillbond Direct 
Desipramine       Sigma 
Diaminobenzidine tetrahydrochloride (DAB)  Sigma 
Dimethyl sulfoxide (DMSO)     Sigma 
DPX mounting medium     Sigma 
Ethanol, absolute (HPLC grade)    Sigma 
Glacial acetic acid      Sigma 
Histoclear       Sigma 
Hydrochloric acid (HCl)     Sigma 
Hydrogen Peroxide (30%)     Sigma 
6-hydroxydopamine (6-OHDA)    Sigma 
Isoflurane       Abbott animal health 
L(+)-2-amino-4-phosphonobutyric acid (L-AP4)  Tocris Cookson 
Magnesium Chloride (MgCl2)    Sigma 
Methanol, absolute (HPLC grade)    Fisher 
Microscope slides – Superfrost plus    VWR    
Microscrews, 1.3mm      Clerkenwell 
Microsyringe, 5 µl Hamiltion 7000 series   VWR 
Microsyringe, 10µl Hamilton 700 series   VWR 
Microtubes, 1.5ml Safe-Lock     VWR 
Normal goat serum      Vector  
Paraformaldehyde (PFA)     Sigma 
Pargyline       Sigma 
Phosphate buffered saline tablets    Sigma 
Pipette tips       G.E. Healthcare 
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Portex tubing       Portex 
Potassium chloride (KCl)     Sigma 
Potassium hydrogen phosphate (KH2PO4)   Sigma 
Sodium azide       Sigma 
Sodium chloride (NaCl)     Sigma 
Sodium Hydroxide (NaOH) crystals    Sigma 
Sodium phosphate, monobasic (NaH2PO4)   Sigma 
Sodium phosphate, dibasic (NaH2PO4)   Sigma 
Tris base / Trizma       Sigma 
Tryptan blue dye      Sigma 
(±)-cis-2-(3,5,-dichlorphenylcarbamoyl)   Ascent Scientific 




















Abbot animal health  Abbott Laboratories Ltd, Kent, UK 
Abcam    Abcam, Cambridge, UK 
Amersham   Amersham Pharmacia Biotech UK Ltd, Bucks, UK 
Ascent Scientific  Ascent Scientific Ltd (UK), Bristol, UK 
B & K    B & K Universal Limited, Hull, UK 
Chemicon/ Millipore  Millipore (U.K.) Ltd, Watford, UK 
Clerkenwell Screws  Clerkenwell Screws, Farringdon, London, UK 
Coopers   Coopers Needleworks, Birmingham, UK 
Dako    Dako UK Ltd, Cambs, UK 
Fisher    Fisher Scientific UK Ltd, Leics, UK 
GE Healthcare  Chalfont St Giles, Bucks, UK 
GraphPad   GraphPad software, San Diego, CA, USA 
KD Scientific   Distributed by Presearch, Hamps, UK 
Kopf    Tujunga, CA 
Leica    Leica Microsystems (UK) Ltd, Milton Keynes, UK 
Portex    Distributed by Scientific Laboratory Supplies (SLS), 
    Nottingham, UK 
Scion Corporation  Scion Corportation, Maryland, USA 
Sigma    Sigma Chemical Company Ltd, Poole, Dorset, UK 
Skillbond   Skillbond direct, Bucks, UK 
RS Components  RS Components Ltd, Northants, UK 
Tocris Cookson  Tocris Cookson Ltd, Avonmouth, Bristol, UK 




Vector Vector Laboratories Ltd, Peterborough, UK 
VWR VWR International Ltd, Leics, UK 
Zeiss Carl Zeiss Ltd, Welwyn Garden City, Herts, UK   
 
